Conditions: Schizophrenia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 617
Healthy volunteers: no

Brief summary:
This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.

Detailed description:
This is a Phase 3, randomized, double-blind, placebo-controlled, in-patient, efficacy, and safety study to evaluate HP-3070 for the treatment of schizophrenia.

This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia, who are in an acute exacerbation and to assess the impacts of covariates on asenapine exposure as delivered in a patch formulation, using a population-based approach.

Arms:
arm 1: Low dose asenapine maleate, transdermal patches will be compared against placebo patches. arm 2: High dose asenapine maleate, transdermal patches will be compared against placebo patches. arm 3: Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches

Interventions: intervention 1: Low Dose Asenapine maleate transdermal patch intervention 2: High Dose Asenapine maleate transdermal patch intervention 3: Placebo
Intervention descriptions: intervention 1: The study will evaluate low dose Asenapine maleate transdermal patch intervention 2: The study will evaluate high dose Asenapine maleate transdermal patch intervention 3: The study will evaluate placebo transdermal patch.

Protocol document:
Prot_000.pdf: 
Clinical Study Protocol 
 
Protocol Title: A Randomized, Double-Blind, Placebo-
Controlled, Fixed-Dose, 6-Week, In-
Patient Study to Assess Efficacy and 
Safety of HP-3070 in Subjects Diagnosed 
with Schizophrenia 
 
Date of Protocol: 20 January 2016 
 
NCT Number: NCT02876900 
 
 


Noven Pharmaceuticals, Inc. 
 
1 
HP-3070-GL-04 
HP-3070 
 
 
 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
   
Clinical Study Protocol 
Protocol Title: 
A Randomized, Double-Blind, Placebo-Controlled, 
Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy 
and Safety of HP-3070 in Subjects Diagnosed with 
Schizophrenia 
Protocol Number: 
HP-3070-GL-04 
Date of Protocol: 
   
20 January 2016 
Protocol Version: 
Version 2.0 Amendment 1 
Product: 
Asenapine Transdermal Patch 
Pre-IND No.: 
125707 
EudraCT No.: 
2015-005134-21 
Study Phase: 
3 
Sponsor: 
Noven Pharmaceuticals, Inc. 
Empire State Building, 350 Fifth Avenue, 37th Floor, 
New York, NY 10118 
Study Director (Medical): 
Susan Kozauer, MD  
Medical Director, Medical and Scientific Services 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, North Carolina 27703 
Susan.Kozauer@quintiles.com 
Study Director (Clinical Operations):  Dana Annunziato 
Senior Director, Clinical Research 
Noven Pharmaceuticals, Inc. 
Empire State Building, 350 Fifth Avenue, 37th Floor, 
New York, NY 10118 
dannunziato@noven.com 
Project Manager: 
Michael Smallwood 
Senior Clinical Project Manager 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, North Carolina 27703 
Michael.smallwood@quintiles.com 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
2


Noven Pharmaceuticals, Inc. 
 
2 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
Medical Advisor: 
Elena Vlad, MD, Psych, PhD 
 
Medical Director, Medical and Scientific Services 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, North Carolina 27703 
elena.vlad@quintiles.com 
 
Confidentiality Statement 
This confidential information in this document is provided to you as an Investigator or 
consultant for review by you, your staff, and the applicable Institutional Review 
Board/Independent Ethics Committee.  Your acceptance of this document constitutes 
agreement that you will not disclose the information contained herein to others without 
written authorization from the Sponsor. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
3


Noven Pharmaceuticals, Inc. 
HP-3070-GL-04 
HP-3070 
Signatures 
PROTOCOL TITLE: 
A Randomized, Double-Blind, Placebo-Controlled, 
Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects 
Diagnosed with Schizophrenia 
PROTOCOL NO: 
HP-3070-GL-04 
Dana Annunziata 
Senior Director, Clinical Research 
Noven Pharmaceuticals, Inc. 
Elena Vlad, MD, Psych, PhD 
Medical Director 
Medical and Scientific Services 
Quintiles, Inc. 
Llk!.1Afi11-_tti 
Signature 
---~ 
Signature 
.di)_C(fr-Y) ~ 
I w 
Date 
3 
Protocol Version 2.0 Amendment I: 20 January 2016 
Protocol Final Version: 16 November 2015 
Confidential 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
4


Noven Pharmaceuticals, Inc. 
 
4 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
SYNOPSIS 
Name of Sponsor/Company: 
Noven Pharmaceuticals, Inc.  
Name of Finished Product: 
HP-3070 
Name of Active Ingredient: 
Asenapine 
Title of Study: 
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week In-Patient 
Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed with 
Schizophrenia 
Protocol No: 
HP-3070-GL-04 
Investigators: 
TBD 
Study center(s): 
Approximately 70 centers 
Study duration: 
Screening/Run-in, Washout Period:  Maximum 14 days  
Double-blind Treatment Period:  6 weeks 
Follow-up Visit/Telephone call:  30 days after the last patch is removed 
Phase:  3 
Objectives: 
Primary Objective: 
The primary objective of the study is to evaluate efficacy of HP-3070 compared with placebo for the treatment 
of schizophrenia as evaluated by Positive and Negative Syndrome Scale (PANSS) total score. 
Secondary Efficacy Objectives: 
 Key Secondary Efficacy Objective: 
o Clinical Global Impression – Severity of Illness Scale (CGI-S) 
 Other Secondary Efficacy Objectives:  To evaluate the efficacy of HP-3070 using the following 
measures: 
o PANSS total score at each time point 
o Clinical Global Impression – Severity of Illness Scale (CGI-S) at each time point 
o Clinical Global Impression – Improvement Scale (CGI-I) at each time point 
o Proportion of CGI-I responders at each time point including Week6; CGI-I responders are 
defined as subjects who have a score of 1 (very much improved) or a score of 2 (much 
improved) 
o Positive, negative, and general pathology subscores of PANSS 
o Proportion of PANSS responders; PANSS responders are defined as subjects  who have a 
≥30% reduction in PANSS total score between Baseline and at each time point including 
Week 6 
o Calgary Depression Scale for Schizophrenia (CDSS) 
o Medication Satisfaction Questionnaire (MSQ) score 
Safety Objectives: 
 Adverse events (AEs), including treatment-emergent AEs (TEAEs), AEs leading to discontinuation 
from the study drug, serious adverse events (SAEs), and deaths 
 Change from Baseline in clinical laboratory results (including prolactin, fasting glucose, and lipids), 
ECG results, body weight, and vital signs 
 Results of C-SSRS, BARS, AIMS, and SAS 
 Dermal safety 
Exploratory Objective: 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
5


Noven Pharmaceuticals, Inc. 
 
5 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
 To assess the impact of covariates on asenapine exposure using a model-based approach and to 
explore the exposure-response relationship with relevant endpoints. 
Methodology: 
This is a Phase 3, randomized, double-blind, placebo-controlled, in-patient, safety, and efficacy study to 
evaluate HP-3070 for the treatment of schizophrenia.  
This study will consist of a Screening/placebo Run-in Period of 3 to 14 days, a 6-week double-blind Treatment 
Period and a 30 day Follow-up Period. 
This study will enroll subjects who are in an acute exacerbation (i.e., have had an acute episode no longer than 
8 weeks prior to the Screening Visit), have a PANSS total score ≥80 with scores of 4 or higher on at least 
2 out of the 4 pre-defined PANSS positive subscale items, and have a CGI-S ≥4.  Subjects will be hospitalized 
at the Screening Visit and will remain hospitalized during the study.  The subject may leave the hospital for 
necessary personal business.  During this time, the subject must be supervised by study staff or a responsible 
caretaker.  Any subject who leaves the site must have an alcohol breathalyzer and urine drug and pregnancy 
tests when they return to the site.  Investigator should contact Medical Advisor to discuss specifics of subject 
off-site overnight travel to confirm appropriateness. 
The study will evaluate 9.0 mg (HP-3070-9.0) and 18.0 mg (HP-3070-18.0) of HP-3070 transdermal patches 
versus placebo transdermal patches. To maintain double-blind each subject will wear two patches.  Patches 
will be applied by site personnel at approximately the same time daily and site personnel will remove the 
patches at approximately 24 hours after patch application.  Each patch will be worn for 24 hours.  Every day, 
approximately 24 hours after patch application, site personnel will remove previous day’s patches and apply 
new patches.  Patch adhesion will be assessed at specified time points and prior to patch removal. 
In this study, efficacy will be evaluated using widely accepted, standard questionnaires.  These include the 
PANSS, CDSS, CGI-S, CGI-I, and MSQ. 
In addition to standard safety measures (AEs, clinical laboratory assessments, vital signs, weight, ECG 
results), this study will also include assessments of EPS symptoms using the Barnes Akathisia Rating Scale 
(BARS), Abnormal Involuntary Movement Scale (AIMS), and Simpson-Angus Scale (SAS).  Suicidality will 
be monitored using the Columbia-Suicide Severity Rating Scale (C-SSRS).  Dermal safety will be assessed by 
a review of any dermal reactions (such as irritation and discomfort due to the patch) reported as AEs. 
Screening/Run-In Period:  At the Screening Visit, subjects will be asked to sign the informed consent form 
(ICF).  No screening procedures may begin prior to obtaining informed consent.  Each subject will be assigned 
a unique subject number after signing the ICF. 
After obtaining informed consent, the subject will be enrolled and hospitalized for the duration of the study.  
The subject will stay in the unit throughout the study, except for supervised leave for personal business.  
While undergoing screening procedures and waiting for results of laboratory tests, electrocardiograms (ECGs), 
and other assessments, the subject will be enrolled in the Run-in Period and start treatment with the 
single-blind placebo patch.  Subjects will be blinded to the treatment during the Run-in Period.  The subject 
must have the single-blind placebo patch applied for a minimum of 3 days prior to entering the double-blind 
Treatment Period.  In addition, current antipsychotic and other prohibited medications will be washed out 
during this period and wash-out must be completed prior to randomization and entering the double-blind 
Treatment Period.  Subjects who do not meet the eligibility criteria at the Screening/Run-In Visit and the 
Baseline Visit will be discontinued from the study.  Subjects who are not compliant with wearing the run-in 
patches will also be discontinued from the study. 
Double-blind Treatment Period:  Subjects eligible for enrollment in the double-blind Treatment Period will 
be randomly assigned to HP-3070-9.0 or HP-3070-18.0, or placebo in a 1:1:1 ratio stratified by country.  All 
trial personnel and subjects will be blinded to the treatment for the duration of the trial.  Subjects will receive 
treatment with study medication daily for 6 weeks.  Patches will be applied by site personnel at approximately 
the same time every day and each patch will be worn for 24 hours.  Every day, approximately 24 hours after 
patch application, site personnel will remove previous day’s patches and apply new patches.  
In the event that the patches are detached completely, new patches should be applied immediately, provided 
that there are at least 6 hours of time remaining before the next dose. 
Blood samples will be collected at 2, 14, and 22 hours with ± 2 hour- window on Day 21 and 42 and analyzed 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
6


Noven Pharmaceuticals, Inc. 
 
6 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
for asenapine and desmethyl asenapine concentrations.  Actual blood sampling time will be recorded.  A 
model-based approach will be used to assess the impact of covariates on asenapine exposure and to explore the 
exposure-response relationship of relevant endpoints.  Details on the methodology will be included in a 
standalone pharmacokinetic (PK) report. 
At discharge (Week 6 or early termination), the subject will be prescribed an approved antipsychotic treatment 
and returned to the care of their physician. 
Follow-up Period:  All subjects will have a follow-up contact (site visit or telephone call, at the discretion of 
the Investigator) 30 days after the last patch is removed.  This contact will be used to collect information about 
any AEs or SAEs that may have occurred since discharge and to follow-up on any AE that was on-going at 
discharge. 
Planned number of subjects: 
Sufficient number of subjects will be screened to randomize 
approximately 612 subjects (approximately 204 in each of the 
3 treatment arms). 
Diagnosis and 
main criteria for inclusion: 
The assessment and documentation of the subject’s eligibility is the 
responsibility of the Investigator.  The Sponsor/designee reserves the 
right to provide final approval of subject eligibility. 
Inclusion Criteria: 
Subjects must meet all of the following criteria to be considered eligible 
to participate in the study: 
1. Adult male or female subjects, ≥18 years of age 
2. Subject is able to undergo informed consent process and signs 
ICF.  
3. Subject has current diagnosis of schizophrenia as per Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5 Criteria, Mini International Neuropsychiatric Interview 
(MINI), and as confirmed by Investigator assessment. 
4. Subject has PANSS total score ≥80, AND score of 4 or more in 
at least 2 of the following PANSS items at Screening and at 
Baseline: 
a. Conceptual disorganization 
b. Delusions 
c. Hallucinatory behavior 
d. Unusual thought content 
5. Subject has CGI-S scale score of ≥4 (moderately ill) at 
Screening and Baseline.  
6. Subject has history of relapse and/or exacerbation of symptoms 
when they are not receiving antipsychotic treatment, excluding 
the current episode. 
7. Subject is confirmed by the Investigator to be experiencing an 
acute exacerbation of schizophrenia, as evidenced by ALL of 
the following: 
a. The duration of the current episode is no more than 
8 weeks. 
b. The subject’s current symptoms represent a marked 
and substantial exacerbation of schizophrenia 
compared with the subject’s symptomatic state prior to 
the emergence of the current episode. 
c. A corresponding functional deterioration to the 
symptomatic exacerbation is evident. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
7


Noven Pharmaceuticals, Inc. 
 
7 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
8. Subject has not been hospitalized for more than 21 days for the 
current episode by the day of the Screening Visit, not including 
social hospitalization (e.g., homelessness or need for shelter that 
is unrelated to the subject’s underlying psychiatric condition). 
9. Subject agrees not to begin formal, structured psychotherapy 
targeting the symptoms of schizophrenia from the time of the 
Screening Visit until the last dose of study drug.  
10. Subject would benefit from hospitalization or continued 
hospitalization for the treatment of schizophrenia (as determined 
by the Investigator).  
11. Subjects must not be treatment naïve or treatment resistant.  
Treatment resistance is defined as having little or no 
symptomatic response to at least 2 courses of antipsychotic 
treatment of an adequate duration (at least 6 weeks) and at a 
therapeutic dose (according to the drug’s package insert). 
12. Subject has had previous positive response to an antipsychotic 
medication other than clozapine in a prior episode. 
13. Subject has a stable living situation and caretaker support when 
not hospitalized. 
14. Subject is male, or a female who is not of childbearing potential 
(i.e., surgically sterile, postmenopausal for at least 1 year) or 
who is non-pregnant, non-lactating, and is using a medically 
accepted method of contraception.  Acceptable methods of 
contraception include condoms (male or female) with a 
spermicidal agent, diaphragm or cervical cap with spermicide, 
medically prescribed intrauterine device, and hormonal 
contraceptives.  A female of child-bearing potential who is not 
currently sexually active must agree to use a medically accepted 
method of contraception should she become sexually active 
while participating in the study.  Each sexually active female of 
child-bearing potential must also agree to use a medically 
accepted method of contraception for 1 month after the final 
dose of study medication. 
15. Subjects must agree that they will not donate sperm or eggs 
from the time of the Screening Visit until 3 months following 
administration of the last treatment or dose of study medication. 
16. Agrees not to use any other transdermal patch products (e.g., 
nicotine replacement patch, hormonal replacement patch, etc.) 
for the duration of the study. 
17. Subjects must be able to wear a transdermal patch for 24 hours. 
Exclusion Criteria 
The subject will be excluded from the study if any of the following 
exclusion criteria are met: 
1. Subject is presenting with a first episode of schizophrenia based 
on the clinical judgment of the Investigator. 
2. Subject has been diagnosed with schizophrenia less than 
6 months prior to Screening Visit. 
3. Subject has received electroconvulsive therapy, transcranial 
magnetic stimulation, vagal nerve stimulation, or other brain 
stimulation treatments within 90 days of Screening Visit. 
4. Subject has a current DSM-5 diagnosis other than schizophrenia 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
8


Noven Pharmaceuticals, Inc. 
 
8 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
including (but not limited to) schizoaffective disorder, major 
depressive disorder, bipolar disorder, post-traumatic stress 
disorder, anxiety disorders, delirium, dementia, amnestic, or 
other cognitive disorders 
5. Subject has a diagnosis of mental retardation, history of 
traumatic brain injury causing ongoing cognitive difficulties, 
Alzheimer’s Disease or another form of dementia (or suspicion 
thereof), or any chronic organic disease of the central nervous 
system that would interfere with the efficacy or safety endpoints 
of the study. 
6. Subject has experienced acute depressive symptoms within 
30 days prior to Screening Visit that requires treatment with an 
antidepressant, as determined by the Investigator.  
7. Subject is a known non-responder to previous asenapine 
treatment, as per Investigator judgment. 
8. Subject is currently taking clozapine for the treatment of 
schizophrenia.  Subjects taking low doses of clozapine (up to 
100 mg/day) for sedative properties and not treatment resistance 
or suicidality may be acceptable as per Investigator judgment 
and as approved by the Sponsor/designee. 
9. Subject with schizophrenia who is considered 
resistant/refractory to antipsychotic treatment by history or who 
has a history of failure to respond to clozapine or response to 
clozapine treatment only.  Treatment resistance is defined as 
having little or no symptomatic response to at least 2 courses of 
antipsychotic treatment of an adequate duration (at least 
6 weeks) and at a therapeutic dose (according to the drug’s 
package insert). 
10. Subject who is unwilling to discontinue or, in the opinion of the 
Investigator, unable to discontinue any prohibited medication 
prior to the Baseline Visit without significant medical or 
psychiatric destabilization, or increased suicidality, as per the 
washout requirements.  Prohibited medications include: 
a. Antipsychotics, including depot or long-acting 
injectables 
b. Antidepressants 
c. Mood stabilizers 
d. Stimulants 
e. Nonpsychopharmacologic medications with 
psychotropic properties, per Investigator and approved 
by Sponsor/designee 
f. Herbal drugs/dietary supplements unless approved by 
Sponsor/designee  
11. Subjects taking drugs (current antipsychotic or other prohibited 
medication) that require >14 days for washout 
12. Subject who is involuntarily committed, incarcerated, or under 
legal compulsion to seek psychiatric treatment. 
13. Subject currently has clinically significant neurological, hepatic, 
renal, metabolic, hematological, immunological, cardiovascular, 
pulmonary, or gastrointestinal disorders such as any history of 
myocardial infarction, congestive heart failure, human 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
9


Noven Pharmaceuticals, Inc. 
 
9 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
immunodeficiency virus seropositive status/acquired 
immunodeficiency syndrome.  Medical conditions that are 
minor or well-controlled may be considered acceptable if the 
condition does not expose the subject to an undue risk of a 
significant adverse event (AE) or interfere with assessments of 
safety or efficacy during the course of the study.  Subjects with 
chronic Hepatitis B or C may be included provided that their 
condition is stable and values for liver function tests and other 
laboratory test results meet the criteria specified in the protocol 
for entry into the study.  The Sponsor/designee should be 
contacted in any instance where the Investigator is uncertain 
regarding the stability of a subject’s medical condition(s) and 
the potential impact of the condition(s) on study participation. 
14. Subject has any other medical condition or laboratory result 
that, in the opinion of the Investigator, may make the subject 
unsuitable for the study. 
15. Subjects with the following laboratory test and ECG results are 
excluded: 
a. Platelets ≤75,000/mm3  
b. Hemoglobin ≤9 g/dL  
c. Neutrophils, absolute ≤1000/mm3  
d. Aspartate transaminase >2×upper limit of normal 
(ULN) 
e. Alanine transaminase >2×ULN 
f. Creatine phosphokinase >3×ULN, unless discussed 
with and approved by the Medical Advisor 
g. Creatinine ≥2 mg/dL or ≥176.8 µmol/L 
h. Hemoglobin A1c (HbA1c) ≥6.5% unless the subject 
has a diagnosis of stable diabetes 
i. QT interval corrected using Fridericia’s formula 
(QTcF) ≥450 msec (males), QTcF ≥470 msec 
(females) 
j. Prolactin.  The enrollment of subjects with prolactin 
levels equal or higher than 5 X ULN 
should be 
discussed with the Medical Advisor 
16. Subject with hypothyroidism or hyperthyroidism (unless 
condition has been stabilized with medications for at least the 
past 90 days); subjects with abnormal free T4 and thyroid 
stimulating hormone (TSH) levels. 
17. Subject is currently treated with insulin for diabetes.  Subjects 
being treated for diabetes with medications other than insulin 
are eligible for the study if their condition is stable as 
determined by satisfying ALL of the following criteria: 
a. HbA1c <7.0%, AND 
b. Screening glucose ≤125 mg/dL or ≤6.94 mmol/L 
(fasting) or <200 mg/dL or <11.1 mmol/L (nonfasting).  
Note:  If the nonfasting screening glucose is 
≥200 mg/dL or ≥11.1 mmol/L, subjects must be 
retested in a fasted state and the retest value must be 
≤125 mg/dL or ≤6.94 mmol/L, AND 
c. Subject has been maintained on a stable regimen of 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
10


Noven Pharmaceuticals, Inc. 
 
10 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
oral anti-diabetic medication(s) for at least 28 days 
prior to Screening or diabetes has been well-controlled 
by diet for at least 28 days prior to Screening, AND 
d. Subject has not had any hospitalizations within the 
12 months prior to Screening due to diabetes or 
complications related to diabetes, AND 
e. Subject’s diabetes is not newly diagnosed during 
Screening. 
18. Subject has epilepsy or history of seizures, with the exception of 
a single seizure episode (e.g., childhood febrile, post traumatic). 
19. Subject has uncontrolled hypertension (diastolic blood pressure 
>95 mmHg in any position) or symptomatic hypotension, or 
orthostatic hypotension which is defined as a decrease of 
≥30 mmHg in systolic blood pressure and/or a decrease of 
≥20 mmHg in DBP after at least 3 minutes standing compared 
with the previous supine blood pressure, OR development of 
symptoms.  Note:  Blood pressure measurements may be 
repeated once to ensure reproducibility of the exclusionary 
result(s) before excluding a subject based on the criteria noted 
above. 
20. Subject has a history of neuroleptic malignant syndrome. 
21. Subject has a score of >2 (mild) on any item of the AIMS at 
Screening. 
22. Subject has a score of 5 (severe akathisia) on the Barnes 
Akathisia Rating Scale (BARS) global clinical assessment of 
akathisia at Screening. 
23. Subject has a history of pituitary adenoma or cancer <5 years 
prior to Screening.  Subjects currently being treated for cancer 
may not be enrolled in the study. 
24. Female subject who is breastfeeding. 
25. Female subject with a positive urine pregnancy test that is 
confirmed positive by serum pregnancy test at Screening or 
Baseline. 
26. Subject who currently (within the past 6 months) meets the 
DSM-5 criteria for substance use disorders (excluding nicotine 
and caffeine). 
27. Subject has positive urine drug/alcohol screen at the Screening 
Visit.  Positive results that are due to short-term prescription 
medications that can be safely discontinued (e.g., opioids for 
acute pain that has resolved) may continue at the discretion of 
the Investigator with the agreement of the Sponsor/designee.  
Subjects with positive cannabis results may be included, 
provided the Investigator does not feel the subject is a 
compliance risk, the subject does not fulfill the criteria for 
substance abuse or dependence as stated in Exclusion 
Criterion 26, the subject agrees to abstain for the duration of the 
study, and with concurrence with the Sponsor/designee. 
28. Subject is at imminent risk of self-harm or harm to others in the 
Investigator’s opinion based on clinical interview and responses 
provided on the Columbia Suicide Severity Rating Scale 
(C-SSRS).  Note that subjects will be excluded if they report 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
11


Noven Pharmaceuticals, Inc. 
 
11 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
suicidal ideation meeting the description of C-SSRS Type 4 or 
5 (i.e., suicidal ideation with intent, with or without a plan) in 
the past 6 months or suicidal behavior (as described by the 
C-SSRS) in the past 12 months at Screening.  Subjects will also 
be excluded at Baseline if they report suicidal ideation of 
Type 4 or 5 or suicidal behavior, as measured by the C-SSRS 
between Screening and Baseline. 
29. Subject has a known allergy or hypersensitivity to asenapine. 
30. Subject has current or history of allergy or hypersensitivity to 
adhesive dressings. 
31. Subject has history of allergy to more than 2 distinct chemical 
classes of drug (e.g., sulfas and penicillins). 
32. Subject has any skin abnormality present at the potential patch 
application site that is likely to be aggravated by the study drug 
(i.e., infection, rash, excessive fragility or dryness, any cut or 
abrasion), presence of tattoo, excessive hair or open sores, or 
scar tissue.  Presence of significant skin disorder such as 
atrophy, psoriasis, or vitiligo. 
33. Subject has participated in a previous HP-3070 study. 
34. Subject has participated in any other investigational trial or used 
investigational drugs within 30 days prior to the Screening Visit 
or has participated in more than 2 studies in the past 12 months. 
35. Any subject who, in the opinion of the Investigator or Medical 
Advisor, should not participate in the study. 
36. Subject is a Study Investigator, sub-Investigator, study 
coordinator, employees of a participating Investigator, or 
immediate family member of the aforementioned. 
Test product, dose and mode of 
administration: 
HP-3070 (Asenapine maleate, transdermal patch) : 
During the double-blind Treatment Period, subjects randomly assigned to 
the HP-3070 treatment arms will have the following 2 patches applied:  
 HP-3070 9.0 mg treatment arm:  one (1) 9.0 mg 20 cm2 patch 
and one (1) placebo patch, once daily  
or 
 HP-3070 18.0 mg treatment arm:  two (2) 9.0 mg 20 cm2 
patches, once daily 
Reference therapy, dose, and 
mode of administration: 
Matching placebo patch: During the double-blind Treatment Period, 
subjects randomly assigned to the placebo treatment arm will have 
2 placebo patches applied (0 mg, 20 cm
2), once daily. 
Patch application and removal 
During the double-blind treatment period, each subject will have 
2 patches applied once daily.  Patches will be removed after 
approximately 24 hours and new patches will be applied daily.  Patches 
will be applied and removed by site personnel. 
Both patches will be applied to one of the following application sites 
daily:  abdomen, hip, upper arm, upper back, and upper chest each day. 
Application sites will be rotated daily.  
In the event that a patch should detach completely, the time and activity 
at the time of patch detachment must be documented.   
If both patches are detached completely then 2 new patches from the 
subject’s kit should be applied immediately, provided that there are at 
least 6 hours of time remaining before the next dose. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
12


Noven Pharmaceuticals, Inc. 
 
12 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
If only one patch detaches completely, then the other patch should also 
be removed and two new patches from the subject’s kit should be applied 
immediately, provided that there are at least 6 hours of time remaining 
before the next dose. Regardless of what time the new patches are 
applied, patch removal time of the new patches will be approximately 
24-hours after the application of the original patches.  In other words, 
removal time of the new patches may not exceed 24 hours from the time 
the first patches were applied. 
Under no circumstances should the detached patch/patches be reapplied 
to the subject. Under no circumstances should the patches be reinforced 
or taped. 
Criteria for evaluation: 
Primary Efficacy Endpoint:  The primary efficacy endpoint is the change in Positive and Negative Syndrome 
Scale (PANSS) total score between Baseline and Week 6. 
Secondary Efficacy Endpoints: 
The key secondary endpoint is: 
 To evaluate the efficacy of HP-3070 compared with placebo for the treatment of schizophrenia as 
evaluated by change in Clinical Global Impression – Severity of Illness Scale (CGI-S) scores between 
Baseline and Week 6 
Other secondary efficacy endpoints include: 
 Change from Baseline in PANSS total score at each time point in addition to Week 6 
 Change from Baseline in CGI-S at each time point in addition to Week 6 
 CGI-I score at each time point  
 The proportion of CGI-I responders at each time point including Week 6; CGI-I responders are  
defined as subjects who have a score of 1 (very much improved) or a score of 2 (much improved) 
 Change from Baseline in positive, negative, and general pathology subscores of PANSS at each time 
point 
 Proportion of PANSS responders; PANSS responders are defined as subjects who have a  ≥30% 
reduction in PANSS total score between Baseline and at each time point including Week 6 
 Change from Baseline in CDSS score at each time point 
 MSQ score at each time point 
Safety Endpoints: 
 AEs, including TEAEs, AEs leading to discontinuation from the study drug, SAEs, and deaths 
 Change from Baseline in clinical laboratory results (including prolactin, fasting glucose, and lipids), 
ECG results, body weight and vital signs 
 Results of C-SSRS, BARS, AIMS, and SAS 
 Dermal safety 
Exploratory Endpoints 
 A model-based approach will be used to assess the impact of covariates on asenapine exposure and to 
explore the exposure-response relationship with relevant endpoints. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
13


Noven Pharmaceuticals, Inc. 
 
13 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
Statistical methods: 
Analysis Sets:  Four analysis sets will be used in analyzing the data obtained from this protocol: 
 Intent-to-Treat (ITT):  includes all consented and randomized subjects. Regardless of any protocol 
deviations, analyses performed on the ITT set will be based on the randomized treatment assignment 
and all available data. 
 Full Analysis Set (FAS):  includes all randomized subjects who have had at least 1 patch of double-
blind study medication applied and who have a Baseline PANSS total score and at least 
1  post-Baseline assessment of the primary efficacy measure (PANSS total score).  Evaluable subjects 
will be defined as those who meet the FAS definition.  The FAS will be used as the primary set for 
analysis of efficacy endpoints based on randomized treatment assignment. 
 Safety Analysis Set (SAF):  includes all subjects who have had at least 1 patch of double-blind study 
medication applied and who have at least 1 post-dose safety measurement during the double-blind 
treatment period.  In the unlikely event that errors may have occurred in treatment arm assignments, 
then analyses using the SAF will be based on treatment actually received.  The SAF will be used for 
the analysis of dermal evaluations and safety endpoints. 
 Pharmacokinetic Analysis Set (PAS):  includes all subjects who have received at least 1 dose of study 
medication during the double blind treatment period and have at least 1 blood sample for PK 
assessment.  Subjects may be excluded from the PAS set if they significantly violate inclusion or 
exclusion criteria, significantly violate the protocol in a way that may influence the PK analysis, if 
any unexpected error occurs during the study that may influence the PK analysis (e.g., early 
detachment of transdermal systems, apparent sample switching, etc.) or if their data are unavailable 
or incomplete.  The PAS will be used for the analysis with model based approach.  Excluded cases 
will be documented together with the reason for exclusion. 
Statistical Analyses: 
 Primary Efficacy Analysis:  The primary efficacy endpoint of this trial is the change from Baseline to 
Week 6 in the PANSS total score by dose; the primary analysis set is the FAS.  The comparisons of 
interest are: 
o HP-3070 9.0 mg versus placebo 
o HP-3070 18.0 mg versus placebo 
The p-values for the comparisons are adjusted for multiple comparisons using Hochberg procedure.  
The primary efficacy variable, change from Baseline to Week 6 in the PANSS total score for each of 
the 3 treatment arms, will be analyzed using a mixed model repeated measures (MMRM) analysis.  
The MMRM model will include change from Baseline in PANSS total score as the repeated 
dependent variable, with country, treatment (HP-3070-9.0 [9.0 mg], HP-3070-18.0 [18.0 mg], and 
placebo), visit, treatment by visit interaction, and the Baseline PANSS total score as covariates.  An 
unstructured covariance matrix will be assumed.  The MMRM model may be repeated on additional 
analysis sets as a sensitivity analysis.  If normality assumption is violated, ANCOVA analysis on 
rank-transformed data will be used as a supportive analysis.  
 Key Secondary Analysis: The key secondary endpoint is CGI-S.. If either or both doses are positive 
in the primary efficacy analysis, analysis for the key secondary efficacy endpoint will be carried out 
using Hochberg-based gatekeeping procedure to limit the overall Type I error rate to <0.05. 
In  summary,  
the  Hochberg-based  
tree-gatekeeping procedure  will  be  applied  
to  p-values  from  
the 
mixed models for repeated measurements (MMRM) analysis to control the family-wise Type I error 
rate at 5% by taking into account multiple doses and multiple primary and key secondary endpoints.  
 Additional Analyses of Primary and Key Secondary Endpoints:  Other sensitivity analyses may be 
performed on the primary and key secondary endpoints to assess the robustness of the results based 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
14


Noven Pharmaceuticals, Inc. 
 
14 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
on the model used for primary analysis.  Details will be provided in the Statistical Analysis Plan.  The 
analyses will be performed according to the National Academy of Sciences (2010) guidelines. 
 Analysis  of  Other  Secondary  Efficacy  Endpoints:    Other  secondary  efficacy  endpoints  will  be 
summarized but will not be adjusted as part of the tree-gatekeeping procedure. 
 Analysis of Safety:  All safety summaries will be descriptive; no statistical significance tests will be 
performed on safety data. 
 Analysis of PK:  model based assessment including the population PK following HP-3070 
administration will be evaluated using asenapine concentrations in plasma and relevant endpoints.  
The methodology and results will be described in a standalone PK report. 
Sample Size Calculation: 
Assuming an effect size of 0.35 on the change in PANSS total score from baseline to Week 6 for the 
2 pairwise comparisons between each active HP-3070 treatment arm and placebo, the power for detecting a 
statistically significant HP-3070 advantage will be approximately 0.90 having 204 evaluable subjects per each 
treatment arm using a 2-side alpha level of 0.025 for each comparison.  A 2-sided overall Type I error is equal 
to 0.05.  Having 3 treatment arms, the total number of subjects randomized in the trial and included in the 
primary analysis set will be approximately 612.  A sufficient number of subjects will be screened to randomize 
the proposed sample size. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
15


Noven Pharmaceuticals, Inc. 
 
15 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
 
TABLE OF CONTENTS 
SIGNATURES .............................................................................................................................. 
3 
1.0 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ......................... 
20 
2.0 
INTRODUCTION ......................................................................................................... 
23 
2.1 
Background Information ................................................................................. 
23 
2.2 
Rationale ............................................................................................................. 
26 
2.3 
Hypothesis........................................................................................................... 
26 
2.4 
Risk Assessment ................................................................................................. 
27 
2.5 
Study Compliance ............................................................................................. 
27 
3.0 
STUDY OBJECTIVES ................................................................................................. 
28 
3.1 
Primary Objective ............................................................................................. 
28 
3.2 
Secondary Objectives ........................................................................................ 
28 
3.3 
Safety Objectives ............................................................................................... 
28 
3.4 
Exploratory Objective ...................................................................................... 
28 
4.0 
INVESTIGATIONAL PLAN....................................................................................... 
29 
4.1 
Summary of Study Design................................................................................ 
29 
4.1.1 Screening/Run-in Period ...................................................................... 
30 
4.1.2 Double-blind Treatment Period ........................................................... 
30 
4.1.3 Follow-up Period .................................................................................. 
30 
4.2 
Discussion of Study Design .............................................................................. 
34 
4.3 
Selection of Study Population .......................................................................... 
35 
4.3.1 Inclusion Criteria 
.................................................................................. 
35 
4.3.2 Exclusion Criteria ................................................................................. 
37 
4.3.3 Subject Withdrawal .............................................................................. 
40 
5.0 
STUDY TREATMENTS .............................................................................................. 
41 
5.1 
Treatments Administered ................................................................................ 
42 
5.2 
Identity of Investigational Product 
................................................................. 
42 
5.3 
Packaging, Labelling and Storage .................................................................. 
42 
5.4 
Study Drug Accountability .............................................................................. 
42 
5.5 
Method of Assigning Subjects to Treatment ................................................. 
43 
5.6 
Selection of Doses in the Study ........................................................................ 
43 
5.7 
Dosing of Subjects ............................................................................................. 
45 
5.8 
Treatment Interruptions or Modifications.................................................... 
46 
5.9 
Blinding ............................................................................................................... 
46 
5.10 Prior and Concomitant Treatments ............................................................... 
46 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
16


Noven Pharmaceuticals, Inc. 
 
16 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
 
5.10.1 Medications Prohibited during the Study ........................................... 
47 
5.10.2 Permitted Medications ......................................................................... 
47 
5.10.3 Concomitant Medication Cautions ...................................................... 
48 
5.10.4 Other Restrictions ................................................................................. 
49 
5.11 Medical Care of Subjects after End of Study ............................................... 
49 
5.12 Treatment Compliance ..................................................................................... 
49 
6.0 
EFFICACY, SAFETY, AND PHARMACOKINETIC 
ASSESSMENTS ............................................................................................................. 
49 
6.1 
Efficacy ................................................................................................................ 
49 
6.1.1 M.I.N.I. International Neuropsychiatric Interview (MINI) ............... 
50 
6.1.2 Positive and Negative Syndrome Scale (PANSS).............................. 
50 
6.1.3 Secondary Efficacy............................................................................... 
50 
6.1.3.1 Clinical Global Impression - Severity of 
Illness Scale (CGI-S) 
......................................................... 
50 
6.1.3.2 Clinical Global Impression - Improvement 
Scale (CGI-I) 
...................................................................... 
51 
6.1.3.3 Calgary Depression Scale for Schizophrenia 
(CDSS) ............................................................................... 
51 
6.1.3.4 Medication Satisfaction Questionnaire (MSQ)................ 
51 
6.2 
Safety ................................................................................................................... 
51 
6.2.1 Adverse Events and Serious Adverse Events ..................................... 
51 
6.2.1.1 Adverse Events .................................................................. 
51 
6.2.1.2 Serious Adverse Events ..................................................... 
52 
6.2.1.3 Categorization of Adverse Events .................................... 
53 
6.2.1.4 Reporting of Adverse Events ............................................ 
55 
6.2.1.5 Reporting of Serious Adverse Events............................... 
55 
6.2.1.6 Follow-up of Adverse Events ........................................... 
56 
6.2.1.7 Pregnancy and Contraception ........................................... 
56 
6.2.2 Clinical Laboratory Evaluations .......................................................... 
57 
6.2.2.1 Clinical Laboratory Assessments ..................................... 
57 
6.2.2.2 Monitoring of Selected Laboratory Values ...................... 
59 
6.2.3 Vital Signs, Physical Findings and Other Safety 
Assessments .......................................................................................... 
60 
6.2.4 Evaluation of Extrapyramidal Symptoms (EPS) ................................ 
60 
6.2.4.1 Simpson Angus Scale (SAS)............................................. 
60 
6.2.4.2 Abnormal Involuntary Movement Scale 
(AIMS) ............................................................................... 
61 
6.2.4.3 Barnes Akathisia Rating Scale (BARS) ........................... 
61 
6.2.5 Suicidality: Columbia-Suicide Severity Rating Scale 
(C-SSRS)............................................................................................... 
62 
6.2.6 Evaluations of Patch and Dermal Assessments .................................. 
62 
6.3 
Pharmacokinetics .............................................................................................. 
64 
6.3.1 Pharmacokinetic Blood Sampling ....................................................... 
64 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
17


Noven Pharmaceuticals, Inc. 
 
17 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
 
6.3.2 Drug Concentration Measurements ..................................................... 
65 
6.4 
Appropriateness of Measurements ................................................................. 
65 
7.0 
QUALITY CONTROL AND QUALITY ASSURANCE ........................................ 
65 
7.1 
Monitoring .......................................................................................................... 
66 
7.2 
Data Management/Coding ............................................................................... 
66 
7.3 
Quality Assurance Audit .................................................................................. 
67 
8.0 
STATISTICAL METHODS ........................................................................................ 
68 
8.1 
Determination of Sample Size ......................................................................... 
68 
8.2 
Sample Size Recalculation ............................................................................... 
68 
8.2.1 Procedures for Sample Size Recalculation ......................................... 
68 
8.3 
Study Endpoints ................................................................................................ 
69 
8.3.1 Primary Analyses Endpoint ................................................................. 
69 
8.3.2 Key Secondary Analysis Endpoint ...................................................... 
69 
8.3.3 Other Secondary Analyses Endpoints ................................................. 
69 
8.3.4 Exploratory Endpoint ........................................................................... 
69 
8.4 
Statistical Methods ............................................................................................ 
70 
8.4.1 Analysis Populations ............................................................................ 
70 
8.4.2 Primary Efficacy Analysis ................................................................... 
71 
8.4.3 Key Secondary Efficacy Analysis ....................................................... 
71 
8.4.4 Other Secondary Efficacy Analyses.................................................... 
72 
8.4.5 Subgroup Analyses ............................................................................... 
72 
8.4.6 Safety Analyses .................................................................................... 
72 
8.4.7 Data to be Analyzed ............................................................................. 
73 
8.4.8 Missing Data ......................................................................................... 
73 
8.5 
Subject Disposition and Characteristics 
........................................................ 
73 
8.6 
Safety ................................................................................................................... 
73 
8.6.1 Adverse Events ..................................................................................... 
74 
8.6.2 Clinical Laboratory Evaluations .......................................................... 
74 
8.6.3 Vital Signs Measurements, Physical Findings and Other 
Safety Evaluations ................................................................................ 
74 
8.6.4 Dermal Evaluations .............................................................................. 
74 
8.7 
Pharmacokinetic Analyses ............................................................................... 
74 
8.8 
Interim Analyses 
................................................................................................ 
74 
9.0 
ETHICS ........................................................................................................................... 
75 
9.1 
Institutional Review Board or Independent Ethics Committee 
................. 
75 
9.2 
Ethical Conduct of the Study........................................................................... 
75 
9.3 
Subject Information and Informed Consent ................................................. 
75 
9.4 
Study Administration ....................................................................................... 
76 
9.5 
Administrative Structure ................................................................................. 
76 
9.6 
Data Handling and Record Keeping .............................................................. 
77 
9.7 
Direct Access to Source Data/Documents ...................................................... 
78 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
18


Noven Pharmaceuticals, Inc. 
 
18 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
 
9.8 
Investigator Information .................................................................................. 
78 
9.8.1 Investigator Obligations 
....................................................................... 
78 
9.8.2 Protocol Signatures .............................................................................. 
78 
9.8.3 Publication Policy................................................................................. 
78 
9.9 
Financing and Insurance .................................................................................. 
79 
10.0 REFERENCES ............................................................................................................... 
80 
11.0 APPENDIX 1: SIGNATURE OF INVESTIGATOR............................................... 
82 
12.0 APPENDIX 2: POSITIVE AND NEGATIVE SYNDROME SCALE 
(PANSS) 
........................................................................................................................... 
83 
13.0 APPENDIX 3: CLINICAL GLOBAL IMPRESSION - SEVERITY 
OF ILLNESS SCALE (CGI-S) 
.................................................................................. 
121 
14.0 APPENDIX 4: CLINICAL GLOBAL IMPRESSION - 
IMPROVEMENT SCALE (CGI-I) 
.......................................................................... 
123 
15.0 APPENDIX 5: CALGARY DEPRESSION SCALE FOR 
SCHIZOPHRENIA (CDSS) ....................................................................................... 
125 
16.0 APPENDIX 6: MEDICATION SATISFACTION QUESTIONNAIRE 
(MSQ) ............................................................................................................................ 
127 
17.0 APPENDIX 7: SIMPSON ANGUS SCALE (SAS)................................................. 
129 
18.0 APPENDIX 8: ABNORMAL INVOLUNTARY MOVEMENT 
SCALE (AIMS) ............................................................................................................ 
136 
19.0 APPENDIX 9: BARNES AKATHISIA RATING SCALE (BARS) .................... 
141 
20.0 APPENDIX 10: COLUMBIA-SUICIDE SEVERITY RATING 
SCALE (C-SSRS) ......................................................................................................... 
144 
21.0 APPENDIX 11: M.I.N.I. INTERNATIONAL 
NEUROPSYCHIATRIC INTERVIEW (MINI) ..................................................... 
151 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
19


Noven Pharmaceuticals, Inc. 
 
19 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
LIST OF TABLES 
Table 1 
Schedule of Events 
...........................................................................................31 
Table 2 
Investigational Products 
...................................................................................42 
Table 3 
Steady-State Pharmacokinetics of HP-3070 Transdermal Patch 
.....................44
 
Table 4 
Prohibited/Restricted Medications and Washout Prior to Baseline 
.................47 
Table 5 
Medications Permitted for Specific Conditions 
...............................................48 
Table 6 
Other Restrictions 
............................................................................................49 
Table 7 
Clinical Laboratory Tests 
.................................................................................58 
Table 8 
Skin Irritation Descriptors................................................................................63 
Table 9 
Adhesive Residue Scale 
...................................................................................64 
Table 10 
Administrative Structure 
..................................................................................77 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
20


Noven Pharmaceuticals, Inc. 
 
20 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
1.0 LIST OF ABBREVIATIONS AND DEFINITIONS OF 
TERMS 
Abbreviation  
Definition 
AE 
Adverse event 
AIDS 
Acquired immunodeficiency syndrome 
AIMS 
Abnormal Involuntary Movement Scale 
ALP 
Alkaline phosphatase 
ALT 
Alanine transaminase 
ANCOVA 
Analysis of covariance 
AR(1) 
Autoregressive (1) 
ARH(1) 
Heterogeneous autoregressive (1) 
AST 
Aspartate transaminase 
AUC 
Area under the concentration time curve 
BARS 
Barnes Akathisia Rating Scale 
BID 
Twice daily 
BUN 
Blood urea nitrogen 
CDSS 
Calgary Depression Scale for Schizophrenia 
CGI-I 
Clinical Global Impression - Improvement scale 
CGI-S 
Clinical Global Impression - Severity of Illness scale 
CI 
Confidence interval 
CPK 
Creatine phosphokinase 
Cmax 
Maximum plasma concentration 
CRA 
Clinical Research Associate 
CRO 
Contract Research Organization 
CS 
Compound symmetry 
CSH 
Heterogeneous compound symmetry 
C-SSRS 
Columbia-Suicide Severity Rating Scale 
DBP 
Diastolic blood pressure 
DSM-5 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
21


Noven Pharmaceuticals, Inc. 
 
21 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
ECT 
Electroconvulsive therapy 
EDC 
Electronic data capture 
EPS 
Extrapyramidal symptoms 
ET 
Early termination 
EU 
European Union 
FA0 
No Diagonal Factor Analytic 
FAS 
Full Analysis Set 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GGT 
Gamma glutamyl transaminase 
HbA1c 
Hemoglobin A1c 
HBAg 
Hepatitis B antigen 
HCV 
Hepatitis C 
HDL 
High-density lipoprotein 
HIV 
Human Immunodeficiency Virus 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
ITT 
Intent-To-treat 
IUD 
Intrauterine device 
IVRS 
Interactive Voice-Activated Response System 
IWRS 
Interactive Web-based Response System 
LDH 
Lactate dehydrogenase 
LDL 
Low-density lipoprotein 
LOCF 
Last Observation Carried Forward   
MAR 
Missing at random 
MCAR 
Missing completely at random 
MedDRA 
Medical Dictionary for Regulatory Activities 
MINI 
Mini International Neuropsychiatric Interview 
MMRM 
Mixed Model Repeated Measures 
MNAR 
Missing not at random 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
22


Noven Pharmaceuticals, Inc. 
 
22 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
MSQ 
Medication Satisfaction Questionnaire 
PANSS 
Positive and Negative Syndrome Scale 
PK 
Pharmacokinetic 
prn 
as needed 
QTcF 
QT interval corrected by Friderica’s formula 
RBC 
Red blood cell 
SAE 
Serious Adverse Event 
SAF 
Safety Analysis Set 
SAP 
Statistical Analysis Plan 
SAS 
Simpson Angus Scale 
SBP 
Systolic blood pressure 
SD 
Standard deviation 
SL 
Sublingual 
SOC 
Standard of care 
SOP 
Standard Operating Procedures 
SSR 
Sample size recalculation 
SUSARs 
Serious Unexpected Adverse Event Reactions 
t
1/2 
Elimination half life 
TEAE 
Treatment-Emergent Adverse Event 
TMS 
Transcranial magnetic stimulation 
TOEPH 
Heterogeneous Toeplitz structure 
TSH 
Thyroid-stimulating hormone 
ULN 
Upper limit of normal 
US 
United States 
VNS 
Vagal nerve stimulation 
WBC 
White blood cell 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
23


Noven Pharmaceuticals, Inc. 
 
23 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
2.0 INTRODUCTION 
2.1 Background Information 
Schizophrenia is a serious and chronic disabling disorder that affects approximately 1% of 
the world’s population.
1  It is characterized by positive symptoms (e.g., delusions, 
hallucinations, and disorganized speech), negative symptoms (e.g., affective flattening, 
alogia, avolition, and anhedonia social withdrawal), cognitive deficits, including attention, 
memory, and learning dysfunction.  Further, anxiety and depression are prominent features of 
schizophrenia.  These symptoms result in marked personal, familial, social, and occupational 
dysfunction.  These subjects are also at an increased risk of suicide, require extensive 
healthcare resource utilization, and have a poor prognosis.  The onset of the disorder occurs 
relatively early in life (adolescence to early adulthood).  Most schizophrenia patients have 
recurrent exacerbations of the positive symptoms and persistent negative and cognitive 
symptoms.  Schizophrenia patients require lifetime disease management and treatment. 
Asenapine is a second-generation antipsychotic agent, and the sublingual dosage form is 
marketed under the trade name of SAPHRIS® in the United States (US) and Sycrest
® in the 
European Union (EU).  Asenapine is a potent multireceptor antagonist with a high affinity 
for several serotonin, dopamine, noradrenaline, and histamine receptors.  In the United 
States, asenapine is indicated for the treatment of schizophrenia as well as for the acute 
treatment (as monotherapy or adjunctive therapy) of manic or mixed episodes associated with 
bipolar disorder.  In the EU it is approved for the treatment of moderate to severe manic 
episodes associated with bipolar I disorder in adults. 
Sublingual (SL) asenapine has to be administered twice daily.  The SL tablet should be 
placed under the tongue and left to dissolve completely and patients are advised to avoid 
eating or drinking for 10 minutes after administration. 
Asenapine can cause dysgeusia (distorted, altered, or unpleasant taste) or oral hypoesthesia 
(numbness) due to its local anesthetic effect and the oral hypoesthesia usually resolves within 
1 hour after dosing.  Across the 6-week schizophrenia trials and the 52-week schizophrenia 
trial with sublingual asenapine 5 or 10 mg administered twice daily, the rate of 
discontinuation due to oral hypoesthesia was 0.27%.  However, in a study that examined the 
effect of absorption site on the pharmacokinetics (PK) of asenapine in healthy male subjects, 
reported rates of oral paresthesias were 75.8%, 55.9%, and 45.7% for the SL, supralingual, 
and buccal absorption sites, respectively. 
Application site reactions, primarily in the SL area, have been reported during post-approval 
use of sublingual asenapine.  These application site reactions included oral ulcers, blisters, 
peeling/sloughing, and inflammation.  In many cases, the occurrence of these application site 
reactions led to discontinuation of therapy. 
Noven has developed HP-3070 (asenapine maleate transdermal drug delivery system), a 
transdermal patch which will be dosed once daily.  The transdermal route of application will 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
24


Noven Pharmaceuticals, Inc. 
 
24 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
provide the patients with another treatment option that may have certain advantages over the 
sublingual (SL) formulation of asenapine, such as: 
 HP-3070 patch will mitigate oral hypoesthesia and/or dysgeusia that is commonly 
observed with SL asenapine; 
 HP-3070 patch may have less variability in asenapine absorption and a more gradual 
increase in plasma concentration compared to the SL route of administration; 
 HP3070 patch may potentially have  improved tolerability over the current SL route 
of administration for SAPHRIS®; because it has better PK characteristics; 
 HP-3070 patch may provide a means for physicians and caregivers to visually check a 
patient’s treatment compliance ; 
 HP-3070 patch has no restrictions related to eating and drinking 
In pre-clinical studies, HP-3070 transdermal patch has shown transdermal absorbability and 
dermal tolerability. 
To date, Noven has conducted a total of 4 Phase 1 clinical studies; 3 PK studies (HP-3070-
US-01, HP-3070-US-02 and HP-3070-US-03) in healthy volunteers and 1 PK study (HP-
3070-US-02b) in patients diagnosed with schizophrenia.  From these PK studies, it can be 
concluded that HP-3070 transdermal patch delivers steady plasma levels throughout the 24-
hour application period with low variability and has reproducible PK metrics across all 
studies. 
HP-3070 was first administered to healthy volunteers in HP-3070-US-01, the first-in-human 
patch application study designed to evaluate the single-dose PK, safety, and tolerability of 
the transdermal patch system HP-3070 compared with SL asenapine.  Eighteen healthy adults 
completed the study. 
After a single SL administration of Sycrest®, asenapine concentrations rose rapidly and 
exhibited single peak profiles, whereas following transdermal patch application, asenapine 
concentrations rose gradually and remained relatively constant over the dosing interval.  
A plateau in the plasma concentration was reached from 12 hours after patch application until 
removal of the patch 24 hours after patch application. 
The mean maximum plasma concentration (Cmax) following SL administration of 5 mg of 
Sycrest® was considerably higher than that attained with 3.6-mg and 4.8-mg patches and was 
attained much sooner.  The lower and more gradual progression to C
max observed with the 
transdermal patches has the potential to reduce the incidence of adverse events (AEs) in the 
immediate post dosing period.  Mean asenapine exposure area under the concentration curve 
(AUC
0-t) following use of the 4.8-mg transdermal patch was slightly higher than after the 
administration of the 5-mg SL tablet.  When the patch was removed, the plasma 
concentration of asenapine and its metabolite, desmethyl-asenapine, decreased at a rate 
similar to that seen after SL dosing (elimination half-life [t
1/2] of ~23 hours). 
HP-3070-US-02 was designed to evaluate the PK profile, dose proportionality, safety, and 
tolerability of HP-3070.  Part 1 evaluated single doses of 9.0 mg, 13.5 mg, and 18.0 mg in 
24 healthy volunteers.  The patch doses (sizes) were chosen based on the results obtained in 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
25


Noven Pharmaceuticals, Inc. 
 
25 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
HP-3070-US-01.  In Part 2, healthy volunteers received 9-mg patches applied for 24-hours 
daily for 7 days. 
Single application of a 13.5-mg patch and multiple applications of a 9.0-mg patch resulted in 
a total of 115 AEs.  As a result, the 18.0-mg dose was not administered due to the 
unfavorable tolerability profile of 13.5 mg in healthy volunteers.  Further, only 3 subjects 
among the 11 subjects who started multiple applications of the 9-mg patch completed the 
7-day multiple applications.  No deaths or other serious adverse events (SAEs) occurred 
during this study.  As healthy volunteers were not able to tolerate higher doses and multiple 
doses of HP-3070, this study in healthy volunteers (HP-3070-US-02) was stopped early and a 
multiple dose PK study (HP-3070-US-02b) was conducted in patients diagnosed with 
schizophrenia. 
The statistical analysis of relative exposure for both asenapine and desmethyl-asenapine were 
within the 80% to 125% limits for both dose-normalized Cmax and AUC, confirming the 
dose-proportionality between the 9.0-mg and the 13.5-mg HP-3070 patches.  These similar 
desmethyl-asenapine/asenapine ratios and the percentage of the drug released between 
9.0 mg and 13.5 mg HP-3070 patches corresponded well to the dose-proportionality results 
for C
max and AUC. 
HP-3070-US-02b was an open-label, non-randomized, multiple-ascending dose study 
designed to evaluate the PK of asenapine and dopamine D2 receptor occupancy relative to 
steady state plasma levels in subjects with schizophrenia treated with HP-3070 patches 
(4.5 mg, 9.0 mg, 13.5 mg, and 18.0 mg) for 7 days. 
Plasma asenapine concentrations following multiple ascending doses 4.5 mg, 9.0 mg, 
13.5 mg, and 18.0 mg of HP-3070 patches increased with increasing dose.  The estimated 
slopes for the steady state C
max, C
min, and AUC
0-24 following multiple ascending doses of 
HP-3070 patches fell within the pre-defined criteria, confirming the dose-proportionality 
between 4.5 mg and 18.0 mg of HP-3070 patches.  These similar desmethyl- 
asenapine/asenapine ratios and percentage of drug released among all 4 dosages 
corresponded well to the dose-proportionality results.  Plasma asenapine concentration 
reached the steady state at around 72 hours after the first patch and showed sustained plasma 
concentrations at steady state. 
The D2/D
3 receptor occupancy in the caudate and putamen regions were increased between 
the doses of 4.5 and 9.0 mg followed by an observed plateau between the 9.0-mg and 
18.0-mg doses, with maximum occupancy of around 60% when 11C-PHNO was used as a 
radiolabeled ligand.  Receptor occupancy observed in this study is comparable to that 
obtained with other antipsychotics such as risperidone and olanzapine (at clinical dose) as 
measured with 11C-PHNO.
2 
Treatment with multiple doses of the HP-3070 patch for a total of 28 days was safe and well 
tolerated in patients with schizophrenia.  A total of 33 treatment-emergent adverse events 
(TEAEs) were observed in this study.  The most frequently reported TEAEs were 
somnolence (6 events), dizziness (4 events), and headache (3 events).  There were no deaths 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
26


Noven Pharmaceuticals, Inc. 
 
26 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
or SAEs reported during the study.  No subjects were discontinued during the study due to 
AEs. 
HP-3070-US-03 was designed to examine the PK, safety, tolerability, adhesion and irritation 
potential of the 9.0-mg HP-3070 transdermal patch at 5 different application sites (upper arm, 
upper chest, upper back, abdomen, and hip area) in healthy Japanese (n = 20) and Caucasian 
(n = 20) subjects. 
All PK parameters assessed were similar among the 5 different application sites and 
asenapine exposure, measured as C
max and AUC, from all tested application sites (upper 
chest, upper back, abdomen, and hip area) was bioequivalent to that of the upper arm 
(reference application site) with the exception of C
max for the abdomen compared with the 
upper arm for which the lower boundary was slightly out of criteria.  The results of this study 
suggest that the 5 application sites evaluated in this study (abdomen, hip area, upper arm, 
upper back, and upper chest) can be used as application sites for the HP-3070 transdermal 
patch. 
Following 24-hour HP-3070 patch applications, no marked ethnic differences between 
Caucasian and Japanese subjects were found for all PK parameters assessed for both 
asenapine and desmethyl-asenapine. 
Treatment with the 9-mg patch applied for 24 hours was safe and well tolerated in healthy 
male and female Caucasian and Japanese subjects.  There were no deaths or SAEs reported 
during the study.  No subjects were discontinued during the study due to AEs.  The most 
frequently reported TEAEs were somnolence (25 events), insomnia (10 events), nausea (8 
events), fatigue (7 events), headache (6 events), influenza-like illness (6 events), irregular 
menstruation (5 events), and dizziness (4 events).  No difference in patch adhesion was seen 
between Caucasian and Japanese subjects and between the application sites of upper back, 
abdomen, upper chest, hip area, and upper arm. 
In all of the PK studies completed to date, adhesion of HP-3070 transdermal patch was good 
and treatment with HP-3070 transdermal patches was safe and well tolerated.  There were no 
difficulties associated with patch application and skin irritation and discomfort scores suggest 
good dermal tolerability of the transdermal patches. 
2.2 Rationale 
This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo 
transdermal patch in subjects diagnosed with schizophrenia, who are in an acute exacerbation 
and to assess the impacts of covariates on asenapine exposure as delivered in a patch 
formulation, using a population-based approach. 
2.3 Hypothesis 
The null hypothesis of the primary endpoint is that there is no difference between treatment 
arms in the change from Baseline in Positive and Negative Syndrome Scale (PANSS) total 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
27


Noven Pharmaceuticals, Inc. 
 
27 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
score at Week 6.  The alternative hypothesis is that the treatment arms differ in the change 
from Baseline in PANSS total score at Week 6. 
2.4 Risk Assessment 
Potential risks associated with participation in this study have been identified through the 
review of information available from marketed formulations containing asenapine 
(SAPHRIS
® and Sycrest
®).  These products have been marketed since 2009 and the safety 
profile of asenapine is well-established. 
The most common AE associated with SAPHRIS® and Sycrest
® have been anxiety and 
somnolence.  Less common AEs include nervous system disorders (as dystonia, akathisia, 
sedation, dizziness, and dyskinesia), oral hypoesthesia, muscle rigidity, and fatigue.  
Increases in liver transaminases have been reported, as well as increased appetite and weight 
increase.  The SAEs known to be associated with antipsychotics include tardive dyskinesia, 
suicidality, and neuroleptic malignant syndrome.  Other risks associated with this drug class 
include orthostatic hypotension, syncope, weight gain, metabolic imbalance, neutropenia, and 
allergic reactions.  More details are presented in the Investigator Brochure. 
The risks specific to the HP-3070 patch (as opposed to the molecule [asenapine] itself) are 
limited to potential dermal reactions to the patch.  A potential risk of the study is treatment 
failure (particularly in the placebo control group), which may result in worsening symptoms.  
Hospitalization of the subjects for the entire duration of the study will enable close 
observation of the subjects whereby the risk of treatment failure as well as potential dermal 
reactions can be addressed in real-time.  The subjects will be under observation and they will 
be monitored for changes in extrapyramidal symptoms (EPS) scores, electrocardiograms 
(ECGs), laboratory values, vital signs, and physical examination.  Psychotropic medications 
which can be used concomitantly to manage the patient’s symptoms are discussed in 
Section 5.10. 
2.5 Study Compliance 
This study will be performed in compliance with the protocol, International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and applicable regulatory 
requirements. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
28


Noven Pharmaceuticals, Inc. 
 
28 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
3.0 STUDY OBJECTIVES  
3.1 Primary Objective  
The primary objective of the study is to evaluate efficacy of HP-3070 compared with placebo 
for the treatment of schizophrenia as evaluated by PANSS total score. 
3.2 Secondary Objectives 
 Key Secondary Efficacy Objective: 
o Clinical Global Impression – Severity of Illness Scale (CGI-S) 
 Other Secondary Efficacy Objectives:  To evaluate the efficacy of HP-3070 using the 
following measures: 
o PANSS total score at each time point 
o Clinical Global Impression – Severity of Illness Scale (CGI-S) at each time 
point 
o Clinical Global Impression – Improvement Scale (CGI-I) at each time point 
o Proportion of CGI-I responders at each time point including Week6; CGI-I 
responders are defined as subjects who have a score of 1 (very much 
improved) or a score of 2 (much improved). 
o Positive, negative, and general pathology subscores of PANSS 
o Proportion of PANSS responders; PANSS responders are defined as subjects  
who have a  ≥30% reduction in PANSS total score between Baseline and at 
each time point including Week 6 
o Calgary Depression Scale for Schizophrenia (CDSS) 
o Medication Satisfaction Questionnaire (MSQ) score 
3.3 Safety Objectives 
 AEs, including TEAEs, AEs leading to discontinuation from the study drug, SAEs, 
and deaths 
 Change from Baseline in clinical laboratory results (including prolactin, fasting 
glucose, and lipids), ECG results, body weight and vital signs 
 Results of C-SSRS, BARS, AIMS, and SAS  
 Dermal Safety 
3.4 Exploratory Objective 
To assess the impact of covariates on asenapine exposure using a model-based approach and 
to explore the exposure-response relationship with relevant endpoints. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
29


Noven Pharmaceuticals, Inc. 
 
29 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
4.0 INVESTIGATIONAL PLAN 
4.1 Summary of Study Design 
This is a Phase 3, randomized, double-blind, placebo-controlled, in-patient, safety, and 
efficacy study to evaluate HP-3070 for the treatment of schizophrenia. 
This study will enroll subjects who are in an acute exacerbation (i.e., have had an acute 
episode no longer than 8 weeks prior to the Screening Visit), have a PANSS total score 
≥80 with scores of 4 or higher on at least 2 out of the 4 pre-defined PANSS positive subscale 
items, and have a CGI-S ≥4.  Subjects will be hospitalized at the Screening Visit and will 
remain hospitalized during the study.  The subject may leave the hospital for necessary 
personal business.  During this time, the subject must be supervised by study staff or a 
responsible caretaker.  Any subject who leaves the site must have an alcohol breathalyzer and 
urine drug and pregnancy tests when they return to the site.  Investigator should contact 
Medical Advisor to discuss specifics of subject off-site overnight travel to confirm 
appropriateness. 
This study will consist of a Screening/placebo Run-in Period of 3 to 14 days (described in 
Section 4.1.1), a 6-week double-blind Treatment Period (described in Section 4.1.2) and a 
30 day Follow-up Period (described in Section 4.1.3). 
The study will evaluate 9.0 mg (HP-3070-9.0) and 18.0 mg (HP-3070-18.0) of HP-3070 
transdermal patches versus placebo transdermal patches.  Patches will be applied by site 
personnel at approximately the same time daily and each patch will be worn for 24 hours.  
Every day, approximately 24 hours after patch application, site personnel will remove 
previous day’s patches and apply new patches.  Patch adhesion will be assessed at specified 
time points. 
In this study, efficacy will be evaluated using widely accepted, standard questionnaires.  
These include the PANSS, CDSS, CGI-S, CGI-I, and MSQ.  Efficacy measures are described 
in Section 6.1.  The methods used for the analysis of efficacy data are presented in 
Section 8.3. 
In addition to standard safety measures (AEs, clinical laboratory assessments, vital signs, 
weight, ECG results), this study will also include assessments of EPS symptoms using the, 
Barnes Akathisia Rating Scale (BARS), Abnormal Involuntary Movement Scale (AIMS), 
and Simpson-Angus Scale (SAS).  Suicidality will be monitored using the Columbia-Suicide 
Severity Rating Scale (C-SSRS).  Dermal safety will be assessed by daily evaluation of 
irritation at the site of patch application and by a review of any dermal reactions reported as 
AEs.  Safety measures are described in Section 6.2. 
The schedule of study procedures and assessments is presented in Table 1. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
30


Noven Pharmaceuticals, Inc. 
 
30 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
4.1.1 
Screening/Run-in Period 
Subjects will be asked to sign the informed consent form (ICF).  No screening procedures 
may begin prior to obtaining informed consent. 
After obtaining informed consent, each subject will be assigned a unique subject number.  
Eligible subjects will be hospitalized for the duration of the study.  While undergoing 
screening procedures, including the MINI, and waiting for results of laboratory tests, ECGs, 
and other assessments, the subject will start treatment with the single-blind placebo patch.  
Subjects will be blinded to the treatment during the Run-in Period.  The subject must have 
the single-blind placebo patch applied for a minimum of 3 days prior to being randomized 
into the double-blind Treatment Period.  In addition, current antipsychotic and other 
prohibited medications will be washed out during the run-in period and must be completed 
prior to randomization into the double-blind treatment period.  Subjects who have a decrease 
in PANSS total score ≥20% from Screening to Baseline or a PANSS total score <80 at 
Screening or Baseline will be discontinued from the study and will not enter the double-blind 
Treatment Period.  Subjects who are not compliant with wearing the run-in patches will also 
be discontinued from the study.  Subjects who are screened but discontinued before 
randomization will be considered screen failures. 
Rescreening of subjects will be considered on a case-by-case basis and must be approved by 
the medical monitor. 
4.1.2 
Double-blind Treatment Period 
Eligible subjects will be randomized at Baseline (Day 0) and randomly assigned to HP-3070 
(9.0 mg or 18.0 mg) or placebo in a 1:1:1 ratio.  Subjects will receive treatment with study 
medication daily starting on Day 1 and up to Day 42 for a total of 6 weeks. 
Efficacy and safety data will be collected in accordance with the Schedule of Events. 
Blood samples will be collected at pre-determined time points and analyzed for asenapine 
and desmethyl asenapine concentrations. 
At discharge (Week 6 or early termination [ET]), the subject will be prescribed an approved 
antipsychotic treatment and returned to the care of their physician. 
4.1.3 
Follow-up Period 
All subjects will have a follow-up contact (site visit or telephone call, at the discretion of the 
Investigator) 30 days after the last patch is removed.  This contact will be used to collect 
information about any AEs or SAEs that may have occurred since discharge and to follow-up 
on any AE that was on-going at discharge. 
The Schedule of Events is presented in Table 1. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
31


Noven Pharmaceuticals, Inc.  
 
 
31 
HP-3070-GL-04 
HP-3070 
 
 
 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
    
  
Confidential 
Table 1  
Schedule of Events 
Study Period 
Screening/ 
Single-blind 
Placebo Run-
In Period [a] 
Double-Blind Treatment Period 
Safety 
Follow-up Visit or
Telephone Call [b] 
Week/Day 
3 to 14 days Baseline
Day 0 [c]
Day 7/ 
Wk 1 
Day 14/ 
Wk 2 
Day 21/  
Wk 3  
Day 28/ 
Wk 4 
Day 35/ 
Wk 5 
Day 42/  
Wk 6 or ET
30 days after 
removal of last patch
Visits 
1  
2  
3  
4  
5  
6  
7  
8 
8 
Informed consent 
X   
  
  
  
  
  
  
 
 
Pre-randomization form 
X 
  
  
  
  
  
  
 
 
Assign subject number from IWRS  
X 
  
  
  
  
  
  
 
 
Inclusion/exclusion criteria 
X  
X  
  
  
  
  
  
 
 
Demographics 
X 
  
  
  
  
  
  
 
 
Physical examination including skin 
examination 
X 
 
 
 
 
 
 
 
 
X 
 
Medical history including 
psychiatric history 
X 
 
 
 
 
 
 
 
 
 
 
MINI [d] 
X 
 
 
 
 
 
 
 
 
 
 
 
PANSS [d] 
X  
X   
X  
X  
X  
X  
X  
X 
 
CDSS [d] 
X  
X  
X  
X  
X  
X  
X  
X 
 
C-SSRS [d] 
X  
X  
X  
X  
X  
X  
X  
X 
 
CGI-S [d] 
X  
X  
X  
X  
X  
X  
X  
X 
 
CGI-I [d] 
 
  
X  
X  
X  
X  
X  
X 
 
AIMS [d] 
X  
X  
X  
X  
X  
X  
X  
X 
 
SAS and BARS [d] 
X  
X  
X  
X  
X  
X  
X  
X 
 
MSQ [d] 
X 
  
  
X  
  
X  
  
X 
 
Vital signs [e] 
X  
X  
X  
X  
X  
X  
X  
X 
 
Weight and height [f]  
X  
X  
X  
X  
X  
X  
X  
X 
 
Standard 12-lead ECG [g] 
X  
X  
X  
X  
X  
X  
X  
X 
 
Clinical laboratory testing (fasting)  
X  
X  
  
  
X  
  
  
X 
 
Urine drug screen/blood alcohol [h] 
X 
 
 
 
 
 
 
 
 
 
 
 
Serum/urine pregnancy test [i] 
X  
X  
X  
X  
X  
X  
X  
X 
 
Serology   
(HIV, HBsAg, anti-HCV) [j] 
X 
 
 
 
 
 
 
 
 
 
 
Concomitant therapies 
X  
X  
X  
X  
X  
X  
X  
X 
X 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
32


Noven Pharmaceuticals, Inc. 
 
 
32 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
    
  
Confidential 
 
   
    
  
 
Study Period 
Screening/ 
Single-blind 
Placebo Run-
In Period [a] 
Double-Blind Treatment Period 
Safety 
Follow-up Visit or
Telephone Call [b] 
Week/Day 
3 to 14 days Baseline
Day 0 [c]
Day 7/ 
Wk 1 
Day 14/ 
Wk 2 
Day 21/  
Wk 3  
Day 28/ 
Wk 4 
Day 35/ 
Wk 5 
Day 42/  
Wk 6 or ET
30 days after 
removal of last patch
Visits 
1  
2  
3  
4  
5  
6  
7  
8 
8 
Adverse events 
X  
X  
X  
X  
X  
X  
X  
X 
X 
PK blood samples [k] 
 
  
  
  
X  
  
  
X 
 
Blood sample for prolactin level [l]  
 
X  
  
  
X  
  
  
X 
 
Dispense run-in kit 
X 
  
  
  
  
  
  
 
 
Randomization/ 
assign double-blind kit 
 
 
X 
 
 
 
 
 
 
 
 
Provide subject identification card  
X 
  
  
  
  
  
  
 
 
Dosing with single-blind patch 
(patch application and removal of 
previous patch, if applicable) 
X 
 
 
 
 
 
 
 
 
 
 
Dosing with double-blind patch  
(patch application and removal of 
previous patch, if applicable) 
 
X  
X  
X  
X  
X  
X  
X 
 
Skin Irritation Assessment [m] 
X  
X  
X  
X  
X  
X  
X  
X 
 
Patch Adhesion Assessment [m]  
X   
X  
X  
X  
X  
X  
X  
X 
 
Patch Discomfort Assessment [m]  
X  
X  
X  
X  
X  
X  
X  
X 
 
Adhesive Residue Assessment [m]  
X  
X  
X  
X  
X  
X  
X  
X 
 
Drug accountability 
X  
X  
X  
X  
X  
X  
X  
X 
 
 
AIMS = Abnormal Involuntary Movement Scale; BARS = Barnes Akathisia Rating Scale; CDSS = Calgary Depression Scale for Schizophrenia; CGI-I = Clinical Global 
Impression - Improvement scale; CGI-S = Clinical Global Impression - Severity of Illness scale; C-SSRS = Columbia-Suicide Severity Rating Scale; ECG = electrocardiogram; 
ET = end of treatment; HBsAg = hepatitis B antigen; HCV = hepatitis C virus; HIV = human immunodeficiency virus; IWRS = Interactive Web-Based Response System; 
MINI = Mini International Neuropsychiatric Interview; MSQ = Medication Satisfaction Questionnaire; PANSS = Positive and Negative Syndrome Scale; PK = pharmacokinetics; 
SAS = Simpson Angus Scale; Wk = week 
 
a. The subject must use the single-blind placebo patch for a minimum of 3 days prior to entering the double-blind Treatment Period.  Washout of the subject’s current 
antipsychotic and other prohibited medications must be completed by the end of the Screening/Run-in Period.  Subjects who have a decrease in PANSS total score ≥20% from 
Screening to Baseline or a PANSS total score <80 at Screening or Baseline will be discontinued from the study. 
b. Subjects will have a follow-up contact (site visit or telephone call, at the discretion of the Investigator) 30 days after the last patch is removed. 
c. All baseline assessments and laboratory samples will be performed prior to randomization. 
d. It is suggested that assessment scales should be performed in the order they appear in the Schedule of Events 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
33


Noven Pharmaceuticals, Inc. 
 
 
33 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
    
  
Confidential 
 
   
    
  
 
e. Blood pressures (sitting) and pulse rates should be measured after subject has rested (sitting quietly) for 5 minutes.  In addition, assessments for orthostatic hypotension will 
be performed at each visit.  Blood pressure readings and pulse rate will be obtained after the subject has been supine for 5 minutes.  These will be repeated after the subject 
has been standing up for approximately1 to 3 minutes. 
f. Height will be obtained at Screening, only. 
g. ECG recordings will be obtained after the subject has been supine and at rest for at least 5 minutes. 
h. Urine drug screen and alcohol breathalyzer test should be completed if the subject leaves the study site. 
i. All positive urine pregnancy test results must be confirmed by a serum test.  Subjects with positive urine and serum pregnancy test results at screening must not be enrolled.  
Subjects with positive urine and serum pregnancy test results during the trial must discontinue treatment.  Urine pregnancy test to be repeated if subject leaves the study site. 
j. Subjects with chronic Hepatitis B or C may be included provided that their condition is stable and that values for liver function tests and other laboratory tests results meet the 
criteria specified for entry into the study. 
k. At least 3 blood samples will be collected at 2, 14, and 22 hours after application of the patch with ± 2 hour- window on Day 21 and 42.  Actual blood sampling time will be 
recorded. 
l. The central laboratory will not report prolactin levels to the sites nor the Sponsor, because this could potentially result in unblinding the treatment.  The central laboratory will 
report prolactin levels as “masked” on the laboratory report (see Section 6.2.2.2.3 for more details).
 
m. Patch adhesion will be evaluated throughout the day including at the time points during which the site staff collects routine vital signs as per hospital policy/SOP; and 
immediately prior to removal of previous day’s patch. In addition, subjects will be asked to check patch adhesion throughout the day and report immediately to site personnel 
if the patch detaches completely or detaches partially (i.e., some edges of the patch are lifting off the skin). Irritation at the site of patch application will be assessed each day 
between 30 and 60 minutes after patch removal.  Subjects will be asked to report to the site staff any discomfort or skin irritation due to the patch.  Discomfort and skin 
irritation reported by the subjects will be recorded as AEs.  Patch application site will be assessed weekly for adhesive residue.  
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
34


Noven Pharmaceuticals, Inc. 
 
34 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
4.2 Discussion of Study Design 
This is a Phase 3, multi-center, placebo-controlled, randomized, double-blind, in-patient 
study designed to demonstrate the efficacy and safety of HP-3070 transdermal patches when 
used in subjects diagnosed with schizophrenia. 
A parallel-group design was selected because it is free of the assumptions underlying 
competing designs (for example, crossover).  A parallel group approach is considered the 
optimal study design to evaluate efficacy. 
The use of a randomized double-blind design will minimize bias by randomly assigning the 
subjects to treatment arms, and ensuring that the subjects, the Investigators and site 
personnel, and the Sponsor/designee are blinded to the treatment allocations. 
A placebo control will be used to allow for an unbiased assessment of treatment effects and 
safety data.  The comparison with placebo is justified as this is an in-patient study and 
subjects will be closely monitored and study treatment will be discontinued and the subject 
will be returned to standard of care (SOC) treatment if their mental status deteriorates. 
The study population will include male and female subjects, ≥18 years of age with a 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of 
schizophrenia who are in an acute exacerbation.  These subjects represent an appropriate 
population in which to evaluate the efficacy of the HP-3070 patch. 
The rationale for dose selection is described in Section 5.6. 
The 6-week duration is considered to be sufficient for achieving a steady state condition of 
HP-3070.  This time period is also sufficient to evaluate changes in the primary and 
secondary outcome measures. 
Subjects will be hospitalized throughout the study to ensure proper medical care, and to 
allow for the close monitoring of mental status and any potential negative effects of 
treatment. 
Severity of illness and psychopathology will be measured using the PANSS and CDSS.  
The CGI-S and the CGI-I will be used to confirm clinical relevance of changes in the 
efficacy assessment scales.  The efficacy measurements chosen for this study are standard 
validated instruments and these are commonly used to evaluate efficacy endpoints in subjects 
with schizophrenia who are in an acute exacerbation. 
The primary efficacy endpoint is change from baseline to Week 6 in Positive and Negative 
Syndrome Scale (PANSS) total score. The PANSS scale is a standard validated instrument 
that is a gold standard in acute schizophrenia studies and is an appropriate instrument to 
evaluate efficacy in patients diagnosed with schizophrenia who are in acute exacerbation.   
This instrument is the primary efficacy endpoint that has been used for pivotal trials for 
several products such as SAPHRIS
®, Latuda
®, and Vraylar
®.   
The key secondary endpoint is change from baseline to week 6 in the CGI-S score. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
35


Noven Pharmaceuticals, Inc. 
 
35 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
The Clinical Global Impression – Severity (CGI-S) scale is an accepted, standard efficacy 
rating scale in acute schizophrenia trials. CGI-S is an acceptable key secondary variable: (i) 
based on precedence (SAPHRIS® and other approved antipsychotics); (ii) CGI-S assesses a 
domain of the illness other than that assessed by the primary efficacy variable, therefore, 
there is no redundancy with the primary efficacy variable (PANSS total score). 
While the PANSS is the cornerstone for evaluation of efficacy of antipsychotic drugs in 
patients with schizophrenia who are in an acute exacerbation and is a useful clinical research 
tool, clinical implications of PANSS scores are not very well defined and the PANSS scores 
are not intuitively understood by clinicians; whereas, scores from the Clinical Global 
Impression (CGI) scale are better understood by clinicians and are better translated into 
clinical practice as they inform the clinician of the subject’s overall clinical status.  
The CGI-S is a valid and reliable clinician administered scale and has widespread use in 
psychiatry clinical trials. The CGI-S scale measures the clinician’s global impression of the 
severity of illness at each time point taking into account the reported and observed symptoms 
in the past 7 days.  In the HP-3070-GL-04 study, the CGI-S will be analyzed as change from 
baseline to Week 6. Inclusion of the CGI-S as key secondary endpoint in the HP-3070-GL-04 
will facilitate replication of SAPHRIS® data. 
The safety measures used in this study are standard safety measures which include AEs, 
concomitant therapy, clinical laboratory results, medical history, physical examination, vital 
signs, weight gain and ECGs.  In addition, the AIMS, BARS, and SAS will be used to assess 
EPS.  The C-SSRS will be used to assess suicidality.  The C-SSRS facilitates prospective, 
systematic monitoring for emergence of suicidality within clinical trials and it is a low-
burden, clinician-administered tool that covers the wide spectrum of suicidality from ideation 
to behavior.  Skin irritation and discomfort reported by the subjects will be recorded as AEs.  
Skin irritation and discomfort at the patch application site is an important assessment because 
the condition of the skin may influence the absorption of the drug from the transdermal 
patch. 
This study also includes assessment of patch adhesion and evaluation of amount of adhesive 
residue at the patch application site.  Adhesion of transdermal patch to the skin is a critical 
factor and one of the most important functional properties directly related to drug delivery 
and therapeutic effect.  Patch adhesion must be satisfactory in order for requirement for any 
clinical conclusions to be valid. 
4.3 Selection of Study Population 
The assessment and documentation of the subject’s eligibility is the responsibility of the 
Investigator.  The Sponsor/designee reserves the right to provide final approval of subject 
eligibility. 
4.3.1 
Inclusion Criteria 
Subjects must meet all of the following criteria to be considered eligible to participate in the 
study: 
1. Adult male or female subjects, ≥18 years of age 
2. Subject is able to undergo informed consent process and signs ICF. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
36


Noven Pharmaceuticals, Inc. 
 
36 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
3. Subject has current diagnosis of schizophrenia as per DSM-5 Criteria, Mini 
International Neuropsychiatric Interview (MINI), and as confirmed by Investigator 
assessment. 
4. Subject has PANSS total score ≥80, AND score of 4 or more in at least 2 of the 
following PANSS items at Screening and at Baseline: 
a. Conceptual disorganization 
b. Delusions 
c. Hallucinatory behavior 
d. Unusual thought content 
5. Subject has CGI-S scale score of ≥4 (moderately ill) at Screening and Baseline. 
6. Subject has history of relapse and/or exacerbation of symptoms when they are not 
receiving antipsychotic treatment, excluding the current episode. 
7. Subject is confirmed by the Investigator to be experiencing an acute exacerbation of 
schizophrenia, as evidenced by ALL of the following: 
a. The duration of the current episode is no more than 8 weeks. 
b. The subject’s current symptoms represent a marked and substantial 
exacerbation of schizophrenia compared with the subject’s symptomatic state 
prior to the emergence of the current episode. 
c. A
 corresponding functional deterioration to the symptomatic exacerbation is 
evident. 
8. Subject has not been hospitalized for more than 21 days for the current episode by the 
day of the Screening Visit, not including social hospitalization (e.g., homelessness or 
need for shelter that is unrelated to the subject’s underlying psychiatric condition). 
9. Subject agrees not to begin formal, structured psychotherapy targeting the symptoms 
of schizophrenia from the time of the Screening Visit until the last dose of study drug. 
10. Subject would benefit from hospitalization or continued hospitalization for the 
treatment of schizophrenia (as determined by the Investigator). 
11. Subjects must not be treatment naïve or treatment resistant.  Treatment resistance is 
defined as having little or no symptomatic response to at least 2 courses of 
antipsychotic treatment of an adequate duration (at least 6 weeks) and at a therapeutic 
dose (according to the drug’s package insert). 
12. Subject has had previous positive response to an antipsychotic medication other than 
clozapine in a prior episode. 
13. Subject has a stable living situation and caretaker support when not hospitalized. 
14. Subject is male, or a female who is not of childbearing potential (i.e., surgically 
sterile, postmenopausal for at least 1 year) or who is non-pregnant, non-lactating, and 
is using a medically accepted method of contraception.  Acceptable methods of 
contraception include condoms (male or female) with a spermicidal agent, diaphragm 
or cervical cap with spermicide, medically prescribed intrauterine device (IUD), and 
hormonal contraceptives.  A
 female of child-bearing potential who is not currently 
sexually active must agree to use a medically accepted method of contraception 
should she become sexually active while participating in the study
.  Each sexually 
active female of child-bearing potential must also agree to use a medically accepted 
method of contraception for 1 month after the final dose of study medication. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
37


Noven Pharmaceuticals, Inc. 
 
37 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
15. Subjects must agree that they will not donate sperm or eggs from the time of the 
Screening Visit until 3 months following administration of the last treatment or dose 
of study medication. 
16. Agrees not to use any other transdermal patch products (e.g., nicotine replacement 
patch, hormonal replacement patch, etc.) for the duration of the study. 
17. Subject must be able to wear a transdermal patch for 24 hours. 
4.3.2 
Exclusion Criteria 
The subject will be excluded from the study if any of the following exclusion criteria are 
met: 
1. Subject is presenting with a first episode of schizophrenia based on the clinical 
judgment of the Investigator. 
2. Subject has been diagnosed with schizophrenia less than 6 months prior to Screening 
Visit. 
3. Subject has received electroconvulsive therapy (ECT), transcranial magnetic 
stimulation (TMS), vagal nerve stimulation (VNS), or other brain stimulation 
treatments within 90 days of Screening Visit. 
4. Subject has a current DSM-5 diagnosis other than schizophrenia including (but not 
limited to) schizoaffective disorder, major depressive disorder, bipolar disorder, post-
traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or other 
cognitive disorders. 
5. Subject has a diagnosis of mental retardation, history of traumatic brain injury 
causing ongoing cognitive difficulties, Alzheimer’s Disease or another form of 
dementia (or suspicion thereof), or any chronic organic disease of the central nervous 
system that would interfere with the efficacy or safety endpoints of the study
. 
6. Subject has experienced acute depressive symptoms within 30 days prior to Screening 
Visit that requires treatment with an antidepressant, as determined by the Investigator. 
7. Subject is a known non-responder to previous asenapine treatment, as per Investigator 
judgment. 
8. Subject is currently taking clozapine for the treatment of schizophrenia.  Subjects 
taking low doses of clozapine (up to 100 mg/day) for sedative properties and not 
treatment resistance or suicidality may be acceptable as per Investigator judgment and 
as approved by the Sponsor/designee. 
9. Subject with schizophrenia who is considered resistant/refractory to antipsychotic 
treatment by history or who has a history of failure to respond to clozapine or 
response to clozapine treatment only.  Treatment resistance is defined as having little 
or no symptomatic response to at least 2 courses of antipsychotic treatment of an 
adequate duration (at least 6 weeks) and at a therapeutic dose (according to the drug’s 
package insert). 
10. Subject who is unwilling to discontinue or, in the opinion of the Investigator, unable 
to discontinue any prohibited medication prior to the Baseline Visit without 
significant medical or psychiatric destabilization, or increased suicidality
, as per the 
washout requirements.  Prohibited medications include: 
a. Antipsychotics, including depot or long-acting injectables 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
38


Noven Pharmaceuticals, Inc. 
 
38 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
b. Antidepressants 
c. Mood stabilizers 
d. Stimulants 
e. Non-psychopharmacologic medications with psychotropic properties, per 
Investigator and approved by Sponsor/designee 
f. Herbal drugs/dietary supplements unless approved by Sponsor/designee 
11. Subjects taking drugs (current antipsychotic or other prohibited medication) that 
require >14 days for washout 
12. Subject who is involuntarily committed, incarcerated, or under legal compulsion to 
seek psychiatric treatment. 
13. Subject currently has clinically significant neurological, hepatic, renal, metabolic, 
hematological, immunological, cardiovascular, pulmonary
, or gastrointestinal 
disorders such as any history of myocardial infarction, congestive heart failure, 
human immunodeficiency virus (HIV) seropositive status/acquired immunodeficiency 
syndrome (AIDS).  Medical conditions that are minor or well-controlled may be 
considered acceptable if the condition does not expose the subject to an undue risk of 
a significant AE or interfere with assessments of safety or efficacy during the course 
of the study
.  Subjects with chronic Hepatitis B or C may be included provided that 
their condition is stable and values for liver function tests and other laboratory test 
results meet the criteria specified in the protocol for entry into the study.  The 
Sponsor/designee should be contacted in any instance where the Investigator is 
uncertain regarding the stability of a subject’s medical condition(s) and the potential 
impact of the condition(s) on study participation. 
14. Subject has any other medical condition or laboratory result that, in the opinion of the 
Investigator, may make the subject unsuitable for the study
. 
15. Subjects with the following laboratory test and ECG results are excluded: 
a. Platelets ≤75,000/mm3  
b. Hemoglobin ≤9 g/dL  
c. Neutrophils, absolute ≤1000/mm3  
d. Aspartate transaminase (AST) >2×upper limit of normal (ULN) 
e. Alanine transaminase (ALT) >2×ULN 
f. Creatine phosphokinase (CPK) >3×ULN, unless discussed with and approved 
by the Medical Advisor 
g. Creatinine ≥2 mg/dL or ≥176.8 µmol/L 
h. Hemoglobin A1c (HbA1c) ≥6.5% unless the subject has a diagnosis of stable 
diabetes 
i. QT interval corrected using Fridericia’s formula (QTcF) ≥450 msec (males), 
QTcF ≥470 msec (females) 
j. Prolactin.  The enrollment of subjects with prolactin levels equal or higher 
than 5 X ULN should be discussed with the Medical Advisor 
16. Subject with hypothyroidism or hyperthyroidism (unless condition has been stabilized 
with medications for at least the past 90 days); subjects with abnormal free T4 and 
thyroid stimulating hormone (TSH) levels. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
39


Noven Pharmaceuticals, Inc. 
 
39 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
17. Subject is currently treated with insulin for diabetes.  Subjects being treated for 
diabetes with medications other than insulin are eligible for the study if their 
condition is stable as determined by satisfying ALL of the following criteria: 
a. HbA1c <7.0%, AND 
b. Screening glucose ≤125 mg/dL or ≤6.94 mmol/L (fasting) or <200 mg/dL or 
<11.1 mmol/L (nonfasting).  Note:  If the nonfasting screening glucose is 
≥200 mg/dL or ≥11.1 mmol/L, subjects must be retested in a fasted state and 
the retest value must be ≤125 mg/dL or ≤6.94 mmol/L, AND 
c. Subject has been maintained on a stable regimen of oral anti-diabetic 
medication(s) for at least 28 days prior to Screening or diabetes has been well-
controlled by diet for at least 28 days prior to Screening, AND 
d. Subject has not had any hospitalizations within the 12 months prior to 
Screening due to diabetes or complications related to diabetes, AND 
e. Subject’s diabetes is not newly diagnosed during Screening 
18. Subject has epilepsy or history of seizures, with the exception of a single seizure 
episode (e.g., childhood febrile, post traumatic). 
19. Subject has uncontrolled hypertension (diastolic blood pressure [DBP] >95 mmHg in 
any position) or symptomatic hypotension, or orthostatic hypotension which is 
defined as a decrease of ≥30 mmHg in systolic blood pressure (SBP) and/or a 
decrease of ≥20 mmHg in DBP after at least 3 minutes standing compared with the 
previous supine blood pressure, OR development of symptoms.  Note:  Blood 
pressure measurements may be repeated once to ensure reproducibility of the 
exclusionary result(s) before excluding a subject based on the criteria noted above. 
20. Subject has a history of neuroleptic malignant syndrome. 
21. Subject has a score of >2 (mild) on any item of the AIMS at Screening. 
22. Subject has a score of 5 (severe akathisia) on BARS global clinical assessment of 
akathisia at Screening. 
23. Subject has a history of pituitary adenoma or cancer <5 years prior to Screening.  
Subjects currently being treated for cancer may not be enrolled in the study. 
24. Female subject who is breastfeeding. 
25. Female subject with a positive urine pregnancy test that is confirmed positive by 
serum pregnancy test at Screening or Baseline. 
26. Subject who currently (within the past 6 months) meets the DSM-5 criteria for 
substance use disorders (excluding nicotine and caffeine). 
27. Subject has positive urine drug/alcohol screen at the Screening Visit.  Positive results 
that are due to short-term prescription medications that can be safely discontinued 
(e.g., opioids for acute pain that has resolved) may continue at the discretion of the 
Investigator with the agreement of the Sponsor/designee.  Subjects with positive 
cannabis results may be included, provided the Investigator does not feel the subject 
is a compliance risk and the subject does not fulfill the criteria for substance abuse or 
dependence as stated in Exclusion Criterion 26 above, the subject agrees to abstain 
for the duration of the study
, and with the concurrence with the Sponsor/designee. 
28. Subject is at imminent risk of self-harm or harm to others, in the Investigator’s 
opinion based on clinical interview and responses provided on the C-SSRS.  Note that 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
40


Noven Pharmaceuticals, Inc. 
 
40 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
subjects will be excluded if they report suicidal ideation meeting the description of 
C-SSRS Type 4 or 5 (i.e., suicidal ideation with intent, with or without a plan) in the 
past 6 months or suicidal behavior (as described by the C-SSRS) in the past 
12 months at Screening.  Subjects will also be excluded at Baseline if they report 
suicidal ideation of Type 4 or 5 or suicidal behavior, as measured by the C-SSRS 
between Screening and Baseline. 
29. Subject has a known allergy or hypersensitivity to asenapine. 
30. Subject has current or history of allergy or hypersensitivity to adhesive dressings. 
31. Subject has history of allergy to more than 2 distinct chemical classes of drug (e.g., 
sulfas and penicillins). 
32. Subject has any skin abnormality present at the potential patch application site that is 
likely to be aggravated by the study drug (i.e., infection, rash, excessive fragility or 
dryness, any cut or abrasion), presence of tattoo, excessive hair or open sores, or scar 
tissue.  Presence of significant skin disorder such as atrophy
, psoriasis, or vitiligo. 
33. Subject has participated in a previous HP-3070 study
. 
34. Subject has participated in any other investigational trial or used investigational drugs 
within 30 days prior to the Screening Visit or has participated in more than 2 studies 
in the past 12 months. 
35. Any subject who, in the opinion of the Investigator or Medical Advisor, should not 
participate in the study
. 
36. Subject is a Study Investigator, sub-Investigator, study coordinator, employees of a 
participating Investigator, or immediate family member of the aforementioned. 
4.3.3 
Subject Withdrawal 
All subjects are free to withdraw from participation in the study at any time, for any reason, 
specified or unspecified, and without prejudice to further treatment.  The criteria for 
enrollment are to be followed explicitly.  If a subject who does not meet enrollment criteria is 
inadvertently enrolled, that subject should be withdrawn from the study and the Sponsor or 
Quintiles must be contacted.  An exception may be granted in rare circumstances where there 
is a compelling reason to allow the subject to continue.  In these rare cases, the Investigator 
must obtain documented approval from the Sponsor/designee to allow the subject to continue 
in the study. 
In addition, subjects will be withdrawn from study drug and from the study in the following 
circumstances: 
 The Investigator decides that the subject should be withdrawn.  Subjects may be 
withdrawn if continuing in the study is not in the subject’s best interest, their condition 
worsens during the study or for safety reasons, as determined by the Investigator. 
o If this decision is made because of an AE or a clinically significant laboratory value, 
the study drug is to be discontinued and appropriate measures are to be taken.  The 
Sponsor/designee is to be notified immediately. 
 The subject is unwilling to continue in the study. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
41


Noven Pharmaceuticals, Inc. 
 
41 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 Subject requires treatment with a prohibited concomitant medication 
 The subject becomes pregnant.  All pregnancies must be followed to conclusion to 
determine their outcome.  
 The subject has one of the following elevated liver enzyme conditions, confirmed by 
repeat testing: 
o ALT or AST >3×ULN and total bilirubin >2×ULN 
o ALT or AST >8×ULN 
o ALT or AST >5×ULN for more than 2 weeks 
o ALT or AST >3×ULN with the appearance of jaundice, worsening of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or 
eosinophilia 
 The subject has an absolute neutrophil count of <1000 per mm3, and after repeat testing 
in the subsequent 48 hours, the values fail to normalize. 
 Lack of compliance with protocol. 
 The Investigator or the Sponsor, for any reason, stops the study. 
Subjects who discontinue the study early will have ET procedures performed as shown in the 
Schedule of Events (see Table 1).  Randomized subjects who discontinue the study early will 
be considered dropouts.  Subjects who withdraw from the study may remain hospitalized as 
needed for safety while they transition to SOC treatment and into the care of their personal 
physician. 
A follow-up phone call will be made to the subject 30 days (±2 days) after the ET visit. 
Subjects who are withdrawn from the study will not be replaced. 
In all cases, the reason for withdrawal must be recorded.  If the reason for subject withdrawal 
is not known, considerable efforts must be made to establish whether the reason for 
withdrawal was an AE.  Subjects, for whom the study drug is discontinued, will be 
encouraged to continue to complete all the scheduled procedures. 
5.0 STUDY TREATMENTS 
5.1 Treatments Administered 
Subjects will receive treatment with HP-3070 (asenapine maleate, transdermal patch) 9.0 mg 
or 18.0 mg or placebo.  Information concerning the application and removal of the patches is 
available in Section 5.7. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
42


Noven Pharmaceuticals, Inc. 
 
42 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
5.2 Identity of Investigational Product 
HP-3070 contains asenapine maleate (trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-
dibenz[2,3:6,7] oxepino[4,5-c]pyrrolidine maleate) as a white crystalline powder.  It is 
supplied as a dermal patch consisting of a plastic film, adhesive matrix and backing film. 
The investigational product and placebo comparator used in this study are described in 
Table 2. 
Table 2  
Investigational Products 
Investigational 
Product 
Dosage Form and Strength  
Dosage Form 
Shape/Size 
HP-3070-9.0  
One patch contains 9.0 mg 
asenapine maleate (0.45 mg 
of asenapine maleate per 
1.0 cm2) 
Transdermal patch  
square with an area of 
20 cm2 
HP-3070-9.0 Placebo  
One patch contains 0 mg 
asenapine maleate 
Transdermal patch  
square with an area of 
20 cm2 
 
5.3 Packaging, Labelling and Storage 
Each patch is packed in an aluminum foil sachet with light shading capacity.  The sachet is 
air tight, and sealed by a heat sealer.  The appropriate number and sizes of sachets are 
provided in a box. 
The study drug will be labeled in accordance with all regulatory requirements.  The 
Investigator/designee will complete the blank spaces on the label for the subject number, site 
number, and date dispensed. 
The Sponsor will be responsible for ensuring that the quality of the study drug is adequate for 
the duration of the trial.  Study drug is to be stored at room temperature in a secure area 
according to local regulations.  The study drug must be dispensed only from official study 
sites by authorized personnel according to local regulations. 
All study drug supplies that will be used in the study must be maintained securely under the 
direct responsibility of the Investigator or delegated by the Investigator to the hospital 
pharmacist, or other personnel licensed to store and dispense drugs.  All drugs shall be 
dispensed in accordance with the Investigator’s prescription, and it is the Investigator’s 
responsibility to ensure that an accurate record of drugs issued and returned is maintained.  
Under no circumstances will the Investigator allow the study drug to be used other than as 
directed by the protocol.  Storage conditions should be monitored by the site personnel for 
adherence to label specifications. 
5.4 Study Drug Accountability 
The Investigator, a member of the investigational staff, or a hospital pharmacist must 
maintain an adequate record of the receipt and distribution of all study medication using a 
drug accountability form.  These forms must be available for inspection at any time. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
43


Noven Pharmaceuticals, Inc. 
 
43 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Used, partially used, the aluminum foil sachet of used and partially used patches, and unused 
study drug products should be retained until the Clinical Research Associate (CRA) has been 
able to complete drug accountability and reconciliation. 
All study medication supplies should be accounted for at the termination of the study and a 
written explanation provided for discrepancies.  All used, partially used, and unused study 
medication supplies and packaging materials are to be inventoried and returned to 
Sponsor/designee by the Investigator.  The Investigator is not permitted to return or destroy 
used, partially used, or unused clinical drug supplies or packaging materials unless 
authorized by the Sponsor/designee. 
5.5 Method of Assigning Subjects to Treatment 
Subjects will be randomly assigned to treatment using a 1:1:1 ratio to 1 of 3 treatment arms 
(HP-3070-9.0, HP-3070-18.0, or placebo) stratified by country. 
Once the subject meets all the eligibility criteria for randomization in the double-blind 
Treatment Period, the study center will request the study medication assignment using the 
Interactive Voice Activated Response System (IVRS) or Interactive Web-based Response 
System (IWRS).  All randomized subjects will be managed by IVRS/IWRS.  Detailed 
information will be provided in the Study Manual. 
5.6 Selection of Doses in the Study 
The results of placebo-controlled clinical trials of SL asenapine have demonstrated a similar 
efficacy of the 5.0 mg and 10.0 mg twice daily (BID) doses in reducing the total PANSS 
score.  The exposure response relationship of the effect of asenapine on the time course of 
PANSS total score using data from the Phase 2 and Phase 3 studies of SL asenapine has been 
characterized and published.
4  Based on this analysis, asenapine effect was best described by 
an inhibitory E
max model and the area under the concentration time curve (AUC) was a better 
predictor of response than dose. 
The rationale supporting the selection of the 2 doses (9.0 mg and 18.0 mg) to be studied in 
Study HP-3070-GL-04 is based on (a) the comparison of exposure (AUC
0-24) between 
approved doses of SAPHRIS
® and selected doses for HP-3070 in the target population and 
(b) safety assessment for HP-3070. 
In Study HP-3070-US-02b, the steady-state PK of HP-3070 transdermal patch at the doses of 
4.5 mg, 9.0 mg, 13.5 mg and 18.0 mg were evaluated in a multiple ascending-dose study in 
patients diagnosed with schizophrenia.  As shown in Table 3, the doses selected to be 
investigated in this study are expected to provide an exposure which is within the range of 
exposure provided by the approved doses of SAPHRIS
®.  The mean AUC
0-24 following the 
9.0  mg of once daily HP-3070 patch is similar to the mean AUC0-24 obtained by the 
administration of SAPHRIS
® 5.0 mg BID while mean exposure following 18.0 mg of once 
daily HP-3070 patch is similar to that following the administration of SAPHRIS® 
10.0 mg BID.
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
44


Noven Pharmaceuticals, Inc. 
 
44 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 
Table 3  
Steady-State Pharmacokinetics of HP-3070 Transdermal Patch  
Formulation  
Dose  
Population 
Mean Body 
Weight (kg) 
Mean Cmax 
ng/mL (%CV) 
Mean AUC0-24 
ng.h/mL (%CV) 
Data source 
HP-3070 
4.5 mg 
(n=22) 
Schizophrenia patient 
(Mostly Caucasian) 
86.6  
1.14 (30%)  
22.3 (28%) 
HP-3070-US-02b 
9.0 mg 
(n=21) 
Schizophrenia patient 
(Mostly Caucasian) 
87.0  
2.26 (24%)  
45.8 (25%) 
13.5 mg 
(n=20) 
Schizophrenia patient 
(Mostly Caucasian) 
87.0  
3.40 (19%)  
69.3 (20%) 
18.0 mg 
(n=20) 
Schizophrenia patient 
(Mostly Caucasian) 
87.0  
4.68 (17%)  
96.2 (19%) 
SAPHRIS® 
5.0 mg BID 
(n=28) 
Schizophrenia patient 
(Caucasian, Black, Other) 82.1  
4.23 (45%)  
53.0 (38%) 
NDA 22-117 (Study 
A7501001)5  
10.0 mg BID 
(n=25) 
Schizophrenia patient 
(Caucasian, Black, Other) 82.1  
6.56 (51%)  
86.8 (53%) 
AUC = area under the plasma concentration time curve; BID = twice daily; Cmax = maximum plasma concentration. 
Note:  AUC0-24 is indicated as arithmetic mean (%CV). 
For SAPHRIS®, mean AUC
0-24 was calculated as double of mean AUC
0-12 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
45


Noven Pharmaceuticals, Inc. 
 
45 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Study HP-3070-US-02b also demonstrated that daily application of HP-3070 transdermal 
patches for 7 days at doses of 4.5 to 18.0 mg was safe and well tolerated.  After dosing with 
HP-3070, there were no clinically significant findings with respect to vital signs, 24-hour 
cardiac Holter, 12-lead ECG, clinical laboratory, or C-SSRS assessments. 
Based on safety assessments and comparison of exposure between approved doses of 
SAPHRIS® and 9.0 mg and 18.0 mg of HP-3070, patches are considered to be appropriate 
doses to be studied in this trial. 
5.7 Dosing of Subjects 
During the single-blind Run-in Period, site personnel will apply 2 placebo patches to subjects 
once daily.  The subject must use the single-blind placebo patch for a minimum of 3 days 
prior to being randomized into the double-blind Treatment Period.  Subjects will be blinded 
regarding the placebo status of the patches. 
During the double-blind Treatment Period (Day 1 through Day 42) site personnel will apply 
2 patches to subjects per the randomization code.  The treatment received by each subject 
will be: 
 HP-3070 9.0-mg treatment arm:  one (1) 9.0-mg 20 cm2 patch and one (1) placebo patch 
(0-mg, 20 cm
2), once daily; 
 HP-3070 18.0-mg treatment arm:  two (2) 9.0-mg 20 cm2 patches, once daily; and 
 Placebo treatment arm:  two (2) placebo patches (0 mg, 20 cm2) once daily. 
Patch Application and Removal 
There are no special requirements related to food and beverage or other medications in regard 
to the timing of patch application. 
The application area should be clean, dry, non-oily, non-hairy, and not irritated.  Patches will 
be applied by site personnel at approximately the same time every day and each patch will be 
worn for 24 hours.  Every day, approximately 24 hours after patch application, site personnel 
will remove previous day’s patches and apply 2 new patches. 
Both patches will be applied in close proximity without overlapping to 1 of the following 
application sites:  abdomen, hip, upper arm, upper back, and upper chest.  Patch application 
site will be rotated daily. 
In the event that a patch should detach completely, the time, activity and reason at the time of 
patch detachment must be documented.  Under no circumstances should the detached 
patch/patches be reapplied to the subject.  Under no circumstances should the detached patch 
be reinforced with tape. 
If both patches are detached completely then 2 new patches from the subject’s kit should be 
applied immediately, provided that there are at least 6 hours of time remaining before the 
next dose.  If only one patch detaches completely, then the other patch should also be 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
46


Noven Pharmaceuticals, Inc. 
 
46 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
removed and 2 new patches from the subject’s kit should be applied immediately, provided 
that there are at least 6 hours of time remaining before the next dose. 
Regardless of the time when the new patches are applied, patch removal time of the new 
patches will be approximately 24 hours after the application of the original patches.  In other 
words, removal time of the new patches may not exceed 24 hours from the time the first 
patches were applied. 
The time of patch application, removal, and detachment will be recorded.  If a patch is 
removed prior to the scheduled removal time, the time and reason for early patch removal 
will be recorded.  
Detailed information regarding patch application and removal will be provided in the Study 
Manual. 
5.8 Treatment Interruptions or Modifications 
Dose modifications are not permitted.  If the patient misses a dose or receives an extra dose 
for any reason, this should be recorded and discussed with the Medical Advisor. 
5.9 Blinding 
This is a randomized, double-blind, placebo-controlled study with limited access to the 
randomization code.  The HP-3070 patches and placebo patches will be identical in physical 
appearance; subjects treated with active drug and placebo will receive the same number of 
patches. 
The treatment each subject will receive will not be disclosed to the Investigator, study center 
staff, subject, or Sponsor/designee.  The treatment codes will be held by the IVRS/IWRS 
vendor. 
The process for breaking the blind will be handled through the IVRS/IWRS. 
Investigators are strongly discouraged from requesting that the blind be broken for an 
individual subject, unless there is an emergency and the Investigator determines that 
unblinding and identification of the study drug is necessary for the purpose of providing 
urgent patient care and knowledge of the subject’s treatment assignment will alter subsequent 
care.  The reason for unblinding should be discussed with the Medical Advisor prior to 
unblinding, if possible.  If the subject’s condition requires unblinding prior to contact with 
the Medical Advisor or if the subject and/or Investigator are inadvertently unblinded during 
the course of the study, then the Medical Advisor should be contacted within 24 hours after 
the unblinding. 
Pertinent information regarding the circumstances of unblinding a subject’s treatment code 
must be documented. 
5.10 Prior and Concomitant Treatments 
Medications taken from 6 months prior to the Screening visit through the End of Study 
(including the 30 day Follow-up Period) must be recorded.  The Investigator should instruct 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
47


Noven Pharmaceuticals, Inc. 
 
47 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
the subject to notify the site about any new medication he or she takes after the start of the 
study. 
5.10.1 
Medications Prohibited during the Study 
Prohibited/restricted medications and washout periods for specific drugs are presented in 
Table 4. 
Table 4 
Prohibited/Restricted Medications and Washout Prior to Baseline 
Prohibited/Restricted Medication  
Washout/Other Conditions  
Antipsychotics, oral or immediate release IM 
Antipsychotics, depot or long acting injectable  
Washout:  3 days, 7 days for aripiprazole 
One full cycle plus ½ cycle as per prescribing labela 
Antidepressants 
Fluoxetine 
Monoamine oxidase inhibitors 
All other antidepressants 
Washout: 
28 Days 
14 days 
7 days 
Prohibited during the study 
Mood stabilizers 
Lithium 
Anticonvulsants 
Washout: 
3 days 
3 days 
Prohibited during the study 
Varenicline 
Washout:  5 days 
Prohibited during the study 
Benzodiazepines other than the ones used as per 
protocol specifications 
Washout:  3 days 
Prohibited during the study 
Ramelteon or Tasimelteon 
Prohibited during the study starting at Screening Visit 
Antihistamines  
Diphenhydramine and hydroxyzine prohibited during 
the study.  Only non-sedating antihistamines are 
allowed for the treatment of allergy during the study 
Narcotic Analgesics 
Subject must have a negative urine drug screen prior to 
Baseline.  Prohibited during the study starting at 
Screening Visit.  Exception:  during study, these drugs 
may be allowed for acute pain conditions (e.g., tooth 
extraction) for a maximum of 3 days. 
Vitamins, non-prescription herbal preparations, 
other supplementsb 
Washout:  7 days, 
(14 days for St. John’s Wort) 
Prohibited during the study 
Antiemetic drugs containing dopamine antagonists  
Prohibited during the study starting at Screening Visit 
Stimulants 
Prohibited during the study starting at Screening Visit 
Other medications with psychotropic properties  
Prohibited during the study, starting at the Screening 
Visit 
Note:  Subjects taking drugs that require a washout-out period >14 days are not eligible for the study. 
Note:  The Investigator should contact the Medical Advisor with any concerns about the acceptability of any medication. 
a. Concerns about label interpretation should be discussed with Medical Advisor. 
b. Supplements for general health and other non-psychiatric purposes, such as daily vitamins may be allowed with the 
approval of the Medical Advisor.  Supplements for established medical conditions, such as iron for iron deficiency 
anemia, are not exclusionary. 
 
5.10.2 
Permitted Medications 
Medications used for chronic non-psychiatric medical conditions (e.g., antihypertensives, 
oral hypoglycemic, etc.) are allowed if the condition and treatment regimen are stable before 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
48


Noven Pharmaceuticals, Inc. 
 
48 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Screening.  Initiation or adjustments of therapies for non-psychiatric concurrent conditions 
will be left to the Investigator’s discretion.  If necessary, the Medical Advisor may be 
contacted. 
Psychotropic medication, other than the study medication, may be initiated during the study.  
Conditions for the use of psychotropic concomitant medications are presented in  Table 5. 
 Table 5  
Medications Permitted for Specific Conditions 
Medication 
Use 
Lorazepam 
Oral medication allowed as needed (prn use only) for the treatment of insomnia, 
agitation, and or anxiety only.  Maximum 6 mg/day during Screening and for the 
first 2 weeks of treatment, 4 mg/day during weeks 3 to 4 of treatment, and 2 
mg/day for the remainder of the study.  If lorazepam is not available in certain 
regions, another locally available benzodiazepine at equivalent doses may be 
approved by the Medical Advisor.
a,b,c 
Benztropine 
Allowed for the use of treatment-emergent EPS, up to 4 mg/day or equivalent 
anticholinergic dose if benztropine is not available in certain countries.
b 
The EPS scales are to be administered before medication is given (except in case of 
dystonia), to ensure documentation of the decision to administer the treatment. 
Not permitted within 12 hours of EPS scale administration. 
Zolpidem 
Allowed on an as needed basis (prn use only) for the treatment of insomnia as per 
prescribing label. If zolpidem is not available in specific regions, another hypnotic 
may be approved by the Medical Advisor.b,c 
Not permitted within 12 hours of EPS scale administration. 
Propranolol 
Not permitted within 12 hours of EPS scale administration. 
Allowed up to 60 mg/day in 20-mg doses for the treatment of akathisia.b 
a. If a subject requires greater than then maximum allowances, then the Investigator must discuss the suitability of the 
subject to continue with the  Medical Advisor 
b. Not to be given within 12 hours prior to efficacy or safety assessments 
c. Recommend reduced dosages for subjects older than 65 years of age 
 
5.10.3 
Concomitant Medication Cautions 
Investigator’s clinical judgment will be used in the following situations (the Medical Advisor 
for the study may be contacted if necessary): 
 Caution should be used with co-administration with agents/conditions that induce 
CYP1A2 (e.g., smoking, rifampin) or inhibit CYP1A2 (e.g., fluvoxamine, ciprofloxacin, 
ketoconazole); 
 Paroxetine (CYP2D6 substrate and inhibitor) dose should be reduced by half when used 
in combination with HP-3070; 
 Potential additive effect on QT-interval prolongation; avoid concomitant use of other 
drugs known to prolong QTc intervals including Class 1A antiarrhythmics (e.g., 
quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), 
antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and 
antibiotics (e.g., gatifloxacin, moxifloxacin); and 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
49


Noven Pharmaceuticals, Inc. 
 
49 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 May enhance hypotensive effects of certain antihypertensive agents and other drugs that 
can cause hypotension or bradycardia.  Use concomitantly with caution; consider 
monitoring orthostatic vital signs in such subjects. 
5.10.4 
Other Restrictions 
Other restrictions are summarized in Table 6. 
Table 6  
Other Restrictions 
Restriction 
Timeframe 
ECT, TMS, VNS, or other brain stimulation 
treatment 
90 days prior to Screening and for the duration of 
study participation 
Formal, structured psychotherapy targeting the 
symptoms of schizophrenia 
For duration of study participation 
Transdermal medical patches other than study drug  For the duration of study participation. 
ECT = electroconvulsive therapy; TMS = transcranial magnetic stimulation; VNS = vagal nerve stimulation 
 
Note:  If a subject is a smoker and the hospital does not allow smoking, they may use 
nicotine replacement options, but the use of a nicotine transdermal patch is not permitted. 
5.11 Medical Care of Subjects after End of Study 
After the end of the study, subjects may remain hospitalized as needed for safety while they 
transition to standard of care (SOC) treatment and into the care of their personal physician. 
5.12 Treatment Compliance 
To ensure treatment compliance, patches will be applied and removed by designated 
qualified staff.  The exact times of patch application and removal will be recorded.  In 
addition, patch adhesion will be assessed throughout the day (during routine check of vital 
signs as per hospital policy/SOP and before removal of previous day’s patch).  
Noncompliance is defined as using less than 80% or more than 120% of study medication 
during any evaluation period (visit to visit).  If the subject is noncompliant, the Medical 
Advisor should be contacted to discuss the subject’s eligibility to continue in the study. 
6.0 EFFICACY, SAFETY, AND PHARMACOKINETIC 
ASSESSMENTS 
6.1 Efficacy 
The raters administering the efficacy assessments must be qualified and experienced.  All 
assessment scales should be performed in the order they appear in the Schedule of Events 
(Table 1).  Raters will be trained to administer these scales.  Raters must be certified to 
administer the PANSS.  Qualified personnel, who are approved by the Sponsor/designee to 
administer the efficacy assessments, will be participating in initial and ongoing training 
sessions.  Details of the training will be provided in the Rater Qualification Methodology.  
The number of raters within each study site should be kept to a minimum.  All efforts will be 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
50


Noven Pharmaceuticals, Inc. 
 
50 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
made to ensure that the same clinician administers the scales for a given subject.  Notations 
in the subject’s trial records should substantiate the ratings. 
6.1.1 
M.I.N.I. International Neuropsychiatric Interview (MINI) 
The MINI. International Neuropsychiatric Interview (MINI 6.0) for Schizophrenia and 
Psychotic Disorders is a short, structured, diagnostic interview developed by psychiatrists 
and clinicians in the United States and Europe for DSM-IV and ICD-10 diagnoses of 
schizophrenia and other psychotic disorders.
6  The MINI is the most widely used psychiatric 
structured diagnostic interview instrument in the world, employed by mental health 
professionals and health organizations in more than 100 countries. The questions on the 
MINI are designed to be answered generally with just “Yes” or “No.”  The MINI has been 
shown to be valid, reliable, and more time-efficient than other, lengthier diagnostic 
interviews. 
6.1.2 
Positive and Negative Syndrome Scale (PANSS) 
The PANSS7 consists of 3 subscales containing a total of 30 items.  For each item, severity is 
rated on an anchored 7-point scale, with a score of 1 indicating the absence of symptoms and 
a score of 7 indicating extremely severe symptoms.  The items for each subscale are as 
follows: 
1)  Positive Subscale (7 positive items:  delusions, conceptual disorganization, 
hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and 
hostility), 
2)  Negative Subscale (7 negative items:  blunted affect, emotional withdrawal, poor 
rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of 
spontaneity and flow of conversation, stereotyped thinking), and 
3)  General Psychopathology Subscale (16 items:  somatic concern, anxiety, guilt feelings, 
tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, 
unusual thought content, disorientation, poor attention, lack of judgment and insight, 
disturbance of volition, poor impulse control, preoccupation, and active social 
avoidance). 
A copy of the PANSS is provided in Appendix 2 (Section 12.0). 
6.1.3 
Secondary Efficacy 
6.1.3.1 Clinical Global Impression - Severity of Illness Scale (CGI-S) 
The severity of illness for each subject will be rated using the CGI-S.
8  To perform this 
assessment, the rater or Investigator will answer the following question:  “Considering your 
total clinical experience with this particular population, how mentally ill is the subject at this 
time?”  Response choices include:  0 = not assessed; 1 = normal, not at all ill, 2 = borderline 
mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
51


Noven Pharmaceuticals, Inc. 
 
51 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
7 = among the most extremely ill subjects.  A sample of the CGI-S is provided in Appendix 3 
(Section 13.0). 
6.1.3.2 Clinical Global Impression - Improvement Scale (CGI-I) 
The efficacy of trial medication will be rated for each subject using the CGI-I.
7  The rater or 
Investigator will rate the subject’s total improvement whether or not it is due entirely to drug 
treatment.  All responses will be compared with the subject’s condition at Baseline prior to 
the first dose of double-blind study drug.  Response choices include:  0 = not assessed, 
1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 
5 = minimally worse, 6 = much worse, and 7 = very much worse.  A sample of the CGI-I is 
provided in Appendix 4 (Section 14.0). 
6.1.3.3 Calgary Depression Scale for Schizophrenia (CDSS) 
The CDSS is a nine-item scale designed for assessment of the level of depression in patients 
with schizophrenia.9  Each of the 9 items is rated on a 4-point scale, scored from 0 to 3.  
The first 8 items are rated on the basis of responses during a semi-structured interview 
conducted by a qualified clinician.  The ninth item (Observed Depression) is rated by 
evaluating signs and symptoms over the course of the interview.  The total score is derived 
by adding each of the 9 items together.  Totals scores of 6 or more identifies the presence of 
treatment-emergent depression predictive of major depressive episodes.  A sample is 
included in Appendix 5 (Section 15.0). 
6.1.3.4 Medication Satisfaction Questionnaire (MSQ) 
The Medication Satisfaction Questionnaire (MSQ) includes one simple question to ask 
patients about their satisfaction with their medication.  Vernon et al. evaluated the 
psychometric properties in psychotic populations of the MSQ and found that responses to 
this one question were able to separate patients receiving active drug from those receiving 
placebo and was a good proxy for efficacy.10  As such, it was determined that a 1-point 
change on the MSQ may be considered clinically meaningful.  A sample is provided in 
Appendix 6 (Section 16.0). 
6.2 Safety 
Safety variables included in this study are:  AEs, physical examinations, vital signs, body 
weight, clinical laboratory tests (including prolactin levels, fasting glucose, and lipids), 
ECGs, C-SSRS, evaluations of EPS (BARS, AIMS, and SAS), and dermal adverse events. 
6.2.1 
Adverse Events and Serious Adverse Events 
6.2.1.1 Adverse Events 
An AE is any untoward medical occurrence in a subject given study drug.  The event does 
not necessarily have to have a causal relationship with this treatment.  The recording of AEs 
will begin when the subject signs the ICF and will continue up to the 30 day follow-up 
period.  AEs that are ongoing at discharge will be followed until resolution or for 30 days 
after the last dose of study drug, whichever comes first. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
52


Noven Pharmaceuticals, Inc. 
 
52 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
An AE can be: 
 Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, whether 
or not considered related to the medicinal product. 
 Any new disease or exacerbation of an existing disease. 
 Any deterioration in non-protocol-required measurements of laboratory values or other 
clinical tests (e.g., ECG or X-ray) that results in symptoms, a change in treatment, or 
discontinuation of study drug. 
 Recurrence of an intermittent medical condition (e.g., headache) not present at Baseline. 
For the purpose of this study, in addition to the AE definitions described above the following 
definitions will also be used. 
 Treatment-emergent depression defined a priori as a CDSS score ≥6. 
 Abnormalities in physical examination findings that require clinical intervention or 
further investigation (beyond ordering a repeat [confirmatory] test) 
 Laboratory abnormalities that require clinical intervention or further investigation 
(beyond ordering a repeat [confirmatory] test) unless they are associated with a clinical 
event that has already been reported. 
 Worsening in the subject’s symptoms of schizophrenia or new symptoms will be 
considered AEs. 
 Symptoms of other psychiatric disorders will be considered AEs if they are new (not part 
of the subject’s medical history) or if their severity and/or frequency are greater than 
those noted in the subject’s medical history. 
 Overdose:  An overdose is defined as the ingestion of study drug beyond the dosing 
regimen defined in the study protocol and/or an overdose of any other product.  An 
overdose, and any symptoms resulting from the overdose, are considered AEs and should 
be recorded.  An overdose will be considered an SAE if it meets the definition of an SAE 
described in Section 6.2.1.2. 
 Spontaneous complaints of dermal reactions (skin irritation, discomfort) will be recorded 
as AEs (see Section 6.2.6 for details).  Spontaneous reports might include but are not 
limited to the following: initial dermal response and exacerbation of an existing response. 
6.2.1.2 Serious Adverse Events 
Definition of SAE:  An SAE, experience or reaction, is any untoward medical occurrence 
(whether considered to be related to study drug or not) that at any dose: 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
53


Noven Pharmaceuticals, Inc. 
 
53 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 Results in death 
 Is life-threatening 
 Requires in-patient hospitalization or prolongation of existing hospitalization 
 Results in persistent or significant disability/incapacity 
 Is a congenital abnormality/birth defect 
 Is an important medical event 
Note:  The term “life-threatening” in the definition of “serious” refers to an event in which 
the subject was at immediate risk of death at the time of the event; it does not refer to an 
event which hypothetically might have caused death if it were more severe (ICH E2A 
Guideline:  Clinical Safety Data Management:  Definitions and Standards for Expedited 
Reporting, Oct 1994).  It should be noted that hospitalization for a pre-planned procedure or 
diagnostic tests is not considered an AE or SAE. 
Medical and scientific judgment should be exercised in deciding whether expedited reporting 
is appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization, but may jeopardize the 
subject or may require intervention to prevent one of the other outcomes listed in the 
definition above.  Examples include allergic bronchospasm, convulsions, and blood 
dyscrasias or development of drug dependency or drug abuse. 
Potential Hy’s Law cases should be reported via the SAE process.  This is defined as: 
 ALT or AST >3×ULN AND 
 ALP <2×ULN AND 
 Increase in bilirubin ≥2×ULN 
The process for reporting SAEs is described in Section 6.2.1.5. 
6.2.1.3 Categorization of Adverse Events 
Each AE is to be evaluated for duration, severity, seriousness, and causal relationship to the 
investigational drug.  The action taken and the outcome must also be recorded. 
6.2.1.3.1 Severity 
 
The severity of the AE will be characterized as “mild, moderate or severe” according to the 
following definitions: 
 Mild events are usually transient and do not interfere with the subject’s daily activities. 
 Moderate events introduce a low level of inconvenience or concern to the subject and 
may interfere with daily activities. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
54


Noven Pharmaceuticals, Inc. 
 
54 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 Severe events interrupt the subject’s usual daily activity. 
6.2.1.3.2 Relationship 
All efforts should be made to categorize an AE by its relationship to drug.  The Investigator 
will determine the relationship of the AE to the study drug by using the following definitions. 
Probable (must meet first 3 criteria):  This category applies to those AEs which are 
considered, with a high degree of certainty, to be related to the test drug.  An AE may be 
considered probable, if: 
 It follows a reasonable temporal sequence from administration of the drug; 
 It cannot be reasonably explained by the known characteristics of the subject’s clinical 
state, environmental or toxic factors, or other modes of therapy administered to the 
subject; 
 It disappears or decreases on cessation or reduction in dose.  (There are important 
exceptions when an AE does not disappear upon discontinuation of the drug, yet 
drug-relatedness clearly exists; e.g., (1) bone marrow depression, (2) tardive dyskinesias); 
 It follows a known pattern of response to the suspected drug; and 
 It reappears upon rechallenge. 
Possible (must meet the first 2 criteria):  This category applies to those AEs in which the 
connection with the test drug administration appears unlikely but cannot be ruled out with 
certainty.  An AE may be considered possible if, or when: 
 It follows a reasonable temporal sequence from administration of the drug; 
 It may have been produced by the subject’s clinical state, environmental or toxic factors, 
or other modes of therapy administered to the subject; and 
 It follows a known pattern of response to the suspected drug. 
Unlikely (must meet the first two criteria):  In general, this category is applicable to an 
adverse event which meets the following criteria: 
 It does not follow a reasonable temporal sequence from administration of the drug; 
 It may readily have been produced by the subject’s clinical state, environmental or toxic 
factors, or other modes of therapy administered to the subject; 
 It does not follow a known pattern of response to the suspected drug; and 
 It does not reappear or worsen when the drug is readministered. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
55


Noven Pharmaceuticals, Inc. 
 
55 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Unrelated:  This category is applicable to those AEs which are judged to be clearly and 
incontrovertibly due only to extraneous causes (disease, environment, etc.) and do not meet 
the criteria for drug relationship listed under unlikely, possible or probable. 
6.2.1.4 Reporting of Adverse Events 
All AEs, regardless of severity and when they occurred (any time after the ICF is signed and 
through the Follow-up Period), are to be recorded.  The Investigator should complete all the 
details requested including dates of onset, severity, action taken, outcome, relationship to 
study drug.  Each event should be recorded separately. 
6.2.1.5 Reporting of Serious Adverse Events 
All SAEs will be recorded using the electronic data capture (EDC) system.  The Investigator 
will be instructed to contact the Sponsor/designee for any questions on SAE reporting.  
Contact details will be provided per country, and per region (please refer to Study Manual for 
the appropriate information).   
Urgent safety queries issued in EDC must be followed up and addressed within 1 business 
day.  Follow-up information and response to non-urgent safety queries should be combined 
for reporting to provide the most complete data possible within each follow-up.  In the event 
that the EDC system is unavailable, SAEs are to be reported by faxing/emailing the paper 
SAE Form to Quintiles using the appropriate fax number provided for each country or project 
safety mailbox. 
6.2.1.5.1  
Notification of Regulatory Authorities, Investigators, and Institutional 
Review Board/Independent Ethics Committee 
Any SAE, including death due to any cause, which occurs during this study, whether or not 
related to the study drug, must be reported immediately (within 24 hours of the site’s 
knowledge of the event).  Additional information will be available in the Study Manual. 
The report will contain as much available information concerning the SAE to enable the 
Sponsor (or an authorized representative) to file a report, which satisfies regulatory reporting 
requirements.  These timelines apply to initial reports of SAEs and to all follow-up reports. 
All SAEs during the 30 day follow-up period will be collected and reported as previously 
described. 
6.2.1.5.2  
Reporting of Serious Adverse Events to Regulatory Authorities and 
Investigators 
Investigators will be notified by the Sponsor or Quintiles of all Serious Unexpected Adverse 
Event Reactions (SUSARs) that require prompt submission to their Institutional Review 
Board (IRB) or Independent Ethics Committee (IEC).  Investigators should provide written 
documentation of IRB/IEC notification for each report to the Sponsor or Quintiles.  
The Sponsor or Quintiles will ensure that all SUSARs are reported to the appropriate 
regulatory authorities. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
56


Noven Pharmaceuticals, Inc. 
 
56 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
6.2.1.6 Follow-up of Adverse Events 
All AEs will be followed up to resolution.  However, AEs and SAEs that are ongoing at the 
subject’s last study visit (i.e., discharge from the clinic at the end of the double-blind 
treatment period or early termination) will be followed until resolution or for 30 days after 
last dose of study drug, whichever comes first.  Resolution means that the subject has 
returned to a baseline state of health or the Investigator does not expect any further 
improvement or worsening of the AE.  All AEs and SAEs that occur during the 30 day 
follow-up period should be reported to the Sponsor or Quintiles. 
6.2.1.7 Pregnancy and Contraception 
It is important that female subjects and the partners of male subjects do not become pregnant 
during the study. 
Instructions for Male Subjects 
All male subjects should avoid fathering a child by the use of an effective means of 
contraception (see below), unless their partner is not of childbearing potential, i.e. 
postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral 
salpingectomy). 
Male subjects (including men who have had vasectomies) whose partners are currently 
pregnant should use a condom for the duration of the study and for 1 month after the last 
patch is removed.  This is to ensure that the fetus is not exposed to the drug product via the 
ejaculate. 
Male subjects must not donate sperm for 3 months following the removal of the last patch.  
Males should continue using contraception for 1 month after the last patch is removed. 
Instructions for Female Subjects 
Female subjects must use contraception unless they are not of childbearing potential, i.e. 
postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral 
salpingectomy).  Sexually active females of child-bearing potential must agree to use a 
medically accepted method of contraception during the study and for 1 month after the final 
dose of study medication.  Female subjects must not donate eggs for 3 months after the last 
patch is removed. 
Acceptable forms of contraception 
 Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository; 
 Established use of oral, injected or implanted hormonal methods of contraception; 
 Established use of medically prescribed topically-applied transdermal contraceptive 
patch; 
 Documented placement of an IUD or intra-uterine system (by female partner); and 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
57


Noven Pharmaceuticals, Inc. 
 
57 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 Male sterilization (with the appropriate post-vasectomy documentation of the absence of 
sperm in the ejaculate). 
The Sponsor/designee must be notified within 24 hours of the site’s knowledge of any 
subject who becomes pregnant while participating in a clinical study.  It is the responsibility 
of the Investigator, or designee, to report any pregnancy in a subject which occurs during the 
study by using the Pregnancy form. 
Although pregnancy is not technically an AE, all pregnancies must be followed to conclusion 
to determine their outcome.  This information is important for both drug safety and public 
health concerns.  The Investigator should make every effort to follow the subject until 
completion of the pregnancy.  If the outcome of the pregnancy meets the criteria for 
immediate classification as an SAE (i.e., post-partum complications, spontaneous abortion, 
stillbirth, neonatal death, or congenital anomaly, including that in an aborted fetus), the 
Investigator should follow the procedures for reporting SAEs. 
6.2.2  
Clinical Laboratory Evaluations 
6.2.2.1 Clinical Laboratory Assessments 
A central laboratory designated by the Sponsor will be used for all laboratory assessments 
during the trial.  If an immediate result is required, a sample should be sent to both the local 
and central laboratory. 
Urine samples and fasting blood samples will be collected from each subject as presented in 
Table 1 (Schedule of Events).  The clinical laboratory parameters evaluated in this study are 
presented in Table 7. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
58


Noven Pharmaceuticals, Inc. 
 
58 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Table 7  
Clinical Laboratory Tests 
Hematology: 
WBC count with differential 
RBC count 
Hematocrit 
Hemoglobin 
Platelet count 
 
Urinalysis: 
pH 
Specific gravity 
Protein 
Ketones 
Glucose 
Blood 
Microscopic exam (performed only if any part of 
the urinalysis is not negative) 
 
Urine Drug Screens: a 
Amphetamines 
Barbiturates 
Benzodiazepines 
Cannabinoids 
Cocaine 
Marijuana 
Methadone 
Opiates 
Phencyclidine 
Propoxyphene 
 
Additional Tests (screening only): 
HIV 
HbsAgd 
Anti-HCVd 
Blood alcohole 
Serum Chemistry: 
ALP 
ALT  
AST  
BUN 
CPKf 
Creatinine 
LDH 
Total bilirubin 
Triglycerides  
Cholesterol (total, LDL, and HDL) 
Calcium 
Chloride 
Glucose 
Insulin 
Magnesium 
Bicarbonate 
Inorganic phosphorus 
Sodium 
 
Potassium 
Total protein 
Uric acid 
GGT 
Prolactinb 
Albumin 
 
Additional Tests: 
Urine pregnancy (women of child-bearing capacity)c 
TSH (free T4,
 if TSH is abnormal) 
HbA1c 
Alcohol breathalyzer testg 
ALP = alkaline phosphatase; ALT = alanine transaminase; AST = aspartate transaminase; BUN = blood urea nitrogen; 
CPK = creatine phosphokinase; GGT = gamma glutamyl transferase; HbA1c = hemoglobin A1c; HBsAg = Hepatitis B 
antigen; HCV = Hepatitis C Virus; HDL = high density lipoprotein; HIV = human immunodeficiency virus; LDH = lactic 
dehydrogenase; LDL = low density lipoprotein; RBC = red blood cell; TSH = thyroid stimulating hormone; WBC = white 
blood cell count. 
a. Urine drug screens may be done at the Investigator’s discretion.  If the subject is allowed to leave the unit, a urine drug 
screen must be done when the subject returns. 
b. The central laboratory will not report prolactin levels to the sites nor the Sponsor, because this could potentially result 
in unblinding the treatment.  The central laboratory will report prolactin levels as “masked” on the laboratory report. 
See Section 6.2.2.2.3 for additional information. 
c. All positive urine pregnancy test results must be confirmed by a serum test.  Subjects with positive urine and serum 
pregnancy test results at Screening must not be enrolled.  Subjects with positive urine and serum pregnancy test results 
during the trial must discontinue treatment and be withdrawn from the trial. If the subject is allowed to leave the unit, a 
urine pregnancy test must be done when the subject returns. 
d. Subjects with chronic Hepatitis B or C may be included in the study provided that their condition is stable and that 
values for liver function tests and other laboratory tests results meet the criteria specified for entry into the study. 
e. A serum blood sample will be collected to test blood alcohol level at the screening visit.      
f. Reflex testing for urine myoglobin will be done in cases where CPK > 1000 U/L. 
g. If the subject is allowed to leave the unit, an alcohol breathalyzer test must be done when the subject returns. 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
59


Noven Pharmaceuticals, Inc. 
 
59 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Clinical laboratory tests will be reviewed for results of potential clinical significance at each 
time point during the study.  The Investigator will evaluate any change in laboratory values.  
If the Investigator determines a laboratory abnormality to be clinically significant, it is 
considered a laboratory AE; however, if the abnormal laboratory value is consistent with a 
current diagnosis, it may be documented accordingly. 
6.2.2.2 Monitoring of Selected Laboratory Values 
6.2.2.2.1 Liver  
Enzymes 
Subjects should be closely observed if they meet the definition of Hy’s Law cases, defined 
as: 
 ALT or AST >3×ULN AND 
 Alkaline phosphatase (ALP) <2×ULN AND 
 increase in bilirubin ≥2×ULN 
If the subject’s laboratory results meet these criteria, the subject should be evaluated and 
repeat or additional testing should be performed.  Elevations in liver enzymes that require 
discontinuation of the subject are presented in Section 4.3.3.  Potential Hy’s Law cases 
should be reported as SAEs. 
6.2.2.2.2 Neutrophil  
Counts 
Subjects with an absolute neutrophil count of <1000 per mm3 should have an additional test 
within 24 hours.  If the values are not within normal limits or increasing, the subject will be 
discontinued from the study. 
6.2.2.2.3 Prolactin 
The central laboratory will not report the prolactin levels after baseline to the sites or 
Sponsor/designee, as this value could unblind the subject’s treatment.  The central laboratory 
will report prolactin levels as “masked” on the laboratory report.  If an Investigator suspects 
hyperprolactinemia (due to symptoms or signs that could be attributed to a high prolactin 
level), a blood sample should be taken and sent to the central laboratory.  Blood samples for 
prolactin levels should not be sent to the local laboratory. 
If a subject’s serum prolactin level is >10×ULN, the site will be notified by the central 
laboratory and the Investigator will do a repeat blood draw within 3 days.  If the subject’s 
prolactin level is still >10×ULN, the Investigator should consider other possible causes of 
hyperprolactinemia (e.g., primary hypothyroidism, chronic renal failure, cirrhosis, use of 
drugs [opiates, estrogens, cimetidine, etc.], pregnancy for female subjects). 
If the laboratory requests a prolactin re-test, a “dummy” request will be sent for another 
subject at the same clinical site and the subject will be selected randomly in order to preserve 
the blind.  Such cases will be discussed with the study Medical Advisor. 
The Medical Advisor and site will remain blinded to the subject’s treatment allocation. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
60


Noven Pharmaceuticals, Inc. 
 
60 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
6.2.3 
Vital Signs, Physical Findings and Other Safety Assessments 
Height will be recorded at Screening, only.  Weight will be recorded at each visit.  
A complete physical examination including examination of the head, neck, ears and throat, 
thorax, abdomen, urogenital, extremities, neurological, and skin and mucosae will be 
performed at Screening and at end of study.  Abnormal physical examination findings at the 
Screening will be recorded as medical history and abnormal physical examinations findings 
at subsequent visits will be recorded as AEs.   
Vital sign measurements will include temperature, systolic blood pressure (SBP), diastolic 
blood pressure (DBP), and heart rate.  Blood pressures (sitting) and pulse rates should be 
measured after subject has rested (sitting quietly) for 5 minutes. 
In addition, assessments for orthostatic hypotension will be performed.  Blood pressure 
readings and pulse rate will be obtained after the subject has been supine for 5 minutes.  
These will be repeated after the subject has been standing up for approximately 1 to 
3 minutes. 
Subjects with a decrease of ≥30 mmHg in SBP and/or a decrease of ≥20 mmHg in DBP after 
≥3 minutes standing compared with the previous supine blood pressure, OR development of 
symptoms are considered to have orthostatic hypotension. 
Twelve-lead ECGs will be recorded at Screening and at the visits specified in Table 1.  
An ECG recordings will be obtained after the subject has been supine and at rest for at least 
5 minutes.  Additional 12-lead ECGs may be obtained at the Investigator’s discretion and 
should always be obtained if the subject discontinues the study.  A central ECG service will 
be utilized for reading all ECGs in order to standardize interpretations for the safety analysis.  
In addition, ECG results will be evaluated at the investigational site to monitor safety during 
the trial.  The Investigator or designee will review, sign, and date each ECG reading, noting 
whether or not any abnormal results are of clinical significance.  The ECG will be repeated if 
any results are considered by the Investigator to be clinically significant. 
6.2.4 
Evaluation of Extrapyramidal Symptoms (EPS) 
The rater who administers the EPS scales must be trained and experienced.  Raters will be 
trained to administer these scales.  The number of raters should be kept to a minimum and all 
efforts should be made to ensure that the same clinician administers the scales for a given 
subject.  Notations in the subject’s trial records should substantiate the ratings. 
6.2.4.1 Simpson Angus Scale (SAS) 
The SAS11 consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder 
shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and 
akathisia).  Each item will be rated on a 5-point scale, with a score of 0 representing absence 
of symptoms, and a score of 4 representing a severe condition.  The SAS Total Score is the 
sum of the scores for all 10 items.  Anticholinergics, propranolol, benzodiazepines, and non-
benzodiazepine sleep aids are not permitted within 12 hours of scale administration (see  
Table 5).  Investigators are encouraged to delay scale administration until 12 hours have 
elapsed, if at all possible.  However, if delaying administration of the scale is not feasible, the 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
61


Noven Pharmaceuticals, Inc. 
 
61 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
SAS should still be administered and the use of the medication documented, including a 
notation of the drug name, dose, and time of administration.  A copy of the scale is included 
in Appendix 7 (Section 17.0). 
6.2.4.2 Abnormal Involuntary Movement Scale (AIMS) 
The AIMS8 assessment consists of 10 items describing symptoms of dyskinesia.  Facial and 
oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk 
movements (item 7) will be observed unobtrusively while the subject is at rest (e.g., in the 
waiting room), and the Investigator will also make global judgments on the subject’s 
dyskinesias (items 8 through 10).  Each item will be rated on a 5-point scale, with a score of 
0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating 
a severe condition (for item 10, awareness, severe distress).  For this scale, the subject is to 
be sitting on a hard, firm chair.  In addition, the AIMS includes 2 yes/no questions that 
address the subject’s dental status.  Anticholinergics, propranolol, benzodiazepines, and non-
benzodiazepine sleep aids are not permitted within 12 hours of scale administration (see  
Table 5).  Investigators are encouraged to delay scale administration until 12 hours have 
elapsed, if at all possible.  However, if delaying administration of the scale is not feasible, the 
AIMS should still be administered and the use of the medication documented, including a 
notation of the drug name, dose, and time of administration.  The AIMS Movement Rating 
Score is defined as the sum of items 1 through 7 (i.e., items 1 through 4, facial and oral 
movements; items 5 and 6, extremity movements; and item 7, trunk movements).  A copy of 
the scale is presented in Appendix 8 (Section 18.0). 
6.2.4.3 Barnes Akathisia Rating Scale (BARS) 
The BARS12 consists of 4 items related to akathisia.  These include objective observation of 
akathisia by the Investigator, subjective feelings of restlessness by the subject, subjective 
distress due to akathisia, and global clinical assessment of akathisia.  The first 3 items will be 
rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 
3 representing a severe condition.  The global clinical evaluation will be made on a 6-point 
scale, with 0 representing absence of symptoms and a score of 5 representing severe 
akathisia.  To complete this scale, subjects will be observed while they are seated and then 
standing for a minimum of 2 minutes in each position.  Symptoms observed in other 
situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) 
may also be rated.  Subjective phenomena are to be elicited by direct questioning.  
Anticholinergics, propranolol, benzodiazepines, and non-benzodiazepine sleep aids are not 
permitted within 12 hours of scale administration (see  Table 5).  Investigators are 
encouraged to delay scale administration until 12 hours have elapsed, if at all possible.  
However, if delaying administration of the scale is not feasible, the BARS should still be 
administered and the use of the medication documented, including a notation of the drug 
name, dose, and time of administration.  The BARS Global Score is defined as the global 
clinical assessment of akathisia.  A copy of the scale is presented in Appendix 9 (Section 
19.0). 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
62


Noven Pharmaceuticals, Inc. 
 
62 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
6.2.5 
Suicidality: Columbia-Suicide Severity Rating Scale (C-SSRS) 
Suicidality will be monitored during the trial using the C-SSRS.
13  The C-SSRS facilitates 
prospective, systematic monitoring for emergence of suicidality within clinical trials and it is 
a low-burden, clinician-administered tool that covers the wide spectrum of suicidality from 
ideation to behavior.  A training tool will be supplied to the site by the Sponsor for use by 
staff members that have not had C-SSRS training within the past 2 years. The site will 
document training of selected staff members and file the training certificates in the trial 
master file. 
This trial will use the “Baseline/Screening” and “Since Last Visit” versions of the scale.  
The “Baseline/Screening” version, which assesses the lifetime experience of the subject with 
suicide events and suicidal ideation and the occurrence of suicide events and/or ideation 
within a specified time period prior to entry into the trial, will be completed for all subjects at 
the Screening and Baseline visits to determine eligibility (prior to the first dose).  Any subject 
with suicidal ideation within the last 6 months or suicidal behavior within the past 12 months 
or who in the clinical judgment of the Investigator presents a serious risk of suicide should be 
excluded from the study. Subjects will also be excluded if they report suicidal ideation or 
suicidal behavior at Baseline. The “Since Last Visit” C-SSRS form will be completed at all 
post-Screening visits.  A copy of the scale is presented in Appendix 10 (Section 20.0). 
6.2.6 
Evaluations of Patch and Dermal Assessments 
Each subject will wear 2 patches simultaneously; both patches will be applied in close 
proximity without overlapping to 1 application site.  Dermal assessments for both patches 
will be assessed but only the worse of the 2 scores will be recorded.  Dermal assessments will 
be conducted as follows:  
 Patch adhesion will be evaluated throughout the day including at the time points during 
which the site staff collects routine vital signs as per hospital policy/SOP; and 
immediately prior to removal of previous day’s patch. In addition, subjects will be asked 
to check patch adhesion throughout the day and report immediately to site personnel if 
the patch detaches completely or detaches partially (i.e., some edges of the patch are 
lifting off the skin). 
 Irritation at the site of patch application will be assessed each day between 30 and 60 
minutes after patch removal. 
 Subjects will be asked to report to the site staff any discomfort or skin irritation due to 
patch.  Discomfort and skin irritation reported by the subjects will be recorded as AEs. 
 Once a week, after removal of the patch, site personnel will assess patch application sites 
for adhesive residue. 
Spontaneous complaints of dermal reactions will be recorded as AEs.  Spontaneous reports 
might include but are not limited to the following:  initial dermal response and exacerbation 
of an existing response. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
63


Noven Pharmaceuticals, Inc. 
 
63 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
The actual time of all scheduled and unscheduled evaluations will be recorded. 
Skin irritation at patch application site  
Thirty to 60 minutes after patch removal site personnel will conduct a visual inspection of the 
skin at the patch application site and will record any irritation observed using the descriptors 
provided in the Berger and Bowman scale14 presented in Table 8. The investigator will assess 
any irritation observed at the patch application site as clinically significant or not clinically 
significant.     
In addition, spontaneous reports of skin irritation by the subject will be recorded as an AE. If 
a subject reports skin irritation, then site personnel will conduct visual inspection of the skin 
at the application site and will record the description of the observed skin irritation using the 
descriptors provided in the Berger and Bowman scale14 presented in Table 8.  
Table 8  
Skin Irritation Descriptors 
Observation 
No evidence of irritation  
Minimal erythema (barely perceptible) 
Definite erythema, readily visible; minimal edema, or minimal papular response 
Erythema and papules 
Definite edema 
Erythema, edema, and papules 
Vesicular eruption 
Strong reaction spreading beyond test (application) site 
Slightly glazed appearance  
Marked glazed appearance  
Glazing with peeling and cracking  
Glazing with fissures  
Film of dried serous exudates covering all or part of the patch site  
Small petechial erosions and/or scabs  
 
Discomfort at patch application site 
Report of discomfort at the patch application site will be recorded as an AE.  If a subject 
reports discomfort at the patch application site, the site personnel will ask the subject to rate 
the discomfort as mild, moderate, or severe, and will ask the subject to describe the 
discomfort.  The description of discomfort as reported by the subject should be recorded 
verbatim. 
Patch adhesion 
Patch adhesion will be assessed by site personnel at the time points defined in the Schedule 
of Events (Table 1).  Adhesion will be evaluated according to Yes/No questions as follows:  
1. Is the patch fully attached to the skin? Yes/No 
2. If ‘No’, did the patch detach completely? Yes/No 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
64


Noven Pharmaceuticals, Inc. 
 
64 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 If “Yes” and the patch/patches are completely detached, the time and activity at the 
time of patch detachment will be documented. 
o If both patches are detached completely, then two new patches from the 
subject’s kit should be applied immediately, provided that there is at least 
6 hours of time remaining before the next dose; 
o If only one patch detaches completely, then the other patch should also be 
removed and two new patches from the subject’s kit should be applied 
immediately, provided that there is at least 6 hours of time remaining before 
the next dose; 
o Under no circumstances should the detached patches be reapplied to the 
subject; and 
o Regardless of what time the new patches are applied, patch removal time of the 
new patches will be approximately 24 hours after the application of the original 
patches.  In other words, removal time of the new patches may not exceed 
24 hours from the time the first patches were applied. 
 If “No” and partial patch detachment (i.e., some edges of the patch are lifting off the 
skin) is observed then the site personnel/subject should smooth the patch down such that 
the complete patch is in contact with the skin again.   
In addition to patch adhesion assessments by site personnel at specified time points, subjects 
should be instructed to should check adhesion of the patch throughout the day and report to 
site personnel immediately if patch detaches completely or if partial patch detachment is 
observed. 
Adhesive Residue 
Once a week, immediately after the removal of a patch, the amount of adhesive residue 
remaining at the application site will be examined by site personnel and graded as described 
in Table 9. 
Table 9  
Adhesive Residue Scale 
Adhesive Residue 
Score  
Definition 
0  
None 
1  
Light  
2  
Medium   
3  
Heavy  
4  
Patch not present 
 
6.3 Pharmacokinetics 
6.3.1 
Pharmacokinetic Blood Sampling 
At least 3 blood samples will be collected at 2, 14, and 22 hours after application of the patch 
with ± 2 hour window on Day 21 and 42.  Actual blood sampling time will be recorded.  
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
65


Noven Pharmaceuticals, Inc. 
 
65 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Blood will be obtained for the determination of asenapine and selected metabolites in human 
plasma as per the instructions provided by the laboratory. 
The samples obtained for PK analysis may be used for analysis of other metabolites in the 
future.  The potential future analysis will be limited to the analysis of study drug metabolites. 
A model-based approach including population PK analysis will be used to assess the impact 
of covariates on asenapine exposure and to explore the exposure-response relationship of 
relevant endpoints.  The detailed methodologies and results will be presented in a separate 
PK analysis report. 
6.3.2 
Drug Concentration Measurements 
The bioanalysis of asenapine and desmethyl-asenapine in plasma samples will be performed 
using a liquid chromatography tandem mass spectrometry method.  The bioanalytical 
methodology and procedures will be documented in a Bioanalytical Study Plan.  The 
Bioanalytical Report will be included in a separate PK analysis report. 
Other asenapine metabolites might be assessed using remaining plasma samples in a separate 
analysis study if deemed necessary. 
6.4 Appropriateness of Measurements 
The efficacy assessments used in this study are standard and validated instruments in this 
population.  The safety assessments include standard measures (hematology, clinical 
chemistry [including prolactin levels], and urinalysis), vital signs, ECGs and physical 
examination findings and dermal adverse events. 
7.0 QUALITY CONTROL AND QUALITY ASSURANCE 
According to the Guidelines of Good Clinical Practice (CPMP/ICH/135/95), the 
Sponsor/designee is responsible for implementing and maintaining quality assurance and 
quality control systems with written Standard Operating Procedures (SOPs).  This study will 
be conducted following Quintiles SOPs. 
Quality control will be applied to each stage of data handling. 
The following steps will be taken to ensure the accuracy, consistency, completeness, and 
reliability of the data: 
 Investigator meeting(s); 
 Central laboratories for clinical laboratory parameters and ECGs; 
 Center Initiation visit; 
 Early center visits post-enrollment; 
 Routine center monitoring; 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
66


Noven Pharmaceuticals, Inc. 
 
66 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
 Ongoing center communication and training; 
 Data management quality control checks; 
 Continuous data acquisition and cleaning;  
 Internal review of data; and 
 Quality control check of the final clinical study report. 
In addition, Sponsor and/or Quintiles Clinical Quality Assurance Department may conduct 
periodic audits of the study processes, including, but not limited to study center, center visits, 
central laboratories, vendors, clinical database, and final clinical study report.  When audits 
are conducted, access must be granted for all study-related documents including medical 
history and concomitant medication documentation to authorized Sponsor’s representatives 
and regulatory authorities. 
7.1 Monitoring 
The Sponsor has engaged the services of a contract research organization (CRO), Quintiles, 
to perform all monitoring functions within this clinical study.  Noven representatives, or their 
designees, will conduct visits to the clinical sites to monitor the various aspects of the study.  
The Investigator agrees to allow these monitors and other authorized Noven personnel, 
including quality assurance monitors, access to the clinical supplies, dispensing and storage 
area, and clinical files of the study subjects, and agrees to assist the Noven personnel in their 
activities, if requested.  Study sites are also subject to inspection by Food and Drug 
Administration (FDA) representatives or other regulatory authorities.  The Investigator 
agrees to assist such inspectors in their duties. 
Prior to each monitoring visit, the Investigator or designee should record all data generated 
since the last visit on the electronic case report forms (eCRFs).  The Investigator and site 
staff will be expected to cooperate with the monitor, and to be available during at least a 
portion of the monitoring visit to sign eCRFs, answer questions, and to provide any missing 
information. 
7.2 Data Management/Coding 
Data generated within this clinical study will be handled according to the relevant SOPs of 
the Data Management and Biostatistics departments of Quintiles. 
Subjects will be enrolled in the study and randomized to a study treatment using the 
IVRS/IWRS.  The IVRS/IWRS and eCRF are validated real-time systems and are compliant 
with Guidance for Industry, Part 11, electronic records; Electronic Signatures – Scope and 
Application; Computerized Systems Used in Clinical Investigations; General Principles of 
Software Validation; Final Guidance for Industry and FDA Staff. 
Electronic Data Capture will be used for this study, meaning that all eCRF data will be 
entered in electronic forms at the study center.  Data collection will be completed by 
authorized study center staff designated by the Investigator.  Appropriate training and 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
67


Noven Pharmaceuticals, Inc. 
 
67 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
security measures will be completed with the Investigator and all authorized study center 
staff prior to the study being initiated and any data being entered into the system for any 
study subjects.  Data management will be conducted under Quintiles SOPs. 
All data must be entered in English.  The eCRFs should always reflect the latest 
observations. 
The eCRF is considered a data entry form and should not constitute the original (or source) 
medical records unless otherwise specified.  Any data captured electronically will be 
pre-specified in the data management plan.  Source documents are all documents used by the 
Investigator or hospital that relate to the subject’s medical history, that verify the existence of 
the subject, the inclusion and exclusion criteria and all records covering the subject’s 
participation in the study.  They include laboratory notes, ECG results, memoranda, 
pharmacy dispensing records, subject files, etc. 
The Investigator is responsible for maintaining source documents.  These will be made 
available for inspection by the Study Monitor at each monitoring visit.  The Investigator must 
submit a completed eCRF for each subject who receives study medication, regardless of 
duration.  All supportive documentation submitted with the eCRF, such as laboratory or 
hospital records, should be clearly identified with the study and subject number.  Any 
personal information, including subject name, should be removed or rendered illegible to 
preserve individual confidentiality. 
Electronic case report form records will be automatically appended with the identification of 
the creator, by means of their unique User ID.  Specified records will be electronically signed 
by the Investigator to document his/her review of the data and acknowledgement that the data 
are accurate.  This will be facilitated by means of the Investigator’s unique User ID and 
password; date and time stamps will be added automatically at time of electronic signature.  
If an entry on an eCRF requires change, the correction should be made in accordance with 
the relevant software procedures.  All changes will be fully recorded in a protected audit trail, 
and a reason for the change will be required. 
Adverse events, medical history, and concomitant diseases will be coded using Medical 
Dictionary for Regulatory Activities (MedDRA) dictionary.  Concomitant medications will 
be coded using the World Health Organization drug dictionary. 
7.3 Quality Assurance Audit 
Study centers, the study database, and study documentation may be subject to Quality 
Assurance audit during the course of the study by the Sponsor or Quintiles.  In addition, 
inspections may be conducted by regulatory bodies at their discretion. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
68


Noven Pharmaceuticals, Inc. 
 
68 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
8.0 STATISTICAL METHODS 
8.1 Determination of Sample Size 
Assuming an effect size of 0.35 on the change in PANSS total score from baseline to Week 6 
for the 2 pairwise comparisons between each active HP-3070 treatment arm and placebo, the 
power for detecting a statistically significant HP-3070 advantage will be approximately 0.90 
having 204 evaluable subjects per each treatment arm using a 2-side alpha level of 0.025 for 
each comparison.  A 2-sided overall Type I error is equal to 0.05.  Having 3 treatment arms, 
the total number of subjects randomized in the trial and included in primary analysis set will 
be approximately 612.  A sufficient number of subjects will be screened to randomize the 
proposed sample size. 
The effect size of 0.35 was chosen based on the lowest effect size observed in results from 
the studies conducted with SL asenapine and approved by FDA (Sycrest
®/SAPHRIS
® 
[Study 041004, and Study 041023]). 
8.2 Sample Size Recalculation 
Sample size recalculation (SSR) will be conducted on the blinded data after approximately 
50% of the desired number of patients have been randomized and completed up to 6 weeks of 
study treatment.  This SSR will be directed and conducted by an independent statistician 
from Quintiles, who is not involved in the trial conduct other than this SSR.   
The purpose of this SSR is to assess the assumption made regarding the sample size 
calculation for the primary endpoint.  No other information will be generated. 
This SSR will NOT be conducted with an intention of decreasing the original sample size or 
stopping the trial early.  There will be no Type I error adjustment due to this SSR. 
8.2.1 
Procedures for Sample Size Recalculation 
The expected common (pooled) standard deviation is 20, which corresponds to a difference 
in means of 7 for our assumed effect size of 0.35.  Using the transferred blinded data, the 
independent statistician will calculate the following metrics for the primary endpoint 
(PANSS Total Score): 
 The common (pooled) SD 
Using these metrics and the original assumptions of mean difference in reduction of PANSS 
scores from Baseline to Week 6, between treatment arms Type I error rate (0.025) and 
90% power of the new sample size will be recalculated.  More details, including decision 
rules and maximum increase in sample size, are available in the Statistical Analysis Plan 
(SAP).  The independent statistician will provide a report which will include the following: 
 Re-estimation of sample size 
 The common SD for the primary endpoint  
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
69


Noven Pharmaceuticals, Inc. 
 
69 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Based on the documented SSR and the observed dropout rate, the independent statistician 
may recommend a new sample size to be sent to the Sponsor for final decision. 
8.3 Study Endpoints 
8.3.1 
Primary Analyses Endpoint 
The primary efficacy endpoint is the change in PANSS total score between Baseline and 
Week 6. 
8.3.2 
Key Secondary Analysis Endpoint 
The key secondary endpoints is: 
 To evaluate the efficacy of HP-3070 compared with placebo for the treatment of 
schizophrenia as evaluated by change in Clinical Global Impression – Severity of Illness 
Scale (CGI-S) scores between Baseline and Week 6 
8.3.3 
Other Secondary Analyses Endpoints 
The other secondary endpoints include: 
 Change from Baseline in PANSS total score at each time point in addition to Week 6; 
 Change from Baseline in CGI-S at each time point in addition to Week 6; 
 CGI-I score at each time point;  
 The proportion of CGI-I responders at each time point including Week 6; CGI-I 
responders are  defined as subjects who have a score of 1 (very much improved) or a 
score of 2 (much improved); 
 Change from Baseline in positive, negative, and general pathology subscores of PANSS 
at each time point; 
 Proportion of PANSS responders; PANSS responders are defined as subjects who have a 
≥30% reduction in PANSS total score between Baseline and at each time point including 
Week 6; 
 Change from Baseline in CDSS score at each time point; and 
 MSQ score at each time point. 
8.3.4 
Exploratory Endpoint 
A model-based approach will be used to assess the impact of covariates on asenapine 
exposure and to explore the exposure-response relationship with relevant endpoints. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
70


Noven Pharmaceuticals, Inc. 
 
70 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
8.4 Statistical Methods 
All analyses, summaries, and listings will be performed using SAS® software (Version 9.2 or 
higher). 
Baseline characteristics, efficacy and safety data will be summarized using the appropriate 
descriptive statistics. 
For the efficacy variables, descriptive statistics (including n, SD, mean, minimum, 
maximum, and 95% CI) for the changes from Baseline during the 6-week treatment period 
will be presented. 
Continuous variables will be summarized by descriptive statistics (sample size [n], mean, 
SD, median, minimum, and maximum).  Categorical variables will be summarized in 
frequency tables (n, frequencies, and percentages).  Individual subject data will be presented 
in listings. 
All statistical tests of treatment effects will be performed at a 2-sided significance level of 
0.05, unless otherwise stated. 
Additional details concerning statistical methods are presented in the SAP. 
All references to study medication refer only to the double-blind treatment period. 
8.4.1 
Analysis Populations 
Four analysis sets will be used in analyzing the data obtained from this protocol: 
Intent-to-Treat (ITT):  includes all consented and randomized subjects.  Regardless of any 
protocol deviations, analyses performed on the ITT set will be based on the randomized 
treatment assignment and all available data. 
Full Analysis Set (FAS):  includes all consented and randomized subjects who have had at 
least 1 patch of double-blind study medication applied and who have a Baseline PANSS total 
score and at least 1 post-Baseline assessment of the primary efficacy measure (PANSS total 
score).  Evaluable subjects will be defined as those who meet the FAS definition.  The FAS 
will be used as the primary set for analysis of efficacy endpoints based on randomized 
treatment assignment. 
Safety Analysis Set (SAF):  includes all subjects who have had at least 1 patch of 
double-blind study medication applied and who have at least 1 post-dose safety measurement 
during the double-blind treatment period.  In the unlikely event that errors may have occurred 
in treatment arm assignments, then analyses using the SAF will be based on treatment 
actually received.  The SAF will be used for the analysis of dermal evaluations and safety 
endpoints. 
Pharmacokinetic Analysis Set (PAS):  includes all subjects who have received at least 1 dose 
of study medication during the double blind treatment period and have at least 1 blood 
sample for PK assessment.  Subjects may be excluded from the PAS set if they significantly 
violate inclusion or exclusion criteria, significantly violate the protocol in a way that may 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
71


Noven Pharmaceuticals, Inc. 
 
71 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
influence the PK analysis, if any unexpected error occurs during the study that may influence 
the PK analysis (e.g., early detachment of transdermal systems, apparent sample switching, 
etc.) or if their data are unavailable or incomplete.  The PAS will be used for the analysis 
with model based approach.  Excluded cases will be documented together with the reason for 
exclusion. 
8.4.2 
Primary Efficacy Analysis 
The primary efficacy analysis (the analysis of the primary variable) will be performed on the 
Full Analysis Set (FAS). 
The primary efficacy variable, change from Baseline to Week 6 in the PANSS total score for 
each of the 3 treatment arms, will be analyzed using a mixed model repeated measures 
(MMRM) analysis.  The MMRM model will include change from Baseline in PANSS total 
score as the repeated dependent variable, with country, treatment (HP-3070-9.0 [9.0 mg], 
HP-3070-18.0 [18.0 mg], and placebo), visit, treatment by visit interaction, and the Baseline 
PANSS total score as covariates.  An unstructured covariance matrix will be assumed.  In the 
event the convergence cannot be attained with the unstructured correlation matrix, the 
following alternative structures will be attempted in the specified order (from least to most 
restrictive):  heterogeneous Toeplitz structure (TOEPH), heterogeneous autoregressive (1) 
(ARH[1]), heterogeneous compound symmetry (CSH), No Diagonal Factor Analytic 
(FA0[q], with q equal to the number of time points), Toeplitz structure (TOEP), 
autoregressive (1) (AR[1]), and compound symmetry (CS).  If either ARH(1) or AR(1) 
structure is used, a random subject intercept will also be included in the model.  
The MMRM model may be repeated on additional analysis sets as a sensitivity analysis. 
If the normality assumption is violated, ANCOVA analysis on rank-transformed data will be 
used as a supportive analysis. 
8.4.3 
Key Secondary Efficacy Analysis 
Change from Baseline to Week 6 in the CGI-S scores will be assessed using the same 
MMRM model used for the change in PANSS scores.   
Each study drug dose will be compared with placebo and model-based point estimates for the 
treatment effects, 95% confidence intervals (CIs), and p-values will be calculated.  The 
analysis set will be the FAS. 
In order to control the family-wise Type I error rate, the Hochberg-based matched parallel 
gatekeeping procedure will be used to account for multiple doses and multiple primary and 
key secondary endpoints.   
The primary and key secondary efficacy hypotheses will be grouped into 2 hierarchical 
families.  Family 1 is the HP-3070-9.0 versus placebo (Hypothesis 1) and HP-3070-18.0 
versus placebo (Hypothesis 2), based on the primary endpoint of change from baseline in 
PANSS total score at Week 6.  Family 2 is HP-3070-9.0 versus placebo (Hypothesis 3) and 
HP3070-18 versus placebo (Hypothesis 4), based on the key secondary endpoint of change 
from Baseline in CGI-S at Week 6.  
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
72


Noven Pharmaceuticals, Inc. 
 
72 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
The matched parallel gatekeeping procedure performs multiplicity adjustments as follows: 
1. The comparisons for the primary endpoint (Hypotheses 1 and 2) are performed using 
a truncated Hochberg procedure (gamma = 0.9). 
2. The comparisons for CGI-S (Hypotheses 3 and 4) corresponding to the doses that 
were significant in Step 1 are performed, using a regular Hochberg procedure. 
Further details are provided in the SAP. 
8.4.4 
Other Secondary Efficacy Analyses 
The same statistical model will be used for the analysis for the change from Baseline in the 
PANSS subscales, CDSS, CGI-S, and the scores for CGI-I, and MSQ at each assessment.  
The differences in proportions of CGI-I, and PANSS responders will be analyzed using the 
Cochran-Mantel-Haenszel Test.  
Details are provided in the SAP. 
8.4.5 
Subgroup Analyses 
Details of subgroup analyses for primary and key secondary objectives are described in the 
SAP. 
8.4.6 
Safety Analyses 
Safety analyses will be performed on the Safety Analysis Set (SAF). 
Scores for C-SSRS, SAS, BARS, and AIMS will be summarized for each treatment arm 
using descriptive statistics at each visit for raw numbers and change from baseline values. 
Adverse events will be coded using MedDRA.  The collection of AEs will begin after the 
subject has signed the ICF.  The TEAEs during the double-blind treatment period are defined 
as AEs with onset date on or after the start of study medication through the 30 day follow-up 
period, or AEs with onset prior to the first dose of study medication and with an increase in 
severity after the start of study medication through the 30 days follow-up period.  The same 
rule applies for Run-in Period. 
For each study treatment, numbers of events and incidence rates will be tabulated by 
preferred term and system organ class.  Adverse events will be summarized separately for the 
Screening/Run-in Period and Double-blind Treatment Period.  Adverse events will be 
summarized by severity and relationship to drug.  If the subject has the same AE on multiple 
occasions, the summary will reflect the maximum severity or closest relationship reported. 
The SAEs, including death as an outcome, and AEs leading to withdrawal of subjects will be 
tabulated for each treatment arm.  Commonly occurring AEs, i.e., those which occur in 5% or 
more of the subjects in any treatment arm will be summarized using descriptive statistics. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
73


Noven Pharmaceuticals, Inc. 
 
73 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
All laboratory test results, vital signs measurements, ECG results, weight, and body mass 
index will be summarized for each treatment arm using descriptive statistics at each visit for 
raw numbers and change from baseline values. 
Patch adhesion and adhesive residue assessment results will be summarized at each visit by 
treatment arm, and by treatment arm overall. 
The results of the PK analyses will be presented in a stand-alone report. 
8.4.7 
Data to be Analyzed 
Data handling will be the responsibility of Quintiles.  The data will be inspected for 
inconsistencies by performing validation checks. 
All details regarding the statistical analysis and the preparation of tables, listings and figures 
will be described in the SAP prepared by Quintiles and approved by the Sponsor before 
database lock. 
The statistical analysis will be performed by Quintiles.  After database lock, the final SAS 
data sets in SDTM and ADaMs formats will be transferred to Noven with SAS programs and 
all supportive documentation. 
8.4.8 
Missing Data 
MMRM is the best method to control Type I error rate and minimize bias in the presence of 
missing data, although this does not fully overcome the issues and assumptions are still 
required to be made regarding the missing data mechanisms.  Nevertheless, in the presence of 
a high dropout rate performance of sensitivity analysis is critical.  The purpose of sensitivity 
analysis is to explore whether different analyses under different sets of missingness 
assumptions provide robust efficacy results.  The sensitivity analysis will be performed on 
primary endpoints.  The extent to which efficacy results are stable across such an analysis 
provides confidence in the statistical conclusions. 
 Missing data can be considered to be missing completely at random (MCAR), missing at 
random (MAR), or missing not at random (MNAR) according to the National Academy 
of Sciences (2010).  Details are provided in the SAP.  
8.5 Subject Disposition and Characteristics 
The disposition summary will include all enrolled subjects.  Subject characteristics will be 
obtained at Screening and will be summarized for all subjects.  Summaries will include 
descriptive statistics for continuous variables (sample size, mean, and SD, median, minimum, 
and maximum) and for categorical variables (sample size, frequency and percent).  Subject 
characteristics may include, but are not limited to:  age, gender, race/ethnicity, height, 
weight, and body mass index. 
8.6 Safety 
Safety variables will be summarized based on the SAF. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
74


Noven Pharmaceuticals, Inc. 
 
74 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
8.6.1 
Adverse Events 
The TEAEs are defined as AEs that first occurred or worsened in severity after the first 
administration of the study drug.  Adverse event summaries will include incidence of TEAEs 
by MedDRA preferred term and system organ class, SAEs (including deaths), AEs that led to 
study drug discontinuation, AEs by severity, and AEs by relationship to study drug. 
8.6.2 
Clinical Laboratory Evaluations 
Laboratory assessments will be presented as mean changes from Baseline and incidence of 
abnormal values.  Shift tables will be presented for selected parameters.  Of special interest 
are prolactin levels, fasting glucose, and lipids. 
8.6.3 
Vital Signs Measurements, Physical Findings and Other Safety Evaluations 
Descriptive statistics for the change from Baseline will be summarized at each visit for 
C-SSRS, SAS, BARS, and AIMS. 
Mean changes from Baseline and incidence of treatment-emergent abnormal vital signs, 
weight, and ECG results will be summarized.  The number and proportion of subjects with 
orthostatic hypotension will also be summarized. 
8.6.4 
Dermal Evaluations 
Data for patch adhesion and adhesive residue assessment will be presented and summarized 
at each visit by treatment arm, and by treatment arm overall.  Data for skin irritation and 
discomfort will be presented as TEAEs. 
8.7 Pharmacokinetic Analyses 
Plasma asenapine and desmethyl asenapine concentrations will be analyzed and listed. 
A model-based approach will be used to assess the impact of covariates on asenapine 
exposure and to explore the exposure-response relationship of relevant endpoints.  Details on 
the methodology of population PK model development, exposure-response analysis and 
model-based simulations will be included in a standalone PK report. 
8.8 Interim Analyses 
No interim analysis for efficacy is planned. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
75


Noven Pharmaceuticals, Inc. 
 
75 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
9.0 ETHICS 
9.1 Institutional Review Board or Independent Ethics Committee 
An Ethics Committee should approve the final protocol, including the final version of the 
ICF and any other written information and/or materials to be provided to the subjects.  
The Investigator will provide the Sponsor or Quintiles with documentation of IRB/IEC 
approval of the protocol and informed consent before the study may begin at the study 
center(s).  The Investigator should submit the written approval to the Sponsor/designee 
before enrollment of any subject into the study. 
Sponsor/designee should approve any modifications to the ICF that are needed to meet local 
requirements. 
The Investigator will supply documentation to the Sponsor or Quintiles of required 
IRB/IEC’s annual renewal of the protocol, and any approvals of revisions to the informed 
consent document or amendments to the protocol. 
The Investigator will report promptly to the IRB/IEC any new information that may 
adversely affect the safety of subjects or the conduct of the study.  Similarly, the Investigator 
will submit written summaries of the study status to the IRB/IEC annually, or more 
frequently if requested by the IRB/IEC.  Upon completion of the study, the Investigator will 
provide the Ethics Committee with a brief report of the outcome of the study, if required. 
9.2 Ethical Conduct of the Study 
This study will be conducted and the informed consent will be obtained according to the 
ethical principles stated in the Declaration of Helsinki (48th General Assembly, Somerset 
West, Republic of South Africa, October 2008 [or current version]), the applicable guidelines 
for GCP (CPMP/ICH/135/95), or the applicable drug and data protection laws and 
regulations of the countries where the study will be conducted. 
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting studies that involve the participation of 
human subjects.  The study will be conducted in compliance with GCP and the applicable 
national regulations so as to assure that the rights, safety, and well-being of the participating 
study subjects are protected consistent with the ethical principles that have their origin in the 
Declaration of Helsinki. 
9.3 Subject Information and Informed Consent 
The ICF will be used to explain the risks and benefits of study participation to the subject in 
simple terms before the subject will be entered into the study.  The ICF contains a statement 
that the consent is freely given, that the subject is aware of the risks and benefits of entering 
the study, and that the subject is free to withdraw from the study at any time.  Written 
consent must be given by the subject and/or legal representative, after the receipt of detailed 
information on the study. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
76


Noven Pharmaceuticals, Inc. 
 
76 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
The Investigator is responsible for ensuring that informed consent is obtained from each 
subject or legal representative and for obtaining the appropriate signatures and dates on the 
informed consent document prior to the performance of any protocol procedures and prior to 
the administration of study medication.  The Investigator will provide each subject with a 
copy of the signed and dated consent form. 
9.4 Study Administration 
9.5 Administrative Structure 
Central organizations used for the conduct, monitoring, and/or evaluation of this trial are 
provided on the Contact List. 
A Medical Advisor will be made available to every Investigator as designated by the 
Sponsor.  The central and regional Medical Advisors will consult with sites on general 
eligibility questions, subject safety, protocol conduct, compliance, as well as additional tasks 
specified in the protocol.  The Medical Advisor will also work closely with the local clinical 
and safety teams designated by the Sponsor.  The administrative structure is presented in 
Table 10. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
77


Noven Pharmaceuticals, Inc. 
 
77 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
Table 10  
Administrative Structure 
Data Management 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, NC 27703  
Biostatistics 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, NC 27703 
Medical Writing 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, NC 27703 
Clinical Manager 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, NC 27703 
Medical Advisor 
Elena Vlad, MD, Psych, PhD 
Medical Director, Medical and Scientific Services
Quintiles, Inc. 
4820 Emperor Drive 
Durham, NC 27703 
Clinical Safety 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, NC 27703 
Electronic Data Capture  
Oracle 
Health Sciences Global Business Unit 
77 Fourth Avenue 
Waltham, MA 02451 
 
ERT (eResearch Technology) 
1818 Market Street, Suite 1000 
Philadelphia, PA 19103 
Clinical Research Organization 
Quintiles, Inc. 
4820 Emperor Drive 
Durham, NC 27703 
Scale Management and Training 
ProPhase, LLC. 
3 Park Avenue, 28th & 37th Floor 
New York, NY 10016 
 
ERT (eResearch Technology) 
1818 Market Street, Suite 1000 
Philadelphia, PA 19103 
Central ECG reading 
Quintiles Data processing Centre (India) Pvt. Ltd. 
502-A, Leela Business Park, 
M.V.Road, Andheri-(East), 
Mumbai-400059 
India 
 
Quintiles Data processing Centre (India) Pvt. Ltd. 
Third Floor, Etamin Block, Prestige Technology Park II, 
Bellandur, Sarjapur-Marathahalli outer Ring road, 
Banglore-560103, Karnataka 
India 
IVRS/IWRS 
Cenduit, LLC 
4825 Creekstone Drive 
Suite 400  
Durham, NC 27703 
Central Laboratory 
Q2 Solutions 
27027 Tourney RoadSuite 2E 
Valencia, CA 91355 
Model Based Analysis 
Metrum Research Group, LLC 
2 Tunxis Rd., Suite 112,  
Tariffville, CT 06081 
Bioanalytic Lab 
Q2 Solutions 
19 Brown Rd 
Ithaca, NY 14850 
 
9.6 Data Handling and Record Keeping 
It is the Investigator’s responsibility to maintain essential study documents (protocol and 
protocol amendments, completed eCRFs, signed ICFs, relevant correspondence, and all other 
supporting documentation).  The study site should plan on retaining such documents for 
approximately 15 years after study completion.  The study site should retain such documents 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
78


Noven Pharmaceuticals, Inc. 
 
78 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
until at least 2 years after the last approval of a marketing application in an ICH region and 
until there are no pending or contemplated marketing applications in an ICH region or at 
least 2 years after the formal discontinuation of clinical development of the investigational 
product.  These documents should be retained for a longer period if required by the 
applicable regulatory requirements or the hospital, institution, or private practice in which the 
study is being conducted.  Subject identification codes (subject names and corresponding 
study numbers) will be retained for this same period of time.  These documents may be 
transferred to another responsible party, acceptable to Sponsor, who agrees to abide by the 
retention policies.  Written notification of transfer must be submitted to Sponsor.  
The Investigator must contact Sponsor prior to disposing of any study records. 
9.7 Direct Access to Source Data/Documents 
The Investigator will prepare and maintain adequate and accurate source documents to record 
all observations and other pertinent data for each subject randomized into the study. 
The Investigator will allow the Sponsor, Quintiles, and authorized regulatory authorities to 
have direct access to all documents pertaining to the study, including individual subject 
medical records, as appropriate. 
9.8 Investigator Information 
9.8.1 
Investigator Obligations 
This study will be conducted in accordance with the ICH Harmonized Tripartite Guideline 
for GCP (GCP, 1997; the US CFR Title 21 parts 50, 56, and 312; and European Legislation); 
and the ethical principles that have their origin in the Declaration of Helsinki. 
The Investigator agrees to conduct the clinical study in compliance with this protocol after 
the approval of the protocol by the IEC/IRB in compliance with local regulatory 
requirements.  The Investigator and the Sponsor will sign the protocol to confirm this 
agreement. 
9.8.2 
Protocol Signatures 
After reading the protocol, each Investigator will sign the protocol signature page and send a 
copy of the signed page to the Sponsor or representative.  By signing the protocol, the 
Investigator confirms in writing that he/she has read, understands and will strictly adhere to 
the study protocol and will conduct the study in accordance with ICH Tripartite Guidelines 
for Good Clinical Practice and applicable regulatory requirements.  The study will not be 
able to start at any center where the Investigator has not signed the protocol. 
9.8.3 
Publication Policy  
The data generated by this study are confidential information of the Sponsor.  The Sponsor 
will make the results of the study publicly available.  The publication policy with respect to 
the Investigator and study center will be set forth in the Clinical Trial Agreement. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
79


Noven Pharmaceuticals, Inc. 
 
79 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
9.9 Financing and Insurance  
The Sponsor has obtained liability insurance, which covers this study as required by local 
law and/or national regulations and/or ICH guidelines whichever is applicable.  The terms of 
the insurance will be kept in the study files. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
80


Noven Pharmaceuticals, Inc. 
 
80 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
10.0 REFERENCES 
1. http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml.  Accessed May 14, 
2015. 
2. Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, et al. 
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors positron 
emission tomography study with [
11C]-PHNOArch. Gen Psychiatry. 
2009;66(6):606-615. 
3. SAPHRIS® Summary Basis of Approval. 
4. Friberg, L.E., de Greef, R., Kerbusch, T. and Karlsson, M.O. Modeling and 
simulation of the time course of asenapine exposure response and dropout patterns in 
acute schizophrenia. Clin Pharmacol Ther.  2009(86):84-91. 
5. Chapel S, Hutmacher M, Haig G, et al.  Exposure-response analysis in patients with 
schizophrenia to assess the effect of asenapine on QTc prolongation.  Journal of 
Clinical Pharm, 2009;49:1297-1308. 
6. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P, Janavs J, Weiller E, 
Hergueta T, Baker R, Dunbar G. The M.I.N.I. International Neuropsychiatric 
Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic 
Psychiatric Interview. J Clin Psychiatry. 1998;59(suppl 20):22-33. 
7. Kay SR, Opler LA, Fiszbein A.  Positive and negative syndrome scale (PANSS) 
rating criteria. Schizophr Bull. 1987;13(2):261-76. 
8. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of 
Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National 
Institute of Mental Health; 1976. 
9. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in 
schizophrenia: The Calgary Depression Scale. Br J Psychiatry Suppl. 
1993;(22):39-44. 
10. Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the 
Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with 
antipsychotic medication among schizophrenia patients. Schizophr Res. 
2010;118(1-3):271-278. 
11. Simpson GN, Angus JWS.  A rating scale for extrapyramidal side effects. 
Acta Psychiatr Scand. 1970;212 (Suppl 44): S11-S19. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
81


Noven Pharmaceuticals, Inc. 
 
81 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
12. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 
1989;154(5):672-6. 
13. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA et al. The 
columbia-suicide severity rating scale. Initial validity and internal consistency 
findings from three multisite studies with adolescents and adults. Am J Psychiatry. 
2011;168(12):1266-1277.  
14. Berger, RS, Bowman, JP. A reappraisal of the 21-day cumulative irritation test in 
man. J. Toxicol. Ot. & Ocular Toxicol. 1982;1(2);109-115. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
82


Noven Pharmaceuticals, Inc. 
 
 
HP-3070-GL-04 
HP-3070 
Protocol Version 2.0 Amendment 1: 20 January 2016 
Protocol Final Version: 16 November 2015  
 
 
Confidential 
 
11.0 APPENDIX 1: SIGNATURE OF INVESTIGATOR 
PROTOCOL TITLE:  A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 
6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 
in Subjects Diagnosed with Schizophrenia 
PROTOCOL NO:  
HP-3070-GL-04 
This protocol is a confidential communication of Noven.  I confirm that I have read this 
protocol, I understand it, and I will work according to this protocol.  I will also work 
consistently with the ethical principles that have their origin in the Declaration of Helsinki 
and that are consistent with good clinical practices and the applicable laws and regulations.  
Acceptance of this document constitutes my agreement that no unpublished information 
contained herein will be published or disclosed without prior written approval from Noven 
Pharmaceuticals, Inc. 
Instructions to the Investigator:  Please SIGN and DATE this signature page.  PRINT your name, title, and the 
name of the center in which the study will be conducted.  Return the signed copy to Quintiles, Inc. 
 
I have read this protocol in its entirety and agree to conduct the study accordingly: 
 
Signature of Investigator:    
___________________________  Date: ______ 
Printed Name:   
  
  
___________________________ 
Investigator Title:    
  
___________________________ 
 
Name/Address of Center:    
___________________________ 
  
  
  
  
  
___________________________ 
  
  
  
  
  
___________________________ 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
83


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
12.0 APPENDIX 2: POSITIVE AND NEGATIVE SYNDROME 
SCALE (PANSS) 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
84


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
85


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
86


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
87


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
88


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
89


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
90


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
91


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
92


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
93


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
94


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
95


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
96


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
97


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
98


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
99


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
100


P
 A
 N
 S
 S
Po
s
i
t
ive
 and
 Nega
t
ive
 Syndrome
 Sca
le
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
101


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
102


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
103


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
104


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
105


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
106


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
107


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
108


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
109


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
110


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
111


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
112


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
113


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
114


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
115


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
116


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
117


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
118


P1. Delusions
P2. Conceptual disorganization
P3. Hallucinatory behavior
P4. Excitement
P5. Grandiosity
P6. Suspiciousness/persecution
P7. Hostility
N1. Blunted affect
N2. Emotional withdrawal
N3. Poor rapport
N4. Passive/apathetic social withdrawal
N5. Difficulty in abstract thinking
N6. Lack of spontaneity and flow of conversation
N7. Stereotyped thinking
G1. Somatic concerns
G2. Anxiety
G3. Guilt feelings
G4. Tension
G5. Mannerisms and posturing
G6. Depression
G7. Motor retardation
G8. Uncooperativeness
G9. Unusual thought content
G10. Disorientation
G11. Poor attention
G12. Lack of judgment and insight
G13. Disturbance of volition
G14. Poor impulse control
G15. Preoccupation
G16. Active social avoidance
S1. Anger
S2. Difficulty in delaying gratification
S3. Affective lability
PANSS
QuikScore™
Form
1 = Absent
2 = Minimal
3 = Mild
4 = Moderate
5 = Moderate/ Severe
6 = Severe
7 = Extreme
Use this scale for all items:
Patient Name or ID: ______________________________      Rater: ________________      Date: ___ / ___ / ___
Copyright © 1992, 2000 Multi-Health Systems Inc.
All  
rights  
reserved.
 In the U.S.A., P
.O. Box 950, North Tonawanda, NY 14120-0950, (800) 456-3003.
In Canada, 3770 Victoria Park Avenue, Toronto, ON M2H 3M6,  (800) 268-6011.
Internationally
,  +1-416-492-2627.
Fax, +1-416-492-3343 or (888) 540-4484.
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
119


P1
P2
P3
P4
P5
P6
P7
N1
N2
N3
N4
N5
N6
N7
G1
G2
G3
G4
G5
G6
G7
G8
G9
G10
G11
G12
G13
G14
G15
G16
S1
S2
S3
SUMS
Positive
Negative
Positive minus
Negative
COMPOSITE
General
Anergia
Thought
Disturbance
Activation
Paranoid/
Belligerence
Depression
Supplemental
Thought
Paranoid/
Positive 
Negative 
General 
Anergia  Disturbance Activation 
Belligerence Depression Supplemental
Thought
Paranoid/
Positive 
Negative 
General 
Anergia  Disturbance Activation 
Belligerence Depression Supplemental
SUMS
PANSS
QuikScore™
Form
Patient Name or ID: ______________________________      Rater: ________________      Date: ___ / ___ / ___
Copyright  ©  1992,  1999,  Multi-Health  Systems  Inc. All  rights  reserved.  In  the  U.S.A.,  P
.O.  Box  950,  North  Tonawanda,  NY  14120-0950,  (800)  456-3003.
In  Canada,  3770  Victoria  Park Avenue,  Toronto,  ON  M2H  3M6,  (800)  268-6011.  Internationally,  +1-416-492-26270.  Fax,  +1-416-492-3343  or  (888)  540-4484.
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
120


General
Thought
Paranoid/
Positive 
Negative 
Composite Psychopath. 
Anergia  Disturbance Activation Belligerence Depression
99 100+
37+ 
87+
27+
20+
27+ 
100+ 99
99 99
36
86
99 
99
99 98
35
85
26
19
26 
98 
99
99 97
84
97 
99
99 96 
49
34
83
21
96 
99
99 95 
48
33
82
25
25 
95 
99
99 94
49
32
81
18
94 
99
99 93 
47
80
20
93 
99
99 92 
46
48
31
24
24 
92 
99
99 91
47
30
79
91 
99
99 90 
45
29
78
17
90 
99
99 89 
44
46
28
77
23
19
23 
89 
99
99 88
76
88 
99
99 87 
43
45
27
75
16
22 
87 
99
99 86
44
26
74
22
18
86 
99
99 85 
42
25
73
85 
99
99 84 
41
43
72
28
21 
84 
99
99 83
42
24
71
21
15
17
83 
99
99 82 
40
23
70
27
82 
99
99 81 
39
41
22
69
20 
81 
99
99 80
21
68
20
26
80 
99
99 79 
38
40
67
14
16
79 
99
99 78
39
20
66
19 
78 
99
99 77 
37
19
65
19
25
77 
99
99 76 
36
38
18
64
15
76 
99
99 75
37
63
24
13
18 
75 
99
99 74 
35
17
62
18
74 
99
99 73 
34
36
16
23
73 
99
99 72
15
61
14
17 
72 
99
99 71 
33
35
14
60
17
22
12
71 
99
98 70
34
59
70 
98
97 69 
32
13
58
21
13
16 
69 
97
96 68 
31
33
12
57
16
68 
96
96 67
32
11
56
20
11
15 
67 
96
95 66 
30
55
12
66 
95
93 65 
29
31
10
54
15
65 
93
92 64
9
53
19
14 
64 
92
90 63 
28
30
8
52
10
63 
90
89 62
29
51
14
18
11
62 
89
86 61 
27
7
50
13 
61 
86
84 60 
26
28
6
49
17
9
60 
84
82 59
5
48
13
10
59 
82
79 58 
25
27
4
47
16
12 
58 
79
76 57 
24
26
46
57 
76
73 56
3
45
12
15
8
56 
73
69 55 
23
25
2
44
9
11 
55 
69
66 54
24
1
43
14
54 
66
62 53 
22
11
53 
62
58 52 
21
23
0
42
7
8
10 
52 
58
54 51
-1
41
13
51 
54
50 50 
20
22
-2
40
10
50 
50
46 49 
19
21
-3
39
12
7
9 
49 
46
42 48
38
6
48 
42
38 47 
18
20
-4
37
9
11
47 
38
35 46
19
-5
36
8
46
35
31 45 
17
-6
35
10
6
45 
31
27 44 
16
18
34
8
5
7 
44 
27
24 43
-7
33
9
43 
24
21 42 
15
17
-8
32
5
42 
21
18 41 
14
16
-9
31
7
8
6 
41 
18
16 40
-10
30
4
40 
16
14 39 
13
15
29
4
39 
14
12 38
14
-11
28
6
7
5 
38 
12
10 37 
12
-12
27
3
37 
10
8
36  
11  
13 
-13  
26
6
36  8
7
35
25  
5
3  
4  
35  7
6
34  
10  
12 
-14
5
34  6
5
33  
9  
11 
-15  
24
33 
5
4
32
-16
Ô23
4
4
32 
4
3
31
Ô8
Ô10
31 
3
2
30
Ô-17
30 
2
Patient Name or ID: ______________________________      Rater: ________________      Date: ___ / ___ / ___
Positive and Negative Syndrome Scale (PANSS) Profile Form
%ile
%ile
T
T
Copyright  ©  1992,  1999,  Multi-Health  Systems  Inc. All  rights  reserved.  In  the  U.S.A.,  P
.O.  Box  950,  North  Tonawanda,  NY  14120-0950,  (800)  456-3003.
In  Canada,  3770  Victoria  Park Avenue,  Toronto,  ON  M2H  3M6,  (800)  268-6011.  Internationally,  +1-416-492-26270.  Fax,  +1-416-492-3343  or  (888)  540-4484.
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
121


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
13.0 APPENDIX 3: CLINICAL GLOBAL IMPRESSION - 
SEVERITY OF ILLNESS SCALE (CGI-S) 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
122


Clinical Global Impression- Severity of Illness Scale
Considering your total clinical experience with this particular population, how mentally ill is the 
patient at this time? 
0 = Not assessed  
  
 
4 = Moderately ill
1 = Normal, not at all ill  
  
5 = Markedly ill
2 = Borderline mentally ill    
6 = Severely ill
3 = Mildly ill   
  
  
7 = Among the most extremely ill patients
Reference:  Guy W. ECDEU Assessment Manual For Psychopharmacology. US Department of Health, Education, 
and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
123


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
14.0 APPENDIX 4: CLINICAL GLOBAL IMPRESSION - 
IMPROVEMENT SCALE (CGI-I) 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
124


Clinical Global Impression - Improvement Scale 
Reference:
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
125


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
15.0 APPENDIX 5: CALGARY DEPRESSION SCALE FOR 
SCHIZOPHRENIA (CDSS) 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
126


Interviewer:  
  
  Ask  
the  
first  question  as  written.  Use  
follow  up  probes  or  qualifiers  at  your  discretion.  Time  
frame 
refers to last two weeks unless stipulated. N.B.The last item, #9, is based on observations of the entire interview. 
1. DEPRESSION: How would you describe your mood over the last two 
weeks? Do you keep reasonably cheerful or have you been very 
depressed or low spirited recently? In the last two weeks how often 
have you (own words) every day? All day? 
0. Absent 
1. Mild  
Expresses some sadness or discouragement on questioning. 
2. Moderate  
Distinct depressed mood persisting up to half the time over last 
2 weeks: present daily. 
3. Severe  
Markedly depressed mood persisting daily over half the time 
interfering with normal motor and social functioning. 
2. HOPELESSNESS: How do you see the future for yourself? Can you 
see any future? - or has life seemed quite hopeless? Have you given 
up or does there still seem some reason for trying? 
0. Absent 
1. Mild  
Has at times felt hopeless over the last two weeks but still has 
some degree of hope for the future. 
2. Moderate  Persistent, moderate sense of hopelessness over last week. Can 
be persuaded to acknowledge possibility of things being better. 
3. Severe  
Persisting and distressing sense of hopelessness. 
3. SELF D
EPRECIATION: What is your opinion of your self compared 
to other people? Do you feel better, not as good, or about the same 
as others? Do you feel inferior or even worthless? 
0. Absent 
1. Mild  
Some inferiority; not amounting to feeling of worthlessness. 
2. Moderate  Subject feels worthless, but less than 50% of the time. 
3. Severe  
Subject feels worthless more than 50% of the time. May be 
challenged to acknowledge otherwise. 
4. GUILTY I
DEAS O
F R
EFERENCE: Do you have the feeling that you  
are being blamed for something or even wrongly accused? What  
about? (Do not include justifiable blame or accusation. Exclude  
delusions of guilt.) 
0. Absent 
1. Mild  
Subject feels blamed but not accused less than 50% of the time. 
2. Moderate  Persisting sense of being blamed, and/or occasional sense of 
being accused. 
3. Severe  
Persistent sense of being accused. When challenged, 
acknowledges that it is not so. 
5. PATHOLOGICAL G
UILT: Do you tend to blame yourself for little 
things you may have done in the past? Do you think that you deserve  
to be so concerned about this? 
0. Absent 
1. Mild  
Subject sometimes feels over guilty about some minor 
peccadillo, but less than 50% of time. 
2. Moderate  Subject usually (over 50% of time) feels guilty about past 
actions the significance of which he exaggerates. 
3. Severe  
Subject usually feels s/he is to blame for everything that has 
gone wrong, even when not his/her fault. 
6. MORNING D
EPRESSION: When you have felt depressed over the last  
2 weeks have you noticed the depression being worse at any  
particular time of day? 
0. Absent  
No depression. 
1. Mild  
Depression present but no diurnal variation. 
2. Moderate  
Depression spontaneously mentioned to be worse in a.m. 
3. Severe  
Depression markedly worse in a.m., with impaired functioning 
which improves in p.m. 
7. EARLY W
AKENING: Do you wake earlier in the morning than is  
normal for you? How many times a week does this happen? 
0. Absent  
No early wakening. 
1. Mild  
Occasionally wakes (up to twice weekly) 1 hour or more before 
normal time to wake or alarm time. 
2. Moderate  
Often wakes early (up to 5 times weekly) 1 hour or more before 
normal time to wake or alarm. 
3. Severe  
Daily wakes 1 hour or more before normal time. 
8. SUICIDE: Have you felt that life wasn’t worth living? Did you ever  
feel like ending it all? What did you think you might do? Did you  
actually try? 
0. Absent 
1. Mild  
Frequent thoughts of being better off dead, or occasional 
thoughts of suicide. 
2. Moderate  
Deliberately considered suicide with a plan, but made no 
attempt. 
3. Severe  
Suicidal attempt apparently designed to end in death (i.e.: 
accidental discovery or inefficient means). 
9. OBSERVED D
EPRESSION: Based on interviewer’s observations  
during the entire interview. The question “Do you feel like crying?”  
used at appropriate points in the interview, may elicit information  
useful to this observation. 
0. Absent 
1. Mild  
Subject appears sad and mournful even during parts of the 
interview, involving affectively neutral discussion. 
2. Moderate 
Subject appears sad and mournful throughout the interview, with 
gloomy monotonous voice and is tearful or close to tears at times. 
3. Severe  
Subject chokes on distressing topics, frequently sighs deeply 
and cries openly, or is persistently in a state of frozen misery if 
examiner is sure that this is present. 
© Dr. Donald Addington and Dr. Jean Addington.  
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
127


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
16.0 APPENDIX 6: MEDICATION SATISFACTION 
QUESTIONNAIRE (MSQ) 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
128


MEDICATION SATISFACTION QUESTIONNAIRE 
Overall, how satisfied are you with your current medication? 
Extremely 
Very 
Somewhat 
Neither 
Somewhat 
Very satisfied 
Extremely 
dissatisfied 
dissatisfied 
dissatisfied 
dissatisfied 
satisfied 
satisfied 
nor satisfied 
0 1  0 2  0 3  0 4 
O s 
0 6  0 7 
"Spanish Medication Satisfaction Questionnaire", translated 
from English lo Spanish by Edith Grandiccelli de Talamo, on September 
3, 2007 from "Medication Satisfaction Questionnaire", . 
© 2010 International Society for 
CNS Drug Development 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
129


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
17.0 APPENDIX 7: SIMPSON ANGUS SCALE (SAS) 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
130


SIMPSON-ANGUS SCALE (SAS) 
Copyright © Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects.  
Acta Psychiatrica Scandinavica 212:11–19, 1970. Reproduced with permission of Blackwell Publishing Ltd 
 
SAS - United States/English - Mapi. 
ID7808 / SAS_AU1.0_eng-USori.doc 
1
SIMPSON-ANGUS SCALE 
 
(SAS) 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
131


SIMPSON-ANGUS SCALE (SAS) 
Copyright © Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects.  
Acta Psychiatrica Scandinavica 212:11–19, 1970. Reproduced with permission of Blackwell Publishing Ltd 
 
SAS - United States/English - Mapi. 
ID7808 / SAS_AU1.0_eng-USori.doc 
2
 
 
1. GAIT:  
The patient is examined as he walks into the examining room, his gait, the swing of his arms, his general 
posture, all form the basis for an overall score for this item. This is rated as follows:  
 
 
 
0 = Normal  
 
 
 
1 = Diminution in swing while the patient is walking  
 
 
 
2 = Marked diminution in swing with obvious rigidity in the arm  
 
 
 
3 = Stiff gait with arms held rigidly before the abdomen  
 
 
 
4 = Stooped shuffling gait with propulsion and retropulsion  
 
 
 
 
 
 
2. ARM DROPPING:  
The patient and the examiner both raise their arms to shoulder height and let them fall to their sides. In 
a normal subject a stout slap is heard as the arms hit the sides. In the patient with extreme Parkinson's 
syndrome the arms fall very slowly:  
 
 
 
0 = Normal, free fall with loud slap and rebound  
 
 
 
1 = Fall slowed slightly with less audible contact and little rebound  
 
 
 
2 = Fall slowed, no rebound  
 
 
 
3 = Marked slowing, no slap at all  
 
 
 
4 = Arms fall as though against resistance; as though through glue  
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
132


SIMPSON-ANGUS SCALE (SAS) 
Copyright © Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects.  
Acta Psychiatrica Scandinavica 212:11–19, 1970. Reproduced with permission of Blackwell Publishing Ltd 
 
SAS - United States/English - Mapi. 
ID7808 / SAS_AU1.0_eng-USori.doc 
3
 
 
 
 
 
3. SHOULDER SHAKING:  
The subject's arms are bent at a right angle at the elbow and are taken one at a time by the examiner 
who grasps one hand and also clasps the other around the patient's elbow. The subject's upper arm is 
pushed to and fro and the humerus is externally rotated. The degree of resistance from normal to 
extreme rigidity is scored as follows: 
 
 
 
0 = Normal  
 
 
 
1 = Slight stiffness and resistance  
 
 
 
2 = Moderate stiffness and resistance  
 
 
 
3 = Marked rigidity with difficulty in passive movement  
 
 
 
4 = Extreme stiffness and rigidity with almost a frozen shoulder  
 
 
 
 
 
 
4. ELBOW RIGIDITY:  
The elbow joints are separately bent at right angles and passively extended and flexed, with the subject's 
biceps observed and simultaneously palpated. The resistance to this procedure is rated. (The presence of 
cogwheel rigidity is noted separately.)  
 
 
 
0 = Normal  
 
 
 
1 = Slight stiffness and resistance  
 
 
 
2 = Moderate stiffness and resistance  
 
 
 
3 = Marked rigidity with difficulty in passive movement  
 
 
 
4 = Extreme stiffness and rigidity with almost a frozen shoulder  
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
133


SIMPSON-ANGUS SCALE (SAS) 
Copyright © Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects.  
Acta Psychiatrica Scandinavica 212:11–19, 1970. Reproduced with permission of Blackwell Publishing Ltd 
 
SAS - United States/English - Mapi. 
ID7808 / SAS_AU1.0_eng-USori.doc 
4
 
 
 
 
 
5. FIXATION OF POSITION or Wrist Rigidity:  
The wrist is held in one hand and the fingers held by the examiner's other hand, with the wrist moved to 
extension, flexion and both ulner and radial deviation:  
 
 
 
0 = Normal  
 
 
 
1 = Slight stiffness and resistance  
 
 
 
2 = Moderate stiffness and resistance  
 
 
 
3 = Marked rigidity with difficulty in passive movement  
 
 
 
4 = Extreme stiffness and rigidity with almost a frozen shoulder  
 
 
 
 
 
 
6. LEG PENDULOUSNESS:  
The patient sits on a table with his legs hanging down and swinging free. The ankle is grasped by the 
examiner and raised until the knee is partially extended. It is then allowed to fall. The resistance to falling 
and the lack of swinging form the basis for the score on this item: 
 
 
 
0 = The legs swing freely  
 
 
 
1 = Slight diminution in the swing of the legs  
 
 
 
2 = Moderate resistance to swing  
 
 
 
3 = Marked resistance and damping of swing  
 
 
 
4 = Complete absence of swing 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
134


SIMPSON-ANGUS SCALE (SAS) 
Copyright © Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects.  
Acta Psychiatrica Scandinavica 212:11–19, 1970. Reproduced with permission of Blackwell Publishing Ltd 
 
SAS - United States/English - Mapi. 
ID7808 / SAS_AU1.0_eng-USori.doc 
5
 
 
 
7. HEAD DROPPING:  
The patient lies on a well-padded examining table and his head is raised by the examiner's hand. The 
hand is then withdrawn and the head allowed to drop. In the normal subject the head will fall upon the 
table. The movement is delayed in extrapyramidal system disorder, and in extreme parkinsonism it is 
absent. The neck muscles are rigid and the head does not reach the examining table. Scoring is as 
follows:  
 
 
 
0 = The head falls completely with a good thump as it hits the table  
 
 
 
1 = Slight slowing in fall, mainly noted by lack of slap as head meets the table  
 
 
 
2 = Moderate slowing in the fall quite noticeable to the eye  
 
 
 
3 = Head falls stiffly and slowly  
 
 
 
4 = Head does not reach the examining table  
 
 
 
 
 
8. GLABELLA TAP:  
Subject is told to open his eyes wide and not to blink. The glabella region is tapped at a steady, rapid 
speed. The number of times patient blinks in succession is noted:  
 
 
 
0 = 0 - 5 blinks  
 
 
 
1 = 6 – 10 blinks  
 
 
 
2 = 11 – 15 blinks  
 
 
 
3 = 16 - 20 blinks  
 
 
 
4 = 21 and more blinks  
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
135


SIMPSON-ANGUS SCALE (SAS) 
Copyright © Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects.  
Acta Psychiatrica Scandinavica 212:11–19, 1970. Reproduced with permission of Blackwell Publishing Ltd 
 
SAS - United States/English - Mapi. 
ID7808 / SAS_AU1.0_eng-USori.doc 
6
 
 
 
9. TREMOR:  
Patient is observed walking into examining room and is then reexamined for this item:  
 
 
 
0 = Normal  
 
 
 
1 = Mild finger tremor, obvious to sight and touch  
 
 
 
2 = Tremor of hand or arm occurring spasmodically  
 
 
 
3 = Persistent tremor of one or more limbs  
 
 
 
4 = Whole body tremor  
 
 
 
 
 
10. SALIVATION:  
Patient is observed while talking and then asked to open his mouth and elevate his tongue. The following 
ratings are given:  
 
 
 
0 = Normal  
 
 
 
1 = Excess salivation to the extent that pooling takes place if the mouth is open and the tongue 
raised.  
 
 
 
2 = When excess salivation is present and might occasionally result in difficulty in speaking  
 
 
 
3 = Speaking with difficulty because of excess salivation  
 
 
 
4 = Frank drooling  
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
136


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
18.0 APPENDIX 8: ABNORMAL INVOLUNTARY 
MOVEMENT SCALE (AIMS) 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
137


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
138


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
139


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
140


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
141


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
19.0 APPENDIX 9: BARNES AKATHISIA RATING SCALE 
(BARS) 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
142


Rating scale for drug-induced akathisia (Barnes 
Akathisia Rating Scale) 
Patient name: 
Patient research no.: 
Hospital No.: 
Ward:
Rater:
Instructions 
Patient should be observed while they are seated, and then standing while 
engaged in neutral conversation (for a minimum of two minutes in each 
position). Symptoms observed in other situations, for example while engaged in 
activity on the ward, may also be rated. Subsequently, the subjective 
phenomena should be elicited by direct questioning. 
Objective
0
Normal, occasional fidgety movements of the limbs 
1
Presence of characteristic restless movements: shuffling or tramping 
movements of the legs/feet, or swinging of one leg while sitting, and/or 
rocking from foot to foot or “walking on the spot” when standing, but
movements present for less than half the time observed 
2
Observed phenomena, as described in (1) above, which are present for at 
least half the observation period 
3
Patient is constantly engaged in characteristic restless movements, and/or 
has the inability to remain seated or standing without walking or pacing, 
during the time observed 
Subjective 
Awareness of restlessness 
0
Absence of inner restlessness 
1
Non-specific sense of inner restlessness 
2
The patient is aware of an inability to keep the legs still, or a desire to 
move the legs, and/or complains of inner restlessness aggravated 
specifically by being required to stand still 
3
Awareness of intense compulsion to move most of the time and/or reports 
strong desire to walk or pace most of the time 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
143


Distress related to restlessness
0
No distress 
1
Mild 
2
Moderate 
3
Severe
Global clinical assessment of akathisia 
0
Absent. No evidence of awareness of restlessness. Observation of 
characteristic movements of akathisia in the absence of a subjective report 
of inner restlessness or compulsive desire to move the legs should be 
classified as pseudoakathisia 
1
Questionable. Non-specific inner tension and fidgety movements 
2
Mild akathisia. Awareness of restlessness in the legs and/or inner
restlessness worse when required to stand still. Fidgety movements 
present, but characteristic restless movements of akathisia not necessarily 
observed. Condition causes little or no distress 
3
Moderate akathisia. Awareness of restlessness as described for mild 
akathisia above, combined with characteristic restless movements such as 
rocking from foot to foot when standing. Patient finds the condition 
distressing 
4
Marked akathisia. Subjective experience of restlessness includes a 
compulsive desire to walk or pace. However, the patient is able to remain 
seated for at least five minutes. The condition is obviously distressing 
5
Severe akathisia. The patient reports a strong compulsion to pace up and 
down most of the time. Unable to sit or lie down for more than a few 
minutes. Constant restlessness which is associated with intense distress 
and insomnia 
Reproduced from: A rating scale for drug-induced akathisia. T.R.E. Barnes, 
British Journal of Psychiatry (1989), 154, 672-676. 
© 1989 The Royal College of Psychiatrists. 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
144


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
20.0 APPENDIX 10: COLUMBIA-SUICIDE SEVERITY 
RATING SCALE (C-SSRS) 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
145


COLUMBIA-SUICIDE SEVERITY
RATING SCALE
(C-SSRS) 
 
 
D
isc
la
imer
: 
Th
is sca
le 
is 
intended to be used by 
ind
iv
idua
ls who have rece
ived tra
in
ing 
in 
its adm
in
istrat
ion. The quest
ions conta
ined 
in the Co
lumb
ia-Su
i
c
ide Sever
ity Rat
ing Sca
le are suggested probes
. U
lt
imate
ly
, the determ
inat
ion of the presence of 
su
ic
ida
l 
ideat
ion or behav
ior depends on the 
judgment of the 
ind
iv
idua
l adm
in
ister
ing the sca
le. 
Def
in
it
ions of behav
iora
l su
ic
ida
l events 
in th
is sca
le are based on those used 
in The Columbia Suicide History 
Form, deve
loped by John Mann
, MD and Mar
ia Oquendo
, MD
, Conte Center for the Neurosc
ience of Menta
l D
isorders 
(CCNMD)
, New York State Psych
iatr
ic Inst
itute
, 1051 R
ivers
ide Dr
ive
, New York
, NY
, 10032
. (Oquendo M
. A
.
, 
Ha
lberstam B
. & Mann J
. J
.
, R
isk factors for su
ic
ida
l behav
ior
: uti
l
ity and 
l
im
itat
ions of researc
h 
instruments
. In M
.B
. F
irst 
[Ed
.] Standardized Evaluation in Clinical Practice, pp
. 103 -130
, 2003
.) 
 
For repr
ints of the C-SSRS contact Ke
l
ly Posner
, Ph
.D.
, New York State Psych
iatr
ic Inst
itute
, 1051 R
ivers
ide Dr
ive
, New 
York
, New York
, 10032
; 
inqu
ir
ies and tra
in
ing requ
irements contact posnerk@nysp
i
.co
lumb
ia
.edu
 
© 2008 The Research Foundation for Mental Hygiene, Inc. 
d by 
ind
iv
id
d by 
ind
iv
i
ver
ity Rat
in
ver
ity Rat
ion or beha
ion or beha
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
146


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
147


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
148


COLUMBIA-SUICIDE SEVERITY
RATING SCALE
(C-SSRS)
D
isc
la
imer
: 
Th
is sca
le 
is 
intended to be used by 
ind
iv
idua
ls who have rece
ived tra
in
ing in 
its adm
in
istrat
ion. The quest
ions conta
ined 
in 
the Co
lumb
ia-Su
ic
ide Sever
ity Rat
ing Sca
le are suggested probes
. U
lt
imate
ly
, the determ
inat
ion of the presence of su
ic
ida
l 
ideat
ion or behav
ior depends on the 
judgment of the 
ind
iv
idua
l adm
in
ister
ing the sca
le. 
Def
in
it
ions of behav
iora
l su
ic
ida
l events 
in th
is sca
le are based on those used 
in The Columbia Suicide History Form, 
deve
loped by John Mann
, MD and Mar
ia Oquendo
, MD
, Conte Center for the Neurosc
ience of Menta
l D
isorders 
(CCNMD)
, New York State Psych
iatr
ic Inst
itute
, 1051 R
ivers
ide Dr
ive
, New York
, NY
, 10032
. (Oquendo M
. A
.
, 
Ha
lberstam B
. & Mann J
. J
., R
isk factors for su
ic
ida
l behav
ior
: uti
l
ity and 
l
im
itat
ions of researc
h 
instruments
. In M
.B
. F
irst 
[Ed
.] Standardized Evaluation in Clinical Practice, pp
. 103 -130
, 2003
.) 
 
For repr
ints of the C-SSRS contact Ke
l
ly Posner
, Ph
.D.
, New York State Psych
iatr
ic Inst
itute
, 1051 R
ivers
ide Dr
ive
, New 
York
, New York
, 10032
; 
inqu
ir
ies and tra
in
ing requ
irements contact posnerk@nysp
i
.co
lumb
ia
.edu
© 2008 The Research Foundation for Mental Hygiene, Inc. 
D
isc
l
D
isc
ua
ls who ha
ua
ls who ha
a
le are sugg
a
le are sug
r depends o
r depends o
a
l su
ic
id
a
l su
i
M
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
149


 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
150


Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
151


Noven Pharmaceuticals, Inc. 
 
HP-3070-GL-04 
HP-3070 
Protocol
 Version 2.0 Amendment 1:
 20 January 2016 
Protocol
 Final
 Version:
 16 November 2015  
 
 
Confidential 
 
21.0 APPENDIX 11: M.I.N.I. INTERNATIONAL 
NEUROPSYCHIATRIC INTERVIEW (MINI) 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
152


 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
153


 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
154


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O 
        
  
 
 
 
  
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
155


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
156


 
 
 
 
 
 
 
 
 
 
  
 
 
 IS 
 
 
 
     
 
  
 
     
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
157


 
 
             
 
 
     
 
                   
                        
               
   
 
   
 
  
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
158


.  
 
 
  
  
                
 
 
 
         
      
              
      
               
         
                         
           
 
  
 
 
 
 
 
 
 
 
 
    
  
  
  
      
  
  
  
                                           
    
 
   
   
 
 
   
 
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
159


 
         
 
 
             
 
 
 
 
 
 
  
   
            
 
 
   
                
   
      
   
               
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
160


. 
 
 
 
  
 
 
  
 
 
  
 
 
 
     
 
  
 
    
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
161


 
 
 
  
 
 
 
a) 
   
 
b) 
   
 
c) 
    
 
 
 
            
 
 
 
                   
                          
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
162


 
 
    
 
 
 
      
                 
           
               
  
    
 
 
 
 
          
 
 
 
 
      
                
           
                    
               
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
163


.  
 
 
 
 
 
  
 
 
  
 
 
b
 
 
 
 
 
 
  
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
164


.  
 
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
165


.  
 
 
 
 
  
 
 
 
 
  
 
 
 
  
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
 
                                          
     
 
 
 
        
  
    
            
   
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
166


.  
 
 
 
 
 
  
 
 
 
 
↓  
 
 
 
 
 
↓  
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
  
 
G5
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
167


.  
 
 
 
 
 
 
 
  
 
 
  
 
 
  
 
  
 
 
 
 
 
  
 
 
 
 
  
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
168


.  
 
 
 
 
 
   
  
 
 
 
 
 
 
           
 
                * 
      
                                       
                           * 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
169


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
170


. 
 
 
 
 
 
 
  
 
 
 
   
  
 
 
 
 
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
171


__________________________________ 
            
 
 
 
   
 
 
       
 __________________________________ 
            
                                              
     
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
172


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
173


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
174


 
        
 
 
 
   
 
 
 
        
 
 
 
   
 
  
c 
               
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
175


 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
176


 
 
 
 
 
 
 
 
 ↓
 ↓
 ↓
  
 
  
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
177


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
178


.  
  
 
 
 
 
 
 
. 
 
 
 
  
          
 
 
   
   
   
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
  
 
 
  
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
179


 
 
 
 
  
 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
 
  
↓ 
 
  
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
180


 
 
 
 
 
  
 
 
 
 
   
 
 
 
   
 
 
 
  
 
   
 
 
   
 
   
 
 
 
  
            
                                          
 
 
 
        
 
 
 
   
 
 
 
        
 
 
 
   
 
 
 
 
 
               
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
181


 
 
 
 
 
 
  
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
182


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
183


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
184


 
≥
<
≥
≥
<
≥
<
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
185


 
 
  
>
<
≥
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
186


 
 
 
 
 
 
 
 
 
• 
• 
 
         
 
  
  
  
 
 
 
 
• 
• 
• 
• 
• 
 
      
 
      
 
  
  
  
 
 
  
    
  
 
  
 
  
 
  
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
187


 
• 
• 
 
 
      
 
 
 
 
  
 
 
 
 
 
 
 
        
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
188


 
 
 
 
 
 
 
 
 
 
  
MOOD DISORDER DUE TO A GENERAL MEDICAL CONDITION
 
 
  
SUBSTANCE INDUCED MOOD DISORDER
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MANIC EPISODE DUE TO A GENERAL MEDICAL CONDITION
 
 
  
HYPOMANIC EPISODE DUE TO A GENERAL MEDICAL CONDITION
 
 
  
SUBSTANCE INDUCED MANIC EPISODE
 
 
 
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
189


  
SUBSTANCE INDUCED HYPOMANIC EPISODE
 
 
 
 
 
  
ANXIETY DISORDER WIITH PANIC ATTACKS DUE TO
A GENERAL MEDICAL CONDITION
 
 
  
SUBSTANCE INDUCED ANXIETY DISORDER WITH PANIC ATTACKS
 
 
 
  
 
 
 
  
OCD DUE TO A GENERAL MEDICAL CONDITION
  
SUBSTANCE INDUCED OCD
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
190


 
 
 
 
 
 
  
GAD DUE TO A GENERAL MEDICAL CONDITION
 
  
SUBSTANCE INDUCED GAD
   
 
  
 
 
 
 
   
 
  
 
 
 
 
   
 
  
 
 
 
 
 
   
 
  
 
 
 
 
   
 
  
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
 
 
 
For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
191


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
192


For Reference Only
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
193

SAP_001.pdf: 
STATISTICAL ANALYSIS PLAN 
 
Protocol Title: 
A Randomized, Double-Blind, Placebo-
Controlled, Fixed-Dose, 6-Week, In-
Patient Study to Assess Efficacy and 
Safety of HP-3070 in Subjects Diagnosed 
with Schizophrenia 
 
Version Number 
& Date of SAP: 
Final V6, 18 January 2018 
 
 
NCT Number: 
NCT02876900 
 
 



*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVH
GLVFORVXUHRUUHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" T*!XS










-*/**'0( -<	EVSZSEESW -.$*)V( )( )/U

 )*($5 : *0' E'$): ' *E*)/-*'' : $3 E*. : YE  &: 
)E/$ )/ /04 /* .. ..
!!$4)! /4*!	EVSZS$)0% /.$")*. 2$/##$5*+#- )$




0/#*-<()#2
,-#)(/',(.6#(&G5BICABI





1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU



Noven Pharmaceuticals, Inc. 
IMS Health&< Oulntiles ate now 
-==IOVIA .. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
Page 2 of 50 
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE 
Statistical Analysis Plan Final V6.0 (Dated 18JAN2018) for Protocol HP-307<>-GL-04. 
Name 
Signature 
Date 
Author: 
Amanda Schwab 
~ 
Senior Biostatistician 
Company: 
IQVIA 
Upon review of this document, the undersigned approves this version of the Statistical Analysis Plan, authorizing 
that the content is acceptable for the reporting of this study. 
Name 
Date 
Approved By: 
Stacy Woodard 
I hlav{2Dl8 2= l\pi-.t CST 
Position: 
Director, Biostatistics 
Company: 
IQVIA 
Approved By: 
Marina Komaroff 
Position: 
Director, Biostatistics 
Company: 
Noven Pharmaceuticals, Inc. 
Approved By: 
Document: 
Author: 
Alex Park 
Position: 
Executive Director - Regulatory Affairs and Pharmacovigilance 
Company: 
Noven Pharmaceuticals, Inc. 
\\quintiles.net\Enterprise\Apps\sasdata\SASb\SAS\Noven\HP-
3070\XWA17541\Blostatistics\Documentation\SAP\Flnal 6\Noven HP-3070-GL-04 SAP text Final 
6_18Jan2018.docx 
Amanda Schwab 
Version Number: 
Version Date: 
Final6 
18Jan2018 
Template No: CS_TP _85016- Revision 3 
Effective Date: 01May2012 
Reference: CS_Wl_BSOOS 
Copyright C 2012 Quintiles Transnational Corp. All rights reserved. 
The contents of this document are confidential and proprietary to Quintiles Transnational Corp. Unauthorized use, disclosure or 
reproduction is strlctly prohibited. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
3


Noven Pharmaceuticals, Inc. 
IMS Health Ir Qulntlle1 .,. now 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
Page 2 of 50 
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE 
Statistical Analysts Plan Final V6.0 (Dated 18JANZ018) for Protocol HP-3070-GL-04. 
Name 
Signature 
Date 
Author: 
Amanda Schwab 
~ 
Senior Biostatistician 
Company: 
IQVIA 
Upon review of this document, the undersigned approves this version of the Statistical Analysis Plan, authorizing 
that the content Is acceptable for the reporting of this study. 
Name 
Signature 
I Date 
Approved By: 
Stacy Woodard 
Position: 
Director, Biostatistics 
Company: 
IQVIA 
Approved By: 
Marina Komaroff 
~orna.f 18 Jan 2018 2:23pm EST 
Position: 
Director, Biostatistics 
Company: 
1 
Noven Pharmaceuticals, Inc. 
Approved By: 
Alex Park 
l~]f\)J ~I~ 
1 
- .. -
2 -0, p~ 0( 
Document: 
Author: 
Position: 
Executive Director - Regulatory Affairs and Pharmacovigilance 
Company: 
Noven Pharmaceuticals, Inc. 
\\qulntlles.net\Enterprise\Apps\sasdata\SASb\SAS\Noven\HP-
3070\XWA17541\Biostatlstlcs\Documentatlon\SAP\Anal 6\Noven HP-3070-GL-04 SAP text Final 
6_18Jan2018.docx 
Amanda Schwab 
Version Number: 
Final 6 
Version Date: 
18Jan2018 
Template No: CS_TP _85016- Revision 3 
Effective Date: 01May2012 
Reference: CS_Wl_BSOOS 
Copyright C 2012 Quintiles Transnational Corp. All rights reserved. 
The contents of this document are confidential and proprietary to Quintiles Transnational Corp. Unauthorized use, disclosure or 
reproduction Is strictly prohibited. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
4



*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" V*!XS








(
!


! 
"

! 
C7B7
,#',3$.#077777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BA
C7C7
3)(,3$.#0-77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BA
C7D7
.",)(,3$.#0-77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BA
C7E7
 .3$.#0-777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BB
C7F7
2*&),.),3$.#0-7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BB
#

!!
D7B7
(,&-,#*.#)(77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BB
D7C7
"/&) 0(.-7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BC
D7D7
"(!-.)(&3-#- ,)',).))&7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BD
$
!#
E7B7
.)(#.),#(!)''#..:;77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BD
E7C7
&#('*&#4&/&.#)(7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BD
E7D7
#(&(&3-#-777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BF
%

!%
F7B7
&&/$.-,(.777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BF
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" W*!XS
F7C7

(.(.9.)9,.(&3-#-.77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BF
F7D7
/&&(&3-#-.77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BF
F7E7
 .3(&3-#-.7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BF
F7F7
",')%#(.#(&3-#-.77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BG
&


!&
G7B7
 ,(.,..(./337777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BG
G7C7
-&#(77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BH
G7D7
,#0#')#(.-77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BH
G7E7
.-.-5(-"/&#-#.-(,&3,'#(.#)(.7777777777777777777777777777777777777777777777777777777777777777777777BH
G7F7
#()1#(!)(0(.#)(-7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BH
G7G7
..#-.#&-.-777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BH
G7H7
)'')(&/&.#)(-77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BI
G7I7
) .1,,-#)(777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BI
'




!(
H7B7
$/-.'(.- ),)0,#.-(.),-.)
(&/#((&3--77777777777777777777777777777777777777777777777777777BI
H7C7
/&.#(.,./#-77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BI
H7D7
#--#(!.7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BI
H7E7
/&.#*&)'*,#-)(-8/&.#*&##.377777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777BJ
H7F7
2'#(.#)() /!,)/*-7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777CA
(

"!
)




	"!
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" X*!XS
!  	
	
	

""
BA7B7
,#0.#)(-777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777CC
!! 
	
"#
!" 

"#
BC7B7
,#0.#)(-777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777CD
!# 


"#
BD7B7
,#0.#)(-777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777CE
!$ 

"$
!% 
"%
BF7B7
,#',3  #377777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777CF
TX=T=T=
-$(-4!!$4-$' O -$1/$*)===================================================================================================UX
TX=T=U=
$..$)"/ /#*.!*--$(-4!!$4-$' ==============================================================================UY
TX=T=V=
-$(-4)'4.$.*!-$(-4!!$4-$' =========================================================================================UY
TX=T=W=
 ).$/$1$/4)'4.$.*!-$(-4!!$4-$' =====================================================================================U[
BF7C7
3)(,3  #3777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777CJ
TX=U=T=
 4 *)-4!!$4-$' .O -$1/$*).=====================================================================================U\
TX=U=T=T= #)" $)
E*-  /2  ). '$) )  &Y======================================================================U\
TX=U=U=
$..$)"/ /#*.!*- 4 *)-4!!$4-$' .=================================================================U\
TX=U=V=
)'4.$.*! 4 *)-4!!$4-$' .==========================================================================================U\
BF7D7
.",)(,3  #3777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777DA
TX=V=T=
3+'*-/*-4!!$4-$' .O -$1/$*).==========================================================================================VS
TX=V=T=T= #)" !-*(. '$) $)*/'*- /  &.T/#-*0"#X==================================================VS
TX=V=T=U= #)" !-*(. '$) $)
E*- /  &.T/#-*0"#X=============================================================VS
TX=V=T=V= 
E
 .+*) -/  &.T/#-*0"#Y==============================================================================================VS
TX=V=T=W= 
E
*- /  &.T/#-*0"#Y======================================================================================================VS
TX=V=T=X= #)" !-*(. '$) $)*.$/$1 0.' /  &.T/#-*0"#Y=========================================VS
TX=V=T=Y= #)" !-*(. '$) $) "/$1 0.' /  &.T/#-*0"#Y=======================================VS
TX=V=T=Z= #)" !-*(. '$) $) ) -'.4#*+/#*'*"40.' /  &.T/#-*0"#Y=============VT
TX=V=T=[=  .+*) -. *)iVSa
(+-*1 ( )/!-*(. '$) $)/*/'.*- /  &.T
/#-*0"#YVT
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" Y*!XS
TX=V=T=\=  .+*) -. *)fca
(+-*1 ( )/!-*(. '$) $)/*/'.*- /  &Y====VT
TX=V=T=TS=#)" !-*(. '$) $)*- /  &.T/#-*0"#Y==============================================================VT
TX=V=T=TT=0.' *- ./  &.U:W:)Y=======================================================================================VU
TX=V=U=
$..$)"/ /#*.!*-/# - *)-4!!$4-$' .==============================================================VU
TX=V=V=
)'4.$.*!/# - *)-4!!$4-$' .======================================================================================VU
TX=V=V=T= /# - *)-4!!$4)+*$)/.. *)*)/$)0*0.-$' .===============================================VU
TX=V=V=U= /# - *)-4!!$4)+*$)/.. *)$)-4I .+*) -J-$' .===================================VU
TX=V=V=V= *)/$)0*0. .+*) -)'4.$./  &Y============================================================================VU
!& ##
BG7B7
,.'(.',!(.0,-0(.-777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777DD
TY=T=T=
''.=====================================================================================================================================================VX
TY=T=T=T= .4 '/$*).#$+/*/04 $/$*)) 1 -$/4==================================================================VX
TY=T=U=
. $)"/*$.*)/$)0/$*)*!/04 $/$*)=========================================================================VX
TY=T=V=
 -$*0.1 -. 1 )/.===========================================================================================================================VX
TY=T=W=
1 -. 1 )/. $)"/* /#===========================================================================================================VX
TY=T=X=
*((*)'40--$)".====================================================================================================================VY
TY=T=Y=
.//#++'$/$*)$/ ==================================================================================================================VY
BG7C7
."-7777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777DG
BG7D7
),.),30&/.#)(-777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777DG
TY=V=T=
*-/*-4 ! - ) )" .)-& '4)*-('-$/ -$============================================================V[
BG7E7
0&/.#)(-77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777DI
TY=W=T=
+ $!$ -$1/$*).=========================================================================================================================V\
TY=W=U=
-& '4)*-('-$/ -$============================================================================================================V\
BG7F7
#.&#!(-77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777DJ
TY=X=T=
$/'$").-& '4)*-('-$/ -$==================================================================================================WS
BG7G7
"3-#&2'#(.#)(777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777EB
BG7H7
.", .3----'(.-77777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777777EB
TY=Z=T=
$(+.*))"0.' ===============================================================================================================================WT
TY=Z=U=
)*-('
)1*'0)/-4*1 ( )/' =================================================================================================WT
TY=Z=V=
-) .&/#$.$/$)"' =================================================================================================================WU
TY=Z=W=
0$$'$/4<*'0($E0$$  1 -$/4/$)"' ================================================================================WU
TY=Z=X=
1'0/$*).*!/#) -('.. ..( )/.=======================================================================================WV
TY=Z=X=T= &$)$--$//$*)/+/#++'$/$*).$/ ==============================================================================================WW
TY=Z=X=U= $.*(!*-//+/#++'$/$*).$/ ==================================================================================================WX
TY=Z=X=V= /## .$*))# .$1  .$0 ==============================================================================================WX
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" Z*!XS
!' 	

$&
!( 
$&
!) $'

! 

$(

" 


		


$(

# 

	



 $)

$ $)




1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" [*!XS








- 1$/$*)
 -(

)*-(':'$)$''4$")$!$)/

1 -. 1 )/


&$& @.
)!*-(/$*)-$/ -$*)


)*-('
)1*'0)/-4*1 ( )/' 

'&'$) #*.+#/. 

')$) -).($). 

)'4.$.*!*1-$) 

)*-(':*/'$)$''4$")$!$)/
ITJ
0/*- "- ..$1 ITJ
	ITJ
0/*- "- ..$1 :	 / -*" ) *0.ITJ

.+-// -).($). 

-) .&/#$.$/$)"' 


*4..
) 3

'"-4 +- ..$*)' !*-#$5*+#- )$

E
'$)$''*'
(+- ..$*)F 1 -$/4*!
'') ..' 

E

'$)$''*'
(+- ..$*)E
(+-*1 ( )/' 


*)!$ ) 
)/ -1'
	
*#-))/ '	 ).5 '
E
*'0($E0$$  1 -$/4/$)"' 

*(+*0)4(( /-4
	
*(+*0)4(( /-4:	 / -*" ) *0.

$./*'$'**- ..0- 

/*)$/*-$)"*(($//  

' /-*-$*"-(
 
' /-*)$.  +*-/*-(

3/-+4-($'4(+/*(.

-'4 -($)/$*)
SI,J
*$"*)'/*-)'4/$*1-$) ./-0/0- I2$/#, ,0'/*/# )0( -*!
/$( +*$)/.J

0'')'4.$. /

**)-0"($)$./-/$*)



)/ -$((+' $5  '0'/$*)



)/ )/E/*E- /



)/ -/$1 *$ E/$1/  .+*). 4./ (



)/ -/$1  E.  .+*). 4./ (

 ./,0- . )

$..$)"/)*(

-&*1#$)*)/ -'*
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" \*!XS
 
 $'$/$*)-4!*- "0'/*-4/$1$/$ .


0'/$+' 
(+0//$*)

$3 * '!*- + /  .0- .

$..$)"*//)*(

 $/$*)/$.!/$*)0 ./$*))$- 


/$*)') -
)./$/0/ *((*) -($)*'*"4-$/ -$!*-1 -. 1 )/.

*.$/$1 ) "/$1 4)-*( ' 

#-(*&$) /$)'4.$. /

#-(*&$) /$

- ! --  -(

 -$*0.1 -. 1 )/

! /4)'4.$. /

//$./$')'4.$.')

$(+.*)E)"0.' 
P
//$./$')'4.$.*!/2- 

4./*'$'**- ..0- 

/)- 1$/$*)


/)-
)/ -)/$*)'

0'$)"0'

4./ (-")'..

(+' $5  '0'/$*)

- /( )/E( -" )/1 -. 1 )/

* +'$/5I*1-$) ./-0/0- J
	
* +'$/5:	 / -*" ) *0.I*1-$) ./-0/0- J

++ -$($/!*-('
	E
*-'	 '/#-")$5/$*)-0"$/$*)-4


1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" TS*!XS
B7


#$.*0( )/ .-$ ./# -0' .)*)1 )/$*)./* 0. $)/# +- . )//$*)))'4.$.*! !!$4)
.! /4/!*--*/**'	EVSZSEESW=
/ .-$ ./# //* .0((-$5 ))'45 :$)'0$)".+ $!$.
*!/# .//$./$')'4. ./* + -!*-( =
#$..//$./$')'4.$.+')IJ$.. *)+-*/**'1 -.$*)V/ UT*1 ( -USTY=
C7

C7B7 


# +-$(-4*% /$1 *!/# ./04$./* 1'0/  !!$4*!	EVSZS*(+- 2$/#+' *!*-/# /- /( )/*!
.#$5*+#- )$. 1'0/ 4*.$/$1 ) "/$1 4)-*( ' IJ/*/'.*- =
C7C7 

 4 *)-4!!$4% /$1 <
x
'$)$''*'
(+- ..$*)F 1 -$/4*!
'') ..' I
EJ
C7D7 	

/# - *)-4!!$4% /$1 .<* 1'0/ /#  !!$4*!	EVSZS0.$)"/# !*''*2$)"( .0- .<
x
/*/'.*- / #/$( +*$)/
x
'$)$''*'
(+- ..$*)F 1 -$/4*!
'') ..' I
EJ/ #/$( +*$)/
x
'$)$''*'
(+- ..$*)F
(+-*1 ( )/' I
E
J/ #/$( +*$)/
x
-*+*-/$*)*!
E
- .+*) -./ #/$( +*$)/
x
*.$/$1 :) "/$1 :)" ) -'+/#*'*"4.0.*- .*!
x
-*+*-/$*)*!- .+*) -.;/ #/$( +*$)/I  &.TFYJ:.0% /.#1$)"VSa*-"- / -
$(+-*1 ( )/!-*(. '$) $)/*/'.*- 2$''  !$) .- .+*) -.
x
'"-4 +- ..$*)' !*-#$5*+#- )$IJ
x
 $/$*)/$.!/$*)0 ./$*))$- IJ.*- 
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" TT*!XS
C7E7 

! /4*% /$1 .- /* 1'0/ /# .! /4)/*' -$'$/4*!	EVSZS*(+- 2$/#+' *:$)'0$)"<
x
1 -.  1 )/.I.J:$)'0$)"/- /( )/E ( -" )/.I.J:.' $)"/*$.*)/$)0/$*)!-*(/# 
./04-0":. -$*0.1 -.  1 )/.I.J:) /#.
x
#)" !-*(. '$) $)'$)$''*-/*-4- .0'/.I$)'0$)"+-*'/$):!./$)""'0*. :)'$+$.J:
- .0'/.:*42 $"#/:)1$/'.$").
x
 .0'/.*!E::
:)
x
 -('.! /4
C7F7 

3+'*-/*-4 *% /$1 . -  /* .. .. /#  $(+/ *! *1-$/ . *) . )+$)   3+*.0-  0.$)"  (* 'E. 
++-*#)/* 3+'*- /#  3+*.0- E- .+*). - '/$*).#$+2$/#- ' 1)/ )+*$)/.=
D7

D7B7 


#$.$.#. V:-)*($5 :*0' E'$):+' *E*)/-*'' :$)E+/$ )/:.! /4:) !!$4./04/* 1'0/ 
	EVSZS!*-/# /- /( )/*!.#$5*+#- )$=
#$../042$''*).$./*!-  )$)"C+' *0)E$) -$**!V/*TW4.:YE2  &*0' E'$)- /( )/
 -$*)VS4*''*2E0+ -$*=
0% /.2$'' #*.+$/'$5 //# -  )$)"$.$/)2$''- ($)#*.+$/'$5 0-$)"/# ./04=# .0% /(4
' 1 /# #*.+$/'./04!*-)  ..-4+ -.*)'0.$) ..=)4.0% /2#*' 1 ./# .$/ (0./#1 )'*#*'
- /#'45 -)0-$) -0"/ ./.2# )/# 4- /0-)/*/# .$/ =
!/ -*/$)$)"$)!*-( *). )/: #.0% /2$'' ..$") 0)$,0 .0% /)0( -='$"$' .0% /.2$''
 #*.+$/'$5 !*-/# 0-/$*)*!/# ./04=#$' 0) -"*$)".-  )$)"+-* 0- .)2$/$)"!*-- .0'/.*!
'*-/*-4 / ./.: .: ) */# - .. ..( )/.: /#  .0% / 2$'' ./-/ /- /( )/ 2$/# /#  .$)"' E'$) +' *
+/#=# .0% /(0./#1 /# .$)"' E'$)+' *+/#++'$ !*-($)$(0(*!V4.+-$*-/* $)"
-)*($5  $)/* /#  *0' E'$) - /( )/  -$*=  
) $/$*): 0-- )/ )/$+.4#*/$ ) */# - +-*#$$/ 
( $/$*).2$'' 2.# *0/0-$)"/# -0)E$)+ -$*)(0./ *(+' / +-$*-/*-)*($5/$*)$)/*/# 
*0' E'$) /- /( )/ + -$*=   /$'. $) - "- /* 2.#E*0/ + -$*. !*- .+ $!$ -0". -  .0((-$5  $)
-*/**' /$*)X=TS=T=0% /.2#*#1  - . $)/*/'.*- iUSa!-*(-  )$)"/*. '$) *-
/*/'.*- e[S/-  )$)"*-. '$) 2$'' $.*)/$)0 !-*(/# ./04)2$'')*/ )/ -/# *0' E
'$)- /( )/ -$*=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" TU*!XS
0% /. '$"$' !*--)*($5/$*)$)/*/# *0' E'$)- /( )/ -$*2$'' -)*('4..$") /*	EVSZS
\=S(":	EVSZST[=S(":*-+' *$)T<T<T-/$*./-/$!$ 4*0)/-4=0% /.2$''-  $1 /- /( )/2$/#
./04( $/$*)$'4!*-Y2  &.=
# ./042$'' 1'0/ \=S("I	EVSZS\=S("J)T[=S("I	EVSZST[=S("J*!	EVSZS/-). -('+/# .
1 -.0.+' */-). -('+/# .=/# .2$'' ++'$ 4.$/ + -.*)) '/++-*3$(/ '4/# .( /$( 
$'4) #+/#2$'' 2*-)!*-UW#*0-.=1 -44:UW#*0-.IgTX($)0/ .J!/ -+/#++'$/$*):.$/ 
+ -.*)) '2$''- (*1 +- 1$*0.4@.+/# .)++'4) 2+/# .=
''.0% /.2$''#1 !*''*2E0+*)//I.$/ 1$.$/*-/ ' +#*) ''://# $.- /$*)*!/# 
)1 ./$"/*-JVS4.
!/ -/# './+/#$.- (*1 =#$.*)//2$'' 0. /**'' /$)!*-(/$*)*0/)41 -. 1 )/.I.J*-
 -$*0.1 -. 1 )/.I.J/#/(4#1 *0-- .$) $.#-" )/*!*''*2E0+*))41 -. 1 )/.
I.J/#/2 - *)E"*$)"/$.#-" =
..0($)") !! /.$5 *!S=VX*)/# #)" $)/*/'.*- !-*(. '$) /*  &Y!*-/# /2*+$-2$. 
*(+-$.*). /2  ) #/$1 	EVSZS/- /( )/-()+' *:/# +*2 -!*- / /$)".//$./$''4
.$")$!$)/	EVSZS1)/" 2$'' ++-*3$(/ '4S=\S#1$)"USW 1'0' .0% /.+ - #/- /( )/-(:
0.$)"/2*E.$ '+#' 1 '*!S=SUX!*- #*(+-$.*)=/2*E.$ *1 -''/4+ 
 --*-$. ,0'/*S=SX=
	1$)"/#-  /- /( )/-(.:/# /*/')0( -*!.0% /.-)*($5 $)/# /-$')$)'0 $)+-$(-4)'4.$.
. /2$'' ++-*3$(/ '4YTU=
#  !! /.$5 *!S=VXI$!! - )  /2  )( ). ,0'/*Z)*((*)./)- 1$/$*)IJ ,0'/*USJ2.
#*. ). *)/# '*2 ./ !! /.$5 *. -1 $)- .0'/.!-*(/# ./0$ .*)0/ 2$/#.0'$)"0'IJ
. )+$) )++-*1 4/# **)-0"($)$./-/$*)IJI4- ./PC	
PK/04SWTSSW:)/04
SWTSUVLJ=
.(+' .$5 - '0'/$*)IJ2$'' *)0/ . .-$ $) /$*)W=U*)/# '$) /!/ -
++-*3$(/ '4XSa*!/# *-$"$)''4+')) )0( -*!.0% /.#1   )-)*($5 )*(+' / 0+/*Y
2  &.*!./04/- /( )/=
D7C7 	

) /#$. ./04:  !!$4 2$''    1'0/  0.$)" 2$ '4  +/ : ./)- ,0 ./$*))$- .=  # .  $)'0  /# 
:
E:
E
:)=

) $/$*) /* ./)- .! /4 ( .0- . I.: '$)$' '*-/*-4 .. ..( )/.: 1$/' .$").: 2 $"#/:
 ' /-*-$*"-( KL - .0'/.J: /#$. ./04 2$'' '.* $)'0  .. ..( )/. *!  3/-+4-($' .4(+/*(. IJ
.4(+/*(.0.$)"/# $(+.*)E)"0.' IJ:-) .&/#$.$/$)"' IJ:))*-('
)1*'0)/-4
*1 ( )/' I
J=0$$'$/42$'' (*)$/*- 0.$)"/# *'0($E0$$  1 -$/4/$)"' IEJ=
/## .$*)2$'' .. .. /.+ $!$ /$( +*$)/.= -('.! /42$'' .. .. 4$'4 1'0/$*)*!
$--$//$*)//# .$/ *!+/#++'$/$*))4- 1$ 2*!)4 -('- /$*).- +*-/ ..=
# .# 0' *!./04+-* 0- .).. ..( )/.$.+- . )/ $)-*/**'' T=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" TV*!XS
D7D7 	

# - - )*#)" ./*)'4.$.!-*(+-*/**'=
E7
# !*''*2$)")'4. .2$'' + -!*-( !*-/#$../04<
x
'$) (+' $5  '0'/$*)
x
$)')'4.$.
E7B7 


:;
# - 2$'' )*!*-/#$../04=
E7C7 



(+' .$5 - '0'/$*)IJ2$'' *)0/ *)/# '$) /!/ -++-*3$(/ '4XSa*!/#  .$- 
)0( -*!+/$ )/.#1   )-)*($5 )*(+' / 0+/*Y2  &.*!./04/- /( )/=#$.2$'' 
$- / )*)0/ 4)$) + ) )/.//$./$$)!-*(

:2#*$.)*/$)1*'1 $)/# /-$'*)0/*/# -
/#)/#$.=
#  +0-+*.  *! /#$.  $. /* .. .. /#  ..0(+/$*) - "-$)" /#  ./)-  1$/$*) (  !*- .(+'  .$5 
'0'/$*)!*-/# +-$(-4 )+*$)/=**/# -$)!*-(/$*)2$'' " ) -/ .+-/*!/# =
#$.2$'')*/ *)0/ 2$/#)$)/ )/$*)*! - .$)"/# *-$"$)'.(+' .$5 *-./*++$)"/# /-$' -'4=
) ..0(  /- /( )/  !! / .$5  *! S=VX 2#$# . -1  . .$. !*- /#  *-$"$)' .(+'  .$5  '0'/$*)
*-- .+*)./*)..0(+/$*)*!( )$!! - ) *!Z$)/# #)" $)/*/'.*- !-*(. '$) /*  &
Y  /2  )  # 	EVSZS /- /( )/ "-*0+ ) +' * )  *((*) ./)-  1$/$*) *! US= # 
$) + ) )/.//$./$$)2$'' ./$(/ +**' ./)- 1$/$*)!-*('$) ///# /$( *!)'4.$.
.!*''*2.<
 

  
  



2# - $./# /*/')0( -*!.0% /2$/##)" $)/*/'.*- !-*(. '$) /*  &Y1$'' /
/# /$( *!)'4.$.:- /# #)" .!-*(. '$) 1'0 .*!/# . .0% /.:)$./# "-)( )*!
/# +**' .(+' =. *)/# - E ./$(/ )0.$)"/# .( ..0(+/$*).!*-''*/# -.+ /.*!
.(+' .$5 '0'/$*).+*./0'/ !*-/# *-$"$)'.(+' .$5  ./$(/$*):/# $) + ) )/.//$./$$)2$''
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" TW*!XS
- *(( ) $/# -/*&  +/# *-$"$)'.(+' .$5 *-/*$)- . $/$)*- -/*($)/$) .$- ' 1 '*!+*2 -=
#  !$)'  $.$*) 2$/# - "- /* .(+'  .$5  2$''   / /#  $.- /$*) *! /#  +*).*- 0+*) - 1$ 2 *! /# 
$) + ) )/.//$./$$)@.- *(( )/$*). *)/#  ./$(/ +**' ./)- 1$/$*))$/.$(+/*)
/# +*2 -*!/# ./04=#  $.$*)2$'' - +*-/ $). +-/ *0( )/=
# /'  '*2+-*1$ . 3(+' .*!$!! - )/. )-$*.*-- .+*)$)"/*1-$*0. ./$(/ 1'0 .*!
)+*..$' *-- .+*)$)".(+' .$5 $)- . .=

'*&#4*,,'<
'*&#4
(,-*,
,'<<
)1,# ,#!#(&'*&
#4#(.#(
CA7A
USW
*/++'$' I-$"$)'J
\Sa
CA7F
UTX
BB
[[a
CB7A
UUX
CB
[Ya
CB7F
UVY
DC
[Xa
CC7A
UWZ
ED
[Va
CC7F
UX[
FE
[Ta
CD7A
UZS
GG
Z\a
CD7F
U[U
HI
ZZa
CE7A
U\W
JA
ZXa
CE7F
VSY
BAC
ZVa
CF7A
VT[
BBE
ZTa
CF7F
VVT
BCH
Y\a
CG7A
VWW
BEA
Y[a
CG7F
VX[
BFE
YYa
CH7A
VZT
BGH
YWa
M(+' .$5 I+ --(J- ,0$- /*//$)\Sa+*2 -=
MM(+' .$5 $)- . I+ --(J- ,0$- /*($)/$)\Sa+*2 -=
*/ <(+' .$5 '0'/$*).- . *)..0( ( )$!! - ) *!Z /2  ) #	EVSZS/- /( )/
"-*0+)+' *)UE.$ /E/ .///# S=SUX.$")$!$) ' 1 '=

$/#/# +-* 0- !*-- E ./$(/$*)*!+**' ./)- 1$/$*))- E'0'/$*)*!.(+' .$5 $)'$) 
()) -:)*4+ 
--*-%0./( )/$.)  ..-4I$ . -)-$  :USSVJ=
E7C7B7




$/$*)' /$'.*!/# .(+' .$5 - '0'/$*)) !*0)$)/# 1 -.$*)T:/ 0'4Z/#:USTZ=# 
.(+'  .$5  - '0'/$*) 2. *)0/  *-$)" /* /#    *) 0'4 TS/#: USTZ= #  *)'0.$*) *! /# 
.(+' .$5 - '0'/$*))'4.$.$.*0( )/ $)/#  
)/ -$((+' $5  '0'/$*)I
J/04- +*-/
/ 0'4UZ/#:USTZ=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" TX*!XS
E7D7 


'' !$)': +'))  )'4. . $ )/$!$  $) /#$.  2$''   + -!*-(  4 

 $*.//$./$. !*''*2$)" +*).*-
0/#*-$5/$*) *! /#$. //$./$' )'4.$. '): /.  *&: +*).*- 0/#*-$5/$*) *! )'4.$.  /. )
)'$)$)"*!- /( )/=# !$)')'4.$.2$''$)'0 . /*!+/$ )/+-*!$' ./* +- . )/ $)/# !$)'- +*-/
.+/$ )/)--/$1 .=# . +-*!$' .2$'' $)'0 !*-.0% /.2#*- +*-/ . -$*0.1 -.  1 )/.:/- /( )/
 ( -" )/1 -.  1 )/.' $)"/*./04$.*)/$)0/$*):*-1 -.  1 )/.*!7
F7

+*).*- "-  ( )/ ) 0/#*-$5/$*) *! .0% /. $)'0 C  3'0  !-*(  # )'4.$. . / 2$''   */$) 
+-$*-/*/# 0)'$)$)"*!/# ./04=
F7B7 
# ''.0% /..-  ) . /2$''*)/$)''.0% /.2#*+-*1$ $)!*-( *). )/!*-/#$../04=#$.)'4.$.
. /2$'' 0. !*--0)E$)+ -$* (*"-+#$)$.+*.$/$*).0((-$ .)2$'' . *)/*'' / $)
/# 
)/ -/$1 *$ /$1/  .+*). 4./ (I
JC
)/ -/$1  E.  .+*). 4./ (I
J=
F7C7 
99


)/ )/E/*E- / I
J )'4.$.  / $)'0 . '' *). )/  ) -)*($5  .0% /.=  "-' .. *! )4 +-*/**'
 1$/$*).:)'4. .+ -!*-( *)/# 
. /2$'' . *)/# -)*($5 /- /( )/..$")( )/)''
1$'' /=
F7D7 

0'' )'4.$.  / IJ $)'0 . '' -)*($5  .0% /. 2#* #1  # / ' ./ T +/# *!*0' E'$) ./04
( $/$*)++'$ )2#*#1 . '$) /*/'.*- )/' ./T+*./E. '$) .. ..( )/*!/# 
+-$(-4 !!$4( .0- I/*/'.*- J=# 2$'' 0. ./# +-$(-4. /!*-)'4.$.*! !!$4
 )+*$)/.. *)-)*($5 /- /( )/..$")( )/=
F7E7 

# ! /4)'4.$. /IJ$)'0 .''.0% /.2#*#1 #/' ./T+/#*!*0' E'$)./04( $/$*)
++'$ )2#*#1 /' ./T+*./E*. .! /4( .0- ( )/0-$)"/# *0' E'$)/- /( )/+ -$*=
)
/# 0)'$& '4 1 )//#/ --*-.(4#1 *0-- $)/- /( )/-(..$")( )/.:/# ))'4. .0.$)"/# 2$''
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" TY*!XS
 . *)/- /( )//0''4-  $1 =# 2$'' 0. !*-/# )'4.$.*! -(' 1'0/$*).).! /4
 )+*$)/.=
F7F7 	



# #-(*&$) /$)'4.$. /IJ$)'0 .''.0% /.2#*#1 /' ./*) *. *!./04( $/$*)
0-$)" /#  *0'  '$) /- /( )/ + -$* ) #1  / ' ./ *)  '** .(+'  !*- +#-(*&$) /$ IJ
.. ..( )/=0% /.(4  3'0 !-*(/# . /$!/# 4.$")$!$)/'41$*'/ $)'0.$*)*- 3'0.$*)-$/ -$:
.$")$!$)/'4 1$*'/  /#  +-*/**' $)  24 /#/ (4 $)!'0 ) /#   )'4.$.: $! )4 0) 3+ /   --*- *0-.
0-$)"/# ./04/#/(4$)!'0 ) /# )'4.$.I ="=: -'4 /#( )/*!/-). -('.4./ (.:++- )/
.(+' .2$/#$)": /=J*-$!/# $-/- 0)1$'' *-$)*(+' / =# 2$'' 0. !*-/# )'4.$.2$/#
(* '. ++-*#.2 ''.!*-/# +- . )//$*)*! .-$+/$1 .0((-$ .*!/=3'0 . .2$''
 *0( )/ /*" /# -2$/#/# - .*)!*- 3'0.$*)=
)'4.$./. /!*-+#-(*&$) /$.. ..( )/.2$'' - / 4 /-0( . -#-*0+:=
G7


G7B7 
/0440-$)"/# -0)E$)+ -$*)0-$)"/# *0' '$)/- /( )/+ -$*2$'' '0'/ !-*(/# 
- ! - ) ./-// :)2$'' 0. /*.#*2./-/C./*+4*!.. ..( )/.) 1 )/.=
 ! - ) ./-// 0-$)"/# *0' '$)/- /( )/+ -$*$. !$) ./# 4*!/# !$-./*. *!./04
( $/$*):I4T$./# 4*!/# !$-./*. *!*0' E'$)./04( $/$*)J:)2$''++ -$) 1 -4'$./$)"
2# - ).. ..( )// *- 1 )// ++ -.=
 ! - ) ./-// 0-$)"/# -0)E$)+ -$*$. !$) ./# 4*!/# !$-./*. *!./04( $/$*)0-$)"
/# -0)E$)+ -$*=
x

!/# / *!/#  1 )/$.*)*-!/ -/# - ! - ) / /# )<
/044cI/ *! 1 )/F- ! - ) / JbT=
x

!/# / *!/#  1 )/$.+-$*-/*/# - ! - ) / /# )<
/044cI/ *! 1 )/F- ! - ) / J=

) /#  .$/0/$*) 2# -  /#   1 )/ /  $. +-/$' *- ($..$)": /04 4: ) )4 *-- .+*)$)" 0-/$*). 2$''
++ -+-/$'*-($..$)"$)/# '$./$)".=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" TZ*!XS
G7C7 

)' ..*/# -2$. .+ $!$ :. '$) $. !$) ./# './)*)E($..$)"( .0- ( )//& )+-$*-/**-*)/# 
/ *!!$-./*. *!*0' E'$)./04( $/$*)I$)'0$)"0).# 0' .. ..( )/.J=*-.. ..( )/.*) 
*)/# / *!!$-./*0' E'$)./04( $/$*)*. :$!/$( *!( .0- ( )/$.1$'' :$/2$'' *(+- 
/*/# / )/$( *!/# !$-./*0' E'$)*. *!./04( $/$*)/* / -($) $!/# ( .0- ( )/$.+- E
*. I. '$) J*-+*./E*. I+*./E. '$) J=
G7D7 



-'4 -($)/$*)IJ1$.$/$)!*-(/$*)/#/$.*'' / +*./E. '$) 2$'' ..$") /*/# ) 3/.# 0' 
1$.$/=#$.2$''++'4/*''/+*$)/.0. $) !!$4).! /4)'4.$.=*- #/4+ *!.. ..( )/:/# 
1$.$//2$'' ..$") /*/# ) 3/.# 0' 1$.$/2# )/#//4+ *!.. ..( )/$.+')) /* *'' / =
# +0-+*. !*-/#$. -$1/$*)$./*$)'0 .. ..( )/.$)/# .0((-4/' .)'$./$)".=
G7E7 5	





)" ) -':!*-4E1$.$/.0((-$ .:/- *- //# )*($)'1$.$/2$'' $)'0 $))'4.$.=).# 0' 
( .0- ( )/. 2$'' )*/   $)'0  $) 4E1$.$/ .0((-$ .: 0/ 2$'' *)/-$0/  /* /#  2*-./ .  1'0  2# - 
- ,0$- I ="=:.#$!//' .J=

)/# . *!- / ./I.( 1$.$/)0( -..$") J:/# '/ ./1$'' ( .0- ( )/!*-/#/1$.$/2$'' 0. 
!*-4E1$.$/.0((-$ .=
0% //'$./$)".2$''+- . )/''1$'' /<.# 0' :0).# 0' :- / ./:)1$.$//=
G7F7 



# -  2$''   )* 1$.$/ 2$)*2$)" !*- /#$. +-*/**'=  '' / 2$''   *-")$5  ) )'4.  *-$)" /* /# 
.# 0' /$( ..*0/'$) $)/# +-*/**')4/# 1$.$/ )*/ *)/#  ' /-*)$.  +*-/*-(I J=
-'4/ -($)/$*)1$.$/$)!*-(/$*)2$'' #)' . .-$ $) /$*)Y=V=
G7G7 


''.//$./$'/ ./.*!/- /( )/ !! /.2$'' + -!*-( /U.$ .$")$!$) ' 1 '*!S=SX:0)' ..*/# -2$. 
.// =*)!$ ) $)/ -1'.2$'' \Xa:0)' ..*/# -2$. .+ $!$ $)/#  .-$+/$*)*!/# )'4. .=
*-+-$(-4)'4.$.))'4.$.*!/# & 4. *)-4 )+*$)/:*/#0)%0./ )%0./ +E1'0 .2$'' 
- +*-/ =
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" T[*!XS
G7H7 

*-,0)/$//$1 ( .0- ( )/.:#)" !-*(. '$) 2$'' '0'/ . ./'0 /$.$/F. '$) '0 =
*)/$)0*0.1-$' .2$'' .0((-$5 4 .-$+/$1 .//$./$.I.(+' .$5 K)L:( ):./)- 1$/$*)KL:
( $):($)$(0(:)(3$(0(J=/ "*-$'1-$' .2$'' .0((-$5 $)!- ,0 )4/' .I):!- ,0 )$ .:
)+ - )/" .J=
G7I7 

'')'4. .2$'' *)0/ 0.$)"P1 -.$*)\=U*-#$"# -=
 /$'. !*- .*!/2-  /*   0.  !*- (* ' .  )'4.$. 2$''    .-$  $)  ./)'*)  (* '$)" )
.$(0'/$*)+')=
H7




H7B7 




# !*''*2$)"*1-$/ .)!/*-.- 0. $)/# )'4. .=*- /$'.*!/# $-$)'0.$*)$)/# (* '.:.  /# 
.+ $!$)'4.$.. /$*)=
x
*0)/-4
x
. '$) 1'0 *-- .+*)$)"/*/# +-( / - $)")'45 
H7C7 


#$. ./04 2$''   *)0/  4 (0'/$+'  $)1 ./$"/*-. / (0'/$+'   )/ -. $)/ -)/$*)''4=  )*($5/$*) /*
/- /( )/-(.2$'' ./-/$!$ 4*0)/-4=*0)/-42$'' 0. .!/*-$).//$./$')'4. .=
H7D7 



) /#  '0'/$*) *! /*/' ) .0.'  .*- .: ($..$)" $)$1$0' $/ (. 0.  $) /#   -$1/$*). *! ""- "/ 
.*- .2$'' #)' . .-$ $)/# . /$*). !$)$)"/# *-- .+*)$)"1-$' .:$)*-) 2$/#
.*-$)"()0'!*- #.' =
$..$)"  )+*$)/ 1'0 . $) /#$. ./04 (4 - .0'/ !-*( +/$ )/. $.*)/$)0$)" !-*( /#  ./04 +- (/0- '4 *-
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" T\*!XS
($..$)"$)/ -( $/ .. ..( )/.2#$' - ($)$)"*)./04=*-+-$(-4)'4.$.*!/# +-$(-4 )+*$)/)
*/# - !!$4 )+*$)/.:($..$)"*. -1/$*).2$'')*/ $(+0/ =# +-$(-4)'4.$.( /#*!*-*)/$)0*0.
 )+*$)/.2$'' . *)($3 (* '2$/#- + / ( .0- .IJ2#$#0/$'$5 .''1$'' /
I*(+' / )+-/$'J!-*(.0% /.$)'0 $)))'4.$.. /=# E. ++-*#..0( ./#//
- ($..$)"/-)*(IJ=- ! -./*($..$)") ..( #)$.(/#/$.$) + ) )/*!($..$)"- .+*). .:
*)$/$*)''4*)*. -1 - .+*). #$./*-4)*1-$/ .=#$...0(+/$*)$)# - )/'4$(+'$ ./#//# /- /( )/
 !! /$..$($'-!*-/#*. 2#*$.*)/$)0 +- (/0- '4)!*-/#*. 2#**(+' / /# ./04$)/# $-- .+ /$1 
/- /( )/-(.=
 ).$/$1$/4 )'4. . /* $)1 ./$"/  -*0./) .. /* ($..$)" / 2$''   + -!*-(  !*- /#  +-$(-4  )+*$)/ .
 .-$ $) /$*)TX=T=W:)& 4. *)-4 )+*$)/. .-$ $) /$*)TX=U=V=
*-)'4.$.*!/ "*-$' !!$4 )+*$)/.:.0#.- .+*) -.. *)+ - )/$(+-*1 ( )/!-*(
. '$) : .0% /. $.*)/$)0$)" !-*( /#  ./04 +- (/0- '4 *- ($..$)" $)/ -( $/  ( .0- ( )/. 2$''  
*).$ - .)*)E- .+*) -.=
$..$)".! /4/2$'')*/ $(+0/ =
H7E7 

8



# +-$(-4)& 4. *)-4 !!$4#4+*/# . .2$'' "-*0+ $)/*/2*#$ --#$'!($'$ .=
x
($'4 T $. /#  	EVSZS \(" 1 -.0. +' * I	4+*/# .$. TJ ) /#  	EVSZS T[ (" 1 -.0. +' *
I	4+*/# .$.UJ:. *)/# +-$(-4 )+*$)/*!#)" !-*(. '$) $)/*/'.*- /  &Y=
x
($'4 U $. /#  	EVSZS \(" 1 -.0. +' * I	4+*/# .$. VJ ) /#  	EVSZS T[ (" 1 -.0. +' *
I	4+*/# .$.WJ:. *)/# & 4. *)-4 )+*$)/*!#)" !-*(. '$) $)
E/  &Y=
(/# +-'' '"/ &  +$)"+-* 0- I# )::USSX:($/-$ )&*::USSZ:($/-$ )&*::USS[J
2$'' 0. /**)/-*'/# *1 -''4+ 
 --*--/ $)./-*)". ). //# ' 1 '*!S=SX=# #4+*/# .$./ ./$)"
0. $)/#$."/ &  +$)"+-* 0- 2$'' . *)/-0)/ )- "0'-	*# -"+-* 0- I.  ++ )$3U
!*- /$'.J.!*''*2.<
T= #  *(+-$.*). !*- /#  +-$(-4  )+*$)/ I#4+*/# . . T ) UJ -  + -!*-(  0.$)"  /-0)/ 
	*# -"+-* 0- 2$/#/-0)/$*)+-( / -8cS=\=
U= # *(+-$.*).!*-
EI#4+*/# . .V)WJ*-- .+*)$)"/*/# *. ./#/2 - .$")$!$)/$)./ +
T- + -!*-( 0.$)"- "0'-	*# -"+-* 0- =
# !($'4T. -1 .."/ &  + -!*-U.0#/#/U2$''  3($) *)'42# )/# "/ &  + -T#.  )
.0 ..!0''4+.. I$= =:/' ./*) *!/# #4+*/# . .$)/# T!($'4$.- % / J=# (/# "/ &  + -
+-* 0-  0/$'$5 . /#  .+ $' '*"$' - '/$*).#$+  /2  ) /#  +-$(-4 ) /#  & 4 . *)-4 +-( / -. /*
 )#) /# +*2 -*!.//$./$'/ ./$)"=# .$")$!$) $)/# & 4. *)-4 )+*$)/!*-*. ' 1 '))*/
 '$( 0)' ..$/.*-- .+*)$)"+-$(-4#4+*/# .$.$.!*0).$")$!$)/=
)*/# -2*-.:/# & 4. *)-4
 )+*$)/ )   - ./-$/  /* /#  *. . 2# -  /#  +-$(-4  )+*$)/ $. .$")$!$)/ /* *0)/ !*- '*"$'
- '/$*).#$+. (*)" /#  (0'/$+'  *(+-$.*).= #  .0. ,0 )/ ($'4 2$''   / ./  !*- /#  #4+*/# .$. /#/
*-- .+*). 2$/# /#  *.  *! /#  #4+*/# .$. $) +- 1$*0. ($'4 /#/  (*)./-/  .$")$!$)/  !! / *1 -
+' *= 0'/$+'$$/4 %0./( )/ 2$''   ++'$  /* /#  )'4.$. *! /#  +-$(-4 ) & 4 . *)-4  )+*$)/.
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" US*!XS
+ -!*-(  *) /#  0'' )'4.$.  /= # -  2$''   )* (0'/$+'$$/4 %0./( )/. (  !*- )'4.$. *) /#  

)'4.$.. /*-!*-/# */# -. *)-4 )+*$)/.=
H7F7 


0"-*0+)'4. .2$'' *)0/ +-$(-4)& 4. *)-4 )+*$)/.*)/# 0'')'4.$. /=
/.#*0' 
)*/ /#//# ./04$.)*/ .$") /* / //- /( )/$!! - ) .2$/#$).0"-*0+.=
# !*''*2$)".0"-*0+.2$'' .. .. ) .-$ 2$/#$)/#  3+'*-/*-4)'4.$.. /$*).<
x
 ) -<
R
 (' 
R
' 
x
" I4 -.J<
R
eXX
R
iXX
x
 $)U/ "*-$ .<
R
'&C!-$)( -$)
R
''*/# -- .*($) I( -$)
)$)C'.&/$1 :.$):/$1 	2$$)C/# -$!$

.') -.:*-#$/ J
x
 1 -$/4/. '$) 
R
e\S*/'*- 
R
i\S*/'*- 
x
 "$*)
R
)$/ // .
R
0..$
R
 ./*!*-'
x

I&"C(UJ
R
eUX
R
iUX/*eVS
R
iVS
x
" *!*). /I4 -.J
R
eUX
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" UT*!XS
R
iUX
x
$. . 0-/$*)I4 -.J
R
eX
R
iX/*eTS
R
iTS/*eUS
R
iUS
$/$*)'.0E"-*0+.(4  !/ -- 1$ 2$)"/# /=
I7

 .-$+/$1 .0((-$ .).//$./$')'4. .2$'' +-*1$ !*-.. ..( )/.+ -!*-( 0-$)"/# *0' E
'$) /- /( )/ + -$* ) !*''*2E0+ + -$*= 
) " ) -': / *'' /  0-$)" /#  .-  )$)" ) .$)"' E'$)
+' *-0)E$)+ ULRGV2$'' +- . )/ $).0% /'$./$)".*)'4:2$/#/#  3 +/$*)*!'0'/ . '$) 1'0 .
2#$#2$'' .0((-$5 )0. $))'4. ..++-*+-$/ =
++ )$3T .-$ ..*( *)1 )/$*).!*-+- . )//$*)*!/$)*0/+0/.=
# / (+'/ .+-*1$ $)$/$*)/*/#$.2$'' .-$ /# +- . )//$*).!*-/#$../04)/# - !*- /# 
!*-(/)*)/ )/*!/# .0((-4/' .:!$"0- .)'$./$)"./* +-*1$ 4

$*.//$./$.=
J7



	
'' .0% /. 2#* +-*1$  $)!*-(  *). )/ 2$''   *0)/  !*- $) /#$. ./04= 0% / $.+*.$/$*) 2$''  
+- . )/ 4/- /( )/"-*0+)*1 -'':.++-*+-$/ =
0( -)+ - )/" *!.0% /.-)*($5 2$'' .0((-$5 4*0)/-4=
0( -)+ - )/" *!.0% /.$)'0 $) #)'4.$. /I. !$) $) /$*)XJ2$'' .0((-$5 =
0( -)+ - )/" *!.0% /.2#**(+' / *-$.*)/$)0 /# ./04+- (/0- '42$'' .0((-$5 
!*-/# *0' E'$)/- /( )/+ -$**1 -''= .*).!*-./04$.*)/$)0/$*)0-$)"/# *0' E'$)+ -$*
2$'' .0((-$5 !*-/# 
::.! /4))'4.$.. /.= .*).!*-./04$.*)/$)0/$*).0-$)"/# 
.$)"' E'$)+ -$*2$'' '$./ !*-''.0% /..-  ) =
 +')E $ - +'*/ *! /$(  /* $.*)/$)0/$*) 0-$)" /#  *0' E'$) + -$* 2$''   +- . )/  !*- /#  

)'4.$.. /4/- /( )/"-*0+:2# - /$( E/*E 1 )/2$'' *(+0/ $)4..K/ *!'./*. *!*0' E
'$)./04( $/$*)F/ *!-)*($5/$*)L=*-.0% /.2#*2 - -)*($5 0/$)*/-  $1 )4
*0' E'$)./04( $/$*):/$( E/*E 1 )/2$''  ,0'/*S=0% /.2#**(+' / /#  )/$- Y2  &.*!
*0' E'$)/- /( )/2$''  ).*- *)/# / *!/# $-'./*. *!*0' E'$)./04( $/$*)=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" UU*!XS
BA7 	
	
	


 (*"-+#$/)*/# -. '$) #-/ -$./$.2$'' .0((-$5  .-$+/$1 '4!*-/# 
)'4.$. /=
*.//$./$'/ ./$)"2$'' --$ *0/!*- (*"-+#$*-*/# -. '$) #-/ -$./$.=
0% /#-/ -$./$.(4$)'0 :0/- )*/'$($/ /*<
x
" I4 -.JE'0'/ - '/$1 /*/ *!$)!*-( *). )/
x
 ) -
x
 
x
/#)$$/4
x
 "$*)
x
 $"#/I&"J
x
	 $"#/I(J
x
*4..
) 3I
JINJC(UJ
x
#$5*+#- )$$")*.$.
R
$( .$) !$-./$")*.$.*!#$5*+#- )$I4 -.J
R
$( .$) ./-/*!0-- )/ 3 -/  +$.* I2  &.J
x
#$5*+#- )$. '$) !!$4
R
. '$) /*/'.*- Ie\S:fc\SJ:. '$) .*- 
x
" I4 -.J*!!$-./$")*.$.*!.#$5*+#- )$
x
)/$+.4#*/$./- /( )/ !*- 0-- )/ +$.* I4 .C)*J
BA7B7


x

I&"C(UJc2 $"#/I&"JC# $"#/I(JU
x
$( .$) !$-./$")*.$.*!#$5*+#- )$I4 -.Jc
I/ *!!$-./*. *!*0' E'$)./04( $/$*)F/ *!!$-./$")*.$.JCVYX=UX
x
$( .$) ./-/*!0-- )/ 3 -/  +$.* I2  &.Jc
I/ *!!$-./*. *!*0' E'$)./04( $/$*)F./-// *!0-- )/ 3 -/  +$.* JCZ
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" UV*!XS
BB7 
	

 $'	$./*-4$)!*-(/$*)2$'' +- . )/ $)'$./$)".*)'4=
 $'	$./*-42$'' * 0.$)" $'$/$*)-4!*- "0'/*-4/$1$/$ .I J=
BC7 


* ).0- /- /( )/*(+'$) :+/# .2$'' ++'$ )- (*1 4 .$")/ ,0'$!$ ./!!=#  3/
/$( .*!+/#++'$/$*))- (*1'2$'' - *- *)/#  =# / *!!$-./)'./*. .*!*0' E
'$)./04( $/$*)($)$./-/$*)2$'' /& )!-*(/#  =
# / )/$( *!!$-./*. *!*0' E'$)./04( $/$*)2$''*-- .+*)/*/# / )/$( 2# )/# 
!$-./*0' E'$)+/#$.++'$ !*- #.0% /=# /  )/$( *!/# './*. *!*0' E'$)./04
( $/$*) 2$'' *-- .+*) /* /#  /  ) /$(  2# ) /#  './ +/# *! *0' E'$) ./04 ( $/$*) $.
- (*1 =
3+*.0- /*./04( $/$*)2$'' .0((-$5 $)/ -(.*!0-/$*)*! 3+*.0- I4.J/*/# *0' E'$)
./04( $/$*).!*-/# ! /4)'4.$.. /4/- /( )/"-*0+=
0-/$*) *!  3+*.0-  /* /#  *0' E'$) ./04 ( $/$*) 2$''   .0((-$5  4 /- /( )/ "-*0+ . 
*)/$)0*0.1-$' =$/$*)''4:0-/$*)*! 3+*.0- /*/# *0' E'$)./04( $/$*)2$'' .0((-$5 
$)/ -(.*!/# )0( -)+ - )/" *!.0% /.2$/# 3+*.0- !*-' ../#)T2  &:)/' ./T:U:V:W:X:
)Y2  &.=# /*/')0( -*!+/# .++'$ 2$'''.* .0((-$5 !*-/# *0' E'$)+ -$*)4
2  &=
BC7B7


0-/$*) *!  3+*.0-  I4.J /* /#  *0' E'$) ./04 ( $/$*) 2$''   '0'/  . I/  *! './ *.  *!
*0' E'$)./04( $/$*)JFI/ *!!$-./*. *!*0' E'$)./04( $/$*)JbT=
BD7 



*(+'$) 2$/#./04( $/$*)0-$)"/# *0' E'$)+ -$*2$'' .0((-$5 !*-/# 
)'4.$.. /=
0-$)"/# *0' E'$)- /( )/ -$*I4T/#-*0"#4WUJ.$/ + -.*)) '2$''++'4U+/# .*) $'4
/*.0% /..-)*($5 =/# .2$'' ++'$ 4.$/ + -.*)) '/++-*3$(/ '4/# .( /$(  1 -44
) #+/#2$'' 2*-)!*-UW#*0-.=

! */# +/# . -   /#  *(+' / '4 /# ) U ) 2 +/# . !-*( /#  .0% /@. &$/ .#*0'   ++'$ 
$(( $/ '4:+-*1$ /#//# - $./' ./Y#*0-.*!/$( - ($)$)" !*- /# ) 3/*. =
!*)'4*) +/#
 /# .*(+' / '4:/# )/# */# -+/#.#*0''.* - (*1 )U) 2+/# .!-*(/# .0% /@.&$/
.#*0' ++'$ $(( $/ '4:+-*1$ /#//# - $./' ./Y#*0-.*!/$( - ($)$)" !*- /# ) 3/*. =
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" UW*!XS
0( -)+ - )/" *!.0% /.2#*- *(+'$)/I !$) .0.$)"i[Sa)hTUSa*!./04( $/$*)J
))*)*(+'$)/I !$) .0.$)"' ../#)[Sa*-(*- /#)TUSa*!./04( $/$*)J0-$)")4 1'0/$*)
+ -$*2$'' +- . )/ =
*(+'$) 2$'' .0((-$5 !*-+ -$*. /2  ) 1 -4*0' E'$)/- /( )/+ -$*1$.$/I  &.T/#-*0"#
YJ)*0' E'$)+ -$**1 -''=
BD7B7


*(+'$) 2$/#./04( $/$*)I. *)/# -0"*0)/$'$/4)+/#++'$/$*))- (*1'/J
2$'' '0'/ ./# )0( -*!+/# .++'$ $1$ 4/# +- .-$ )0( -*!+/# .*1 -"$1 )
+ -$*: 3+- .. .+ - )/" =
/# .- +- .-$ *) $'4:U+/# .+ -($)$./-/$*):*)/# 4.2#$' /# .0% /- ($).*)./04
/- /( )/0-$)"/# *0' E'$)/- /( )/+ -$*=
# )0( -*!+/# ./#/)   /* - +' 0 /* /#( )/(*- /#)Y#*0-. !*- /# ) 3/*. 
I.  .-$  $)  /$*) TVJ 2$''   *0)/  $) /#  )0( - *! +/# . +- .-$ = $($'-'4: /#  )0( - *!
+/# ./#/2 - ++'$ .- .0'/*!.0# /#( )/2$'' *0)/ $)/# /*/')0( -*!+/# .++'$ =
BE7 


 $/$*). /& ) !-*( Y (*)/#. +-$*- /* /#  -  )$)" 1$.$/ /#-*0"# /#  ) *! /04 I$)'0$)" !*''*2E0+
+ -$*J(0./ - *- )2$'' .0((-$5 !*-/# ! /4 )'4.$.. /. $/# -+-$*-:*)*($/)/:*-
+*./E/- /( )/ ( $/$*).== '' ( $/$*). 2$''   *  0.$)" *-' 	 '/# -")$5/$*) -0" $/$*)-4
I	EJ1 -.$*)T\=
-$*- ( $/$*). -  ( $/$*). 2#$# ./-/  ) ./*++  +-$*- /* /#  !$-./ *.  *! *0' E'$) ./04
( $/$*)= -$*- ( $/$*). /#/ ./*++  2$/#$) /#  .$3 (*)/#. +-$*- /* .-  )$)" ( $/$*) 2$''  
.0((-$5 =''( $/$*).- +*-/ *)/#  2$'' $)'0 $)/# '$./$)"=
*)*($/)/ ( $/$*). -  ( $/$*). 2#$# -  ($)$./ -  /* /#  .0% / 0-$)" /#  + -$* *! /$( 
./-/$)"//# / *!!$-./*. *!*0' E'$)./04( $/$*)0+/*T4!/ -/# / *!'./*. *!./04
( $/$*)=# 4$)'0 ( $/$*).2#$#<
H
./-/ *):*-!/ -/# !$-./*. *!*0' E'$)./04( $/$*)I)*'/ -T4!*''*2$)"/# / *!
'./*. *!./04( $/$*)J:)
H
 ) *)*-!/ -/# / *!!$-./*. *!*0' E'$)./04( $/$*)*-2 - *)"*$)"//#  )*!
/# ./04=
*./E/- /( )/( $/$*).- ( $/$*).2#$#./-/ (*- /#)T4!/ -/# / *!'./*. *!*0' E
'$)./04( $/$*)=

) /#  .  2# -  $/ $. )*/ +*..$'  /*  !$)   ( $/$*) . +-$*-: *)*($/)/: *- +*./E/- /( )/: /# 
( $/$*)2$'' '..$!$ .*)*($/)/=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" UX*!XS
0( -*!.0% /.2$/#*)*($/)/( $/$*).2$'' .0((-$5 4	E- ! --  -(:*1 -'')
4/- /( )/"-*0+!*-/# ! /4)'4.$. /=0'/$+' *0-- ) .*!( $/$*).* /*/# .( $)
.0% /2$'' *0)/ *)'4*) 2$/#$)/# =
# !*''*2$)"'"*-$/#(2$''++'4/*+-/$'/ .=
(+0/ / .2$'' +- . )/ $)/# '$./$)".0/(4
 0. /* / -($) /# / "*-4*!( $/$*).I+-$*-:*)*($/)/:*-+*./E/- /( )/J=

!( $/$*):.- +*-/ *)/#  :#.+-/$''4*-*(+' / '4($..$)"./-/*- )/ :0. /# !*''*2$)"
'"*-$/#( /* $(+0/  ($..$)" *(+*) )/. *! /#  / I.J= 
(+0/  / . 2$''   0.  $) *- - /*  / -($) 
+-$*-C*)*($/)/C+*./E/- /( )/.//0.*!/# -+4=

 /- +- . )//# ( $/$*)./-// )- +- . )//# ( $/$*)./*+/ =


!/# -+4#..*( ($..$)"*(+*) )/.$)*/#/# ./-/) )/ .:!$-./$(+0/ /#  )/ .!*''*2.
I*)'4$!/# /# -+4$.)*/*)"*$)"J<
T= 
!*)/$).*)'44 -)(*)/#F$(+0/ /# ($..$)"4/*/# './4*!/# *-- .+*)$)"
(*)/#I ="=:VT!*-)0-4:*-VS!*-+-$'J=
U= 
!  *)/$). *)'4 4 - F $(+0/  /#  ($..$)" 4 ) (*)/# /* /#  VT./ *!   ( - *! /# 
*-- .+*)$)"4 -=
V= 
!$.*(+' / '4($..$)"$(+0/ /*/# / *!/# './*)//2$/#/# .0% /=
*/ <#  )/ .#*0'- ($))0''!*-( $/$*)./#/- *)"*$)"=

!/ -#1$)"$(+0/ /#  )/ I$!)   J:$(+0/ /# /# -+4./-// $!$/$.+-/$'*-($..$)".!*''*2.<
T= 
!*)/$).*)'44 -)(*)/#F$(+0/ /# ($..$)"4/*/# T./4*!/# *-- .+*)$)"
(*)/#=
U= 
!  *)/$). *)'4 4 - F $(+0/  /#  ($..$)" 4 ) (*)/# /* /#  T./ *! )0-4 *! /# 
*-- .+*)$)"4 -=

!  $. *(+' / '4 ($..$)" $(+0/  /* /#  /  *! $)!*-(  *). )/ *- /* /#  ( $/$*)  ) / 
I+- 1$*0.'4$(+0/ $!)   J:2#$# 1 -$. -'$ -=
BF7 

BF7B7


BF7B7B7



=


# +-$(-4 !!$4 )+*$)/$./# #)" $)/*/'.*-  /2  ). '$) )  &Y=
# *).$./.*!V.0.' .*)/$)$)"/*/'*!VS$/ (.=*- #$/ (:. 1 -$/4$.-/ *)))#*- 
ZE+*$)/.' :2$/#.*- *!T$)$/$)"/# . ) *!.4(+/*(.).*- *!Z$)$/$)" 3/- ( '4. 1 - 
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" UY*!XS
.4(+/*(.=
# /*/'.*- $./# .0(*!''VS$/ (.=# .*- -)" .!-*(VS/#-*0"#UTS:2$/##$"# -1'0 .
- +- . )/$)""- / -. 1 -$/4*!$'') ..=

!*) *-(*- $/ (.- ($..$)"/"$1 ).. ..( )/:/# /*/'.*- 2$'' . //*($..$)"=
BF7B7C7


	



$..$)"/*/'.*- .2$'')*/ $(+0/ !*-+-$(-4)'4.$.=# +-$(-4)'4.$.( /#*::2$''
0/$'$5 ''/1$'' 0-$)"/# *0' E'$)/- /( )/+ -$*I*(+' / )+-/$'J!-*(.0% /.$)'0 
$)/# )'4.$.. /=
)'4.$.*!. ).$/$1$/4/*($..$)"/!*-/# +-$(-4 )+*$)/2$'' + -!*-( . .-$ $) /$*)TX=T=W=
$..$)"/+// -).2$''  .-$ "-+#$''44+'*//$)"( )#)" .!-*(. '$) $)/*/'.*- :
+*.$/$1 : ) "/$1  ) " ) -' +.4#*+/#*'*"4 .0.' . -*.. 1$.$/. 4 /- /( )/ "-*0+ ) .0"-*0+. *!
.0% /. /#/  $/# - *(+' /  /#  *0' E'$) /- /( )/ + -$* *- $.*)/$)0   -'4= 0% /. 2#*
$.*)/$)0  -'42$'' "-*0+ 42  &/2#$#/# 4$.*)/$)0 IT/#-*0"#YJ=
BF7B7D7






# +-$(-4 !!$4)'4.$.2$'' + -!*-( !*-/# 0'')'4.$. /=
#  ./$()$)/# +-$(-4)'4.$.!*- !!$4!*- #*. $./# $!! - )  /2  )/- /( )/."-*0+.I	E
VSZS *.  "-*0+ 1.= +' *J $) /#  #)"  !-*( . '$)  /*   & Y $)  /*/' .*-  $) '' .0% /. .
-)*($5 : 0) - /#  ..0(+/$*) /#/ '' -)*($5  +/$ )/. - ($) *) /# $- -)*($5  /- /( )/
/#-*0"#*0//# /-$'=.*- .*/$) UW#*0-.!/ -- (*1'*!/# *0' E'$)./04( $/$*)*)4
WU*-.*- .*/$) (*- /#)UW#*0-.!/ -$.*)/$)0/$*)*!*0' E'$)./04( $/$*))/# 
.0% /.2$/# /*)++-*1 )/$+.4#*/$/- /( )/2$''  3'0 .*0/'$ -.=0/'$ -.2$''  !$) 
.I$J/*/'.*- .*/$) (*- /#)UW#*0-.!/ -- (*1'*!*0' E'$)./04( $/$*)*)
4 WU; *- I$$J  /*/' .*- . */$)  (*-  /#) UW #*0-. !/ - $.*)/$)0/$*) *! *0' E'$) ./04
( $/$*))/# .0% /.2$/# /*)++-*1 )/$+.4#*/$/- /( )/=*)E*(+'$) C)*)E# - ) 
/*./04/- /( )/(4' /*+**-*0/*( .)$)/-*0 1-$$'$/4=# / -($)'#'!E'$! *!. )+$) !-*(
+#-$.C4- ./$.UW#*0-.)/# ( )#'!E'$! *!. )+$) !-*(	EVSZS+/#-)" !-*(U\=Z#*0-./*
VT=V#*0-.!*-''/# ++'$/$*).$/ .=
*).$ -'  !!*-/.2$'' ( 0-$)"/# ./04*)0//*+- 1 )/*0/'$ -.=*- 3(+' <.$/ + -.*)) '2$''
  $)./-0/  /* )*/ $..0   4 +.. /* +/$ )/. *) 4 WT I'./ 4 *! *0' E'$) +/# ++'$/$*)J )
+/$ )/.2$'' ''*2 /*' 1 /# '$)$*)'4!/ -''4WUI  &YJ.. ..( )/.- *(+' / =0% /.
2$/#*0/  /*/' .*-  /   & Y 2$''   (* '  . .$($'- /* /#*.  2$/# / *)$/$*)' *) *. -1 
- .+*). #$./*-4)*1-$/ .=''$.*)/$)0 .0% /.2$'' .. .. 2$/#/*/'.*- //# /$( *!
/- /( )/$.*)/$)0/$*)=
#  +-$(-4  !!$4 1-$' : #)"  !-*( . '$)  /*   & Y $) /#   /*/' .*-  !*-  # *! /#  V
/- /( )/-(.:2$'' )'45 0.$)"))'4.$.=# (* '2$''$)'0 #)" !-*(. '$) 
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" UZ*!XS
$)/*/'.*- ./# - + /  + ) )/1-$' :2$/#*0)/-4:/- /( )/I	EVSZS\(":	EVSZST[
(":)+' *J:1$.$/I  &.T:U:V:W:X:)YJ:/- /( )/41$.$/$)/ -/$*):)/# . '$) /*/'
.*- .*1-$/ .=)0)./-0/0- *1-$) (/-$32$'' ..0( =
)/#  1 )//# *)1 -" ) ))*/ 
//$) 2$/#/# 0)./-0/0- *-- '/$*)(/-$3:/# !*''*2$)"'/ -)/$1 ./-0/0- .2$'' // (+/ $)/# 
.+ $!$  *- - I!-*( ' ./ - ./-$/$1  /* (*./ - ./-$/$1 J< # / -*" ) *0. * +'$/5 ./-0/0-  I	J:
# / -*" ) *0. 0/*- "- ..$1 ITJ I	ITJJ: # / -*" ) *0. *(+*0) .4(( /-4 I	J: * $"*)' /*-
)'4/$ISI,J:2$/#, ,0'/*/# )0( -*!/$( +*$)/.J:* +'$/5./-0/0- IJ:0/*- "- ..$1 ITJIITJJ:
)*(+*0).4(( /-4IJ=# !$-././-0/0- $)/#$.'$./2$/#2#$#/# (* '*)1 -" .2$'' 0. =
!
 $/# - 	ITJ *- ITJ ./-0/0-  $. 0. :  -)*( .0% / $)/ - +/ 2$'' '.*   $)'0  $) /#  (* '= # 
 ./-$/ 3$(0($& '$#**IJ( /#*2$'' 0. !*-/#  ./$(/$*)*!/# *1-$) +-( / -.=
#  )2-E*" -.( /#*2$'' 0. /* ./$(/ /#  )*($)/*- "-  .*!!-  *(=# /- /( )/E4E
/$(  $)/ -/$*) / -( ''*2. !*- *(+-$.*). *! /#  /- /( )/ "-*0+. /  # /$(  +*$)/= - /( )/
*(+-$.*).*! #	EVSZS*. /*+' */  &Y2$'' 0. !*-/# +-$(-4)'4.$.=
+-* 0- 
2$'' 0. /*+ -!*-(/#$.)'4.$..!*''*2.<
+-*($3 /ce)'4.$./. /f;


'..


;


(* '	c

M

C!(c&-;


- + / 

C/4+ c0).0% /c
;


'.( ).M

C'+$!!c'';

-0);
# !*''*2$)".//$./$.2$'' - +*-/ . *)/# )'4.$.<' ./.,0- .( )IJ ./$(/ .!*-
#)" !-*(. '$) $).*- /  &Y:./)- --*-.)\Xa*)!$ ) $)/ -1'.I
.J!*-.4
/- /( )/"-*0+=$!! - ) . /2  )/- /( )/"-*0+.I$= =:	EVSZS\("1.=+' *)	EVSZST[
("1.=+' *J:/# *-- .+*)$)"./)- --*-.:\Xa
.:)+E1'0 .2$'' +- . )/ !*-  &Y=E1'0 .
*-- .+*)$)" /*   & Y *(+-$.*). 2$''   0.  !*- $)! - )/$' +0-+*. . *! /#  +-$(-4 )'4.$. ) /# 
*(+-$.*).  /2  )  # *! /#  /2* 	EVSZS *. . 1 -.0. +' * 2$''   %0./  !*- (0'/$+'$$/4 .
 .-$ $) /$*)Z=W=
. -1 1'0 .)#)" !-*(. '$) /*  &Y2$'''.* .0((-$5  .-$+/$1 '4=
)  (* ' 2$/# # / -*" ) *0. 1-$) . 2$''   !$//  I0.$)"  ce/- /( )/f *+/$*) $) /# 
.// ( )/*!
J)/# &$& @.
)!*-(/$*)-$/ -$*)I
J!-*(/#$.(* '2$'' 
*(+- /*/# 
1'0 !-*(/# +-$(-4)'4.$.(* '=
!/# 
1'0 !*-/# (* '2$/## / -*" ) *0.
1-$) .$..('' -:/# - .0'/.!-*(/#$.(* '2$'' +- . )/ =
 .$0'.)$)!'0 ) $")*./$.2$'' + -!*-( !*-/# +-$(-4:)$!/# - $.)$)$/$*)/#/
/# )*-('$/4..0(+/$*)$.1$*'/ )C*- 3/- ( '4$)!'0 )/$'*. -1/$*).- $ )/$!$ =
* '$")*./$.2$'' + -!*-( /#-*0"# 3($)/$*)*!"-+#$'$.+'4.*!./0 )/$5 - .$0'.1 -.0.
+- $/  ( ):  ,0)/$' E,0)/$'  +'*/ *! ./0 )/$5  - .$0'.: !$3   !! /. $)!'0 )  $")*./$. )
*1-$) +-( / -$)!'0 ) $")*./$.=# . $")*./$+'*/.2$'' +-*0 0.$)"/# 	

!0)/$*)'$/4*!
I0.$)"*+/$*).
)
I
cXce.0% /fJ=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" U[*!XS
BF7B7E7








#  !*''*2$)" /#-   +// -). 2$''   *).$ -  /* . +-/  $)!*-(/$1  I/- /( )/ !$'0- .J 1 -.0. )*)E
$)!*-(/$1 . .. *)/# - .*)I.J*!$.*)/$)0/$*)2# )$(+0//$*)*!($..$)"1'0 .+ -!*-( !*-
.0% /.$.*)/$)0  -'4<
..,(B<$.*)/$)0/$*)!*-)4*!/# - .*).<)1 -.  1 )/: /#:)*)E*(+'$) :'&*! !!$4:
.0% / - ,0$-  /- /( )/ 2$/#  +-*#$$/  ( $/$*): +- "))4: +#4.$$)  $.$*): ./04 / -($)/  4
$)1 ./$"/*-:./04/ -($)/ 4.+*).*-:.0% /2$/#- 2*). )/:*-*/# -$.$)!*-(/$1 ;
..,(C<$.*)/$)0/$*)0 /*'&*! !!$4:1 -.  1 )/:*- /#$.$)!*-(/$1 )$.*)/$)0/$*).
0 /*''*/# -- .*).- )*)E$)!*-(/$1 ;
..,(D<$.*)/$)0/$*)0 /*'&*! !!$4$.$)!*-(/$1 )$.*)/$)0/$*).0 /*''*/# -- .*).- 
)*)E$)!*-(/$1 =
# !*''*2$)". ).$/$1$/4)'4. .2$'' + -!*-( !*-/# +-$(-4 !!$41-$' <
(,#) >B<  +// -)E($3/0-  (* ' IJ ++-*#=  ).$/$1$/4 )'4.$. 2$'' *).$ -  $..$)" */ /
)*(IJ( #)$.(!*-/# ($..$)"/:2# - $/2$'' ..0( /#/.0% /.2#*$.*)/$)0  -'4
!-*(/# 	EVSZS/- /( )/2$''!*''*2/# /-% /*-4*!*0/*( ..$($'-/*/# *) $)/# +' *-(!/ -
$.*)/$)0/$*)*!/# 	EVSZS/- /( )/:/&$)"$)/**0)/*. -1 1'0 .+-$*-/*$.*)/$)0/$*)I$//' 
)0:T\\Y;/$/# /'=:USTVJ=0% /.$.*)/$)0$)" -'4!-*(/# +' *-(2$'' ..0( /*#1 
0)*. -1  *0/*( . .$($'- /* +' * .0% /. 2#* - ($) *) +' * /- /( )/= #  ..0(+/$*) /#/
 !!$4+-*!$' .*!-*+*0/.!/ -$.*)/$)0/$*)*!/$1 /- /( )/- .$($'-/*/#*. *!+' *.0% /.
+-*1$ . )  ./$(/  *!  !!$4 //-$0/'  /* /#  /$1  /- /( )/ $! -  $1  /#-*0"# /#  /$(  +*$)/ *!
$)/ - ./: 2#$'  '$($/$)"  !!$4 !/ -  -'4 $.*)/$)0/$*) /* /#/ *! /#  +' * ) /-$'  !! /=  +// -)E
($3/0- (* '++-*#0.$)"+' *E. (0'/$+' $(+0//$*)2$'' 0. !*-/#$.)'4.$.=

)/ -($// )/ ($..$)" / 2$''   (0'/$+'4 $(+0/  0.$)" /#   ..0(+/$*) 2$/#$)  # /- /( )/ -(=
*)*/*) ($..$)"/I/($..$)"!/ -) -'4$.*)/$)0/$*)J!*-''.0% /.I!-*(+' *)	EVSZS
/- /( )/-(.J2$'' (0'/$+'4$(+0/ 0.$)"+' *E. $(+0//$*)(* '=# ./ +./*$(+' ( )//#$.
. ).$/$1$/4)'4.$.-  /$' $)++ )$3V=
)'4.$.(4'.* + -!*-( *-$)"/*+// -).U)V=*-/# . )'4. .:*)'4/# $.*)/$)0/$*)
- .*).*).$ - .$)!*-(/$1 2$'' $(+0/ 0.$)"/# +' *E. $(+0//$*)(* ';$.*)/$)0/$*).
!*- )*)E$)!*-(/$1  - .*). 2$''   (0'/$+'4 $(+0/  0.$)" /#   ..0(+/$*) 2$/#$)  # /- /( )/ -(=
)'4. .!*-+// -)U)C*-+// -)V(4*)'4 + -!*-( $!-*+*0/$.*).$ - #$"#=
(,#)>C<*)/$)0*0.- .+*) -)'4.$.. *)$(+-*1 ( )/!-*(. '$) $)/*/'.*- 2$'''.*
 + -!*-( . .-$ $) /$*)TX=V=T=\=
(,#)>D<$( E/*E!$'0- )'4.$.2$''*($) /2*/4+ .*!($..$)"/I($..$)"/-)*()($..$)")*/
/ -)*(J= $( E/*E!$'0-  )'4.$. 2$''   + -!*-(  /- /$)" $)!*-(/$1  ($..$)" / . !$'0- . !*''*2$)"
+// -)T:U:)V:)0.$)" ).*-$)"-0' .!*-)*)E$)!*-(/$1 . .=$( /*!$'0- 2$'' '0'/ !-*(
/# !$-./.*- !/ -. '$) /#/$.eUSa$(+-*1 ( )/!-*(. '$) $!/# - $.) 1 -)$(+-*1 ( )/$)
.*- fcUSa0-$)"/# ./04*-!-*(/# !$-./.*- /#/$.eUSa$(+-*1 ( )/!-*(. '$) !/ -
/$( +*$)/2$/#fcUSa$(+-*1 ( )/=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" U\*!XS
(,#)>E<)'4.$.*!*1-$) IJ*)-)&E/-).!*-( //  &Y:%0./ !*-. '$) )
*0)/-4:2$'' '.*+ -!*-( .. ).$/$1$/4)'4.$.=

)*- -/*+ -!*-()*)-)&E/-).!*-( /:#)" .!-*(. '$) /*  &Y$)/# /*/'
.*-  2$''   /-).!*-(  /* -)&. .  .-$  $) ++ )$3 W=  !*-  + -!*-($)" /#  -)& /-).!*-(/$*):
.0% /.2$/#($..$)"//  &Y2$'' $(+0/ 2$/##)" !-*(. '$)  ,0'/*/# 2*-./I'-" ./J
#)" !-*(. '$) $)*. -1 /+'0.T!*-$)!*-(/$1 . .!*''*2$)"+// -)T:.*/#//# . .0% /.
2*0'#1 /# 2*-./I#$"# ./J-)&!/ -/# /-).!*-(/$*)=I
/.#*0' )*/ /#/2$/#)..$")( )/*!/# 
#$"# ./-)&/*.0% /.2$/#($..$)"/:/# -)&E. :*)/--4/*/# +-$(-4)'4.$.:* .)*/
..0( ( #)$.(:0/-/# -$(+'$ ./# 2*-./*0/*( !*-'' -'4$.*)/$)0 .0% /.- "-' ..*!
/- /( )/-(J=#  /$'.*!/# -)&E. -  .-$ $)++ )$3W=
 ).$/$1$/4)'4.$./*$)1 ./$"/ $(+/*!*0/'$ -.*)+-$(-4 !!$4<*$)1 ./$"/ /# $(+/*!*0/'$ -.*)
/# +-$(-4 !!$4)'4.$.:. ).$/$1$/4)'4.$.2$'' + -!*-( 4$)'0$)"*0/'$ -.=
BF7C7

BF7C7B7


=


TX=U=T=T=
#)" $)
E*-  /2  ). '$) )  &Y
# . 1 -$/4*!$'') ..!*- #.0% /2$'' -/ 0.$)"/# 
E=*+ -!*-(/#$... ..( )/:/# -/ -*-

)1 ./$"/*-2$'').2 -/# !*''*2$)",0 ./$*)<A*).$ -$)"4*0-/*/''$)$' 3+ -$ ) 2$/#/#$.+-/$0'-
+*+0'/$*):#*2( )/''4$''$./# .0% ///#$./$( 9B .+*). #*$ .$)'0 <Sc)*/.. .. ;Tc)*-(':
)*//''$'':Uc*- -'$) ( )/''4$'';Vc($''4$'';Wc(* -/ '4$'';Xc(-& '4$'';Yc. 1 - '4$'';)Zc
(*)"/# (*./ 3/- ( '4$''.0% /.=
0( -$'1'0 .T/#-*0"#Z*-- .+*)$)"/* #- .+*). / "*-4I 3 +/A)*/.. .. B/ "*-4J2$'' 
0. $))'4.$.=# / "*-4*!A)*/.. .. B2$'' /- / .($..$)")0( -$'1'0 !*-)'4.$.=
BF7C7C7


	


$..$)" / !*- /#  & 4 . *)-4  )+*$)/ *! #)"  $) 
E .*-   /2  ) . '$)  )   & Y 2$''  
/- / $)/# .( 24.!*-/# +-$(-4 !!$4 )+*$)/=
BF7C7D7




)'4.$. *! /#  & 4 . *)-4  !!$4  )+*$)/ 2$''   + -!*-(  !*- /#  0'' )'4.$.  / 2$/# (0'/$+'$$/4
%0./( )/. .-$ $) /$*)Z=W=
#)" !-*(. '$) $)
E.*- /  &Y2$'' )'45 $)/# .( 24. .-$ $) /$*)TX=T=V
!*-/# +-$(-4 )+*$)/:2$/#/# *)'4$!! - ) /#//# .2$''0. . '$) 1'0 *!
E.*1-$/ 
$)./ *!. '$) /*/'.*- =
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" VS*!XS
 ).$/$1$/4)'4.$.*!/# & 4. *)-4 )+*$)/2$'' + -!*-( $)/# .( 24. .-$ $) /$*)
TX=T=W!*-/# +-$(-4 )+*$)/=
BF7D7	

BF7D7B7


=


TX=V=T=T=
#)" !-*(. '$) $)*/'*- /  &.T/#-*0"#X
/*/'.*- 2$'' '0'/ !*- #.0% /)/$( +*$)/. .-$ $) /$*)TX=T=T=
TX=V=T=U=
#)" !-*(. '$) $)
E*- /  &.T/#-*0"#X

E.*- ./ #/$( +*$)/2$'' .. .. . .-$ $) /$*)TX=U=T=T=
TX=V=T=V=

E
 .+*) -/  &.T/#-*0"#Y
#  !!$4*!/-$'( $/$*)2$'' -/ !*- #.0% /0.$)"/# 
E
=# -/ -*-
)1 ./$"/*-2$''-/ 
/#  .0% /@. /*/' $(+-*1 ( )/ 2# /# - *- )*/ $/ $. 0   )/$- '4 /* -0" /- /( )/=  '' - .+*). . 2$''  
*(+- /*/# .0% /@.*)$/$*)/. '$) +-$*-/*/# !$-./*. *!*0' E'$)./04-0"= .+*). 
#*$ .$)'0 <Sc)*/.. .. :Tc1 -4(0#$(+-*1 :Uc(0#$(+-*1 :Vc($)$(''4$(+-*1 :Wc)*
#)" :Xc($)$(''42*-. :Yc(0#2*-. :)Zc1 -4(0#2*-. =# / "*-4*!A)*/.. .. B2$'' 
/- / .($..$)")0( -$'1'0 !*-)'4.$.=
E
- .+*) -.-  !$) ..0% /.2#*#1 .*- *!T
I1 -4(0#$(+-*1 J*-.*- *!UI(0#$(+-*1 J=
TX=V=T=W=

E
*- /  &.T/#-*0"#Y
0( -$'1'0 .T/#-*0"#Z*-- .+*)$)"/* #
E
- .+*). / "*-4. .-$ $) /$*)TX=V=T=V
I 3 +/A)*/.. .. B/ "*-4J2$'' 0. $))'4.$.=# / "*-4*!A)*/.. .. B2$'' /- / .
($..$)")0( -$'1'0 !*-)'4.$.=
E
.*- / #2  &2$'' )'45 $)/# .( 24. .-$ $)
 /$*)TX=T=V!*-/# +-$(-4 )+*$)/:2$/#/# *)'4$!! - ) /#//# 2$''0. . '$) 1'0 *!
E
.*1-$/ $)./ *!. '$) /*/'.*- =
TX=V=T=X=
#)" !-*(. '$) $)*.$/$1 0.' /  &.T/#-*0"#Y
 *.$/$1  0.'  $.  .0( *! Z +*.$/$1  $/ (.<   '0.$*).: *) +/0' $.*-")$5/$*): #''0$)/*-4
 #1$*-: 3$/ ( )/:"-)$*.$/4:.0.+$$*0.) ..C+ -. 0/$*):)#*./$'$/4=

!*) *-(*- $/ (.$)/# .0.' - ($..$)"/"$1 ).. ..( )/:/# .0.' .*- 2$'' . //*($..$)"=
TX=V=T=Y=
#)" !-*(. '$) $) "/$1 0.' /  &.T/#-*0"#Y
  "/$1  0.'  $.  .0( *! Z ) "/$1  $/ (.<  '0)/  !! /:  (*/$*)' 2$/#-2': +**- -++*-/:
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" VT*!XS
+..$1 C+/# /$.*$'2$/#-2':$!!$0'/4$)./-//#$)&$)":'&*!.+*)/) $/4)!'*2*!*)1 -./$*):
./ - */4+ /#$)&$)"=

!*) *-(*- $/ (.$)/# .0.' - ($..$)"/"$1 ).. ..( )/:/# .0.' .*- 2$'' . //*($..$)"=
TX=V=T=Z=
#)" !-*(. '$) $) ) -'.4#*+/#*'*"40.' /  &.T/#-*0"#Y
 ) -'.4#*+/#*'*"40.' $..0(*!TY$/ (.<.*(/$*) -):)3$ /4:"0$'/!  '$)".:/ ).$*):
()) -$.(. ) +*./0-$)":  +- ..$*): (*/*- - /-/$*): 0)**+ -/$1 ) ..: 0)0.0' /#*0"#/ *)/ )/:
$.*-$ )//$*): +**- // )/$*): '& *! %0"( )/ ) $).$"#/: $./0-)  *! 1*'$/$*): +**- $(+0'.  *)/-*':
+- *0+/$*):)/$1 .*$'1*$) =

!*) *-(*- $/ (.$)/# .0.' - ($..$)"/"$1 ).. ..( )/:/# .0.' .*- 2$'' . //*($..$)"=
TX=V=T=[=
 .+*) -. *)iVSa
(+-*1 ( )/!-*(. '$) $)/*/'.*- /
  &.T/#-*0"#Y
/ #/$( +*$)/:.0% /.#1$)"VSa*-"- / -$(+-*1 ( )/!-*(. '$) $)/*/'.*- 2$'' 
 !$) .A- .+*) -.B=
# /*/'.*- + - )/" #)" 2$''  !$) .I'0 /  &F. '$) 1'0 JTSSCI. '$) 
1'0 J=
# - .+*) -$)$/*-2$'' . //*T$!/# + - )/" #)" $.' ../#)*- ,0'/*EVSa). //*S$!/# 
+ - )/" #)" $."- / -/#)EVSa*-($..$)"=
TX=V=T=\=
 .+*) -. *)fca
(+-*1 ( )/!-*(. '$) $)/*/'.*- /
  &Y
/  &Y:- .+*) -.//0.2$''  -$1 $).$($'-24. .-$ $). /$*)TX=V=T=[/$!! - )/' 1 '.*!
- ,0$- + - )/$(+-*1 ( )/!-*(. '$) 2# - cXa/*TSSa2$/#Xa$)- ( )/.=
*)/$)0*0.- .+*) -)'4.$.2$'' + -!*-( . *)/# .  -$1/$*).. .-$ $) /$*)TX=V=V=V=
TX=V=T=TS=
#)" !-*(. '$) $)*- /  &.T/#-*0"#Y
# $.)$) E$/ (.'  .$") !*-.. ..( )/*!/# ' 1 '*! +- ..$*)$)+/$ )/.2$/#.#$5*+#- )$=
#*!/# \$/ (.$.-/ *)WE+*$)/.' :.*- !-*(SEV=# !$-./[$/ (.- -/ *)/# .$.*!
- .+*). . 0-$)"  . ($E./-0/0-  $)/ -1$ 2 *)0/  4  ,0'$!$  '$)$$   	 	
 
		


#  /*/' .*-  $.  -$1  4 $)"  # *! /#  \ $/ (. /*" /# -=  */'. .*- . *! Y *- (*-  $ )/$!$ . /# 
+- . ) *!/- /( )/ ( -" )/ +- ..$*)+- $/$1 *!(%*- +- ..$1  +$.* .=
!*) *-(*- $/ (.- 
($..$)"/"$1 ).. ..( )/:/# /*/'.*- 2$'' . //*($..$)"=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" VU*!XS
TX=V=T=TT=
0.' *- ./  &.U:W:)Y
# $..$)"' E$/ (,0 ./$*))$- 0. /*.. ../# ' 1 '*!+/$ )/@../$.!/$*)*-$../$.!/$*)2$/#
/# ( $/$*)/# 4- /&$)"= .+*). .)-)" !-*(3/- ( '4$../$.!$ ITJ/*3/- ( '4/$.!$ IZJ=
BF7D7C7


		


*-*)/$)0*0.1-$' .:($..$)"/2$'' #)' $)/# .( 24.!*-/# +-$(-4 !!$4 )+*$)/=
*- - .+*) -E/4+   )+*$)/.: .0% /. 2$/# ($..$)" / /  "$1 ) /$(  +*$)/ 2$''   '..$!$  . )*)E
- .+*) -.//#//$( +*$)/=
BF7D7D7

	


''*/# -. *)-4 !!$4 )+*$)/.2$'')'4. !*-/# 0'')'4.$. /=
TX=V=V=T=
/# - *)-4!!$4)+*$)/.. *)*)/$)0*0.-$' .
''  )+*$)/. .  *) *)/$)0*0. 1-$' . I''  3 +/  - .+*) -  )+*$)/. .  *) + - )/" 
$(+-*1 ( )/J2$'' )'45 $)/# .( 24. .-$ $) /$*)TX=T=V!*-/# +-$(-4 )+*$)/:2$/#/# 
*)'4 $!! - )  $) /#/ /#   (* '. 2$'' 0.  . '$)  1'0  *! /#  *-- .+*)$)"  !!$4 1-$'  .
*1-$/ $)./ *!. '$) /*/'.*- =
TX=V=V=U=
/# - *)-4!!$4)+*$)/.. *)$)-4I .+*) -J-$' .
!! /*!/- /( )/*)/# +-*+*-/$*)*!- .+*) -.!-*(. '$) $)/*/'.*- .2 ''.*)/# 
+-*+*-/$*)*!
E
- .+*) -./  &.T/#-*0"#Y2$'' / ./ 0.$)"/# *#-))/ '	 ).5 'I	J
( /#*./-/$!$ 4*0)/-4=# #4+*/# .$./ ./2$'' . *)/#  ) -'..*$/$*).//$./$=
 .-$+/$1 .0((-$ .2$'' +-*1$ !*-/# )0( -)+ - )/" *!- .+*) -./  &.T/#-*0"#Y4
/- /( )/"-*0+='.*: ./$(/ .*!/# +-*+*-/$*)*!- .+*) -.$) #/- /( )/"-*0+)$!! - ) .*!
+-*+*-/$*).I-$.&$!! - ) J /2  )/# /- /( )/"-*0+.2$'' +-*1$ 0.$)"/# ./)-( /#*. 
*)/# $)*($'$./-$0/$*)=2*E.$ \Xa
.!*-+-*+*-/$*) ./$(/ .. *)/# $'.*)( /#*)UE
.$ \Xa
.!*--$.&$!! - ) .. *)/#  2*( ( /#*2$'' - +*-/ =
TX=V=V=V=
*)/$)0*0. .+*) -)'4.$./  &Y
*)/$)0*0.- .+*) -)'4.$.2$'' + -!*-( . *) !$)$/$*)*!- .+*) -/(0'/$+' ' 1 '.*!+ - )/
$(+-*1 ( )/!-*(. '$) :!-*(Xa/*TSSa2$/#Xa$)- ( )/.= .0'/.2$'' - +*-/ 4( ).*!"-+#
2$/# - .+*).  /#- .#*' *) /#  E3$. ) +-*+*-/$*) *! - .+*) -. $)  # /- /( )/ "-*0+ *) /#  E3$.=
*-- .+*)$)"/2$'' +- . )/ $).0((-4/' =
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" VV*!XS
BG7 
''*0/+0/.!*-.! /4*0/*( .2$'' . *)/# ! /4)'4.$. /=
# -  2$''   )* .//$./$' *(+-$.*).  /2  ) /#  /- /( )/ "-*0+. !*- .! /4 /: 0)' .. */# -2$. 
.+ $!$ 2$/#$)/# - ' 1)/. /$*)=
BG7B7
1 -.  1 )/.2$'' * 0.$)"  )/-'*$)"$/$*)-4:1 -.$*)US=T= 1 -$/4!*-.$.'..$!$ 
$)/#  .?($'@:?(* -/ @:*-?. 1 - @=
- /( )/( -" )/1 -. 1 )/.I.J-  !$) ../#/!$-./*0-- *-2*-. ) $). 1 -$/4!/ -/# 
!$-./($)$./-/$*)*!/# ./04-0"=
.0-$)"/# *0' E'$)/- /( )/+ -$*$. !$) .)2$/#./-// *)*-!/ -/# / *!!$-./
*. *!*0' E'$)./04( $/$*)/#-*0"#/# VS4!*''*2E0++ -$*=# .( -0' ++'$ .!*-0)E$)
 -$*I!*-/#*.  )-*'' $)/# *0' E'$)+ -$*J
./#/*0-2$/#$)VS4.!/ -'./*. *!*0' E'$)./04( $/$*)2$'' - +*-/ =

)/# . 2# - $/$.)*/+*..$' /* !$) )./- /( )/E ( -" )/*-)*/:/# 2$'' '..$!$ 4/# 
2*-./. $= =/- /( )/E ( -" )/=
1 -.   1 )/ .0((-$ . 2$'' $)'0  )0( -. *!  1 )/. ) .0% / $)$ )  I)0( - ) + - )/"  *!
.0% /.2$/#/' ./*)  1 )/J4/- /( )/"-*0+)!0-/# -/ "*-$5/$*). .-$  '*2=
)*1 -1$ 2*!.2$/#$) #*!/# / "*-$ . .-$  '*22$'' +-*1$ <
x
.I!*-/#*. 2#* )-*'' $)/# *0' E'$)+ -$*J2#$#*0-- 0-$)"/# .$)"' E'$)-0)E$)*-
*0' E'$)+ -$*
x
.
x
.4#$"# ./. 1 -$/4
x
.4./-*)" ./- '/$*).#$+/*./04( $/$*)I*/ '/ : '/ J
x
.' $)"/*./04( $/$*)$.*)/$)0/$*)
x
 -$*0..
x
 -$*0..4./-*)" ./- '/$*).#$+/*./04( $/$*)I*/ '/ : '/ J
x
.' $)"/* /#
x
*((*)'4 *0--$)" . I !$)  . /#*.  2#$# *0- $) Xa *- (*-  *! /#  .0% /. $) )4
/- /( )/-(J
x
.//# +/#++'$/$*).$/ 
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" VW*!XS
0'/$+' *0-- ) .*!/# .( / "*-4*!.2$'' *0)/ *) !*- #.0% /://# #$"# ./. 1 -$/4
)./-*)" ./- '/$*).#$+/*./04( $/$*).++-*+-$/ =
$./$)".2$''$)'0 ''.I.))*)E.J*'' / *)/#  !*- #./04+ -$*. *)/# 
*). // =
# !*''*2$)"'"*-$/#(2$''++'4/*+-/$'/ .=
(+0/ / .2$'' +- . )/ $)/# '$./$)".0/(4
 0. /* / -($) /- /( )/E ( -" )/.//0.*!.)/ "*-4*!( $/$*).I+-$*-:*)*($/)/:*-
+*./E/- /( )/J=

!)1 -.  1 )/:.- +*-/ *)/#  :#.+-/$''4*-*(+' / '4($..$)" 1 )/./-/*- )/ :0. /# 
!*''*2$)"'"*-$/#(/*$(+0/ ($..$)"*(+*) )/.*!/# / I.J=
(+0/ / .2$'' 0. $)*- -/* / -($) 
/- /( )/E ( -" )/.//0.*!).2 ''./*..$")/# /**) *!/# /- /( )/+ -$*.=

 /- +- . )//# ./-// )- +- . )//# ./*+/ =


!)#..*( ($..$)"*(+*) )/.$)*/#/# ./-/) )/ .:!$-./$(+0/ /#  )/ .!*''*2.I*)'4$!
$.)*/*)"*$)"J<
T= 
!*)/$).*)'44 -)(*)/#F$(+0/ /# ($..$)"4/*/# './4*!/# *-- .+*)$)"
(*)/#I ="=:VT!*-)0-4:*-VS!*-+-$'J=
U= 
!  *)/$). *)'4 4 - F $(+0/  /#  ($..$)" 4 ) (*)/# /* /#  VT./ *!   ( - *! /# 
*-- .+*)$)"4 -=
V= 
!$.*(+' / '4($..$)"$(+0/ /*/# / *!/# './*)//2$/#/# .0% /=
*/ < )/ .#*0'- ($))0''!*-./#/- *)"*$)"=

!/ -#1$)"$(+0/ /#  )/ I$!)   J:$(+0/ /# ./-// $!$/$.+-/$'*-($..$)".!*''*2.<
T= 
!*)/$).*)'44 -)(*)/#
T=T 
!c4 -E(*)/#+-/*!/# !$-./*. / *!./04( $/$*)<
T=T=T

!$.)*/*)"*$)"F$(+0/ /*/#  -'$ -*!/# !$-./*. / *!*0' E'$)./04
( $/$*)) )/ I+- 1$*0.'4$(+0/ $!)   J=
T=T=U

!$.*)"*$)"F$(+0/ /*/# !$-./*. / *!*0' E'$)./04( $/$*)=
T=U 
!d4 -E(*)/#+-/*!/# !$-./*. / *! *0' E'$)./04( $/$*):$(+0/ /# 
($..$)"4/*/# !$-./4*!/# (*)/#=
U

!./-// *)/$).*)'44 -
U=T 
!c4 -+-/*!/# !$-./*. / *!*0' E'$)./04( $/$*)<
U=T=T

!$.)*/*)"*$)"F$(+0/ /*/#  -'$ -*!/# !$-./*. / *!*0' E'$)./04
( $/$*)) )/ I+- 1$*0.'4$(+0/ $!)   J=
U=T=U

!$.*)"*$)"F$(+0/ /*/# !$-./*. / *!*0' E'$)./04( $/$*)=
U=U 
!d4 -+-/*!/# !$-./*. / *!*0' E'$)./04( $/$*)$(+0/ /*)0-4T./*!
/# 4 -$)=
V

!./-// $.*(+' / '4($..$)"
V=T 
!$.)*/*)"*$)"F$(+0/ /*/#  -'$ -*!/# !$-./*. / *!*0' E'$)./04( $/$*))
 )/ I+- 1$*0.'4$(+0/ $!)   J=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" VX*!XS

!$.*)"*$)"F$(+0/ /*/# !$-./*. / *!*0' E'$)./04( $/$*)=
BG7B7B7


)$ ) *!.2$'' +- . )/ 4))'.*-*& )*2)!0-/# -4(3$(0(. 1 -$/4)
- '/$*).#$+/*./04( $/$*)=0((-$ .2$'' .*-/ 4$)$ ) <4)42$/#$)=
TY=T=T=T=
.4 '/$*).#$+/*/04 $/$*)) 1 -$/4
 '/$*).#$+:.$)$/ 4/# 
)1 ./$"/*-:$.'.. .B)- '/ B:A)'$& '4B:A*..$' B:)A-*' B
I$)- .$)" . 1 -$/4 *! - '/$*).#$+J=  B '/ B  $.  !$)  .   2$/#  - '/$*).#$+ /* ./04
( $/$*).B*..$' B*-B-*' B=.2$/#($..$)"- '/$*).#$+/*./04( $/$*)2$'' - "- 
A '/ B= 
!  .0% / - +*-/. /#  .(   (*-  /#) *)  2$/#$)  C: /#   2$/# /#  2*-./ . 
- '/$*).#$+/*./04( $/$*)2$'' 0. $)/# *-- .+*)$)".0((-4=
 1 -$/42$'' +- . )/ 2$/#$) '/$*).#$+= 1 -$/4$.'.. .($'C(* -/ C. 1 - I$)- .$)". 1 -$/4J=
../-/$)"!/ -/# !$-./*. *!./04( $/$*)2$/#($..$)". 1 -$/42$'' '..$!$ .. 1 - =
!
.0% /- +*-/.(*- /#)*) 2$/#$)C//# 2*-./- '/$*).#$+' 1 ':/# 2$/#/# 2*-./
. 1 -$/42$'' 0. $)/# *-- .+*)$)".0((-4=
BG7B7C7







.' $)"/*+ -() )/$.*)/$)0/$*)*!./04( $/$*)2$'' $ )/$!$ 40.$)"/# / "*-4*!A-0"
$/#-2)I-0"$.*)/$)0 JB!-*(/#  !$ '.A/$*)& )$) "-/*/04-0"B*)/# A1 -. 
1 )/.B +" =
*-.' $)"/*$.*)/$)0/$*)*!./04( $/$*):.0((-$ .4)2$'' +- +- =.0% /
/'$./$)"!*-.' $)"/*$.*)/$)0/$*)*!./04( $/$*)2$'' +-*1$ =
BG7B7D7


 -$*0. 1 -.   1 )/. -  /#*.   1 )/. - *-  . A -$*0.B *) /#  1 -.  1 )/. +"  *! /#   = 
.0((-4*!. -$*0..4)2$'' +- +- =.0% //'$./$)"!*-''.2$'' +-*1$ =
BG7B7E7

	
.' $)"/* /#- /#*.  1 )/.2#$#- - *- .A/'B*)/# 1 -. 1 )/.+" *!/#  =
.0((-4*!.' $)"/* /#4)2$'' +- +- =.0% //'$./$)"!*-.' $)"/*
 /#2$'' +-*1$ =
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" VY*!XS
BG7B7F7


*((*)'4*0--$)".-  !$) ./#*. 2#$#*0-$)Xa*-(*- *!/# .0% /.$))4/- /( )/-(=
.0((-4*!*((*)'4*0--$)".4)2$'' +- +- =.0% //'$./$)"!*-*((*)'4
*0--$)".2$'' +-*1$ =
BG7B7G7
	



+*)/) *0.*(+'$)/.*! -('- /$*).I.&$)$--$//$*):$.*(!*-/J2$'' - *- ..=+*)/) *0.
- +*-/.($"#/$)'0 0/- )*/'$($/ /*/# !*''*2$)"<$)$/$' -('- .+*). ) 3 -/$*)*!) 3$./$)"
- .+*). =.//# +/#++'$/$*).$/ 2$'' .0((-$5 4). 1 -$/4!*-/#  1 )/.*0--$)"0-$)"
/# *0' E'$)+ -$*=.0% //'$./$)"*!.//# +/#++'$/$*).$/ 2$'' +-*1$ =
BG7C7	

!)4.0% /.$ 0-$)"/# ./04:/# $)!*-(/$*)2$'' +- . )/ $).0% //'$./$)"=
BG7D7

 )/-''*-/*-4 .$")/ 4/# +*).*-2$'' 0. !*-'''*-/*-4.. ..( )/.0-$)"/# /-$'=
!)
$(( $/ - .0'/$.- ,0$- :.(+' .#*0' . )//**/#/# '*') )/-''*-/*-4=
*-/*-4 .. ..( )/. 2$'' $)'0  ./)- ( .0- . *! # (/*'*"4: '$)$' # ($./-4 K$)'0$)" +-*'/$)
' 1 '.L:0-$)'4.$.:0-$) -0".-  ):).*( $/$*)'/ ./..+ -+-*/**': /$*)Y=V=- "))4/ ./$)"
2$'' *) !*-2*( )*!#$'E -$)"+$/4=
#  )/-''*-/*-42$'')*/- +*-/+-*'/$)' 1 './*/# .$/ .:+*).*-:*-*/# -+ -.*)) '$)1*'1 $)/# 
./04 *)0/ 0)/$' /#  *1 -'' ./04 0)'$)$)" / !$)' )'4.$.:  0.  /#$. *0' +*/ )/$''4 - .0'/ $)
0)'$)$)"/# /- /( )/=
-$) -0".-  ).(4 *) //# 
)1 ./$"/*-@.$.- /$*)=
!/# .0% /$.''*2 /*' 1 /# #*.+$/'
0-$)"./04:)'*#*'- /#'45 -)0-$) -0"/ ./.(0./ *) 2# )/# .0% /- /0-).=
0((-4 /' . 2$'' .0((-$5  '*-/*-4 / !*-  # .# 0'  /$(  +*$)/ .  *) /#  1$.$/. / 2#$#
.(+' . 2 -  *'' / = ).# 0'   1'0/$*). 2$''   +- . )/  $) .0% / '$./$)".: 0/ 2$'' )*/  
.0((-$5 $)/' .=).# 0'  1'0/$*).2$'' 0. $)/#  / -($)/$*)*!. '$) 1'0 .=
''1$'' '*-/*-4/2$'' +- . )/ $).0% /'$./$)".=
- . )//$*).2$''0. ./)-$)/ -)/$*)'I
J)$/.!*-'''*-/*-4/ ./.=
0)/$//$1 '*-/*-4( .0- ( )/.- +*-/ .AeB:$= = '*2/# '*2 -'$($/*!,0)/$!$/$*):*-AfB:$= =
*1 /# 0++ -'$($/*!,0)/$!$/$*):2$'' *)1 -/ /*!*-/# +0-+*. *!,0)/$//$1 .0((-$ .:0/2$''
 +- . )/ .*-$"$)''4- *- :$= =.AeB*-AfB$)/# .0% /'$./$)".=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" VZ*!XS
*-/*-4!$)$)".2$'' '..$!$ .*2:*-(':)	$"#- '/$1 /*/# '*-/*-4= )/-''*-/*-$ .2$''
'.*+-*1$ '..$!$/$*)*!'$)$''4$")$!$)/*-*/'$)$''4$")$!$)/)*-('$/$ .=	 (/*'*"4)
. -0( # ($./-4 '*-/*-4 !$)$)". 2$'' '.*   "-  *-$)" /* /$*)' ) - 
)./$/0/  *((*)
 -($)*'*"4-$/ -$!*-1 -. 1 )/.I
J-$/ -$:1 -.$*)W=SV:.++'$' =
# !*''*2$)" .-$+/$1 .0((-$ .2$'' +-*1$ !*-# (/*'*"4:. -0(# ($./-4:)0-$)'4.$./4
/- /( )/"-*0+<
x
/0')#)" !-*(. '$) 41$.$/!*-,0)/$//$1 ( .0- ( )/.
x
#$!/ !-*( . '$)  /* /#  2*-./ *)E/- /( )/ - .0'/ !*-  # / "*-4 *! - .0'/ !*- / "*-$'
( .0- ( )/.= *-./ *)E/- /( )/ - .0'/ $.  !$)  . /#  2*-./ - .0'/ *0--$)" !/ - /# 
($)$./-/$*)*!/# !$-./*. *!*0' E'$)./04( $/$*)=
x
0( -)+ - )/" *!.0% /.2$/#).*'0/ ) 0/-*+#$'*0)/*!eTSSS+ -((V41$.$/
x
0( -)+ - )/" *!.0% /.2#*(  //#  !$)$/$*)*!+*/ )/$'	4@.2. ./)4+*$)/
0-$)"/# ./04=*/ )/$'	4@.2. .-  / -($) . *)/# 0$) !*-
)0./-4*)
-0"
)0 $1 -
)0./-4:0'4USS\=
R
')$) /-).($). IJ*-.+-// /-).($). IJfV30++ -'$($/*!)*-('IJ
)
R
'&'$) +#*.+#/. IJeU3)
R

)- . $)$'$-0$)iU3
	4@.2 1'0/$*). *)/# *1 
R
IJhU3K!*-.0% /./#/(  //# -$/ -$*!hU:+- . )/*- ' 1/$*).2$/#
iV3L
R
iV3
R
iV3
)" .*!
)/ - ./
R
- /$) &$). iV3
R
-*'/$)iW3
R
$'$-0$)iU3
x
#$!/!-*(. '$) /*/# 2*-./*)E/- /( )/- .0'/. *)'..$!$/$*)*!*2:*-(':)	$"#
- '/$1 /*/# '*-/*-4- ! - ) -)" .I.   /$*)TY=V=TJ=*-./*)E/- /( )/- .0'/$. !$) .
/# 2*-./- .0'/*0--$)"!/ -/# ($)$./-/$*)*!/# !$-./*. *!*0' E'$)./04( $/$*)=
x
#$!/!-*(. '$) /*/# 2*-./*)E/- /( )/- .0'/. *)'..$!$/$*)*!'$)$''4.$")$!$)/)
)*/ '$)$''4 .$")$!$)/= 
! / ' ./ *)  '*-/*-4 !$)$)" $. '$)$''4 .$")$!$)/: /#  .0% / 2$''  
*0)/ $)/# '$)$''4.$")$!$)// "*-4=*-./*)E/- /( )/- .0'/$. !$) ./# 2*-./- .0'/
*0--$)"!/ -/# ($)$./-/$*)*!/# !$-./*. *!*0' E'$)./04( $/$*)=
x
#$!/!-*(. '$) /*/# 2*-./*)E/- /( )/- .0'/. *)
"- .=*-./*)E/- /( )/
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" V[*!XS
- .0'/$. !$) ./# 2*-./- .0'/*0--$)"!/ -/# ($)$./-/$*)*!/# !$-./*. *!*0' E'$)
./04( $/$*)=
 .0% / '$./$)" *! .0% /. 2$/# '$)$''4 $")$!$)/ *- 
  -  i V )*-(' +*./E. '$) 
( .0- ( )/. 2$''   +-*1$ = #$. '$./$)" 2$'' $)'0  '' 1$''  - .0'/. I)*-(' ) )*-('J !-*(
'*-/*-4/ ./.!*-2#$#.0% /#/' ./*) '$)$''4$")$!$)/*-
- iV)*-('+*./E
. '$) 1'0 =
 .0'/.*!0-$) -0".-  ).)+- "))4/ ./$)"2$'' +- . )/ $).0% /'$./$)".*)'4=
BG7D7B7



0)/$//$1 '*-/*-4( .0- ( )/.2$'' *(+- 2$/#/# - ' 1)/'*-/*-4- ! - ) -)" .$)
0)$/.
)/ "*-$5 .<
x
*2< '*2/# '*2 -'$($/*!/# '*-/*-4- ! - ) -)" =
x
*-('<$/#$)/# '*-/*-4- ! - ) -)" I0++ -)'*2 -'$($/$)'0 J=
x
	$"#<*1 /# 0++ -'$($/*!/# '*-/*-4- ! - ) -)" =

)$/$*)/*/# #$"#)'*2,0)/$//$1 '*-/*-4..$")( )/.I.$ )/$!$ 4( ).*!/# '*-/*-4
- ! - )  -)" .J: '*-/*-4 .. ..( )/. 2$'' '.*   "-  $) *-)  2$/# /#  +-  !$)  -$/ -$ .
+- . )/ $)
-$/ -$:1 -.$*)W=SVI) -# -+41'0/$*)-*"-(:*((*) -($)*'*"4-$/ -$
!*-1 -. 1 )/.: -.$*)W=SV::
:
	:		;I#//+<CC/ +=) -="*1J:0'$.#/ <0) TW:USTSJ
BG7E7

2 '1 E' .2$'' - *- /-  )$)")/ #1$.$/0-$)"/# *0' E'$)/- /( )/+ -$*)/
/# /$( /# .0% /$.*)/$)0 ./# ./04 -'4= )/-'. -1$ 2$'' 0/$'$5 !*-- $)"''.$)
*- - /* ./)-$5  $)/ -+- //$*). !*- /#  .! /4 )'4.$.= 
) $/$*):  - .0'/. 2$''    1'0/  / /# 
$)1 ./$"/$*)'.$/ /*(*)$/*-.! /40-$)"/# /-$'=# 
)1 ./$"/*-*- .$")  2$'')*/ 2# /# -*-)*/)4
)*-('- .0'/.- *!'$)$'.$")$!$) =
# !*''*2$)"+-( / -.2$'' - +*-/ !*-/#$../04<
x

)/ -1'I(. J
x

)/ -1'I(. J
x

)/ -1'I(. J
x

)/ -1'I(. J
x

)/ -1'I(. J
x

)/ -1'I(. J
x
	I+(J
x
1 -''.. ..( )/*!I
)1 ./$"/*-@.%0"( )/J<
*
*-('
*
)*-(':*/'$)$''4$")$!$)/IJ
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" V\*!XS
*
)*-(':'$)$''4$")$!$)/IJ
# !*''*2$)".0((-$ .2$'' +-*1$ !*-/<
x
/0')#)" !-*(. '$) 41$.$/!*-,0)/$//$1 ( .0- ( )/.
x
0( -)+ - )/" *!.0% /.2$/# #/ "*-4*!*1 -''.. ..( )/I
)1 ./$"/*-@.%0" ( )/J
41$.$/
x
#$!/!-*(. '$) /*2*-./*)E/- /( )// "*-4*!*1 -''.. ..( )/*!=*-./*)E/- /( )/
- .0'/$. !$) ./# 2*-./- .0'/*0--$)"!/ -/# ($)$./-/$*)*!/# !$-./*. *!*0' E'$)
./04( $/$*)=
x
0( -)+ - )/" *!.0% /.2$/#(-& '4)*-('- .0'/.I.   /$*)TY=W=UJ41$.$/
)$)$ ) *!(-& '4)*-('- .0'/.!*-./04*1 -''I+*./E. '$) J
'$./$)"*!.0% /.2$/#/' ./*) +*./E. '$) (-& '4)*-('- .0'/2$'' +- . )/ )2$''
$)'0 ''1$'' /!*-.0#.0% /.=
BG7E7B7





* -$1/$*).2$'' )  ..-4=''+-( / -.2$'' +-*1$ $- /'44/#  )/-'- $)" )/ -=
BG7E7C7



-& '4)*-(',0)/$//$1 ( .0- ( )/.2$'' $ )/$!$ $)*-) 2$/#/# !*''*2$)"-$/ -$<
x
.*'0/ 1'0 .!*-$)/ -1':$)/ -1':$)/ -1')2$'' '..$!$ .<
R
fWXS(. 
R
fW[S(. 
R
fXSS(. 

x
#)" !-*(. '$) !*-$)/ -1':$)/ -1':$)/ -1')2$'' '..$!$ .<
R
iVS(. $)- . !-*(. '$) 
R
iYS(. $)- . !-*(. '$) 

x
/# -)*-('1'0 .<
R
	I+(JiTSS+(
R
$)/ -1'I(. JiUTS(. 
R
$)/ -1'I(. JiTUS(. 
BG7F7


# !*''*2$)"$/'$").( .0- ( )/.2$'' - +*-/ !*-/#$../04/ #1$.$/<
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" WS*!XS
x
$//$)":.0+$) :)./)$)"4./*'$'**- ..0- KLI((	"J
x
$//$)":.0+$) :)./)$)"$./*'$'**- ..0- KLI((	"J
x
$//$)":.0+$) :)./)$)"0'. / I+(J
x
 .+$-/*-4/ I- /#.C($)J
x
 (+ -/0- I]J
x
 $"#/I&"J
	 $"#/I(J2$''( .0- /-  )$)"*)'4=
0% /.2$/# - . *!iVS((	"$))C*- - . *!iUS((	"$)!/ -iV($)0/ ../)$)"
*(+- /*/# +- 1$*0..0+$) '**+- ..0- 2$'' '..$!$ .#1$)"*-/#*.//$#4+*/ ).$*)=
# !*''*2$)".0((-$ .2$'' +-*1$ !*-1$/'.$")./<
x
/0')#)" !-*(. '$) 41$.$/
x
0( -)+ - )/" *!.0% /.2$/#*-/#*.//$#4+*/ ).$*)41$.$/
x

)$ ) *!(-& '4)*-('1'0 .I.   /$*)TY=X=TJ41$.$/
BG7F7B7





-& '4)*-(',0)/$//$1 $/'$").( .0- ( )/.2$'' $ )/$!$ $)*-) 2$/#/# !*''*2$)"
-$/ -$<
,#&
(#.
)1
	#!"

((	"
h\S((	"
#)" !-*(. '$) hEUS((	"
iT[S((	"
#)" !-*(. '$) iUS((	"

((	"
hXS((	"
#)" !-*(hETX((	"
iTSX((	"
#)" !-*(. '$) iTX((	"
	 -/-/ 
+(
hXS+(
#)" !-*(. '$) hETX+(
iTUS+(
#)" !-*(. '$) iTX+(
*4
/ (+ -/0- 
6

iV[=V6
#)" !-*(. '$) iT=T6
 $"#/
"
+ - )/" #)" !-*(. '$) h
EZ=Sa
+ - )/" #)" !-*(. '$) i
Z=Sa
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" WT*!XS
BG7G7	



*(+' / +#4.$' 3($)/$*)$)'0$)" 3($)/$*)*!/# # :) &: -.)/#-*/:/#*-3:*( ):
0-*" )$/': 3/- ($/$ .:) 0-*'*"$':).&$))(0*. 2$'' + -!*-( /-  )$)"=)*-('+#4.$'
 3($)/$*)!$)$)".0-$)".-  )$)"2$'' - *- .( $'#$./*-4))*-('+#4.$' 3($)/$*)
!$)$)"./.0. ,0 )/1$.$/.2$'' - *- .1 -.  1 )/.=
BG7H7	
BG7H7B7


# *).$./.*!'$./*!TS.4(+/*(.*!-&$).*)$.(I"$/:-(-*++$)":.#*0' -.#&$)": '*2-$"$$/4:
2-$./-$"$$/4:# -*//$*):"' ''/+:/- (*-:.'$1/$*):)&/#$.$J=#$/ (2$'' -/ *)XE+*$)/
.' : 2$/#  .*-  *! S I5 -*J - +- . )/$)" . )  *! .4(+/*(.: )  .*-  *! W - +- . )/$)"  . 1 - 
*)$/$*)=
# /*/'.*- $./# .0(*!/# .*- .!*-''TS$/ (.)-)" . /2  )S)WS=*2 -1'0 .*!/# 
/*/'.*- $)$/ ($' -.4(+/*(.=
!*) *-(*- $/ (.- ($..$)"/1$.$//# /*/'.*- 2$'' 
. //*($..$)"=
 .-$+/$1 .0((-$ .*!/0')#)" !-*(. '$) $)/*/'.*- .41$.$/2$'' +-*1$ !*- #
/- /( )/"-*0+=
''/:$)'0$)"$)$1$0'$/ (.)/*/'.*- :2$'' +- . )/ $).0% /'$./$)"=
BG7H7C7


# 
.. ..( )/*).$./.*!TS$/ (. .-$$)".4(+/*(.*!4.&$) .$=$')*-'(*1 ( )/.I$/ (.
T /#-*0"# WJ:  3/- ($/4 (*1 ( )/. I$/ (. X ) YJ: ) /-0)& (*1 ( )/. I$/ ( ZJ 2$''   *. -1 
0)*/-0.$1 '42#$' /# .0% /$./- ./I ="=:$)/# 2$/$)"-**(J:)/# 
)1 ./$"/*-2$'''.*(& "'*'
%0"( )/.*)/# .0% /@.4.&$) .$.I$/ (.[/#-*0"#TSJ=#$/ (2$'' -/ *)XE+*$)/.' :2$/#
.*- *!S- +- . )/$)". ) *!.4(+/*(.I!*-$/ (TS:)*2- ) ..J:).*- *!W$)$/$)". 1 - 
*)$/$*)I!*-$/ (TS:2- ) ..:. 1 - $./- ..J=*-/#$..' :/# .0% /$./* .$//$)"*)#-:!$-(
#$-=
)$/$*):/# 
$)'0 .U4 .C)*,0 ./$*)./#/- ../# .0% /@. )/'.//0.=
#  "'*' . 1 -$/4 .*-  $. /#  - .+*).  /* A 1 -$/4 *! )*-(' (*1 ( )/.B !*0) 2$/#$) /#  "'*'
%0"( )/.. /$*)=
# 
*1 ( )//$)"*- $. !$) ./# .0(*!$/ (.T/#-*0"#ZI$= =:$/ (.T/#-*0"#W:!$')
*-'(*1 ( )/.;$/ (.X)Y: 3/- ($/4(*1 ( )/.;)$/ (Z:/-0)&(*1 ( )/.J=# +*..$' -)" !*-/# 
/*/' 
 .*-  $. S /* U[= 	$"# - 1'0 . *! /#  /*/' 
 .*-  $)$/  $)- .  . 1 -$/4 $) )*-('
(*1 ( )/=
!*) *-(*- *!/# 
/*/'.*- $/ (.- ($..$)"/1$.$/:/# .*- 2$'' . //*($..$)"=
 .-$+/$1 .0((-$ .*!/0')#)" !-*(. '$) $)/# "'*'. 1 -$/4.*- )
/*/'.*- 4
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" WU*!XS
1$.$/2$'' +-*1$ !*- #/- /( )/"-*0+=
''/:$)'0$)"$)$1$0'$/ (.)
/*/'.*- :2$'' +- . )/ $).0% /'$./$)"=
BG7H7D7
	



#   *).$./. *! W $/ (. - '/  /* &/#$.$=  # .  $)'0  *% /$1  *. -1/$*) *! &/#$.$ 4 /# 

)1 ./$"/*-:.0% /$1 !  '$)".*!- ./' ..) ..4/# .0% /:.0% /$1 $./- ..0 /*&/#$.$:)"'*'
'$)$'.. ..( )/*!&/#$.$=# !$-./V$/ (.2$'' -/ *)WE+*$)/.' :2$/#.*- *!S- +- . )/$)"
. ) *!.4(+/*(.).*- *!V- +- . )/$)". 1 - *)$/$*)=# "'*''$)$' 1'0/$*)2$'' 
( *)YE+*$)/.' :2$/#SI5 -*J- +- . )/$)". ) *!.4(+/*(.).*- *!X- +- . )/$)". 1 - 
&/#$.$=
# '*'*- $. !$) ./# "'*''$)$'.. ..( )/*!&/#$.$=
# /*/'.*- $./# .0(*!$/ (.T/#-*0"#V)-)" .!-*(S/*\=	$"# -1'0 .*!/# /*/'
.*- $)$/ &/#$.$$.#$"# -$). 1 -$/4=
!*) *-(*- $/ (./1$.$/- ($..$)"/# /*/'2$'')*/ 
'0'/ =
 .-$+/$1 .0((-$ .*!/0')#)" !-*(. '$) $)/# '*'*- )/*/'.*- 41$.$/2$''
 +-*1$ !*- #/- /( )/"-*0+=
''/:$)'0$)"$)$1$0'$/ (.)/*/'.*- :2$'' +- . )/ $).0% /'$./$)"=
BG7H7E7



6
9




0$$'$/42$'' (*)$/*- 0-$)"/# /-$'0.$)"/# E=#$./-$'2$''0. /# A. '$) C-  )$)"B)
A$) ./$.$/B1 -.$*).*!/# .' =# A. '$) C-  )$)"B1 -.$*):2#$#.. .. ./# '$! /$(  3+ -$ ) 
*!/# .0% /2$/#.0$$  1 )/.).0$$'$ /$*))/# *0-- ) *!.0$$  1 )/.)C*-$ /$*)
2$/#$).+ $!$ /$( + -$*+-$*-/* )/-4$)/*/# /-$':2$'' *(+' / !*-''.0% /.//# -  )$)"1$.$/
/* / -($)  '$"$$'$/4=# A$) ./$.$/BE!*-(2$'' *(+' / /. '$) /**)!$-( '$"$$'$/4
I+-$*-/*/# !$-./*. J)/''+*./E. '$) 1$.$/.=
0$$'
 /$*)$.-/ *)YE+*$)/.' !-*(ScB*$ /$*)+- . )/B/*XcB/$1 $ /$*)2$/#+'))
$)/ )/B=.*- *!W*-X*)/#$..' $)$/ .. -$*0..0$$'$ /$*)=)4.*- "- / -/#)S2$'' *0)/ 
.#1$)".0$$'$ /$*)=
# 
		
$./# .0(*!!$1 $/ (.!-*(/# 
 /$*)
)/ ).$/4.' <!- ,0 )4:0-/$*):
*)/-*''$'$/4: / -- )/.:)- .*).!*-$ /$*)=
	

!
.0% /$)*/ )*-. )4.0$$'$ /$*):.*- *!S!*-/# $)/ ).$/4/*/'.*- 2$'' "$1 )=
0$$' #1$*-$.*'' / ./0'// (+/:$)/ --0+/ // (+/:)*-/ // (+/=)4// (+/2$'' 
 !$) ..0$$' #1$*-=
# !*''*2$)".0((-$ .2$'' +- . )/ <
x
0$$'$ /$*)<
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" WV*!XS
R
#  )0( - ) + - )/"  *! .0% /. 2$/#  # /4+  *! .0$$' $ /$*) *- )4 .0$$'
$ /$*)2$'' .0((-$5 41$.$/
R
# )0( -)+ - )/" *!.0% /.2$/#)4.0$$'$ /$*))4/# $-(*./. 1 - 
.0$$' $ /$*) /4+  0-$)"  # ./04 + -$* I. '$) C-  )$)" ) *0' E'$)
- /( )/ -$*J
R
# )0( -)+ - )/" *!.0% /.2$/#)*.0$$'$ /$*)/. '$) C-  )$)":)
)4/4+ *!.0$$'$ /$*)+*./E. '$) 
R
#  )0( - ) + - )/"  *! .0% /. 2$/# 2*-. )$)" *! .0$$' $ /$*) I(*./ . 1 - 
.0$$'$ /$*)+*./E. '$) 2.(*- . 1 - /#)$/2./. '$) C-  )$)"J
x
0$$' #1$*-<
R
# )0( -)+ - )/" *!.0% /.4/# $-(*./. 1 - .0$$' #1$*-/4+ 0-$)" #
./04+ -$*I. '$) C-  )$)")*0' E'$)- /( )/ -$*J
R
#  )0( - ) + - )/"  *! .0% /. 2$/# )4 .0$$'  #1$*- ) /#*.  *(+' /$)"
.0$$ 2$'' .0((-$5 41$.$/)*1 -''4./04+ -$*
R
# )0( -)+ - )/" *!.0% /.2$/#)*.0$$' #1$*-/. '$) C-  )$)":)
)4/4+ *!.0$$' #1$*-+*./E. '$) 
x
0$$'$/4<0$$'$/4$. !$) .#1$)"/' ./*) *0-- ) *!.0$$'$ /$*)*-/' ./*) 
*0-- )  *! .0$$'  #1$*-= /  # 1$.$/: /#  .0$$'$/4 $)$/*- 2$''   . / /* T $! /#  .0% /
 3#$$/..0$$'$/4:S$!/# .0% /* .)*/ 3#$$/.0$$'$/4:)($..$)"*/# -2$. =
R
# )0( -)+ - )/" *!.0% /.2$/#.0$$'$/42$'' .0((-$5 *1 -''4./04
+ -$*I. '$) C-  )$)")*0' E'$)- /( )/ -$*J
R
# )0( -)+ - )/" *!.0% /.2$/#)*.0$$'$/4/. '$) :))4.0$$'$/4+*./E
. '$) 
R
# )0( -)+ - )/" *!.0% /.2$/#/' ./*) *0-- ) *!.0$$'$ /$*))/
' ./*) *0-- ) *!.0$$' #1$*-+*./E. '$) 
R
# )0( -)+ - )/" *!.0% /.2$/#*0/*/#.0$$'$ /$*)).0$$' #1$*-/
. '$) 2$/#/' ./*) *0-- ) *!.0$$'$ /$*))/' ./*) *0-- ) *!.0$$'
 #1$*-+*./E. '$) 

''E/2$'' +- . )/ $).0% /'$./$)"=
BG7H7F7

	
# .0% / 2$'' 2 - U +/# . .$(0'/) *0.'4; */# +/# . 2$''   ++'$  /* T ++'$/$*) .$/  $) '*. 
+-*3$($/42$/#*0/*1 -'++$)"= -('.. ..( )/.!*-*/#+/# .2$'' .. .. 0/*)'4/# 2*-. *!/# 
U.*- .2$'' - *- =
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" WW*!XS
# /0'/$( *!''.# 0' )0).# 0'  1'0/$*).2$'' - *- =
TY=Z=X=T=
&$)$--$//$*)/+/#++'$/$*).$/ 

--$//$*) .. ..  / /#  +/# ++'$/$*) .$/   # 4 !/ - +/# - (*1' 2$''   - *-  0.$)" /# 
 .-$+/*-.+-*1$ $)/#  -" -)*2().' ))4$--$//$*)*. -1 2$'' - *- .)=
)
$/$*):.+*)/) *0.- +*-/.*!.&$)$--$//$*)4/# .0% /2$'' - *- .)=
!.0% /- +*-/..&$)
$--$//$*):/# ).$/ + -.*)) '2$''*)0/1$.0'$).+ /$*)*!/# .&$)//# ++'$/$*).$/ )2$''- *-/# 
 .-$+/$*)*!/# *. -1 .&$)$--$//$*)0.$)"/#  .-$+/*-.+-*1$ $)/#  -" -)*2().' =# 
(3$(0(- .0'/.!-*(/#  -" -)*2().' - .0'/.2$'' .0((-$5 !*- #./042  &)*1 -
/#  )/$- *0' E'$)/- /( )/+ -$*=' - .0'/.2$'' *($) $)/# !*''*2$)"24.<
T= 4*)/ )/$)"/# U.*- .I$= =:S:T:U:U:U:V:V:V:V:V: /=J=
U= 4 .0((/$*) *! /#   -(' - .+*).  .'  .*-  )  )0( -$  ,0$1' )/ !*- /#  */# -  !! /.
*. -1/$*). .' = #  #-/ - "- . 2$''   *)1 -/  /* )0( -$'  ,0$1' )/. $) /#  !*''*2$)"
24<cS:cS:cT:cU:cV:cV)	cV=4/# .0((/$*):*($) .*- $.*/$) !*- #
+/# /  #  1'0/$*) /$(  +*$)/ I ="=: UcUbUcWJ= 
! )* "-  2. ..$")  !*- /#  */# -  !! /.
*. -1/$*).IJ.' /# *($) .*- 2$''*).$./*!/#  -('- .+*). .' .*- *)'4=

 -('- .+*). .' <
),
%#(**,(
S
* 1$ ) *!$--$//$*)
T
$)$(' -4/# (I- '4+ - +/$' J
U
 !$)$/  -4/# (:- $'41$.$' ;($)$('  (*-($)$('++0'-
- .+*). 
V
-4/# ()++0' .
W
 !$)$/   (
X
-4/# (:  ()++0' .
Y
 .$0'- -0+/$*)
Z
/-*)"- /$*).+- $)" 4*)/ ./I++'$/$*)J.$/ 

/# -!! /.<
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" WX*!XS
),:(/',#
+/#0&(.;
..,,
ISJ
'$"#/'4"'5 ++ -) 
ITJ
-& "'5$)"
IUJ
'5$)"2$/#+  '$)")-&$)"
IVJ
'5$)"2$/#!$..0- .
IVJ
$'(*!-$ . -*0. 30/ *1 -$)"''*-+-/*!/# +/#.$/ 
	IVJ
(''+ / #$' -*.$*).)C*-..
TY=Z=X=U=
$.*(!*-//+/#++'$/$*).$/ 
 +*-/*!$.*(!*-///# +/#++'$/$*).$/ 2$'' - *- .)=
!.0% /- +*-/.$.*(!*-///# 
+/#++'$/$*).$/ :/# .$/ + -.*)) '2$''.&/# .0% //*-/ /# $.*(!*-/.($':(* -/ :*-. 1 - :
)2$''.&/# .0% //* .-$ /# $.*(!*-/=#  .-$+/$*)*!$.*(!*-/.- +*-/ 4/# .0% /
.#*0' - *- 1 -/$(=
# . /2$'' .0((-$5 .+-/*!.)./+/#++'$/$*).$/ .0((-$ .. .-$ $) /$*)
TY=T=
TY=Z=X=V=
/## .$*))# .$1  .$0 
/## .$*)2$'' .. .. 4.$/ + -.*)) '//# /$( +*$)/. !$) $)/# -*/**'# 0' *!1 )/.=

) $/$*) /* +/# # .$*) .. ..( )/. 4 .$/  + -.*)) ' / .+ $!$  /$(  +*$)/.: .0% /. .#*0'  
$)./-0/ /*# &# .$*)*!/# +/#/#-*0"#*0//# 4)- +*-//*.$/ + -.*)) '$(( $/ '4$!+/#
 /# .*(+' / '4*-$!+-/$'+/# /#( )/$.*. -1 =
# .$*)2$''  1'0/ *-$)"/* .C*,0 ./$*)..!*''*2.<
T=

./# +/#!0''4//# /*/# .&$)9 .C*
U=

!?*@:$/# +/# /#*(+' / '49 .C*
# !*''*2$)"1-$' .2$''  -$1 !*- #.0% /!*-/#  1'0/$*)*!# .$*)<
x
)4 *0-- )  *! *(+' /   /#( )/ !*-  # ./04 2  & ) *1 - /#   )/$-  *0' E'$)
/- /( )/+ -$*
x
)4*0-- ) *!+-/$' /#( )/!*- #./042  &)*1 -/#  )/$- *0' E'$)/- /( )/
+ -$*
 .-$+/$1 .0((-$ .*!/# *1 1-$' .2$'' +- . )/ =''# .$*)/*'' / 0-$)"/# .$)"' E
'$)-0)E$))*0' E'$)+ -$*2$'' +- . )/ $).0% /'$./$)".=

(( $/ '4!/ -/# - (*1'*!+/#:/# (*0)/*!# .$1 - .$0 - ($)$)"//# ++'$/$*).$/ 2$''
  3($) 4/# 
)1 ./$"/*-*- .$")  )"- . .-$  '*2=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" WY*!XS
"-#0-#/
),
 #(#.#)(
S
*) 
T
$"#/
U
 $0(
V
	 14
# !*''*2$)"1-$' 2$''  -$1 !*- #.0% /!*-/#  1'0/$*)*!# .$1 - .$0 <
x
)4*0-- ) *!( $0(*-# 14# .$1 - .$0 !*- #./042  &)*1 -/#  )/$- *0' E
'$)/- /( )/+ -$*
 .-$+/$1 .0((-$ .*!/# *1 1-$' 2$'' +- . )/ =''# .$1 - .$0 /*'' / 0-$)"/# 
.$)"' E'$)-0)E$))*0' E'$)+ -$*2$'' +- . )/ $).0% /'$./$)".=
BH7 	


/' ./V'**.(+' .2$'' *'' / /U:TW:)UU#*0-.!/ -++'$/$*)*!/# +/#2$/#gU#*0-E
2$)*2*)4UT)WU=

)$1$0' +'.( *) )/-/$*). 2$''   +- . )/  $) .0% / '$./$)". )  .-$+/$1  .//$./$. !*- +'.(
*) )/-/$*)2$'''.* .0((-$5 =/0'.(+'$)"/$( !/ -*$)"2$'' 0. !*-/# )'4.$.=
 (* 'E.  ++-*# 2$''   0.  /* .. .. /#  $(+/ *! *1-$/ . *) . )+$)   3+*.0-  I+*+0'/$*)
+#-(*&$) /$.J)/* 3+'*- /#  3+*.0- E- .+*). - '/$*).#$+*!- ' 1)/ )+*$)/.=# . )'4.$.2$''
 *) 4 /-0( . -#-*0+=
# . )'4.$.2$'' *)0/ 0.$)"./)-+*+0'/$*))*)'$) -($3  !! /.(* '$)"( /#*.= /$'.
!*-(* '. )'4.$.I.0#./# #*$ *!./0$ .C//* $)'0 !*-)'4.$.:*1-$/ ./* / ./ :
/#)'$)":(* ' 1 '*+( )/:(* '1'$/$*)J$.)*/*1 - 4/#$..//$./$')'4.$.+'))2$'' 
 .-$ $)./)E'*) (* '$)").$(0'/$*)+')+-$*-/*/. '*&=
BI7 

# */# -1-$' .)C*-*($).)*/.0((-$5 *-+- . )/ - <
x
$/ C$)1 ./$"/*-*(( )/.



1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" WZ*!XS
BJ7 
# ):0*=# ++'$/$*)*! )#) "/ &  +$)"./-/ "$ .=	
	USSX;UWI\J<TV[XETV\Z=
($/-$ )&*: (#) =/ &  +$)"+-* 0- .2$/#'$)$'/-$'++'$/$*).=			USSZ;
YIVJ<TZTFT[S=
($/-$ )&* :  (#)  : $ ). =  ) -' 0'/$./"  / &  +$)" -* 0- .= 	  USS[;
XSIXJ<YYZFYZZ=$ . -:-$  =$(+' +-* 0- .!*-'$) .(+' .$5 %0./( )//#/*)*/!! //# /4+ 

 --*--/ =	
	USSV;UU<VXZTFVX[T=
$//' :0=
)/ )/E/*E/- /)'4.$.!*-'*)"$/0$)'./0$ .2$/#-*+E*0/.=	T\\Y;XU<TVUWFTVVV=
/$/#:N ''4:*.$ ''*=/$..$)"/$)'$)$'/-$'.<!-*('$)$'..0(+/$*)./*.//$./$')'4.$.
0.$)"+// -)($3/0- (* '.=			USTV;TUIYJ<VVZEVWZ=
== +-/( )/*!	 '/#)	0() -1$ .**)-0"($)$.//$*)=0$) !*-$)0./-4=-0"E$)0 
$1 -4$)%0-4<+- (-& /$)"'$)$' 1'0/$*)USS\;0'4=







1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" W[*!XS

T= 


.-=#'-
 + )$)"*)/1$'' :/ .)/$( .2$''/& /# !*-(4444E((E##<((<..=
,-(..#)() ,.'(.,)/*-
*-*0/+0/.:/- /( )/"-*0+.2$'' - +- . )/ .!*''*2.)$)/#/*- -<
,.'(.,)/*
),&-5#-.#(!-5(,*"-
	EVSZST[=S("
	EVSZST[=S("
	EVSZS\=S("
	EVSZS\=S("
' *
' *

U=



6
		

*).$ -" ) -'+-*' (*!/ ./$)")0''#4+*/# . . )*/ 4T:>:= /T:>: )*/ /# ..*$/ 
-2 I0)%0./ J E1'0 .= 0-/# -: ' / ITJe>eIJ  )*/  /#  *- -  E1'0 . ) ITJ:>:IJ  )*/  /# 
#4+*/# . .*-- .+*)$)"/*/# *- - E1'0 .=$)''4:' /7 )*/ /# *1 -''4+ 
 --*--/ =
# - "0'-	*# -"+-* 0- $.. *)/# !*''*2$)"/ ./$)"'"*-$/#(<
x
/ +T<
!IJfD: +/IJ)"*/*/ +U:*/# -2$. - % /'')0''#4+*/# . .)./*+=
x
/ +cU:>:ET<
!ITJfDC: +/ITJ)"*/*/ +bT:*/# -2$. - % /''- ($)$)")0''
#4+*/# . .)./*+=
x
/ +<
!ITJfDC: +/ITJ:*/# -2$. - % /ITJ=
# /-0)/ 	*# -"+-* 0- $. !$) .*)1 3*($)/$*)*!/# *)! --*)$+-* 0- )- "0'-
	*# -"+-* 0- . *)+- E.+ $!$ /-0)/$*)+-( / -Sh8eTI($/-$ )&*:;USS[J=# 
/-0)/ 	*# -"+-* 0- $.. *)/# !*''*2$)"/ ./$)"'"*-$/#(<
x
/ +T<
!IJfIJbITEJJCJD: +/IJ)"*/*/ +U:*/# -2$. - % /'')0''#4+*/# . .)./*+=
x
/ +  c U:>:ET< 
! ITJ f IJbITEJJCJD:  +/ ITJ ) "* /* / + bT: */# -2$.  - % / ''
- ($)$)")0''#4+*/# . .)./*+=
x
/ +<
!ITJfDC: +/ITJ:*/# -2$. - % /ITJ=
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" W\*!XS

V=


	9




x
/ + T< 
) *- - /* $(+0/  ($..$)" / !*-  "$1 )  !!$4 1-$'  I ="=:  /*/' .*- J: XSS
/. /.2$'' " ) -/ 2# - ($..$)"//$)/ -( $/ 1$.$/I.J2$'' $(+0/ . *))*)E
($..$)"//. '$) )''*0' E'$)/- /( )/+ -$*/$( +*$)/.*!/# *-- .+*)$)"1-$' 
!-*( '' .0% /. 2$/#$)  # /- /( )/ "-*0+ 0.$)"  (0'/$1-$/  )*-(' $./-$0/$*) (* ' ) 
-&*1#$)*)/ -'*IJ$(+0//$*)( /#*=*0)/-42$'' $)*-+*-/ $)/# $(+0//$*)
(* '0.$)"0((4E*$)"*! #'..$!$/$*)' 1 '!*-/# *0)/-44$)-4I4 .C)*J1-$' =#$.
$(+0//$*)./ +2$'' $(+' ( )/ 0.$)"/# .// ( )/$)/# P
+-* 0- )
/#  
c *+/$*) /* */$) +-/$' $(+0//$*) 2# -   # $(+0/  /. / 2$'' #1 
$)/ -($// )/($..$)"1'0 .$(+0/ :2#$' (*)*/*) ($..$)"/2$''- ($))*/$(+0/ =)*+/$*)
/* 0.  (0'/$+'  #$). $) /#   ( /#* 2$''   0.  I*+/$*) 	
c
 $) 
.// ( )/J=)*()0( -" ) -/*-.  *![ZVWYX2$'' 0. //#$../ +=
x
/ +U<*- #/. /!-*(/ +T:(*)*/*) ($..$)"/2$'' $(+0/ . *)$)!*-(/$*)
!-*( /#  +' * "-*0+= .  - .0'/: XSS $(+0/  *(+' /  /. /. 2$''   " ) -/ = #$. 2$''  
$(+' ( )/  4 0.$)"  1\=W  
: .// ( )/   Ie1-$'  /* $(+0/ f C
cIe/- /( )/1-$' fc@e+' *' 1 'f@JJ=# $(+0//$*)(* '2$''$)'0 . '$) 1'0 
)''+*./. '$) /$( +*$)/.+-$*-/*/# *)  $)"$(+0/ =)*()0( -" ) -/*-.  *!
TUYZY[XW2$'' 0. //#$../ +=
x
#)"  !-*( . '$)  /*  # +*./E. '$)  /$(  +*$)/ 2$''   *(+0/  .  *) *. -1  )
$(+0/  / !-*( / + U= # $(+0/  *(+' /  /. / 2$''   )'4.  2$/# /#  .(  
(* '.0. !*-/# +-$(-4)'4.$.=
x
./$(/ .*/$) !-*(/# )'4.$.++'$ /* #$(+0/ /. /2$'' *($) 0.$)"

+-* 0- =

W=
9
 *) -)&E/-).!*-(  / /* *(+-  #)" . !-*( . '$)  /  .+ $!$ /$(  +*$)/  /2  )
/- /( )/"-*0+.:%0./$)"!*-. '$) )*0)/-4:2$'' --$ *0/. *)/# ( /#**'*"4 .-$ $)
*# /'=IT\[U:T\\SJ)/*& . /'=IUSTUJ.!*''*2.=
$-./ /#  1'0 . *! /#  #)"  !-*( . '$)  1-$'  . 2 '' . . '$)  *1-$/  2$''   /-).!*-(  /*
./)-$5 -)&.2$/#$) #*0)/-4:0.$)"!-/$*)'-)&.)( )( /#*!*-/$ .<
+-*-)&)+'0.T/$ .c( )*0/cG;

4ef;

1-e
fe	GG
f;
-0);
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU




*0( )/<
DD,0$)/$' .=) /D)/ -+-$. D++.D../DDD*1 )D	E
VSZSDTZXWTD$*.//$./$.D*0( )//$*)DD$)'YD*1 )	EVSZSEESW/ 3/$)'
YGT[)UST[=*3
0/#*-<
()#2
 -.$*)0( -<
$)'Y


 -.$*)/ <
T[)UST[
 (+'/ *<GGSTYF 1$.$*)V
 ! - ) <G
GSSX
!! /$1 / <ST4USTU

&RS\ULJKW4XLQWLOHV7UDQVQDWLRQDO&RUS$OOULJKWVUHVHUYHG
7KHFRQWHQWVRIWKLVGRFXPHQWDUHFRQILGHQWLDODQGSURSULHWDU\WR4XLQWLOHV7UDQVQDWLRQDO&RUS8QDXWKRUL]HGXVHGLVFORVXUHRU
UHSURGXFWLRQLVVWULFWO\SURKLELWHG
*1 )#-( 0/$'.:
)=



<	EVSZSEESW
" XS*!XS
# ):. +-/ - "- ..$*)(* '.2$'' !$/!*- #*0)/-40.$)"- "- ..$*)(* '!*-#)" !-*(. '$) 
2$/#. '$) .+- $/*-= .$0'.!-*(/#$.- "- ..$*)(* '2$'' +/0- !*-!0-/# -/ ./$)"*!$!! - ) .
 /2  )/- /( )/"-*0+.<
+-*- "ceGf;

4ef;

(* 'e	GG
fce
f;

*0/+0/*0/c-c
;
-0);
$)''4:/# ./-/$!$ I!*-*0)/-4J*#-)E)/ 'E	 ).5 '/ ./. *)/# *2 )*- $!! -.//$./$
0.$)" /#  1'0 . *! /#  - .$0'. . .*- . 2$''   0.  /* *(+-  /- /( )/ "-*0+. $)  +$-2$.  !.#$*)
I$)'0$)"*) 	EVSZS*. "-*0+)+' *//$( J<
+-*!- ,c
;

/' .efMefM
C	U;
-0);


1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU





Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
6KHOOV3DJHRI

Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 

 
 
 
 
 
STATISTICAL ANALYSIS PLAN 
 
 
Protocol Number: HP-3070-GL-04 Version 3 Amendment 2 
 
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess 
Efficacy and Safety of HP-3070 in Subjects Diagnosed with Schizophrenia 

 
 
 
Author: Amanda Schwab 
Version Number and Date: Draft V3 (SAP V6), 18Jan2018
 
 
 
 
 
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU



-DQSP(67
1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU



 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 3 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
MODIFICATION HISTORY 
 
 
Unique 
Identifier 
for this 
Version 
Date of the 
Document 
Version 
Author 
Significant Changes from  
Previous Authorized Version 
1.0 (SAP 
Draft V4) 
06OCT2016 
Lauren Dobson 
Murray 
Not Applicable – First Version 
2.0 (SAP 
Draft V5) 
 
12JAN2018 
Amanda Schwab 
Review Comments Implemented 
Key changes: 
Coordinated with SAP updates to 
reflect updated protocol 
Removed sensitivity for 
secondary efficacy 
Added disposition and 
demographic summaries from 
IVRS/IWRS 
Added additional information on 
screening to Analysis sets table 
Updated table formatting 
Removed disposition during run-
in table 
Reorganized Analysis Sets, 
Disposition and Randomization 
Tables 
Added new figures by PANSS 
subscales 
Added table and listing for PK 
Updated skin irritation table to 
include combined and 
concatenated scores 
Updated presentation of region to 
North America, Russia and Rest 
of the World 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
55


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 4 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
3.0 (SAP 
Draft V6) 
18JAN2018 
Amanda Schwab 
Removed ATC coding for 
concomitant medications 
Removed analysis using ITT 
population for primary efficacy 
variable 
Added sensitivity analysis for 
secondary efficacy variable 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
56


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 5 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
TABLE OF CONTENTS 
 
1. 
TABLES AND FIGURES .................................................................................... 15 
1.1 
Disposition, Demographics, and Baseline Characteristics .................................... 15 
Table 14.1.1 Analysis Sets .................................................................................... 16 
Table 14.1.2 Randomization by Country ITT Analysis Set .................................. 18 
Table 14.1.3 Disposition During the Double-Blind Period All Analysis Sets ...... 19 
Table 14.1.4 Time to Discontinuation During the Double-Blind Period ITT 
Analysis Set ........................................................................................................... 23 
Figure 14.1.4 Time to Discontinuation During the Double Blind Period, 
Kaplan Meier Plot ITT Analysis Set ..................................................................... 24 
Table 14.1.5 Demographic Characteristics  ITT Analysis Set .............................. 25 
Table 14.1.6 Baseline Psychiatric Characteristics  ITT Analysis Set ................... 27 
Table 14.1.7 Exposure to Double Blind Study Medication  Safety Analysis 
Set .......................................................................................................................... 29 
Table 14.1.8 Study Medication Compliance Safety Analysis Set ......................... 29 
Table 14.1.9 Prior Medications ITT Analysis Set ................................................. 32 
Table 14.1.10 Concomitant Medications Safety Analysis Set .............................. 33 
1.2 
Efficacy ................................................................................................................. 34 
Table 14.2.1.1.1 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 Full Analysis Set ............................................................... 35 
Table 14.2.1.1.2 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 ITT Analysis Set ............................................................... 37 
Table 14.2.1.2.1.1 Treatment Comparison of Change from Baseline in 
PANSS Total Score at Week 6 – Pattern-Mixture Model Full Analysis Set ........ 39 
Table 14.2.1.2.1.2 Treatment Comparison of Change from Baseline in 
PANSS Total Score at Week 6 – Pattern-Mixture Model for Dropout Pattern 
2 Full Analysis Set ................................................................................................ 39 
Table 14.2.1.2.2.3 Treatment Comparison of Change from Baseline in 
PANSS Total Score at Week 6 – Pattern-Mixture Model for Dropout Pattern 
3 Full Analysis Set ................................................................................................ 39 
Table 14.2.1.2.3 Time-to-Failure Based on Change from Baseline in PANSS 
Total Score and Dropout Pattern 1 Full Analysis Set ........................................... 41 
Table 14.2.1.2.4 Time-to-Failure Analysis Based on Change from Baseline in 
PANSS Total Score and Dropout Pattern 2 Full Analysis Set .............................. 42 
Table 14.2.1.2.5 Time-to-Failure Analysis Based on Change from Baseline in 
PANSS Total Score and Dropout Pattern 3 Full Analysis Set .............................. 42 
Table 14.2.1.2.6 ANCOVA on Rank-Transformed PANSS Total Score Data 
at Week 6 Full Analysis Set .................................................................................. 43 
Table 14.2.2.1 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 Full Analysis Set ........................................................................ 44 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
57


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 6 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.2.2 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 – Pattern-Mixture Model Full Analysis Set ............................... 44 
Table 14.2.2.3 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 – Pattern-Mixture Model for Dropout Pattern 2 Full 
Analysis Set ........................................................................................................... 44 
Table 14.2.2.4 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 – Pattern-Mixture Model for Dropout Pattern 3 Full 
Analysis Set ........................................................................................................... 44 
Table 14.2.2.5 Time-to-Failure Based on Change from Baseline in CGI-S 
Score and Dropout Pattern 1 Full Analysis Set ..................................................... 45 
Table 14.2.2.6 Time-to-Failure Analysis Based on Change from Baseline in 
CGI-S Score and Dropout Pattern 2 Full Analysis Set ......................................... 45 
Table 14.2.2.7 Time-to-Failure Analysis Based on Change from Baseline in 
CGI-S Score and Dropout Pattern 3 Full Analysis Set ......................................... 46 
Table 14.2.2.8 ANCOVA on Rank-Transformed CGI-S Score Data at Week 6 
Full Analysis Set ................................................................................................... 46 
Table 14.2.3.1.1 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Weeks 1 - 6 Full Analysis Set ........................................................ 48 
Figure 14.2.3.1.1 Mean Changes from Baseline in PANSS Total Score 
Across Visits  Full Analysis Set ............................................................................ 50 
Table 14.2.3.1.2 Treatment Comparison of Change from Baseline in PANSS 
Positive Subscale at Weeks 1 - 6 Full Analysis Set .............................................. 51 
Figure 14.2.3.1.2 Mean Changes from Baseline in PANSS Positive Subscale 
Across Visits  Full Analysis Set ............................................................................ 51 
Table 14.2.3.1.3 Treatment Comparison of Change from Baseline in PANSS 
Negative Subscale at Weeks 1 - 6 Full Analysis Set ............................................. 51 
Figure 14.2.3.1.3 Mean Changes from Baseline in PANSS Negative Subscale 
Across Visits  Full Analysis Set ............................................................................ 51 
Table 14.2.3.1.4 Treatment Comparison of Change from Baseline in PANSS 
General Psychopathology Subscale at Weeks 1 - 6 Full Analysis Set .................. 51 
Figure 14.2.3.1.4 Mean Changes from Baseline in PANSS General 
Psychopathology Subscale Across Visits  Full Analysis Set ................................ 52 
Table 14.2.3.1.5 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Weeks 1 – 6 by Completion Status Full Analysis Set ................... 53 
Figure 14.2.3.1.5 Mean Changes From Baseline in PANSS Total Score 
Across Visits by Completion Status Full Analysis Set ......................................... 55 
Table 14.2.3.1.6 Treatment Comparison of Change from Baseline in PANSS 
Positive Subscale at Weeks 1 – 6 by Completion Status Full Analysis Set .......... 56 
Figure 14.2.3.1.6 Mean Changes From Baseline in PANSS Positive Subscale 
Across Visits by Completion Status Full Analysis Set ......................................... 56 
Table 14.2.3.1.7 Treatment Comparison of Change from Baseline in PANSS 
Negative Subscale at Weeks 1 – 6 by Completion Status Full Analysis Set ........ 56 
Figure 14.2.3.1.7 Mean Changes From Baseline in PANSS Negative Subscale 
Across Visits by Completion Status Full Analysis Set ......................................... 56 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
58


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 7 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.3.1.8 Treatment Comparison of Change from Baseline in PANSS 
General Psychopathology Subscale at Weeks 1 – 6 by Completion Status Full 
Analysis Set ........................................................................................................... 57 
Figure 14.2.3.1.8 Mean Changes From Baseline in PANSS General 
Psychopathology Subscale Across Visits by Completion Status Full Analysis 
Set .......................................................................................................................... 57 
Table 14.2.3.2 Treatment Comparison of Change from Baseline in CGI-S 
Score at Weeks 1 - 6 Full Analysis Set ................................................................. 58 
Table 14.2.3.3 Treatment Comparison of CGI-I Responders Full Analysis Set ... 59 
Table 14.2.3.4 Treatment Comparison of CGI-I Score Full Analysis Set ............ 60 
Table 14.2.3.5 Treatment Comparison of PANSS Responders Based on >= 
30% Improvement from Baseline Full Analysis Set ............................................. 61 
Table 14.2.3.6 Treatment Comparison of PANSS Responders Based on >= 
30% Improvement from Baseline ITT Analysis Set ............................................. 61 
Table 14.2.3.7 Treatment Comparison of PANSS Responders Based on >= 
X% Improvement from Baseline to Week 6 Full Analysis Set ............................. 62 
Figure 14.2.3.7 Continuous Responder Analysis Based on Change from 
Baseline in PANSS Total Score at Week 6 Full Analysis Set .............................. 63 
Table 14.2.3.8 Treatment Comparison of PANSS Responders Based on >= 
X% Improvement from Baseline ITT Analysis Set .............................................. 64 
Figure 14.2.3.8 Continuous Responder Analysis Based on Change from 
Baseline in PANSS Total Score at Week 6 ITT Analysis Set .............................. 64 
Table 14.2.3.9 Treatment Comparison of Change from Baseline in CDSS 
Total Score Full Analysis Set ................................................................................ 64 
Table 14.2.3.10 Treatment Comparison of MSQ Score Full Analysis Set ........... 65 
Table 14.2.4.1 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 by Gender Full Analysis Set ............................................. 67 
Table 14.2.4.2 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 by Gender Full Analysis Set ...................................................... 69 
Table 14.2.4.3 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 by Age Full Analysis Set .................................................. 69 
Table 14.2.4.4 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 by Age Full Analysis Set ........................................................... 69 
Table 14.2.4.5 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 by Race Full Analysis Set ................................................. 70 
Table 14.2.4.6 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 by Race Full Analysis Set .......................................................... 70 
Table 14.2.4.7 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 by Severity at Baseline ..................................................... 70 
Table 14.2.4.8 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 by Severity at Baseline ............................................................... 70 
Table 14.2.4.9 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 by Region Full Analysis Set ............................................. 71 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
59


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 8 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.4.10 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 by Region Full Analysis Set....................................................... 71 
Table 14.2.4.11 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 by BMI at Baseline Full Analysis Set .............................. 71 
Table 14.2.4.12 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 by BMI at Baseline Full Analysis Set ........................................ 71 
Table 14.2.4.13 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 by Age of Onset Full Analysis Set ................................... 72 
Table 14.2.4.14 Treatment Comparison of Change from Baseline in CGI-S 
Total Score at Week 6 by Age of Onset Full Analysis Set ................................... 72 
Table 14.2.4.15 Treatment Comparison of Change from Baseline in PANSS 
Total Score at Week 6 by Disease Duration Full Analysis Set ............................. 72 
Table 14.2.4.16 Treatment Comparison of Change from Baseline in CGI-S 
Score at Week 6 by Disease Duration Full Analysis Set ...................................... 73 
1.3 
Safety ..................................................................................................................... 74 
Table 14.3.1.1 Overview of Adverse Events Safety Analysis Set ........................ 75 
Table 14.3.1.2 Treatment-Emergent Adverse Events During the Double-Blind 
Period by System Organ Class and Preferred Term Safety Analysis Set ............. 76 
Table 14.3.1.3 Treatment-Emergent Adverse Events During the Double-Blind 
Period by System Organ Class, Preferred Term, Relationship to Study 
Medication, and Severity Safety Analysis Set ...................................................... 77 
Table 14.3.1.4 Treatment-Emergent Adverse Events During the Double-Blind  
Period Leading to Study Drug Discontinuation by System Organ Class and  
Preferred Term Safety Analysis Set………………………………………………78 
Table 14.3.1.5 Treatment-Emergent Adverse Events During the Double-Blind 
Period Leading to Study Drug Discontinuation by Region and by System 
Organ Class and Preferred Term Safety Analysis Set ........................................... 79 
Table 14.3.1.6 Serious Treatment-Emergent Adverse Events During the 
Double-Blind Period by System Organ Class and Preferred Term Safety 
Analysis Set ........................................................................................................... 80 
Table 14.3.1.7 Serious Treatment-Emergent Adverse Events During the 
Double-Blind Period by Region and by System Organ Class and Preferred 
Term Safety Analysis Set ...................................................................................... 80 
Table 14.3.1.8 Serious Treatment-Emergent Adverse Events During the 
Double-Blind Period by System Organ Class, Preferred Term, Relationship to 
Study Medication, and Severity Safety Analysis Set ............................................ 80 
Table 14.3.1.9 Treatment-Emergent Adverse Events During the Double-Blind 
Period Leading to Death by System Organ Class and Preferred Term Safety 
Analysis Set ........................................................................................................... 80 
Table 14.3.1.10 Commonly Occurring (>= 5%) Treatment-Emergent Adverse 
Events During the Double-Blind Period by System Organ Class and Preferred 
Term Safety Analysis Set ...................................................................................... 80 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
60


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 9 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.3.1.11 Commonly Occurring (>= 5%) Treatment-Emergent Adverse 
Events During the Double-Blind Period by Region and by System Organ 
Class and Preferred Term Safety Analysis Set ...................................................... 81 
Table 14.3.1.12 All Commonly Occurring (>= 5%) Adverse Events During 
the Double-Blind Period by Region and by System Organ Class and Preferred 
Term Safety Analysis Set ...................................................................................... 81 
Table 14.3.1.13 Commonly Occurring (>= 2%) Treatment-Emergent Adverse 
Events During the Double-Blind Period by System Organ Class and Preferred 
Term Safety Analysis Set ...................................................................................... 81 
Table 14.3.1.14 Treatment-Emergent Adverse Events at Patch Application 
Site During the Double-Blind Period by Preferred Term and Severity Safety 
Analysis Set ........................................................................................................... 82 
Table 14.3.2.1 Clinical Laboratory Quantitative Results and Change from 
Baseline by Visit - Hematology Safety Analysis Set ............................................ 83 
Table 14.3.2.2 Clinical Laboratory Quantitative Results and Change from 
Baseline by Visit – Serum Chemistry Safety Analysis Set ................................... 84 
Table 14.3.2.3 Clinical Laboratory Quantitative Results and Change from 
Baseline by Visit – Urinalysis ............................................................................... 84 
Table 14.3.2.4 Clinical Laboratory Shifts from Baseline to Worst On-
Treatment Result for Categorical Measurements Safety Analysis Set.................. 85 
Table 14.3.2.5.1 Clinical Laboratory Shifts from Baseline to Maximum On-
Treatment Result - Hematology Safety Analysis Set ............................................ 86 
Table 14.3.2.5.2 Clinical Laboratory Shifts from Baseline to Minimum On-
Treatment Result – Hematology Safety Analysis Set ........................................... 87 
Table 14.3.2.6.1 Clinical Laboratory Shifts from Baseline to Maximum On-
Treatment Result – Serum Chemistry Safety Analysis Set ................................... 87 
Table 14.3.2.6.2 Clinical Laboratory Shifts from Baseline to Minimum On-
Treatment Result – Serum Chemistry Safety Analysis Set ................................... 87 
Table 14.3.2.7.1 Clinical Laboratory Shifts from Baseline to Maximum On-
Treatment Result – Urinalysis Safety Analysis Set............................................... 87 
Table 14.3.2.7.2 Clinical Laboratory Shifts from Baseline to Minimum On-
Treatment Result – Urinalysis Safety Analysis Set............................................... 87 
Table 14.3.2.8 Clinical Laboratory Shifts in NCI CTCAE Grades from 
Baseline to Worst On-Treatment Result  Safety Analysis Set .............................. 88 
Table 14.3.2.9 Clinical Laboratory Neutrophil Results Below 1000 per Cubic 
Millimeter by Visit Safety Analysis Set ................................................................ 89 
Table 14.3.2.10 Clinical Laboratory Liver Function Abnormalities Safety 
Analysis Set ........................................................................................................... 90 
Table 14.3.3.1 12-Lead ECG Quantitative Results and Change from Baseline 
by Visit Safety Analysis Set .................................................................................. 91 
Table 14.3.3.2 12-Lead ECG Overall Assessment by Visit Safety Analysis 
Set .......................................................................................................................... 92 
Table 14.3.3.3 12-Lead ECG Overall Assessment Shifts from Baseline to 
Worst On-Treatment Result Safety Analysis Set .................................................. 93 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
61


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 10 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.3.3.4 12-Lead ECG Markedly Abnormal Results by Visit Safety 
Analysis Set ........................................................................................................... 94 
Table 14.3.3.5 12-Lead ECG Markedly Abnormal Shifts from Baseline to 
Worst On-Treatment Result Safety Analysis Set .................................................. 96 
Table 14.3.4.1 Vital Signs Results and Change from Baseline by Visit Safety 
Analysis Set ........................................................................................................... 97 
Table 14.3.4.2 Orthostatic Hypotension by Visit Safety Analysis Set ................. 98 
Table 14.3.4.3 Vital Signs Markedly Abnormal Results by Visit Safety 
Analysis Set ........................................................................................................... 99 
Table 14.3.5.1 SAS Total Score Results and Change from Baseline by Visit 
Safety Analysis Set .............................................................................................. 100 
Table 14.3.5.2.1 AIMS Global Severity Score Results and Change from 
Baseline by Visit Safety Analysis Set ................................................................. 101 
Table 14.3.5.2.2 AIMS Total Score Results and Change from Baseline by 
Visit Safety Analysis Set ..................................................................................... 101 
Table 14.3.5.3.1 BARS Global Score Results and Change from Baseline by 
Visit Safety Analysis Set ..................................................................................... 101 
Table 14.3.5.3.2 BARS Total Score Results and Change from Baseline by 
Visit Safety Analysis Set ..................................................................................... 101 
Table 14.3.5.4.1 C-SSRS Suicidal Ideation by Visit Safety Analysis Set .......... 102 
Table 14.3.5.4.2 C-SSRS Most Severe Suicidal Ideation and Suicidal 
Behavior Safety Analysis Set .............................................................................. 103 
Table 14.3.6 Summary of Patch Adhesion, Adhesive Residue, and Skin 
Irritation Safety Analysis Set .............................................................................. 105 
Table 14.3.6 Summary of Patch Adhesion, Adhesive Residue, and Skin 
Irritation Safety Analysis Set .............................................................................. 107 
Table 14.3.7 Summary of Plasma Asenapine and Desmethyl-asenapine 
Concentrations (ng/mL)) by Treatment PK Analysis Set ................................... 108 
2. 
LISTINGS ........................................................................................................... 109 
Listing 16.2.1.1 Randomization ITT Analysis Set .............................................. 110 
Listing 16.2.1.2 Disposition All Subjects Screened Analysis Set ....................... 111 
Listing 16.2.1.3 Demographics ITT Analysis Set ............................................... 113 
Listing 16.2.1.4 Inclusion/Exclusion Criteria Not Met ITT Analysis Set ........... 115 
Listing 16.2.1.5 Medical History ITT Analysis Set ............................................ 116 
Listing 16.2.1.6 Patch Application ITT Analysis Set.......................................... 117 
Listing 16.2.1.7 Adhesive Residue Assessment ITT Analysis Set ..................... 118 
Listing 16.2.1.8 Day Passes ITT Analysis Set .................................................... 119 
Listing 16.2.1.9 Prior, Concomitant, and Post-Treatment Medications ITT 
Analysis Set ......................................................................................................... 120 
Listing 16.2.1.10 Mini International Neuropsychiatric Interview (MINI) at 
Screening ITT Analysis Set ................................................................................. 121 
Listing 16.2.2.1 Positive and Negative Syndrome Scale (PANSS) ITT 
Analysis Set ......................................................................................................... 124 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
62


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 11 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Listing 16.2.2.2 Clinical Global Impression – Severity of Illness Scale (CGI-
S) ITT Analysis Set ............................................................................................. 126 
Listing 16.2.2.3 Clinical Global Impression – Improvement Scale (CGI-I) 
ITT Analysis Set .................................................................................................. 127 
Listing 16.2.2.4 Calgary Depression Scale for Schizophrenia (CDSS) ITT 
Analysis Set ......................................................................................................... 128 
Listing 16.2.2.5 Medical Satisfaction Questionnaire ITT Analysis Set .............. 129 
Listing 16.2.3.1.1 Adverse Events Safety Analysis Set ...................................... 130 
Listing 16.2.3.1.2 Serious Adverse Events Safety Analysis Set ......................... 132 
Listing 16.2.3.1.3 Adverse Events Leading to Discontinuation of Study 
Medication Safety Analysis Set .......................................................................... 133 
Listing 16.2.3.1.4 Adverse Events Leading to Death Safety Analysis Set ......... 133 
Listing 16.2.3.1.5 Commonly Occurring Adverse Events  Safety Analysis Set . 133 
Listing 16.2.3.1.6 Adverse Events at Patch Application Site Safety Analysis 
Set ........................................................................................................................ 133 
Listing 16.2.3.2.1 Clinical Laboratory Results - Hematology Safety Analysis 
Set ........................................................................................................................ 134 
Listing 16.2.3.2.2 Clinical Laboratory Results – Blood Chemistry Safety 
Analysis Set ......................................................................................................... 135 
Listing 16.2.3.2.3 Clinical Laboratory Results – Urinalysis Safety Analysis 
Set ........................................................................................................................ 135 
Listing 16.2.3.2.4 Subjects with Clinically Significant or NCI CTCAE Grade 
>= 3 Laboratory Results Safety Analysis Set ...................................................... 136 
Listing 16.2.3.3 12-Lead ECG Safety Analysis Set ............................................ 137 
Listing 16.2.3.4 Vital Signs Safety Analysis Set ................................................ 139 
Listing 16.2.3.5 Simpson Angus Scale (SAS) Safety Analysis Set .................... 140 
Listing 16.2.3.6 Abnormal Involuntary Movement Scale (AIMS) Safety 
Analysis Set ......................................................................................................... 141 
Listing 16.2.3.7 Barnes Akathisia Rating Scale (BARS) Safety Analysis Set ... 142 
Listing 16.2.3.8 Columbia-Suicide Severity Rating Scale (C-SSRS) Safety 
Analysis Set ......................................................................................................... 143 
Listing 16.2.3.9 Plasma Concentrations of Asenapine and Desmethyl-
asenapine (ng/mL) by Treatment PK Analysis Set ............................................. 144 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
63


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 12 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
OUTPUT CONVENTIONS 
 
General: 
• The first row in the body of the table or listing should be blank 
• The left hand column should start in column 1. No indenting or centering of the output should 
occur. 
• Rounding should be done with the SAS function ROUND. 
• Numbers in tables should be rounded, not truncated. 
• Alphanumeric output should be left aligned. 
• Numbers should be decimal point aligned. 
• Whole numbers should be right aligned. 
• Text values should be left aligned. 
• The first letter of a text entry should be capitalized 
• Listings of adverse events, concomitant medications, medical histories etc. should be sorted in 
chronological order, with earliest adverse event, medication or history coming first. 
• All listing outputs should be sorted (preferably by Treatment, Site Number and Subject Number). 
• Do not use superscripts and subscripts 
• Exponentiation will be expressed using a double asterisk, i.e., mm3 will be written as mm**3. 
 
Univariate Statistics: 
• Statistics should be presented in the same order across tables (i.e., n, Mean, SD, Median, Minimum, 
Maximum) 
• Table statistics should line up under the N part of the (N=XXX) in the table header. All decimal 
points should line up. If the minimum and maximum are output on one line as Minimum, 
Maximum then the comma should line up with the decimal point. 
• If the original data has N decimal places, then the summary statistics should have the following 
decimal places: 
Minimum and maximum: N 
Mean, median and CV%: N + 1 
SD: N + 2 
 
Frequencies and percentages (n and %): 
• Percent values should be reported inside parentheses, with one space between the count and the left 
parenthesis of the percentage. Parentheses should be justified to accept a maximum of 100.0 as a 
value and padded with blank space if the percent is less than 100.0. An example is given below: 
77 (100.0) 
50 ( 64.9) 
0 ( 0.0) 
• Percentages will be reported to one decimal place, except percents <100.0% but >99.9% will be 
presented as ‘>99.9%’ (e.g., 99.99% is presented as >99.9%); and percents < 0.1% will be 
presented as ‘<0.1%’ (e.g., 0.08% is presented as <0.1%). Rounding will be applied after the 
<0.1% and >99.9% rule. 
E.g. ( <0.1%) 
( 6.8%) 
(>99.9%) 
Percentages may be reported to 0 decimal places as appropriate (for example, where the 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
64


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 13 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
denominator is relatively small). 
• Where counts are zero, percentages of 0.0% should appear in the output. 
 
Confidence Intervals: 
• As a rule confidence intervals are output to one place more than the raw data, and standard 
deviations and standard errors to two places more than the raw data 
• Confidence intervals should be justified so that parentheses displayed on consecutive lines of a 
table “line up”. 
• Boundary values of confidence intervals should be separated by a comma. 
• Boundary values should be padded as necessary to accept negative values and to allow alignment of 
the decimal place. 
• An example is given below: 
(-0.12, -0.10) 
( 9.54, 12.91) 
 
P-values: 
• P-values should be reported to three decimal places, except values <1.000 but >0.999 will be 
presented as ‘>0.999’ (e.g., 0.9998 is presented as >0.999); and values <0.001 will be presented as 
‘<0.001’ (e.g., 0.0009 is presented as <0.001). Rounding will be applied after the <0.001 and 
>0.999 rule 
 
Ratios: 
• Ratios should be reported to one more decimal place than the original data. 
 
Spacing: 
• There must be a minimum of 1 blank space between columns (preferably 2) 
 
Denominators: 
• If a different count other than the population count is used for a denominator (within the table) to 
calculate percentages, there should be a row in the table that identifies that number “N”. 
• Alternatively, a footnote should be included in each table with percentages to indicate the 
denominator for percentages. 
 
Missing values 
• A “0” should be used to indicate a zero frequency. 
• A blank will be used to indicate missing data in an end-of-text table or subject listing. 
 
 
• Figures should be provided in RTF files using the SAS Output Delivery System (ODS), as 
Computer Graphics Metafile (CGM) formatted graphical output generated by SAS. 
• The CGM file itself should contain the title and footer. 
• The image should be clear and of high quality when viewed in the Word document, and when 
printed. 
• In general, boxes around the figures should be used. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
65


 
 
Author: 
Amanda Schwab 
Version Number: 
 
 
Draft 2 
 
 
Version Date: 
 
 
18Jan2018 
Shells Page 14 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Footers should be defined as follows: 
• A continuous line of underscores (‘_’) will follow the body of the table or listing prior to any 
footnotes at the bottom of the page 
• Table footnotes should be defined using compute statements in the proc report, and should appear 
directly after the body of the table 
• The program path and name and version number (if applicable), and the date/time stamp, should 
appear in the last footnote at the bottom of the page 
 
• Footnotes should be left-aligned. 
• Footnotes should be in sentence case. 
• Only “typewriter” symbols are permitted – e.g. “*”, “$”, “#”, “@”, “&” and “+”. 
• The choice of footnote symbols should be consistent. E.g. if you have the footnote “# indicates last 
observation carried forward” for one table, the same symbol and footnote should indicate LOCF 
for all tables. 
• If text wraps across more than one line (for a note), the first letter for all lines of text after the first 
one will be indented to align beneath the first letter of the text in the first line. 
• The page identification in the format Page X of Y (where Y is the total number of pages for the 
output) should appear in the header line, right aligned 
 
Ordering of footnotes should be as follows: 
 
1.) Abbreviations 
2) Definitions 
3.) Formulae 
4.) P-value significance footnote 
5.) Symbols 
6.) Specific notes 
• Common notes from table to table should appear in the same order. 
• The symbols should appear in the same order as what they are defined in the table or listing, from 
left to right. 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
66


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 15 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
1. 
TABLES AND FIGURES 
1.1 
Disposition, Demographics, and Baseline Characteristics 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
67


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 16 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.1 Analysis Sets 
 
Statistic 
HP-3070 18.0 mg 
HP-3070 9.0 mg 
Placebo 
Overall 
 
 
 
 
 
 
Number of Subjects Screened in Run-in 
N  
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
Number of Subjects Randomized in Double-blind 
N 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
Number of Subjects in the ITT Analysis Set 
N 
xxx 
xxx  
xxx  
xxx  
Reasons for Exclusion from the ITT Analysis Set: 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
   Not Consented 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
   Not Randomized 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
   Protocol Deviation 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
 
 
 
 
 
 
Number of Subjects in the Full Analysis Set 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
Reasons for Exclusion from the Full Analysis Set: 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
   No Double-Blind Study Medication Applied 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
   No Baseline Assessment of PANSS Total Score 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
   No Post-Baseline Assessment of PANSS Total Score 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
 
 
 
 
 
 
Note: ITT = Intent-to-treat, PK = Pharmacokinetic, IVRS = Interactive Voice Activated Response System, IWRS = Interactive Web-
based Response System. 
Note: The all subjects screened set contains all subjects who provided informed consent for this study. This analysis set and the 
reasons for screening/run-in failure are based on data collected in the IVRS/IWRS. Some subjects in this analysis set do not 
have data recorded in the eCRF. 
Note: The ITT analysis set includes all consented and randomized subjects. 
Note: The Full analysis set includes all randomized subjects who have at least one patch of double-blind study medication applied, 
who have a baseline PANSS total score, and who have at least one post-baseline assessment of the PANSS total score. 
Note: The Safety analysis set includes all subjects who have had at least one patch of double-blind study medication applied and 
who have at least one post-dose safety measurement during the double-blind treatment period.  
Note: The PK analysis set includes all subjects who have at least one dose of double-blind study medication and have at least one 
blood sample for PK assessment. Subjects may be excluded from the PK analysis set if they significantly violate inclusion or 
exclusion criteria, significantly violate the protocol in a way that may influence the PK analysis, if any unexpected error 
occurs during the study that may influence the PK analysis (e.g., early detachment of transdermal systems, apparent sample 
switching, etc.), or if their data are unavailable or incomplete. 
Note: Percentages for Full analysis set, Safety analysis set, and PK analysis set are calculated out of the total ITT analysis 
set. Percentages for reasons for exclusion are out of the total number of subjects excluded from the given analysis set. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
68


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 17 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 2 of x  
Table 14.1.1 Analysis Sets 
 
Statistic 
HP-3070 18.0 mg 
HP-3070 9.0 mg 
Placebo 
Overall 
 
 
 
 
 
 
Number of Subjects in the Safety Analysis Set 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
Reasons for Exclusion from the Safety Analysis Set: 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
   No Double-Blind Study Medication Applied 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
   No Post-Dose Safety Measurements 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
 
 
 
 
 
 
Number of Subjects in the PK Analysis Set 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
Reasons for Exclusion from the PK Analysis Set: 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
  No study medication HP-3070 9.0mg or 18.0mg applied 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
  Significant protocol or inclusion/exclusion criteria 
violation 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
  Unexpected errors that may influence the PK analysis 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
  Unavailable/incomplete data 
n (%) 
xxx (xx.x)      
xxx (xx.x)      xxx (xx.x)   xxx (xx.x)   
 
 
 
 
 
 
Note: ITT = Intent-to-treat, PK = Pharmacokinetic, IVRS = Interactive Voice Activated Response System, IWRS = Interactive Web-
based Response System. 
Note: The all subjects screened set contains all subjects who provided informed consent for this study. This analysis set and the 
reasons for screening/run-in failure are based on data collected in the IVRS/IWRS. Some subjects in this analysis set do not 
have data recorded in the eCRF. 
Note: The ITT analysis set includes all consented and randomized subjects. 
Note: The Full analysis set includes all randomized subjects who have at least one patch of double-blind study medication applied, 
who have a baseline PANSS total score, and who have at least one post-baseline assessment of the PANSS total score. 
Note: The Safety analysis set includes all subjects who have had at least one patch of double-blind study medication applied and 
who have at least one post-dose safety measurement during the double-blind treatment period.  
Note: The PK analysis set includes all subjects who have at least one dose of double-blind study medication and have at least one 
blood sample for PK assessment. Subjects may be excluded from the PK analysis set if they significantly violate inclusion or 
exclusion criteria, significantly violate the protocol in a way that may influence the PK analysis, if any unexpected error 
occurs during the study that may influence the PK analysis (e.g., early detachment of transdermal systems, apparent sample 
switching, etc.), or if their data are unavailable or incomplete. 
Note: Percentages for Full analysis set, Safety analysis set, and PK analysis set are calculated out of the total ITT analysis 
set. Percentages for reasons for exclusion are out of the total number of subjects excluded from the given analysis set. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
69


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 18 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.2 Randomization by Country 
ITT Analysis Set 
 
 
Region / Country 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
Overall 
(N=xxx) 
n (%) 
 
 
 
 
 
Rest of the World 
 
 
 
 
  Bulgaria 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
  Serbia 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
  Ukraine 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Russia 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
North America 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
  United States 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Note: ITT = Intent-to-treat, N = number of subjects in the ITT analysis set by treatment group. 
Note: Percentages are calculated as (n/N)*100. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
70


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 19 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.3 Disposition During the Double-Blind Period 
All Analysis Sets 
 
 
 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
Overall 
(N=xxx) 
n (%) 
 
 
 
 
 
ITT Analysis Set 
 
 
 
 
 
 
 
 
 
Number of Subjects who Completed the Study 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Number of Subjects who Discontinued the Study 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
   Primary reason for early discontinuation 
 
 
 
 
       Adverse event  
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Death 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Non-compliance 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Lack of efficacy 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Subject requires treatment with a prohibited medication 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Pregnancy 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Physician decision 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Study terminated by investigator 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Study terminated by sponsor 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Subject withdrew consent 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Other 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Note: ITT = Intent-to-treat, PK = Pharmacokinetic, N = number of subjects in the ITT analysis set by treatment group. 
Note: Percentages are calculated as (n/N)*100. 
Note: This summary is based on data recorded in the eCRF. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
71


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 20 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 2 of x  
Table 14.1.3 Disposition During the Double-Blind Period 
All Analysis Sets 
 
 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
Overall 
(N=xxx) 
n (%) 
 
 
 
 
 
Full Analysis Set 
 
 
 
 
 
 
 
 
 
Number of Subjects who Completed the Study 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Number of Subjects who Discontinued the Study 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
   Primary reason for early discontinuation 
 
 
 
 
       Adverse event  
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Death 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Non-compliance 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Lack of efficacy 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Subject requires treatment with a prohibited medication 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Pregnancy 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Physician decision 
 
 
 
 
       Study terminated by investigator 
 
 
 
 
       Study terminated by sponsor 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Subject withdrew consent 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Other 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Note: ITT = Intent-to-treat, PK = Pharmacokinetic, N = number of subjects in the ITT analysis set by treatment group. 
Note: Percentages are calculated as (n/N)*100. 
Note: This summary is based on data recorded in the eCRF. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
72


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 21 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 3 of x  
Table 14.1.3 Disposition During the Double-Blind Period 
All Analysis Sets 
 
 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
Overall 
(N=xxx) 
n (%) 
 
 
 
 
 
Safety Analysis Set 
 
 
 
 
 
 
 
 
 
Number of Subjects who Completed the Study 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Number of Subjects who Discontinued the Study 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
   Primary reason for early discontinuation 
 
 
 
 
       Adverse event  
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Death 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Non-compliance 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Lack of efficacy 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Subject requires treatment with a prohibited medication 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Pregnancy 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Physician decision 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Study terminated by investigator 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Study terminated by sponsor 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Subject withdrew consent 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Other 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Other 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Note: ITT = Intent-to-treat, PK = Pharmacokinetic, N = number of subjects in the ITT analysis set by treatment group. 
Note: Percentages are calculated as (n/N)*100. 
Note: This summary is based on data recorded in the eCRF. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
73


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 22 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 4 of x  
Table 14.1.3 Disposition During the Double-Blind Period 
All Analysis Sets 
 
 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
Overall 
(N=xxx) 
n (%) 
 
 
 
 
 
PK Analysis Set 
 
 
 
 
 
 
 
 
 
Number of Subjects who Completed the Study 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Number of Subjects who Discontinued the Study 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
   Primary reason for early discontinuation 
 
 
 
 
       Adverse event  
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Death 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Non-compliance 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Lack of efficacy 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Subject requires treatment with a prohibited medication 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Pregnancy 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Physician decision 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Study terminated by investigator 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Study terminated by sponsor 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Subject withdrew consent 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
       Other 
xx (xx.x)     
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
Note: ITT = Intent-to-treat, PK = Pharmacokinetic, N = number of subjects in the ITT analysis set by treatment group. 
Note: Percentages are calculated as (n/N)*100. 
Note: This summary is based on data recorded in the eCRF. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
74


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 23 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.4 Time to Discontinuation During the Double-Blind Period 
ITT Analysis Set 
 
Time (Days) 
HP-3070 18.0 mg 
(N=xxx) 
% 
HP-3070 9.0 mg 
(N=xxx) 
% 
Placebo 
(N=xxx) 
% 
Overall 
(N=xxx) 
% 
 
 
 
 
 
Day 0 
xx  
xx  
xx  
xx  
Day 7 
xx  
xx  
xx  
xx  
Day 14 
xx  
xx  
xx  
xx  
Day 21 
xx  
xx  
xx  
xx  
Day 28 
xx  
xx  
xx  
xx  
Day 35 
xx  
xx  
xx  
xx  
Day 42 
xx  
xx  
xx  
xx  
 
 
 
 
 
Note: ITT = Intent-to-treat, N = number of subjects in the ITT analysis set by treatment group. 
Note: Percents are based on Kaplan Meier failure rates at each week. 
Note: Time to discontinuation is computed as date of last dose of double-blind study medication – date of randomization. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
75


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 24 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
Figure 14.1.4 Time to Discontinuation During the Double Blind Period, Kaplan Meier Plot 
ITT Analysis Set 
 
 
 
Note: ITT = Intent-to-treat. 
Note: Time to discontinuation is computed as date of last dose of double-blind study medication – date of randomization. 
Note: Reference Table 14.1.4 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Figures\xxxxx.sas ddmmmyyyy hh:mm        
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
76


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 25 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.5 Demographic Characteristics  
ITT Analysis Set 
 
 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
Overall 
(N=xxx) 
 
 
 
 
 
 
Age (years) 
n 
  xx 
  xx 
  xx 
  xx 
 
Mean 
   x.x 
   x.x 
   x.x 
   x.x 
 
SD 
   x.xx 
   x.xx 
   x.xx 
   x.xx 
 
Median 
   x.x 
   x.x 
   x.x 
   x.x 
 
Min 
   x 
   x 
   x 
   x 
 
Max 
   x 
   x 
   x 
   x 
  < 55 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  >= 55 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
 
 
 
 
 
 
Gender 
 
 
 
 
 
  Male 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  Female 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
 
 
 
 
 
 
Race 
 
 
 
 
 
  American Indian or Alaska Native 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  Asian 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  Black or African American 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  Native Hawaiian or Other Pacific Islanders 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  White 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  Other 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
 
 
 
 
 
 
Ethnicity 
 
 
 
 
 
  Hispanic or Latino 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  Not Hispanic or Latino 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
 
 
 
 
 
 
Region 
 
 
 
 
 
  Rest of the World 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  Russia 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
  North America 
n (%) 
  xx (xx.x)        xx (xx.x)        xx (xx.x)     xx (xx.x)     
 
 
 
 
 
 
Note: ITT = Intent-to-treat, BMI = Body Mass Index, N = number of subjects in the ITT analysis set by treatment group. 
Note: Rest of the World includes Bulgaria, Serbia and Ukraine. 
Note: Percentages are calculated as (n/N)*100. 
Note: A subject may select more than one race in the eCRF. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
77


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 26 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 2 of x  
Table 14.1.5 Demographic Characteristics 
ITT Analysis Set 
 
 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
Overall 
(N=xxx) 
 
 
 
 
 
 
Baseline Height (cm) 
n 
  xx 
  xx 
  xx 
  Xx 
 
Mean 
   x.x 
   x.x 
   x.x 
   x.x 
 
SD 
   x.xx 
   x.xx 
   x.xx 
   x.xx 
 
Median 
   x.x 
   x.x 
   x.x 
   x.x 
 
Min 
   x 
   x 
   x 
   X 
 
Max 
   x 
   x 
   x 
   X 
 
 
 
 
 
 
Baseline Weight (kg) 
n 
  xx 
  xx 
  xx 
  Xx 
 
Mean 
   x.x 
   x.x 
   x.x 
   x.x 
 
SD 
   x.xx 
   x.xx 
   x.xx 
   x.xx 
 
Median 
   x.x 
   x.x 
   x.x 
   x.x 
 
Min 
   x 
   x 
   x 
   X 
 
Max 
   x 
   x 
   x 
   X 
 
 
 
 
 
 
Baseline BMI (kg/m2) 
n 
  xx 
  xx 
  xx 
  Xx 
 
Mean 
   x.x 
   x.x 
   x.x 
   x.x 
 
SD 
   x.xx 
   x.xx 
   x.xx 
   x.xx 
 
Median 
   x.x 
   x.x 
   x.x 
   x.x 
 
Min 
   x 
   x 
   x 
   x 
 
Max 
   x 
   x 
   x 
   x 
  < 25 
n (%) 
  xx (xx.x)        xx (xx.x)      
  xx (xx.x)     xx (xx.x)   
  >= 25 to < 30 
n (%) 
  xx (xx.x)        xx (xx.x)      
  xx (xx.x)     xx (xx.x)   
  >= 30 
n (%) 
  xx (xx.x)        xx (xx.x)      
  xx (xx.x)     xx (xx.x)   
 
 
 
 
 
 
Note: ITT = Intent-to-treat, BMI = Body Mass Index, N = number of subjects in the ITT analysis set by treatment group. 
Note: Rest of the World includes Bulgaria, Serbia and Ukraine. North America includes the United States. 
Note: Percentages are calculated as (n/N)*100. 
Note: A subject may select more than one race in the eCRF. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
78


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 27 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.6 Baseline Psychiatric Characteristics  
ITT Analysis Set 
 
 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
Overall 
(N=xxx) 
 
 
 
 
 
 
Time Since First Diagnosis of Schizophrenia (years) 
n 
  xx 
  xx 
  xx 
  xx 
 
Mean 
   x.x 
   x.x 
   x.x 
   x.x 
 
SD 
   x.xx 
   x.xx 
   x.xx 
   x.xx 
 
Median 
   x.x 
   x.x 
   x.x 
   x.x 
 
Min 
   x 
   x 
   x 
   x 
 
Max 
   x 
   x 
   x 
   x 
  < 5 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
  >= 5 to < 10 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
  >= 10 to < 20 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
  >= 20 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
 
 
 
 
 
 
Time Since Current Exacerbated Episode (weeks) 
n 
  xx 
  xx 
  xx 
  xx 
 
Mean 
   x.x 
   x.x 
   x.x 
   x.x 
 
SD 
   x.xx 
   x.xx 
   x.xx 
   x.xx 
 
Median 
   x.x 
   x.x 
   x.x 
   x.x 
 
Min 
   x 
   x 
   x 
   x 
 
Max 
   x 
   x 
   x 
   x 
 
 
 
 
 
 
Baseline PANSS Total Score 
 
 
 
 
 
  < 90 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
  >= 90 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
 
 
 
 
 
 
Note: ITT = Intent-to-treat, PANSS = Positive and Negative Syndrome Scale, MSQ = Medication Satisfaction Questionnaire, N = number 
of subjects in the ITT analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.   
Note: Percentages are calculated as (n/N)*100.  
Note: Time since is calculated as date of first dose of double blind medication – current exacerbated episode or first diagnosis 
of schizophrenia 
Note: The MSQ is a single-item questionnaire used to assess the level of patient’s satisfaction or dissatisfaction with the 
medication they are taking. Responses can range from Extremely Dissatisfied (1) to Extremely Satisfied (7). 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
79


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 28 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 2 of x  
Table 14.1.6 Baseline Psychiatric Characteristics 
ITT Analysis Set 
 
 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
Overall 
(N=xxx) 
 
 
 
 
 
 
Age of First Diagnosis of Schizophrenia (years) 
n 
  xx 
  xx 
  xx 
  xx 
 
Mean 
   x.x 
   x.x 
   x.x 
   x.x 
 
SD 
   x.xx 
   x.xx 
   x.xx 
   x.xx 
 
Median 
   x.x 
   x.x 
   x.x 
   x.x 
 
Min 
   x 
   x 
   x 
   x 
 
Max 
   x 
   x 
   x 
   x 
  < 25 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
  >= 25 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
 
 
 
 
 
 
Antipsychotic Treatment Before Current Episode 
 
 
 
 
 
  Yes 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
  No 
n (%) 
  xx (xx.x)        xx (xx.x)       xx (xx.x)       xx (xx.x)     
 
 
 
 
 
 
Baseline MSQ Score 
n 
  xx 
  xx 
  xx 
  xx 
 
Mean 
   x.x 
   x.x 
   x.x 
   x.x 
 
SD 
   x.xx 
   x.xx 
   x.xx 
   x.xx 
 
Median 
   x.x 
   x.x 
   x.x 
   x.x 
 
Min 
   x 
   x 
   x 
   x 
 
Max 
   x 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat, PANSS = Positive and Negative Syndrome Scale, MSQ = Medication Satisfaction Questionnaire, N = number 
of subjects in the ITT analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.   
Note: Percentages are calculated as (n/N)*100.  
Note: Time since is calculated as date of first dose of double blind medication – current exacerbated episode or first diagnosis 
of schizophrenia 
Note: The MSQ is a single-item questionnaire used to assess the level of patient’s satisfaction or dissatisfaction with the 
medication they are taking. Responses can range from Extremely Dissatisfied (1) to Extremely Satisfied (7). 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm       mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
80


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 29 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.7 Exposure to Double Blind Study Medication  
Safety Analysis Set 
 
 
 
 
 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
Overall 
 (N=xxx) 
Statistic 
Subjects 
Patches  
Subjects 
Patches  
Subjects 
Patches 
Subjects 
Patches 
 
 
 
 
 
 
 
 
 
 
Exposed to Double-
Blind Study Medication 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
 
 
 
 
 
 
 
 
 
Duration of Exposure 
(days) 
Mean 
          x.x 
 
 x.x 
 
 x.x 
 
 x.x 
 
 
SD 
             x.xx 
 
 x.xx 
 
 x.xx 
 
 x.xx 
 
 
Median 
             x.x 
 
 x.x 
 
 x.x 
 
 x.x 
 
 
Min 
             x 
 
 x 
 
 x 
 
 x 
 
 
Max 
             x 
 
 x 
 
 x 
 
 x 
 
 
 
 
 
 
 
 
 
 
 
  Week 1 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
  Week 2 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
  Week 3 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
  Week 4 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
  Week 5 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
  Week 6 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
 
 
 
 
 
 
 
Note: N = the number of subjects in the safety analysis set by treatment group. 
Note: Percentages are calculated as (n/N)*100. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
81


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 30 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.8 Study Medication Compliance 
Safety Analysis Set 
 
 
Visit/Abnormality 
Statistic 
HP-3070 18.0 mg  
(N=XXX) 
HP-3070 9.0 mg 
(N=XXX) 
Placebo 
(N=XXX) 
Overall 
(N=XXX) 
 
 
 
 
 
 
Overall Double-Blind Period 
N 
xxx 
xxx 
xxx 
xxx 
  Compliant 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
  Noncompliant 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
    <80% 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
    >=120% 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
 
 
 
 
 
 
Period from Day 0 to Week 1 Visit 
N 
xxx 
xxx 
xxx 
xxx 
  Compliant 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
  Noncompliant 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
    <80% 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
    >=120% 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
 
 
 
 
 
 
Period from Week 1 to Week 2 Visit 
N 
 
 
 
 
  Compliant 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
  Noncompliant 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
    <80% 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
    >=120% 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
 
 
 
 
 
 
Period from Week 2 to Week 3 Visit 
N 
xxx 
xxx 
xxx 
xxx 
  Compliant 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
  Noncompliant 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
    <80% 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
    >=120% 
n (%) 
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
xx (xx.x)      
 
 
 
 
 
 
Note: Compliant is defined as using >=80% and <=120% of study medication during the evaluation period. Noncompliant is defined as 
using <80% or >120% of study medication during the evaluation period. 
Note: Compliance with study medication is calculated as the number of patches applied divided by the prescribed number of patches 
over a given period. 
Note: Percentages are calculated as (n/N)*100 where N is the number of subjects for the period being summarized. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
82


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 31 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.8 Study Medication Compliance 
Safety Analysis Set 
 
Visit/Abnormality 
Statistic 
HP-3070 18.0 mg  
(N=XXX) 
HP-3070 9.0 mg 
(N=XXX) 
Placebo 
(N=XXX) 
Overall 
(N=XXX) 
 
 
 
 
 
 
Period from Week 3 to Week 4 Visit 
N 
xxx 
xxx 
xxx 
xxx 
  Compliant 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
  Noncompliant 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
    <80% 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
    >=120% 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
 
 
 
 
 
 
Period from Week 4 to Week 5 Visit 
N 
xxx 
xxx 
xxx 
xxx 
  Compliant 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
  Noncompliant 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
    <80% 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
    >=120% 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
 
 
 
 
 
 
Period from Week 5 to Week 6 Visit 
N 
xxx 
xxx 
xxx 
xxx 
  Compliant 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
  Noncompliant 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
    <80% 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
    >=120% 
n (%) 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)      
xx (xx.x)   
 
 
 
 
 
 
Note: Compliant is defined as using >=80% and <=120% of study medication during the evaluation period. Noncompliant is defined as 
using <80% or >120% of study medication during the evaluation period. 
Note: Compliance with study medication is calculated as the number of patches applied divided by the prescribed number of patches 
over a given period. 
Note: Percentages are calculated as (n/N)*100 where N is the number of subjects for the period being summarized. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
83


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 32 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.9 Prior Medications 
ITT Analysis Set 
 
 
  Preferred Term 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
Overall 
(N=xxx) 
n (%) 
 
 
 
 
 
Number of Subjects with at Least One Prior Medication 
xx (xx.x)      
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
<<Preferred Term>> 
xx (xx.x)      
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)      
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)      
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)      
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)      
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)      
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)      
xx (xx.x)     
xx (xx.x)     
xx (xx.x)   
 ... 
 
 
 
 
 
 
 
 
 
Note: N = number of subjects in the ITT analysis set by treatment group. Overall includes all subjects in the safety analysis set. 
Note: Prior medications are medications which started and stopped prior to the first dose of double-blind study medication. 
Medications taken from 6 months prior to screening are included. 
Note: Percentages are calculated as (n/N)*100. 
Note: At each level of summarization, subjects reporting more than one medication are counted once. 
Note: Medications are coded using World Health Organization Drug Dictionary (WHO-DD) Version xx.x. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
84


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 33 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                   
Protocol HP-3070-GL-04                                                                                                     Page 1 of x  
Table 14.1.10 Concomitant Medications 
Safety Analysis Set 
 
 
  Preferred Term 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
Overall 
(N=xxx) 
n (%) 
 
 
 
 
 
Number of Subjects with at Least One Concomitant Medication 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)     
xx (xx.x)   
 
 
 
 
 
<<Preferred Term>> 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)     
xx (xx.x)   
<<Preferred Term>> 
xx (xx.x)     
xx (xx.x)      
xx (xx.x)     
xx (xx.x)   
 ... 
 
 
 
 
 
 
 
 
 
Note: N = number of subjects in the safety analysis set by treatment group. Overall includes all subjects in the safety analysis 
set. 
Note: Concomitant medications are medications which started prior to, on, or after the first dose of double-blind study medication 
and no later than 1 day following the date of last study medication patch application, and ended on or after the date of 
first dose of study medication or were ongoing at the end of the study. 
Note: Percentages are calculated as (n/N)*100. 
Note: Prefered Terms are presented in order of decreasing frequency. 
Note: Medications are coded using World Health Organization Drug Dictionary (WHO-DD) Version xx.x. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
85


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 34 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
1.2 
Efficacy 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
86


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 35 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
 
Table 14.2.1.1.1 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Baseline 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
Week 6 
 
 
 
 
 
 
 Observed 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Note: Adjusted p-values are calculated according to the truncated Hochberg procedure with a truncation factor γ=0.9. Adjustment for 
multiple comparisons uses a parallel gatekeeping procedure. Adjusted p-values are presented for the secondary endpoint CGI-S 
Score change from baseline only if at least one of the primary hypotheses for the primary endpoint PANSS total score change from 
baseline are rejected.  
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
87


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 36 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.2.1.1.1 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Week 6 
 
 
 
 
 
 
 Change from Baseline to Week 6 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
   x.x 
   x.x 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
   x.xxx 
   x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
   x.xxx 
   x.xxx 
   Adjusted p-value 
 
 
 
 
   x.xxx 
   x.xxx 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Note: Adjusted p-values are calculated according to the truncated Hochberg procedure with a truncation factor γ=0.9. Adjustment for 
multiple comparisons uses a parallel gatekeeping procedure. Adjusted p-values are presented for the secondary endpoint CGI-S 
Score change from baseline only if at least one of the primary hypotheses for the primary endpoint PANSS total score change from 
baseline are rejected.  
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: If unstructured covariance model does not converge, modify footnote to specify the actual covariance structure used 
in the final model. If AIC from heterogeneous variances is smaller, update accordingly. Same notes apply to similar outputs below. 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04  
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
88


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 37 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
                                                                                                     
Table 14.2.1.1.2 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 
ITT Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Place\(N=xxx) 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Baseline 
 
 
 
 
 
 
   n 
xx 
xx 
xx 
 
 
 
   Mean 
x.x 
x.x 
x.x 
 
 
 
   SD 
x.xx 
x.xx 
x.xx 
 
 
 
   Median 
x.x 
x.x 
x.x 
 
 
 
   Min 
x 
x 
x 
 
 
 
   Max 
x 
x 
x 
 
 
 
 
 
 
 
 
 
 
Week 6 
 
 
 
 
 
 
 Observed 
 
 
 
 
 
 
   n 
xx 
xx 
xx 
 
 
 
   Mean 
x.x 
x.x 
x.x 
 
 
 
   SD 
x.xx 
x.xx 
x.xx 
 
 
 
   Median 
x.x 
x.x 
x.x 
 
 
 
   Min 
x 
x 
x 
 
 
 
   Max 
x 
x 
x 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-Treat, PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = 
Confidence Interval, N = number of subjects in the ITT analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh: 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
89


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 38 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04  
                                                                                                     
Table 14.2.1.1.2 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 
ITT Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
 Change from Baseline to Week 6 
 
 
 
 
 
 
   n 
xx 
xx 
xx 
 
 
 
   Mean 
x.x 
x.x 
x.x 
 
 
 
   SD 
x.xx 
x.xx 
x.xx 
 
 
 
   Median 
x.x 
x.x 
x.x 
 
 
 
   Min 
x 
x 
x 
 
 
 
   Max 
x 
x 
x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
x.x 
x.x 
x.x 
 
x.x 
x.x 
   SE 
x.xxx 
x.xxx 
x.xxx 
 
x.xxx 
x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
x.xxx 
x.xxx 
 
 
 
 
 
 
 
Note: ITT = Intent-to-Treat, PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = 
Confidence Interval, N = number of subjects in the ITT analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
90


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 39 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.1.2.1.1 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 – Pattern-Mixture Model 
Full Analysis Set 
This table will be similar to 14.2.1.1.2. 
Footnotes will be: 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: A pattern-mixture model approach using a placebo-based multiple imputation has been used for this analysis. 
Note: Imputed datasets are analyzed with the mixed linear repeated measures model including treatment, country, visit, treatment by 
visit interaction, and baseline value as covariates, and subject as random effect. The correlation of repeated measures within a 
subject is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of 
freedom. 
 
Table 14.2.1.2.1.2 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 – Pattern-Mixture Model 
for Dropout Pattern 2 
Full Analysis Set 
This table will be similar to 14.2.1.1.2. 
Footnotes will be: 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: A pattern-mixture model approach using a placebo-based multiple imputation for discontinuation due to lack of efficacy, adverse 
event, or death has been used for this analysis. 
Note: Imputed datasets are analyzed with the mixed linear repeated measures model including treatment, country, visit, treatment by 
visit interaction, and baseline value as covariates, and subject as random effect. The correlation of repeated measures within a 
subject is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of 
freedom. 
 
 
 
Table 14.2.1.2.1.3 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 – Pattern-Mixture Model 
for Dropout Pattern 3 
Full Analysis Set 
This table will be similar to 14.2.1.1.2. 
Footnotes will be: 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
91


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 40 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: A pattern-mixture model approach using a placebo-based multiple imputation for discontinuation due to lack of efficacy has been 
used for this analysis. 
Note: Imputed datasets are analyzed with the mixed linear repeated measures model including treatment, country, visit, treatment by 
visit interaction, and baseline value as covariates, and subject as random effect. The correlation of repeated measures within a 
subject is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of 
freedom. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
92


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 41 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04    
                                                                                                   
Table 14.2.1.2.3 Time-to-Failure Based on Change from Baseline in PANSS Total Score and Dropout Pattern 1 
Full Analysis Set 
 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
 
 
 
Failures, n (%) 
xx (x.xx) 
xx (x.xx) 
xx (x.xx) 
 
 
 
 
Time to Failure (Days) 
 
 
 
   25th Percentile  
x.xx 
x.xx 
x.xx 
   Median  
x.xx 
x.xx 
x.xx 
   75th Percentile 
x.xx 
x.xx 
x.xx 
 
 
 
 
Log Rank p-value 
x.xxx 
x.xxx 
x.xxx 
 
 
 
 
Probability of Failure at 
 
 
 
    Week 1 
x.xx 
x.xx 
x.xx 
    Week 2 
x.xx 
x.xx 
x.xx 
    Week 3 
x.xx 
x.xx 
x.xx 
    Week 4 
x.xx 
x.xx 
x.xx 
    Week 5 
x.xx 
x.xx 
x.xx 
    Week 6 
x.xx 
x.xx 
x.xx 
  
 
Note: PANSS = Positive and Negative Syndrome Scale, N = number of subjects in the full analysis set by treatment group. 
Note: a subject is considered to have failed if there is never an improvement in PANSS score >=20% during the study or if there is an 
improvement >=20% during the study but a subsequent change from baseline <20%, or if the subjectdiscontinues for any reason.  
Note: Time to Failure is calculated based on Kaplan-Meier methodology. 
Note: Percentages are calculated as (n/N)*100.     
                                                                                                                                       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
93


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 42 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
Table 14.2.1.2.4 Time-to-Failure Analysis Based on Change from Baseline in PANSS Total Score and Dropout Pattern 2 
Full Analysis Set 
This table will be similar to 14.2.1.2.3. 
Second Footnote will be: 
Note: a subject is considered to have failed if there is never an improvement in PANSS score >=20% during the study or if there is an 
improvement >=20% during the study but a subsequent change from baseline <20%, or if the subject discontinues due to lack of efficacy, 
adverse event, or death. Discontinuations for other reasons are censored at discontinuation date. 
Table 14.2.1.2.5 Time-to-Failure Analysis Based on Change from Baseline in PANSS Total Score and Dropout Pattern 3 
Full Analysis Set 
This table will be similar to 14.2.1.2.3. 
Second Footnote will be: 
Note: a subject is considered to have failed if there is never an improvement in PANSS score >=30% during the study or if there is an 
improvement >=30% during the study but a subsequent change from baseline <30%, or if the subject discontinues due to lack of efficacy. 
Discontinuations for other reasons are censored at discontinuation date. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
94


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 43 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04   
                                                                                                    
Table 14.2.1.2.6 ANCOVA on Rank-Transformed PANSS Total Score Data at Week 6 
Full Analysis Set 
 
 
Treatment Group 
 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Rank-Transformed Change from 
Baseline to Week 6 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
 
 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
 
 
   p-value 
 
 
 
 
x.xxx 
x.xxx 
 
 
 
 
 
 
 
Note: ANCOVA = Analysis of Covariance, PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI 
= Confidence Interval, N = number of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: The values of the change from baseline variable as well as baseline covariate are transformed to standardized ranks within each 
country, using fractional ranks and mean method for ties. Before performing the rank transformation, subjects with missing data 
at Week 6 due to discontinuation for any reason are imputed with a change from baseline equal to the largest change from baseline 
in observed data plus 1, so that these subjects have the highest rank after the transformation. 
Note: Separate regression models are fit for each country using a regression model for change from baseline with baseline as predictor.  
Note: P-value is based on the Cochran-Mantel-Haenszel test, controlling for country. The hypothesis tested is the Row Mean Score Differ 
statistic, using the values of the residuals as scores. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
95


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 44 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
Table 14.2.2.1 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 
Full Analysis Set 
This table will be similar to 14.2.1.1.1. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Note: Adjusted p-values are calculated according to the Hochberg procedure. Adjustment for multiple comparisons uses a parallel 
gatekeeping procedure. Adjusted p-values are presented for the secondary endpoint CGI-S Score change from baseline only if at least 
one of the primary hypotheses for the primary endpoint PANSS total score change from baseline are rejected. 
 
Table 14.2.2.2 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 – Pattern-Mixture Model 
Full Analysis Set 
This table will be similar to 14.2.1.1.2. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: A pattern-mixture model approach using a placebo-based multiple imputation has been used for this analysis. 
Note: Imputed datasets are analyzed with the mixed linear repeated measures model including treatment, country, visit, treatment by 
visit interaction, and baseline value as covariates, and subject as random effect. The correlation of repeated measures within a 
subject is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of 
freedom. 
 
Table 14.2.2.3 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 – Pattern-Mixture Model for 
Dropout Pattern 2 
Full Analysis Set 
This table will be similar to 14.2.1.1.2. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
96


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 45 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: A pattern-mixture model approach using a placebo-based multiple imputation for discontinuation due to lack of efficacy, adverse 
event, or death has been used for this analysis. 
Note: Imputed datasets are analyzed with the mixed linear repeated measures model including treatment, country, visit, treatment by 
visit interaction, and baseline value as covariates, and subject as random effect. The correlation of repeated measures within a 
subject is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of 
freedom. 
 
 
 
Table 14.2.2.4 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 – Pattern-Mixture Model for 
Dropout Pattern 3 
Full Analysis Set 
This table will be similar to 14.2.1.1.2. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: A pattern-mixture model approach using a placebo-based multiple imputation for discontinuation due to lack of efficacy has been 
used for this analysis. 
Note: Imputed datasets are analyzed with the mixed linear repeated measures model including treatment, country, visit, treatment by 
visit interaction, and baseline value as covariates, and subject as random effect. The correlation of repeated measures within a 
subject is estimated with an unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of 
freedom. 
 
Table 14.2.2.5 Time-to-Failure Analysis Based on Change from Baseline in CGI-S Score and Dropout Pattern 1 
Full Analysis Set 
This table will be similar to 14.2.1.2.3. 
Footnotes will be:  
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, N = number of subjects in the full analysis set by treatment 
group. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: a subject is considered to have failed if there is never an improvement in CGI-S score >=20% during the study or if there is an 
improvement >=20% during the study but a subsequent change from baseline <20%, or if the subject discontinues for any reason.  
Note: Time to Failure is calculated based on Kaplan-Meier methodology. 
Note: Percentages are calculated as (n/N)*100.     
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
97


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 46 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
 
Table 14.2.2.6 Time-to-Failure Analysis Based on Change from Baseline in CGI-S Score and Dropout Pattern 2 
Full Analysis Set 
This table will be similar to 14.2.1.2.3. 
Footnotes will be:  
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, N = number of subjects in the full analysis set by treatment 
group. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: a subject is considered to have failed if there is never an improvement in CGI-S score >=20% during the study or if there is an 
improvement >=20% during the study but a subsequent change from baseline <20%, or if the subject discontinues due to lack of efficacy, 
adverse event, or death. Discontinuations for other reasons are censored at discontinuation date. 
Note: Time to Failure is calculated based on Kaplan-Meier methodology. 
Note: Percentages are calculated as (n/N)*100.  
    
Table 14.2.2.7 Time-to-Failure Analysis Based on Change from Baseline in CGI-S Score and Dropout Pattern 3 
Full Analysis Set 
This table will be similar to 14.2.1.2.3. 
Footnotes will be:  
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, N = number of subjects in the full analysis set by treatment 
group. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: a subject is considered to have failed if there is never an improvement in CGI-S score >=30% during the study or if there is an 
improvement >=30% during the study but a subsequent change from baseline <30%, or if the subject discontinues due to lack of efficacy. 
Discontinuations for other reasons are censored at discontinuation date. 
Note: Time to Failure is calculated based on Kaplan-Meier methodology. 
Note: Percentages are calculated as (n/N)*100.  
 
Table 14.2.2.8 ANCOVA on Rank-Transformed CGI-S Score Data at Week 6 
Full Analysis Set 
This table will be similar to 14.2.1.2.6. 
Footnotes will be: 
Note: ANCOVA = Analysis of Covariance, CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = 
Standard Error, CI = Confidence Interval, N = number of subjects in the full analysis set by treatment group. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
98


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 47 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: The values of the change from baseline variable as well as baseline covariate are transformed to standardized ranks within each 
country, using fractional ranks and mean method for ties. Before performing the rank transformation, subjects with missing data at 
Week 6 due to discontinuation for any reason are imputed with a change from baseline equal to the largest change from baseline in 
observed data plus 1, so that these subjects have the highest rank after the transformation. 
Note: Separate regression models are fit for each country using a regression model for change from baseline with baseline as 
predictor.  
Note: P-value is based on the Cochran-Mantel-Haenszel test, controlling for country. The hypothesis tested is the Row Mean Score 
Differ statistic, using the values of the residuals as scores. 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
99


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 48 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04  
                                                                                                     
Table 14.2.3.1.1 Treatment Comparison of Change from Baseline in PANSS Total Score at Weeks 1 - 6 
Full Analysis Set 
 
 
Treatment Group 
 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Baseline 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
Week 1 
 
 
 
 
 
 
 Observed 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
100


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 49 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04  
                                                                                                     
Table 14.2.3.1.1 Treatment Comparison of Change from Baseline in PANSS Total Score at Weeks 1 - 6 
Full Analysis Set 
 
 
Treatment Group 
 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Change from Baseline 
to Week 1 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
   x.x 
   x.x 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
   x.xxx 
   x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
    x.xxx 
   x.xxx 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
Programming note: Repeat for weeks 2-6 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
101


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 50 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Figure 14.2.3.1.1 Mean Changes from Baseline in PANSS Total Score Across Visits  
Full Analysis Set 
 
 
Note: PANSS = Positive and Negative Syndrome Scale. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.  
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing.   
Note: ‘*’ represents a statistically significant p-value<0.05 for the comparison of HP-3070 9.0mg to placebo at that week. ‘**’ 
represents a statistically significant p-value<0.05 for the comparison of HP-3070 18.0mg to placebo at that week. 
Note: Reference table 14.2.3.1.1 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Figures\xxxxx.sas ddmmmyyyy hh:mm 
 
* 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
102


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 51 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.3.1.2 Treatment Comparison of Change from Baseline in PANSS Positive Subscale at Weeks 1 - 6 
Full Analysis Set 
This table will be similar to 14.2.3.1.1. 
Second Footnote will be: 
Note: The PANSS positive subscale is the sum of 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, 
grandiosity, suspiciousness/persecution, and hostility 
 
Figure 14.2.3.1.2 Mean Changes from Baseline in PANSS Positive Subscale Across Visits  
Full Analysis Set 
This figure will be similar to 14.2.3.1.1 
Third Footnote will be:  
Note: The PANSS positive subscale is the sum of 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, 
grandiosity, suspiciousness/persecution, and hostility 
 
Table 14.2.3.1.3 Treatment Comparison of Change from Baseline in PANSS Negative Subscale at Weeks 1 - 6 
Full Analysis Set 
This table will be similar to 14.2.3.1.1. 
Second Footnote will be: 
Note: The PANSS negative subscale is the sum of 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social 
withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. 
 
Figure 14.2.3.1.3 Mean Changes from Baseline in PANSS Negative Subscale Across Visits  
Full Analysis Set 
This figure will be similar to 14.2.3.1.1 
Third Footnote will be:  
Note: The PANSS negative subscale is the sum of 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social 
withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. 
 
Table 14.2.3.1.4 Treatment Comparison of Change from Baseline in PANSS General Psychopathology Subscale at Weeks 1 - 6 
Full Analysis Set 
This table will be similar to 14.2.3.1.1. 
Second Footnote will be: 
Note: The PANSS general psychopathy subscale is the sum of 16 items: somatic concern, anxiety, guilt feelings, tension, mannerisms and 
posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment 
and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
103


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 52 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Figure 14.2.3.1.4 Mean Changes from Baseline in PANSS General Psychopathology Subscale Across Visits  
Full Analysis Set 
This figure will be similar to 14.2.3.1.1 
Third Footnote will be:  
Note: The PANSS general psychopathy subscale is the sum of 16 items: somatic concern, anxiety, guilt feelings, tension, mannerisms and 
posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment 
and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
104


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 53 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04       
                                                                                                
Table 14.2.3.1.5 Treatment Comparison of Change from Baseline in PANSS Total Score at Weeks 1 – 6 by Completion Status 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Subjects who Completed 
the Study 
 
 
 
 
 
 
Baseline 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
Week 1 
 
 
 
 
 
 
 Observed 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
105


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 54 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04       
                                                                                                
Table 14.2.3.1.5 Treatment Comparison of Change from Baseline in PANSS Total Score at Weeks 1 – 6 by Completion Status 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
 Change from Baseline 
to Week 1 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
   x.x 
   x.x 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
   x.xxx 
   x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
    x.xxx 
   x.xxx 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the full analysis set by treatment group and completion status. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for weeks 2-6, then repeat for subjects who discontinued the study. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
106




Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
3DJHRI

Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 

)LJXUH0HDQ&KDQJHV)URP%DVHOLQHLQ3$1667RWDO6FRUH$FURVV9LVLWVE\&RPSOHWLRQ6WDWXV
)XOO$QDO\VLV6HW
0LVVLQJGDWDSDWWHUQVZLOOEHGHVFULEHGJUDSKLFDOO\E\SORWWLQJPHDQFKDQJHVIURPEDVHOLQHLQ3$166WRWDOVFRUHDFURVVYLVLWVE\
WUHDWPHQWJURXSDQGVXEJURXSVRIVXEMHFWVWKDWHLWKHUFRPSOHWHGWKHGRXEOHEOLQGWUHDWPHQWSHULRGRUGLVFRQWLQXHGHDUO\6XEMHFWVZKR
GLVFRQWLQXHGHDUO\ZLOOEHJURXSHGE\ZHHNDWZKLFKWKH\GLVFRQWLQXHGWKURXJK

1RWH3$166 3RVLWLYHDQG1HJDWLYH6\QGURPH6FDOH1 QXPEHURIVXEMHFWVLQWKHIXOODQDO\VLVVHWE\WUHDWPHQWJURXSDQGFRPSOHWLRQ
VWDWXV
1RWH%DVHOLQHLVGHILQHGDVWKHODVWQRQPLVVLQJPHDVXUHPHQWWDNHQSULRUWRILUVWGRVHRIGRXEOHEOLQGVWXG\PHGLFDWLRQ
1RWH7KH3$166WRWDOVFRUHLVWKHVXPRIDOOLWHPV+LJKHUYDOXHVUHSUHVHQWJUHDWHUVHYHULW\RILOOQHVV,IRQHRUPRUHLWHPVDUH
PLVVLQJDWDJLYHQDVVHVVPHQWWKHWRWDOVFRUHLVVHWWRPLVVLQJ
1RWH1¶VIRUHDFKZHHNUHSUHVHQWWKHQXPEHURIVXEMHFWVLQWKHIXOODQDO\VLVVHWE\WUHDWPHQWJURXSDQGFRPSOHWLRQVWDWXV
1RWHµ¶UHSUHVHQWVDVWDWLVWLFDOO\VLJQLILFDQWSYDOXHIRUWKHFRPSDULVRQRI+3PJWRSODFHERDWWKDWZHHNIRUVXEMHFWV
ZKRFRPSOHWHGWKHVWXG\µ¶UHSUHVHQWVVWDWLVWLFDOVLJQLILFDQFHIRUWKHFRPSDULVRQRI+3PJWRSODFHERIRUVXEMHFWV
ZKRFRPSOHWHGWKHVWXG\µ¶UHSUHVHQWVVWDWLVWLFDOVLJQLILFDQFHIRUWKHFRPSDULVRQRI+3PJWRSODFHERIRUVXEMHFWVZKR
GLVFRQWLQXHGWKHVWXG\µ¶UHSUHVHQWVVWDWLVWLFDOVLJQLILFDQFHIRUWKHFRPSDULVRQRI+3PJWRSODFHERIRUVXEMHFWV
ZKRGLVFRQWLQXHGWKHVWXG\
1RWH5HIHUHQFHWDEOH

1RYHQ?+3?;:$?%LRVWDWLVWLFV?3URGXFWLRQ?)LJXUHV?[[[[[VDVGGPPP\\\\KKPP


1RYHQ3KDUPDFHXWLFDOV
9HUVLRQ1R
3URWRFRO1R+3*/
6HSWHPEHU



 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 56 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
 
Table 14.2.3.1.6 Treatment Comparison of Change from Baseline in PANSS Positive Subscale at Weeks 1 – 6 by Completion 
Status 
Full Analysis Set 
This table will be similar to 14.2.3.1.5. 
Second Footnote will be: 
Note: The PANSS positive subscale is the sum of 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, 
grandiosity, suspiciousness/persecution, and hostility. 
 
Figure 14.2.3.1.6 Mean Changes From Baseline in PANSS Positive Subscale Across Visits by Completion Status 
Full Analysis Set 
This figure will be similar to 14.2.1.2.2 
Third Footnote will be:  
Note: The PANSS positive subscale is the sum of 7 items: delusions, conceptual disorganization, hallucinatory behavior, excitement, 
grandiosity, suspiciousness/persecution, and hostility. 
 
Table 14.2.3.1.7 Treatment Comparison of Change from Baseline in PANSS Negative Subscale at Weeks 1 – 6 by Completion 
Status 
Full Analysis Set 
This table will be similar to 14.2.3.1.5. 
Second Footnote will be: 
Note: The PANSS negative subscale is the sum of 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social 
withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. 
Figure 14.2.3.1.7 Mean Changes From Baseline in PANSS Negative Subscale Across Visits by Completion Status 
Full Analysis Set 
This figure will be similar to 14.2.1.2.2 
Third Footnote will be:  
Note: The PANSS negative subscale is the sum of 7 items: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social 
withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking. 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
108


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 57 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.3.1.8 Treatment Comparison of Change from Baseline in PANSS General Psychopathology Subscale at Weeks 1 – 6 
by Completion Status 
Full Analysis Set 
This table will be similar to 14.2.3.1.5. 
Second Footnote will be: 
Note: The PANSS general psychopathy subscale is the sum of 16 items: somatic concern, anxiety, guilt feelings, tension, mannerisms and 
posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment 
and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance. 
 
Figure 14.2.3.1.8 Mean Changes From Baseline in PANSS General Psychopathology Subscale Across Visits by Completion 
Status 
Full Analysis Set 
This figure will be similar to 14.2.1.2.2 
Third Footnote will be:  
Note: The PANSS general psychopathy subscale is the sum of 16 items: somatic concern, anxiety, guilt feelings, tension, mannerisms and 
posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment 
and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
109


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 58 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.3.2 Treatment Comparison of Change from Baseline in CGI-S Score at Weeks 1 - 6 
Full Analysis Set 
This table will be similar to 14.2.3.1. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
110


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 59 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.2.3.3 Treatment Comparison of CGI-I Responders 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Week 1 
 
 
 
 
 
 
   Responders, n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
   Estimate 
 x.xx 
 x.xx 
 x.xx 
 
 x.xx 
 x.xx 
   SE 
  x.xxx 
  x.xxx 
  x.xxx 
 
  x.xxx 
  x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
x.xxx 
x.xxx 
 
 
 
 
 
 
 
Week 2 
 
 
 
 
 
 
   Responders, n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
   Estimate 
 x.xx 
 x.xx 
 x.xx 
 
 x.xx 
 x.xx 
   SE 
 x.xxx 
 x.xxx 
  x.xxx 
 
  x.xxx 
  x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
  x.xxx 
  x.xxx 
 
 
 
 
 
 
 
Note: CGI-I = Clinical Global Impression – Improvement Scale, SE = Standard Error, CI = Confidence Interval, N = number of subjects in 
the full analysis set by treatment group. 
Note: CGI-I responders are defined as subjects who have a score of 1 (very much improved) or a score of 2 (much improved.) 
Note: Percentages are calculated as (n/N)*100. 
Note: Estimates of the proportion of responders in each treatment group and differences of proportions between the treatment groups are 
based on the standard method based on the binomial distribution. 95% CIs for proportion estimates are based on the Wilson method. 
95% CIs for the differences of proportions are based on the Newcombe method. 
Note: P-value is based on the Cochran-Mantel-Haenszel test, stratified by country. The hypothesis tested is the general association 
statistic. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming Note: Repeat for weeks 3 through 6 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
111


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 60 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.2.3.4 Treatment Comparison of CGI-I Score 
Full Analysis Set 
 
Treatment Group 
 
Treatment Group Comparison  
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Week 1 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
   x.x 
   x.x 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
   x.xxx 
   x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
   x.xxx 
   x.xxx 
 
 
 
 
 
 
 
Week 2 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
   x.x 
   x.x 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
   x.xxx 
   x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
   x.xxx 
   x.xxx 
Note: CGI-I = Clinical Global Impression – Improvement Scale, CGI-S = Clinical Global Impression – Severity Scale, LSM = Least Squares 
Mean, SE = Standard Error, CI = Confidence Interval, N = number of subjects in the full analysis set by treatment group. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
of CGI-S as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Note: To perform this assessment, the rater or Investigator rates the subject's total improvement whether or not it is due entirely to 
drug treatment.  Lower values represent greater improvement. 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming Note: Repeat for weeks 3 through 6 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
112


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 61 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 Programming Note: Repeat for weeks 3 through 6 
 
Table 14.2.3.5 Treatment Comparison of PANSS Responders Based on >= 30% Improvement from Baseline 
Full Analysis Set 
This table will be similar to 14.2.3.3. 
Footnotes will be: 
Note: PANSS = Positive and Negative Syndrome Scale, SE = Standard Error, CI = Confidence Interval, N = number of subjects in the full 
analysis set by treatment group. 
Note: PANSS responders are defined as subjects who have >= 30% improvement from baseline. 
Note: Estimates of the proportion of responders in each treatment group and differences of proportions between the treatment groups 
are based on the standard method based on the binomial distribution. 95% CIs for proportion estimates are based on the Wilson method. 
95% CIs for the differences of proportions are based on the Newcombe method. 
Note: P-value is based on the Cochran-Mantel-Haenszel test, stratified by country. The hypothesis tested is the general association 
statistic. 
 
Table 14.2.3.6 Treatment Comparison of PANSS Responders Based on >= 30% Improvement from Baseline 
ITT Analysis Set 
This table will be similar to 14.2.3.3. 
Footnotes will be: 
Note: ITT = Intent-to-Treat, PANSS = Positive and Negative Syndrome Scale, SE = Standard Error, CI = Confidence Interval, N = number 
of subjects in the ITT analysis set by treatment group. 
Note: PANSS responders are defined as subjects who have >= 30% improvement from baseline. 
Note: Estimates of the proportion of responders in each treatment group and differences of proportions between the treatment groups 
are based on the standard method based on the binomial distribution. 95% CIs for proportion estimates are based on the Wilson method. 
95% CIs for the differences of proportions are based on the Newcombe method. 
Note: P-value is based on the Cochran-Mantel-Haenszel test, stratified by country. The hypothesis tested is the general association 
statistic. 
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
113


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 62 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04             
                                                                                          
Table 14.2.3.7 Treatment Comparison of PANSS Responders Based on >= X% Improvement at Week 6 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
>= 5% Improvement 
 
 
 
 
 
 
    Responders, n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
    Estimate 
x.x 
x.x 
x.x 
 
x.x 
x.x 
    SE 
  x.xxx 
  x.xxx 
  x.xxx 
 
  x.xxx 
  x.xxx 
    95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
 
 
 
 
 
 
 
>= 10% Improvement 
 
 
 
 
 
 
    Responders, n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
    Estimate 
x.x 
x.x 
x.x 
 
x.x 
x.x 
    SE 
  x.xxx 
  x.xxx 
  x.xxx 
 
  x.xxx 
  x.xxx 
    95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, SE = Standard Error, CI = Confidence Interval, N = number of subjects in the full 
analysis set by treatment group. 
Note: PANSS responders are defined as subjects who have >= X% improvement from baseline. 
Note: Percentages are calculated as (n/N)*100. N includes subjects who have a baseline and at least one post-baseline measurement. 
Note: Estimates of the proportion of responders in each treatment group and differences of proportions between the treatment groups are 
based on the standard method based on the binomial distribution. 95% CIs for proportion estimates are based on the Wilson method. 
95% CIs for the differences of proportions are based on the Newcombe method. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming Note: Repeat by 5% Increments up to 100% 
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
114


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 63 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04         
                                                                                              
Figure 14.2.3.7 Continuous Responder Analysis Based on Change from Baseline in PANSS Total Score at Week 6 
Full Analysis Set 
 
A continuous responder analysis will be performed based on definition of responder at multiple levels of percent improvement from 
Baseline, from >=5% to 100% with 5% increments. Results will be reported by means of a graph with response threshold on the X-axis and 
proportion of responders in each treatment group on the Y-axis.  
 
Note: PANSS = Positive and Negative Syndrome Scale. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: PANSS responders are defined as subjects who have >=X% improvement from baseline  
Note: Reference Table 14.2.3.7 
   
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Figures\xxxxx.sas ddmmmyyyy hh:mm 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
115


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 64 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.3.8 Treatment Comparison of PANSS Responders Based on >= X% Improvement at Week 6 
ITT Analysis Set 
This table will be similar to 14.2.3.10. 
Footnotes will be: 
Note: ITT = Intent-to-Treat, PANSS = Positive and Negative Syndrome Scale, SE = Standard Error, CI = Confidence Interval, N = number 
of subjects in the ITT analysis set by treatment group. 
Note: PANSS responders are defined as subjects who have >= X% improvement from baseline. 
Note: Percentages are calculated as (n/N)*100. 
Note: Estimates of the proportion of responders in each treatment group and differences of proportions between the treatment groups 
are based on the standard method based on the binomial distribution. 95% CIs for proportion estimates are based on the Wilson method. 
95% CIs for the differences of proportions are based on the Newcombe method. 
 
Figure 14.2.3.8 Continuous Responder Analysis Based on Change from Baseline in PANSS Total Score at Week 6 
ITT Analysis Set 
This figure will be similar to figure 14.2.1.2.1.1. 
First footnote will be: 
Note: PANSS = Positive and Negative Syndrome Scale, SE = Standard Error, CI = Confidence Interval, ITT = Intent-to-Treat, N = number 
of subjects in the ITT analysis set by treatment group. 
Table 14.2.3.9 Treatment Comparison of Change from Baseline in CDSS Total Score 
Full Analysis Set 
This table will be similar to 14.2.3.5. 
Footnotes will be: 
Note: CDSS = Calgary Depression Scale for Schizophrenia, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = 
number of subjects in the ITT analysis set by treatment group. 
Note: The CDSS is a nine-item scale designed for assessment of the level of depression in patients with schizophrenia.The CDSS total 
score is the sum of all 9 items. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
116


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 65 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                 
Table 14.2.3.10 Treatment Comparison of MSQ Score 
Full Analysis Set 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Week 2 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
   x.x 
   x.x 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
   x.xxx 
   x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
   x.xxx 
   x.xxx 
 
 
 
 
 
 
 
Week 4 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
   x.x 
   x.x 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
   x.xxx 
   x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x,xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
   x.xxx 
   x.xxx 
 
 
 
 
 
 
 
Note: MSQ = Medication Satisfaction Questionnaire, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = number 
of subjects in the full analysis set by treatment group. 
Note: The MSQ is a single-item questionnaire used to assess the level of patient’s satisfaction or dissatisfaction with the medication 
they are taking. Responses can range from Extremely Dissatisfied (1) to Extremely Satisfied (7). 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline as 
covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
117


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 66 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.2.3.10 Treatment Comparison of MSQ Score 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Week 6 
 
 
 
 
 
 
   n 
  xx 
  xx 
  xx 
 
 
 
   Mean 
   x.x 
   x.x 
   x.x 
 
 
 
   SD 
   x.xx 
   x.xx 
   x.xx 
 
 
 
   Median 
   x.x 
   x.x 
   x.x 
 
 
 
   Min 
   x 
   x 
   x 
 
 
 
   Max 
   x 
   x 
   x 
 
 
 
 
 
 
 
 
 
 
   LSM estimate 
   x.x 
   x.x 
   x.x 
 
   x.x 
   x.x 
   SE 
   x.xxx 
   x.xxx 
   x.xxx 
 
   x.xxx 
   x.xxx 
   95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
   p-value 
 
 
 
 
   x.xxx 
   x.xxx 
 
 
 
 
 
 
 
Note: MSQ = Medication Satisfaction Questionnaire, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = number 
of subjects in the full analysis set by treatment group. 
Note: The MSQ is a single-item questionnaire used to assess the level of patient’s satisfaction or dissatisfaction with the medication 
they are taking. Responses can range from Extremely Dissatisfied (1) to Extremely Satisfied (7). 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline as 
covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an 
unstructured covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
118


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 67 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04   
                                                                                                    
Table 14.2.4.1 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by Gender 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
Female, n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
  Baseline 
 
 
 
 
 
 
     n 
xx 
xx 
xx 
 
 
 
     Mean 
 x.x 
 x.x 
 x.x 
 
 
 
     SD 
 x.xx 
 x.xx 
 x.xx 
 
 
 
     Median 
 x.x 
 x.x 
 x.x 
 
 
 
     Min 
 x 
 x 
 x 
 
 
 
     Max 
 x 
 x 
 x 
 
 
 
 
 
 
 
 
 
 
  Week 6 
 
 
 
 
 
 
   Observed 
 
 
 
 
 
 
     n 
xx 
xx 
xx 
 
 
 
     Mean 
 x.x 
 x.x 
 x.x 
 
 
 
     SD 
 x.xx 
 x.xx 
 x.xx 
 
 
 
     Median 
 x.x 
 x.x 
 x.x 
 
 
 
     Min 
 x 
 x 
 x 
 
 
 
     Max 
 x 
 x 
 x 
 
 
 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = number 
of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.  
Note: Percentages are calculated as (n/N)*100. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value as 
covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
119


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 68 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04   
                                                                                                    
Table 14.2.4.1 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by Gender 
Full Analysis Set 
 
 
Treatment Group 
 
Treatment Group Comparison 
(Active - Placebo) 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 
 
 
 
 
 
 
   Change from 
Baseline to Week 6 
 
 
 
 
 
 
     n 
xx 
xx 
xx 
 
 
 
     Mean 
 x.x 
 x.x 
 x.x 
 
 
 
     SD 
 x.xx 
 x.xx 
 x.xx 
 
 
 
     Median 
 x.x 
 x.x 
 x.x 
 
 
 
     Min 
 x 
 x 
 x 
 
 
 
     Max 
 x 
 x 
 x 
 
 
 
 
 
 
 
 
 
 
     LSM estimate 
x.x 
x.x 
x.x 
 
x.x 
x.x 
     SE 
  x.xxx 
  x.xxx 
  x.xxx 
 
  x.xxx 
  x.xxx 
     95% CI 
x.xx, x.xx 
x.xx, x.xx 
x.xx, x.xx 
 
x.xx, x.xx 
x.xx, x.xx 
 
 
 
 
 
 
 
Note: PANSS = Positive and Negative Syndrome Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence Interval, N = number 
of subjects in the full analysis set by treatment group. 
Note: The PANSS total score is the sum of all 30 items. Higher values represent greater severity of illness. If one or more items are 
missing at a given assessment, the total score is set to missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.  
Note: Percentages are calculated as (n/N)*100. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value as 
covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming Note: Repeat for Male 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
120


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 69 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.2.4.2 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 by Gender 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: Percentages are calculated as (n/N)*100. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Table 14.2.4.3 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by Age 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘Age < 55’ and ‘Age >= 55’. 
 
Table 14.2.4.4 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 by Age 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘Age < 55’ and ‘Age >= 55’. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: Percentages are calculated as (n/N)*100. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
121


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 70 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
Table 14.2.4.5 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by Race 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘Black/African American’ and ‘All Other Races Combined’. 
Include the Footnote:  
Note: All Other Races Combined includes: American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islanders, White 
and Other. 
 
Table 14.2.4.6 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 by Race 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘Black/African American’ and ‘All Other Races Combined’. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: Percentages are calculated as (n/N)*100. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Note: All Other Races Combined includes: American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islanders, White 
and Other. 
 
Table 14.2.4.7 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by Severity at Baseline 
Full Analysis Set  
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘PANSS Total Score < 90’ and ‘PANSS Total Score >= 90’. 
 
 
Table 14.2.4.8 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 by Severity at Baseline 
Full Analysis Set  
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘PANSS Total Score < 90’ and ‘PANSS Total Score >= 90’. 
Footnotes will be: 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
122


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 71 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: Percentages are calculated as (n/N)*100. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Table 14.2.4.9 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by Region 
Full Analysis Set  
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘North America’ ‘Rest of the World and ‘Russia’. 
 
 
Table 14.2.4.10 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 by Region 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘North America, ‘Rest of the World and ‘Russia’. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: Percentages are calculated as (n/N)*100. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
 
Table 14.2.4.11 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by BMI at Baseline 
Full Analysis Set  
This table will be similar to 14.2.4.1. 
Instead of 2 categories of ‘Female’ and ‘Male’, there will be 3 categories of ‘< 25 kg/m2’, ‘>= 25 to < 30 kg/m2’, and ‘>= 30 kg/m2’. 
 
 
Table 14.2.4.12 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 by BMI at Baseline 
Full Analysis Set  
This table will be similar to 14.2.4.1. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
123


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 72 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Instead of 2 categories of ‘Female’ and ‘Male’, there will be 3 categories of ‘< 25 kg/m2’, ‘>= 25 to < 30 kg/m2’, and ‘>= 30 kg/m2’. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: Percentages are calculated as (n/N)*100. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
Table 14.2.4.13 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by Age of Onset 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘Onset Age < 25’ and ‘Onset Age >= 25’. 
 
Table 14.2.4.14 Treatment Comparison of Change from Baseline in CGI-S Total Score at Week 6 by Age of Onset 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
‘Female’ and ‘Male’ are replaced with ‘Onset Age < 25’ and ‘Onset Age >= 25’. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression - Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: Percentages are calculated as (n/N)*100. 
Note: CGI-S score is determined by answering the question "Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?" on a scale of 0-7, with 0 indicating not assessed and 7 indicating the most extremely 
ill subjects. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect.  The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix.  The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
Note: To perform this assessment, the rater or Investigator answers the following question: "Considering your total clinical 
experience with this particular population, how mentally ill is the subject at this time?"  Higher values represent greater severity 
of illness.  The maximum score is 7. 
 
Table 14.2.4.15 Treatment Comparison of Change from Baseline in PANSS Total Score at Week 6 by Disease Duration 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
Instead of 2 categories of ‘Female’ and ‘Male’, there will be 4 categories of ‘< 5 years’, ‘>= 5 to < 10 years’, ‘>= 10 to < 20 
years’, and ‘>= 20 years’. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
124


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 73 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
 
Table 14.2.4.16 Treatment Comparison of Change from Baseline in CGI-S Score at Week 6 by Disease Duration 
Full Analysis Set 
This table will be similar to 14.2.4.1. 
Instead of 2 categories of ‘Female’ and ‘Male’, there will be 4 categories of ‘< 5 years’, ‘>= 5 to < 10 years’, ‘>= 10 to < 20 
years’, and ‘>= 20 years’. 
Footnotes will be: 
Note: CGI-S = Clinical Global Impression – Severity of Illness Scale, LSM = Least Squares Mean, SE = Standard Error, CI = Confidence 
Interval, N = number of subjects in the full analysis set by treatment group. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: CGI-S score is determined by answering the question “Considering your total clinical experience with this particular population, 
how mentally ill is the subject at this time?” on a scale of 0-7, with 0 indicating not assessed and  7 indicating the most extremely 
ill subjects. 
Note: Percentages are calculated as (n/N)*100. 
Note: The mixed linear repeated measures model includes treatment, country, visit, treatment by visit interaction, and baseline value 
as covariates, and subject as random effect. The correlation of repeated measures within a subject is estimated with an unstructured 
covariance matrix. The Kenward-Rogers method is used to estimate the denominator degrees of freedom. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
125


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 74 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
1.3 
Safety 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
126


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 75 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.3.1.1 Overview of Adverse Events 
Safety Analysis Set 
 
 
 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
Statistic 
Subjects [a] 
Events [b] 
Subjects [a] 
Events [b] 
Subjects [a] 
Events [b] 
 
 
 
 
 
 
 
 
Any AE 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
Any TEAE 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
Any Severe TEAE 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
Any Related TEAE 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
Any TEAE Leading to Discontinuation 
of Study Medication 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
Any Serious TEAE 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
Any Related Serious TEAE 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
Any TEAE Leading to Death 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
Any TEAE Occurring at Patch 
Application Site 
n (%) 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
 
 
 
 
 
 
Note: AE = Adverse Event, TEAE = Treatment-Emergent Adverse Event, N = number of subjects in the safety analysis set by treatment 
group. 
Note: TEAEs are defined as all AEs which start (or increase in severity) prior to, on or after the date of first dose of double-blind 
study medication through the 30 day follow-up period.  
Note: Related is defined as any investigator assessment of possible or probable. TEAEs with missing relationship to study medication 
are counted as related. 
Note: Percentages are calculated as (n/N)*100. 
[a]: Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than one 
category are counted once in each of those categories.   
[b]: Multiple events for a subject that are in the same AE category are counted multiple times in that AE category. Multiple events 
belonging to more than one AE category are counted multiple times in each of those AE categories. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm      
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
127


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 76 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04     
                                                                                                  
Table 14.3.1.2 Treatment-Emergent Adverse Events During the Double-Blind Period by System Organ Class and Preferred 
Term 
Safety Analysis Set 
 
System Organ Class 
   Preferred Term 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
 
 
 
 
Total number of TEAE  
xx 
xx 
xx 
 
 
 
 
Subjects with any TEAE  
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
SYSTEM ORGAN CLASS 1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Preferred Term 1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Preferred Term 2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
   … 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
SYSTEM ORGAN CLASS 2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Preferred Term 1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Preferred Term 2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
… 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
Note: TEAE = Treatment-Emergent Adverse Event, AE = Adverse Event, N = number of subjects in the safety analysis set by treatment 
group. 
Note: TEAEs are defined as all AEs which start (or increase in severity) prior to, on or after the date of first dose of double-
blind study medication through the 30 day follow-up period.  
Note: Percentages are calculated as (n/N)*100. 
Note: Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more 
than one category are counted once in each of those categories.   
Note: This summary is sorted by decreasing frequency of system organ class, and within system organ class, by decreasing 
frequency of preferred term in the HP-3070 18.0mg column. 
Note: Adverse events are coded using Medical Dictionary for Regulatory Activities (MedDRA) Version xx.x. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: SOC should be displayed in all caps. Preferred Term should include lower case. 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
128


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 77 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04        
                                                                                               
Table 14.3.1.3 Treatment-Emergent Adverse Events During the Double-Blind Period by System Organ Class, Preferred Term, 
Relationship to Study Medication, and Severity 
Safety Analysis Set 
 
System Organ Class  
   Preferred Term 
Relationship 
  Severity 
HP-3070 18.0 mg 
(N=XXX) 
HP-3070 9.0 mg 
(N=XXX) 
 Placebo 
(N=XXX) 
Subjects [a] 
Events [b] 
Subjects [a] 
Events [b] 
Subjects [a] 
Events [b] 
 
 
 
 
 
 
 
 
Subjects with any TEAE 
Related 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Mild 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Moderate 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Severe 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
Not Related 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Mild 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Moderate 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Severe 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
 
 
 
 
 
 
 
SYSTEM ORGAN CLASS 1 
Related 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Mild 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Moderate 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
  Severe 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx 
 
 
 
 
 
 
 
Note: TEAE = Treatment-Emergent Adverse Event, AE = Adverse Event, N = number of subjects in the safety analysis set by treatment group. 
Note: TEAEs are defined as all AEs which start (or increase in severity) prior to, on or after the date of first dose of double-blind 
study medication through the 30 day follow-up period.  
Note: Related is defined as any investigator assessment of possible or probable. TEAEs with missing relationship to study medication are 
counted as related. 
Note: TEAEs with a missing severity are counted as severe. 
[a]: Subjects with more than one TEAE are counted once in each category. The worst case relationship is summarized, at the maximum 
severity.  
[b]: Multiple events for a subject that are in the same AE category are counted multiple times in that AE category. 
Note: Adverse events are coded using Medical Dictionary for Regulatory Activities (MedDRA) Version xx.x. 
Note: Percentages are calculated as (n/N)*100. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all Related and Not Related options for every SOC and PT. SOC should be displayed in all caps. Preferred 
Term should include lower case. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
129


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 78 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Programming note: In the Subjects [a] column, each subject is counted once per SOC/PT. At a given SOC or PT level, identify the worst 
case relationship per subject, then within that relationship level identify the worst case severity. In the Events [b] column, all 
TEAEs meeting the relationship/severity condition should be counted. (A subject may contribute to the events count in a row where 
he/she is not counted at the subject level, if it is not the worst case event.) 
Table 14.3.1.4 Treatment-Emergent Adverse Events During the Double-Blind Period Leading to Study Drug Discontinuation 
by System Organ Class and Preferred Term 
Safety Analysis Set 
This table will be similar to 14.3.1.2. 
Programming note: Replace the first row with “Total number of TEAEs leading to study drug discontinuation” and the second row with 
“Subjects with any TEAE Leading to Study Drug Discontinuation”.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
130


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 79 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04   
                                                                                                    
Table 14.3.1.5 Treatment-Emergent Adverse Events During the Double-Blind Period Leading to Study Drug Discontinuation 
by Region and by System Organ Class and Preferred Term 
Safety Analysis Set 
 
System Organ Class  
   Preferred Term 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
 
 
 
 
Rest of the World 
 
 
 
  Total number of TEAEs Leading 
to Study Drug Discontinuation 
xx 
xx 
xx 
  Subjects with any TEAE Leading 
to Study Drug Discontinuation 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
  SYSTEM ORGAN CLASS 1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Preferred Term 1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
    Preferred Term 2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
     … 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
  SYSTEM ORGAN CLASS 2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 Preferred Term 1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 Preferred Term 2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  … 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Note: TEAE = Treatment-Emergent Adverse Event, AE = Adverse Event, N = number of subjects in the safety analysis set by treatment 
group. 
Note: TEAEs are defined as all AEs which start (or increase in severity) prior to, on or after the date of first dose of double-
blind study medication through the 30 day follow-up period.  
Note: Percentages are calculated as (n/N)*100. 
Note: Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more 
than one category are counted once in each of those categories.   
Note: This summary is sorted by decreasing frequency of system organ class, and within system organ class, by decreasing 
frequency of preferred term in the HP-3070 18.0mg column. 
Note: Adverse events are coded using Medical Dictionary for Regulatory Activities (MedDRA) Version xx.x. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: SOC should be displayed in all caps. Preferred Term should include lower case. Repeat table for each region: Rest of 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
131


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 80 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
the World, Russia then North America. 
 
Table 14.3.1.6 Serious Treatment-Emergent Adverse Events During the Double-Blind Period by System Organ Class and 
Preferred Term 
Safety Analysis Set 
This table will be similar to 14.3.1.2. 
Programming note: Replace the first row with “Total number of serious TEAEs” and the second row with “Subjects with any Serious TEAE”.  
Table 14.3.1.7 Serious Treatment-Emergent Adverse Events During the Double-Blind Period by Region and by System Organ 
Class and Preferred Term 
Safety Analysis Set 
This table will be similar to 14.3.1.5. 
Programming note: Replace the first row with “Total number of serious TEAEs” and the second row with “Subjects with any Serious TEAE”.  
Table 14.3.1.8 Serious Treatment-Emergent Adverse Events During the Double-Blind Period by System Organ Class, 
Preferred Term, Relationship to Study Medication, and Severity 
Safety Analysis Set 
This table will be similar to 14.3.1.3. 
Programming note: Replace the first row with “Subjects with any Serious TEAE”.  
Table 14.3.1.9 Treatment-Emergent Adverse Events During the Double-Blind Period Leading to Death by System Organ Class 
and Preferred Term 
Safety Analysis Set 
This table will be similar to 14.3.1.2. 
Programming note: Replace the first row with “Total number of TEAEs leading to death” and the second row with “Subjects with any TEAE 
Leading to Death”.  
Table 14.3.1.10 Commonly Occurring (>= 5%) Treatment-Emergent Adverse Events During the Double-Blind Period by 
System Organ Class and Preferred Term 
Safety Analysis Set 
This table will be similar to 14.3.1.2. 
Add a footnote: 
Note: Commonly Occurring TEAE is defined as any TEAE occurring in at least 5% of subjects in any treatment arm. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
132


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 81 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.3.1.11 Commonly Occurring (>= 5%) Treatment-Emergent Adverse Events During the Double-Blind Period by 
Region and by System Organ Class and Preferred Term 
Safety Analysis Set 
This table will be similar to 14.3.1.5. 
Add a footnote: 
Note: Commonly Occurring TEAE is defined as any TEAE occurring in at least 5% of subjects in any treatment arm. 
Table 14.3.1.12 All Commonly Occurring (>= 5%) Adverse Events During the Double-Blind Period by Region and by System 
Organ Class and Preferred Term 
Safety Analysis Set 
This table will be similar to 14.3.1.5. 
Add a footnote: 
Note: Commonly Occurring AE is defined as any AE occurring in at least 5% of subjects in any treatment arm. 
 
Table 14.3.1.13 Commonly Occurring (>= 2%) Treatment-Emergent Adverse Events During the Double-Blind Period by 
System Organ Class and Preferred Term 
Safety Analysis Set 
This table will be similar to 14.3.1.2. 
Add a footnote: 
Note: Commonly Occurring TEAE is defined as any TEAE occurring in at least 2% of subjects in any treatment arm. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
133


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 82 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04             
                                                                                          
Table 14.3.1.14 Treatment-Emergent Adverse Events at Patch Application Site During the Double-Blind Period by Preferred 
Term and Severity 
Safety Analysis Set 
 
Preferred Term 
  Severity 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
 
 
 
 
Total number of Dermal TEAEs  
xx 
xx 
xx 
Subjects with any Dermal TEAE 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
Preferred Term 1 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Mild 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Moderate 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Severe 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Preferred Term 2 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Mild 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Moderate 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Severe 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Preferred Term 3 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Mild 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Moderate 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  Severe 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
… 
… 
… 
… 
 
 
 
 
Note: TEAE = Treatment-Emergent Adverse Event, AE = Adverse Event, N = number of subjects in the safety analysis set by treatment 
group. 
Note: TEAEs are defined as all AEs which start (or increase in severity) prior to, on or after the date of first dose of double-
blind study medication through the 30 day follow-up period.  
Note: TEAEs with a missing severity are counted as severe. 
Note: Percentages are calculated as (n/N)*100. 
Note: Subjects with multiple events in the same category are counted only once in that category. Subjects with events in more than 
one category are counted once in each of those categories.   
Note: This summary is sorted by decreasing frequency of preferred term in the HP-3070 18.0mg column. 
Note: Adverse events are coded using Medical Dictionary for Regulatory Activities (MedDRA) Version xx.x. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
134


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 83 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04          
                                                                                             
Table 14.3.2.1 Clinical Laboratory Quantitative Results and Change from Baseline by Visit - Hematology 
Safety Analysis Set 
 
Laboratory Test (SI Unit) 
 
 Visit 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
Hemoglobin (g/dL) 
 
 
 
 
 
 
Baseline 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
   
 
 
 
 
 
  Week 3 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
 
 
 
 
 
 
Change from Baseline to Week 3 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
 
 
 
 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: Unscheduled visits are not included in this summary. 
       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
Programming note: Repeat at week 6 and for all tests planned in the protocol 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
135


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 84 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.3.2.2 Clinical Laboratory Quantitative Results and Change from Baseline by Visit – Serum Chemistry 
Safety Analysis Set 
This table will be similar to 14.3.2.1. 
 
Table 14.3.2.3 Clinical Laboratory Quantitative Results and Change from Baseline by Visit – Urinalysis 
Safety Analysis Set 
This table will be similar to 14.3.2.1. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
136


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 85 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04   
                                                                                                    
Table 14.3.2.4 Clinical Laboratory Shifts from Baseline to Worst On-Treatment Result for Categorical Measurements 
Safety Analysis Set 
 
Laboratory Test 
Treatment Group 
Baseline Result 
Worst On-Treatment Result 
Negative 
n (%) 
Trace 
n (%) 
1+ 
n (%) 
2+ 
3+ 
4+ 
Categorical Lab 
Test 1 
 
 
 
 
 
 
 
 
 
HP-3070 18.0 mg 
(N=XX) 
Negative 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
 
 
Trace 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
 
 
… 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
HP-3070 9.0 mg 
(N=XX) 
Negative 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
 
 
Trace 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
 
 
… 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
Placebo (N=XX) 
Negative 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
 
 
Trace 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
 
 
… 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
  
 
 
 
 
 
 
 
 
Note: N is the number of subjects with both baseline and post-baseline assessments in a treatment group.   
Note: Worst on-treatment result is defined as the worst result occurring after the administration of the first dose of double-blind 
study medication.    
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: Percentages are calculated as (n/N)*100. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all tests planned in the protocol 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
137


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 86 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04    
                                                                                                   
Table 14.3.2.5.1 Clinical Laboratory Shifts from Baseline to Maximum On-Treatment Result - Hematology 
Safety Analysis Set 
 
Laboratory Test 
Treatment Group 
Baseline Result 
Worst On-Treatment Result 
Low 
n (%) 
Normal 
n (%) 
High 
n (%) 
Hemoglobin 
 
 
 
 
 
 
HP-3070 18.0 mg (N=XX) 
Low 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
Normal 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
High 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
HP-3070 9.0 mg (N=XX) 
Low 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
Normal 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
High 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
Placebo (N=XX) 
Low 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
Normal 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
High 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
  
 
 
 
 
 
Note: N is the number of subjects with both baseline and post-baseline assessments in a treatment group.   
Note: Maximim on-treatment result is defined as the maximum result occurring after the administration of the first dose of double-
blind study medication.    
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: Percentages are calculated as (n/N)*100. 
Note: Low is less than the normal low range value, Normal is inclusive of the normal low and high range values, and High is 
greater than the normal high range value. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all tests planned in the protocol 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
138


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 87 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.3.2.5.2 Clinical Laboratory Shifts from Baseline to Minimum On-Treatment Result – Hematology 
Safety Analysis Set 
This table will be similar to 14.3.2.5.1. 
 
Table 14.3.2.6.1 Clinical Laboratory Shifts from Baseline to Maximum On-Treatment Result – Serum Chemistry 
Safety Analysis Set 
This table will be similar to 14.3.2.5.1. 
 
Table 14.3.2.6.2 Clinical Laboratory Shifts from Baseline to Minimum On-Treatment Result – Serum Chemistry 
Safety Analysis Set 
This table will be similar to 14.3.2.5.1. 
 
Table 14.3.2.7.1 Clinical Laboratory Shifts from Baseline to Maximum On-Treatment Result – Urinalysis 
Safety Analysis Set 
This table will be similar to 14.3.2.5.1. 
 
Table 14.3.2.7.2 Clinical Laboratory Shifts from Baseline to Minimum On-Treatment Result – Urinalysis 
Safety Analysis Set 
This table will be similar to 14.3.2.5.1. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
139


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 88 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                              
Table 14.3.2.8 Clinical Laboratory Shifts in NCI CTCAE Grades from Baseline to Worst On-Treatment Result  
Safety Analysis Set 
Laboratory Test 
(Upper or Lower 
Limit of Normal) 
Treatment Group 
Baseline Result 
Worst On-Treatment Result 
0 
1 
2 
3 
4 
Hemoglobin (Low) 
 
 
 
 
 
 
 
 
HP-3070 18.0 mg (N=XX) 
0 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
1 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
2 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
3 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
4 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
HP-3070 9.0 mg (N=XX) 
0 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
1 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
2 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
3 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
4 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
 
Placebo (N=XX) 
0 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
1 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
2 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
3 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
4 
xx (xx.x) xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
 
 
Note: NCI = National Cancer Institute, CTCAE = Common Terminology Criteria for Adverse Events. 
Note: N is the number of subjects with both baseline and post-baseline assessments in a treatment group.   
Note: Worst on-treatment result is defined as the worst result occurring after the administration of the first dose of double-
blind study medication.    
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.  
Note: Grade refers to the severity. As a general guideline: Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically 
significant but not immediately life-threatening, and Grade 4 is life-threatening consequences.    
Note: Percentages are calculated as (n/N)*100. 
Note: Grades are assigned using CTCAE Version x.xx. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all tests planned in the protocol. For tests with grades in both high and low directions, show each 
direction separately, with high or low indicated in the laboratory test column. 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
140


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 89 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04     
                                                                                                  
Table 14.3.2.9 Clinical Laboratory Neutrophil Results Below 1000 per Cubic Millimeter by Visit 
Safety Analysis Set 
 
Visit 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
 
 
 
 
Baseline 
N 
   xx                      xx  
   xx  
 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Week 3 
N 
   xx  
   xx  
   xx  
 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Week 6 
N 
   xx  
   xx  
   xx  
 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
Note: Percentages are calculated as (n/N)*100, where N is the number of subjects with data at the given visit for each treatment 
group. 
Note: Unscheduled visits are not included in this summary. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
141


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 90 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.3.2.10 Clinical Laboratory Liver Function Abnormalities 
Safety Analysis Set 
 
Abnormality 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
 
 
 
 
ALT > 3xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
AST > 3xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
ALP < 2xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Potential Hy’s Law Cases 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
ALP <= 2xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
ALT >= 3xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
AST >= 3xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
Other Tests 
 
 
 
  Creatine Kinase >= 3xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
  Prolactin >= 4xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
  Total Bilirubin >= 2xULN 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
Note: ALT = Alanine Transaminase, AST = Aspartate Transaminase, ALP = Alkaline Phosphatase, ULN = Upper Limit of Normal. 
Note: Potential Hy’s Law Cases are defined as subjects who at any point during the study meet the criteria of ALT or AST > 3xULN, 
ALP < 2xULN, and Total Bilirubin >= 2xULN.  
Note: Percentages are calculated as (n/N)*100. 
Note: Values for ALT >=3xULN and AST >=3xULN are only presented for subjects that meet the criteria of ALP<=2xULN. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
142


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 91 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04     
                                                                                                  
Table 14.3.3.1 12-Lead ECG Quantitative Results and Change from Baseline by Visit 
Safety Analysis Set 
 
Parameter (Unit) 
 
 Visit 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
PR Interval (msec) 
 
 
 
 
 
 
  Baseline 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
   
 
 
 
 
 
  Week 1 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
 
 
 
 
 
 
 Change from Baseline to Week 
1 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
 
 
 
 
 
Note: ECG = Electrocardiogram. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.   
Note: Unscheduled visits are not included in this summary.  
       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all visits and all tests planned in the protocol. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
143


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 92 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.3.3.2 12-Lead ECG Overall Assessment by Visit 
Safety Analysis Set 
 
Visit/ 
  Assessment 
Statistic 
HP-3070 18.0 mg  
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
 
 
 
 
Baseline 
N 
   xx                     xx  
   xx  
  Normal 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
  Abnormal, Not Clinically Significant 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
  Abnormal, Clinically Significant 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Week 1 
N 
   xx                     xx  
   xx  
  Normal 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
  Abnormal, Not Clinically Significant 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
  Abnormal, Clinically Significant 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Week 2 
N 
   xx                     xx  
   xx  
  Normal 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
  Abnormal, Not Clinically Significant 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
  Abnormal, Clinically Significant 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Note: ECG = Electrocardiogram. 
Note: Overall assessment of ECG is based on investigator’s judgment. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.  
Note: Unscheduled visits are not included in this summary.  
Note: Percentages are calculated as (n/N)*100, where N is the number of subjects with data at the given visit. 
  
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all visits. 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
144


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 93 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04         
                                                                                              
Table 14.3.3.3 12-Lead ECG Overall Assessment Shifts from Baseline to Worst On-Treatment Result 
Safety Analysis Set 
 
Treatment Group 
Baseline Result 
Worst On-Treatment Result 
Normal 
n (%) 
Abnormal, NCS 
n (%) 
Abnormal, CS 
n (%) 
 
 
 
 
 
HP-3070 18.0 mg (N=XX) 
Normal 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Abnormal, NCS 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Abnormal, CS 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
HP-3070 9.0 mg (N=XX) 
Normal 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Abnormal, NCS 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Abnormal, CS 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Placebo (N=XX) 
Normal 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Abnormal, NCS 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Abnormal, CS 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Note: ECG = Electrocardiogram, NCS = Not Clinically Significant, CS = Clinically Significant 
Note: N is the number of subjects with both baseline and post-baseline assessments in a treatment group.   
Note: Worst on-treatment result is defined as the worst result occurring after the administration of the first dose of double-
blind study medication.    
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: Percentages are calculated as (n/N)*100. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
145


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 94 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.3.3.4 12-Lead ECG Markedly Abnormal Results by Visit 
Safety Analysis Set 
 
Visit/ 
  Abnormality 
Statistic 
HP-3070 18.0 mg  
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
 
 
 
 
Overall Post-baseline 
N 
   xx                     xx  
   xx  
  Any Marked Abnormality 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  QT Interval 
 
 
 
 
    Result > 450 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result > 480 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result > 500 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Change from Baseline >= 30 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Change from Baseline >= 60 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  QTcB Interval 
 
 
 
 
    Result > 450 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result > 480 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result > 500 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    CFB >= 30 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    CFB >= 60 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Note: ECG = Electrocardiogram, QTcB = QT interval corrected by Bazett's formula, QTcF = QT interval corrected by Fridericia's 
formula, HR = Heart Rate. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.   
Note: Percentages are calculated as (n/N)*100, where N is the number of subjects with data at the given visit. 
Note: Unscheduled visits are not included in this summary. 
 
  
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
146


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 95 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.3.3.4 12-Lead ECG Markedly Abnormal Results by Visit 
Safety Analysis Set 
 
Visit/ 
  Abnormality 
Statistic 
HP-3070 18.0 mg 
(N=xxx)  
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
 
 
 
 
  QTcF Interval 
 
 
 
 
    Result > 450 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result > 480 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result > 500 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Change from Baseline >= 30 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Change from Baseline >= 60 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  HR  
 
 
 
 
    >= 100 bpm 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  PR Interval  
 
 
 
 
    >= 210 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  QRS Interval  
 
 
 
 
    >= 120 msec 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Week 1 
 
 
 
 
  … 
 
 
 
 
 
 
 
 
 
Note: ECG = Electrocardiogram, QTcB = QT interval corrected by Bazett’s formula, QTcF = QT interval corrected by Fridericia’s 
formula, HR = Heart Rate,  
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.   
Note: Percentages are calculated as (n/N)*100, where N is the number of subjects with data at the given visit. 
Note: Unscheduled visits are not included in this summary. 
  
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for week 2 through 6. 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
147


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 96 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04        
                                                                                               
Table 14.3.3.5 12-Lead ECG Markedly Abnormal Shifts from Baseline to Worst On-Treatment Result 
Safety Analysis Set 
 
Parameter 
 
Baseline Result 
Worst On-Treatment Result 
Treatment Group 
No Marked Abnormality 
n (%) 
At Least One Marked 
Abnormality 
n (%) 
 
 
 
 
 
Any Parameter 
HP-3070 18.0 mg (N=XX) 
No Marked Abnromality 
xx (xx.x) 
xx (xx.x) 
 
 
At Least One Marked Abnormality 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
HP-3070 9.0 mg (N=XX) 
No Marked Abnormality 
xx (xx.x) 
xx (xx.x) 
 
 
At Least One Marked Abnormality 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Placebo (N=XX) 
No Marked Abnormality 
xx (xx.x) 
xx (xx.x) 
 
 
At Least One Marked Abnormality 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
QT Interval 
HP-3070 18.0 mg (N=XX) 
No Marked Abnormality 
xx (xx.x) 
xx (xx.x) 
 
 
At Least One Marked Abnormality 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
 
Note: ECG = Electrocardiogram, QTcB = QT interval corrected by Bazett’s formula, QTcF = QT interval corrected by Fridericia’s 
formula, HR = Heart Rate,  
Note: N is the number of subjects with both baseline and post-baseline assessments in a treatment group.   
Note: Worst on-treatment result is defined as the worst result occurring after the administration of the first dose of double-blind 
study medication.    
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.  
Note: Markedly abnormal is defined as an absolute value > 450 msec or a CFB >= 30 msec for parameters QT interval, QTcB interval, 
or QTcF interval; value >= 100 bpm for HR parameter; value >= 210 msec for PR interval parameter; >=120 msec for QRS 
interval. 
Note: Percentages are calculated as (n/N)*100. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all parameters and treatment groups. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
148


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 97 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.3.4.1 Vital Signs Results and Change from Baseline by Visit 
Safety Analysis Set 
 
Parameter (Unit) 
 
 Visit 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
Sitting Systolic Blood Pressure 
(mmHg) 
 
 
 
 
 
 
  Baseline 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
   
 
 
 
 
 
  Week 1 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
 
 
 
 
 
 
Change from 
Baseline to 
Week 1 
n 
 xx      
 xx      
 xx      
 
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
 
Median 
 xx  
 xx  
 xx  
 
 
Min 
 xx 
 xx 
 xx 
 
 
Max 
 xx 
 xx 
 xx 
 
 
 
 
 
 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: Unscheduled visits are not included in this summary. 
       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all visits and all measurements planned in the protocol.  
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
149


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 98 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.3.4.2 Orthostatic Hypotension by Visit 
Safety Analysis Set 
 
Visit 
Statistic 
HP-3070 18.0 mg  
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
 
 
 
Baseline 
N 
xx 
xx 
xx 
 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Week 1 
N 
xx 
xx 
xx 
 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
Week 2 
N 
xx 
xx 
xx 
 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Week 3 
N 
xx 
xx 
xx 
 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
Week 4 
N 
xx 
xx 
xx 
 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
Week 5 
N 
xx 
xx 
xx 
 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
Week 6 
N 
xx 
xx 
xx 
 
n (%) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
Note: Subjects with a decrease of >= 30 mmHg in Systolic Blood Pressure and/or a decrease of >= 20 mmHg in Diastolic Blood 
Pressure after >=3 minutes standing compared to the previous supine blood pressure are classified as having orthostatic 
hypotension. 
Note: Percentages are calculated as (n/N)*100, where N is the number of subjects with data at the given visit.  
Note: Unscheduled visits are not included in this summary. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
150


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 99 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Table 14.3.4.3 Vital Signs Markedly Abnormal Results by Visit 
Safety Analysis Set 
 
Visit/ 
  Abnormality 
Statistic 
HP-3070 18.0 mg  
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
Placebo 
(N=xxx) 
 
 
 
 
 
Overall Post-baseline 
N 
   xx                     xx  
   xx  
  Any Marked Abnormality 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  Systolic Blood Pressure 
 
 
 
 
    Result <= 90 mmHg and CFB <= -20 mmHg 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result >= 180 mmHg and CFB >= 20 mmHg 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  Diastolic Blood Pressure 
 
 
 
 
    Result <= 50 mmHg and CFB <= -15 mmHg 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result >= 105 mmHg and CFB >= 15 mmHg 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  Heart Rate 
 
 
 
 
    Result <= 50 bpm and CFB <= -15 bpm 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Result >= 120 bpm and CFB >= 15 bpm 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  Body Temperature 
 
 
 
 
    Result >= 38.3 C and CFB >= 1.1 C 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
  Weight 
 
 
 
 
    CFB <= 7.0% 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    CFB >= 7.0% 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
 
Note: CFB = Change from baseline. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.   
Note: Percentages are calculated as (n/N)*100, where N is the number of subjects with data at the given visit. 
Note: Unscheduled visits are not included in this summary. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for week 1 through week 6.  
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
151


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 100 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                         
                                                                              
Table 14.3.5.1 SAS Total Score Results and Change from Baseline by Visit 
Safety Analysis Set 
 
 
Visit 
Statistic 
HP-3070 18.0 mg 
 (N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
 (N=xxx) 
 
 
 
 
 
  Baseline 
n 
 xx      
 xx      
 xx      
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
Median 
 xx  
 xx  
 xx  
 
Min 
 xx 
 xx 
 xx 
 
Max 
 xx 
 xx 
 xx 
   
 
 
 
 
  Week 1 
n 
 xx      
 xx      
 xx      
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
Median 
 xx  
 xx  
 xx  
 
Min 
 xx 
 xx 
 xx 
 
Max 
 xx 
 xx 
 xx 
 
 
 
 
 
  Change from Baseline to Week 1 
n 
 xx      
 xx      
 xx      
 
Mean 
 xx.x  
 xx.x  
 xx.x  
 
SD 
 xx.xx      
 xx.xx      
 xx.xx      
 
Median 
 xx  
 xx  
 xx  
 
Min 
 xx 
 xx 
 xx 
 
Max 
 xx 
 xx 
 xx 
 
 
 
 
 
Note: SAS = Simpson Angus Scale,  
Note: The SAS total score is the sum of the scores for all 10 items and ranges between 0 and 40. If one or more items are missing 
at a visit the SAS total score is missing. Lower values of the SAS total score indicate milder symptoms. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all visits.  
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
152


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 101 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Table 14.3.5.2.1 AIMS Global Severity Score Results and Change from Baseline by Visit 
Safety Analysis Set 
This table will be similar to 14.3.5.1. 
Footnotes will be: 
Note: AIMS = Abnormal Movement Scale,  
Note: The AIMS global severity score is the response to “Severity of abnormal movements” found within the global judgments section. 
Note: The AIMSassessment consists of 10 items describing symptoms of dyskinesia. Each subject is observed unobtrusively while at rest 
(e.g., in the waiting room). Each item is rated on a 5-point scale, where 0 is the absence of symptoms and 4 is a severe condition. 
The AIMS Score is the sum of scored movements of the face, oral, extremities, trunk, and the Investigator‘s judgments. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
 
Table 14.3.5.2.2 AIMS Total Score Results and Change from Baseline by Visit 
Safety Analysis Set 
This table will be similar to 14.3.5.1. 
Footnotes will be: 
Note: AIMS = Abnormal Movement Scale,  
Note: The AIMS total score is the sum of the scores for all 7 items and ranges between 0 and 28. If one or more items are missing at a 
visit the AIMS total score is missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
 
Table 14.3.5.3.1 BARS Global Score Results and Change from Baseline by Visit 
Safety Analysis Set 
This table will be similar to 14.3.5.1. 
Footnotes will be: 
Note: BARS = Barnes Akathisia Rating Scale,  
Note: The BARS Global Score is defined as the global clinical assessment of akathisia and assesses extrapyramidal symptoms on a 6-
point scale, whith 0 representing absence of symptoms and 5 representing severe akathesia. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
 
Table 14.3.5.3.2 BARS Total Score Results and Change from Baseline by Visit 
Safety Analysis Set 
This table will be similar to 14.3.5.1. 
Footnotes will be: 
Note: BARS = Barnes Akathisia Rating Scale, Note: The BARS total score is the sum of the scores for the first 3 items and ranges 
between 0 and 9. If one or more items are missing at a visit the BARS total score is missing. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
153


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 102 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                    
                                                                                   
Table 14.3.5.4.1 C-SSRS Suicidal Ideation by Visit 
Safety Analysis Set 
 
 
 Visit/ Assessment 
Statistic 
HP-3070 18.0 mg 
(N=xxx) 
HP-3070 9.0 mg 
(N=xxx) 
 Placebo 
(N=xxx) 
 
 
 
 
 
Baseline 
N 
   xx                 xx  
   xx  
Subjects reporting at least one occurrence of 
suicidal 
ideation or behavior 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Subjects reporting any type of suicidal behavior 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Subjects reporting any type of sucicidal ideation 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Week 1 
N 
   xx                 xx  
   xx  
Subjects reporting at least one occurrence of 
suicidal 
ideation or behavior 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Subjects reporting any type of suicidal behavior 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Subjects reporting any type of sucicidal ideation 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Note: C-SSRS = Columbia-Suicide Severity Rating Scale. 
Note: Any Suicidal Ideation is defined as any score greater than 0. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: Percentages are calculated as (n/N)*100, where N is the number of subjects with data at the given visit. 
       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all visits.  
 
 
 
 
 
 
 
 
 
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
154


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 103 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04     
                                                                                                  
Table 14.3.5.4.2 C-SSRS Most Severe Suicidal Ideation and Suicidal Behavior 
Safety Analysis Set 
 
 
 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
 
 
 
 
Any Suicidal Ideation During Screening/Baseline 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    1: Wish to be Dead 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    2: Non-Specific Active Suicidal Thoughts 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    5: Active Suicidal Ideation with Specific Plan and Intent 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
Any Suicidal Behavior During Screening/Baseline 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Actual Attempt 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Interrupted Attempt 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Aborted Attempt 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Preparatory Acts or Behavior 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Completed Suicide During Screening/Baseline 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
Any Ideation or Behavior Suicidality During Screening/Baseline 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Both Ideation and Behavior Suicidality During Screening/Baseline 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
Note: C-SSRS = Columbia-Suicide Severity Rating Scale. 
Note: Any Suicidal Ideation is defined as any score greater than 0. 
Note: Treatment-emergent suicidal ideation is defined as no suicidal ideation at baseline/screening and any suicidal ideation post-
baseline. 
Note: Worsening suicidal ideation is defined as most severe suicidal ideation post-baseline more severe than at baseline/screening. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: Percentages are calculated as (n/N)*100.  
Note: Subjects are counted only at their most severe suicidal ideation type and at their most severe behavior type. 
 
      
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
155


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 104 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04        
                                                                                               
Table 14.3.5.4.2 C-SSRS Most Severe Suicidal Ideation and Suicidal Behavior  
Safety Analysis Set 
 
 
 
HP-3070 18.0 mg  
(N=xxx) 
n (%) 
HP-3070 9.0 mg 
(N=xxx) 
n (%) 
Placebo 
(N=xxx) 
n (%) 
 
 
 
 
Any Suicidal Ideation During Double-Blind Treatment Period 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    1: Wish to be Dead 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    2: Non-Specific Active Suicidal Thoughts 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    3: Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    4: Active Suicidal Ideation with Some Intent to Act, without Specific Plan 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    5: Active Suicidal Ideation with Specific Plan and Intent 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
Any Suicidal Behavior During Double-Blind Treatment Period 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Actual Attempt 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Interrupted Attempt 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Aborted Attempt 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Preparatory Acts or Behavior 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Completed Suicide During Double-Blind Treatment Period 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
Any Ideation or Behavior Suicidality During Double-Blind Treatment Period 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
     Without Ideation or Behavior Suicidality During Screening/Baseline 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
Both Ideation and Behavior Suicidality During Double-Blind Treatment Period 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
     Without Ideation and Behavior Suicidality During Screening/Baseline 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
Note: C-SSRS = Columbia-Suicide Severity Rating Scale. 
Note: Any Suicidal Ideation is defined as any score greater than 0. 
Note: Treatment-emergent suicidal ideation is defined as no suicidal ideation at baseline/screening and any suicidal ideation post-
baseline. 
Note: Worsening suicidal ideation is defined as most severe suicidal ideation post-baseline more severe than at baseline/screening. 
Note: Baseline is defined as the last non-missing measurement taken prior to first dose of double-blind study medication.    
Note: Percentages are calculated as (n/N)*100.  
Note: Subjects are counted only at their most severe suicidal ideation type and at their most severe behavior type. 
      
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
156


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 105 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04       
                                                                                                
Table 14.3.6 Summary of Patch Adhesion, Adhesive Residue, and Skin Irritation 
Safety Analysis Set 
 
 Visit/ Assessment 
Statistic 
HP-3070 18.0 mg 
HP-3070 9.0 mg 
 Placebo 
 
 
 
 
 
Over the Entire Double-Blind Treatment Period 
N 
   xx                     xx  
   xx  
    Any Complete Detachment 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Any Partial Detachment 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
    Adhesive Residue 
 
 
 
 
       0=None 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
  xx (xx.x) 
       1=Mild 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
  xx (xx.x) 
       2=Medium 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
  xx (xx.x) 
       3=Heavy 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
  xx (xx.x) 
       Any Occurrence of Medium or Heavy 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
  xx (xx.x) 
 
 
 
 
 
Week 1 
N 
   xx                     xx  
   xx  
    Any Complete Detachment 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
    Any Partial Detachment 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Note: N = number of subjects with data at the given visit. 
Note: A subject’s maximum adhesive residue score and maximum skin irritation score per visit are shown. 
Note: Percentages are calculated as (n/N)*100. 
Note: Patch adhesion is determined from the following yes/no questions: “Is the patch fully attached to the skin?” and “If ‘No’, 
did the patch detach completely?” 
Note: Skin irritation combined score is the sum of the numerical scores from the skin irritation – dermal response score and the 
skin irritation – other effects scores, where N=0, A=0, B=1, C=2, F=3, G=3 and H=3 for the other effects score. If no grade 
was assigned for the other effects observations (N) score the combined score will consist of the dermal response scale 
score only. 
Note: Skin irritation concatenated score is determined by concatenating the dermal response score and other effects score (i.e., 
0N, 1N, 2N, 2A, 2B, 3N, 3A, 3B, 3C, 3F, etc.). 
       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
157


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 106 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04                                                                     
Table 14.3.6 Summary of Patch Adhesion, Adhesive Residue, and Skin Irritation 
Safety Analysis Set 
 
 Visit/ Assessment 
Statistic 
HP-3070 18.0 mg 
HP-3070 9.0 mg 
 Placebo 
 
 
 
 
 
    Adhesive Residue 
 
 
 
 
       0=None 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       1=Mild 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       2=Medium 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       3=Heavy 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       Any Occurrence of Medium or Heavy 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
    Skin Irritation – Dermal Response Scale 
 
 
 
 
       0=No evidence of irritation 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       1=Minimal erythema 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       2=Definite erythema, readily visible; minimal edema or minimal 
papular response 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       3=Erythema and papules 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       4=Definite edema 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       5=Erythema, edema, and papules 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       6=Vesicular eruption 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       7=Strong reaction spreading beyond test (application) site 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
Note: N = number of subjects with data at the given visit. 
Note: A subject’s maximum adhesive residue score and maximum skin irritation score per visit are shown. 
Note: Percentages are calculated as (n/N)*100. 
Note: Patch adhesion is determined from the following yes/no questions: “Is the patch fully attached to the skin?” and “If ‘No’, did 
the patch detach completely?” 
Note: Skin irritation combined score is the sum of the numerical scores from the skin irritation – dermal response score and the 
skin irritation – other effects scores, where N=0, A=0, B=1, C=2, F=3, G=3 and H=3 for the other effects score. If no grade 
was assigned for the other effects observations (N) score the combined score will consist of the dermal response scale score 
only. 
Note: Skin irritation concatenated score is determined by concatenating the dermal response score and other effects score (i.e., 0N, 
1N, 2N, 2A, 2B, 3N, 3A, 3B, 3C, 3F, etc.). 
       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
158


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 107 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 3 of x 
Protocol HP-3070-GL-04                                                                     
Table 14.3.6 Summary of Patch Adhesion, Adhesive Residue, and Skin Irritation 
Safety Analysis Set 
 
 Visit/ Assessment 
Statistic 
HP-3070 18.0 mg 
HP-3070 9.0 mg 
 Placebo 
 
 
 
 
 
    Skin Irritation – Other Effects 
 
 
 
 
       A(0)=Slightly glazed appearance 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       B(1)=Marked glazing 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       C(2)=Glazing with peeling and cracking 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       F(3)=Glazing with Fissures 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       G(3)=Film of dried, serous exudate covering all or part of the 
patch site 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
       H(3)=Small petechial erosions and/or scabs 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
 
 
 
 
 
   Skin Irritation - Combined Score (Concatenated Score) 
 
 
 
 
      0=No evidence of irritation / No other effects (0N) 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
      1=Minimal erythema, barely perceptible / No other effects (1N) 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
      2=Definite erythema / No other effects (2N) 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
      3=Erythema and papules / No other effects (3N) 
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
      …  
n (%) 
   xx (xx.x) 
   xx (xx.x) 
   xx (xx.x) 
      <repeat for all combinations of dermal response scale and other effects> 
 
 
 
 
 
Note: N = number of subjects with data at the given visit. 
Note: A subject’s maximum adhesive residue score and maximum skin irritation score per visit are shown. 
Note: Percentages are calculated as (n/N)*100. 
Note: Patch adhesion is determined from the following yes/no questions: “Is the patch fully attached to the skin?” and “If ‘No’, did 
the patch detach completely?” 
Note: Skin irritation combined score is the sum of the numerical scores from the skin irritation – dermal response score and the 
skin irritation – other effects scores, where N=0, A=0, B=1, C=2, F=3, G=3 and H=3 for the other effects score. If no grade 
was assigned for the other effects observations (N) score the combined score will consist of the dermal response scale score 
only. 
Note: Skin irritation concatenated score is determined by concatenating the dermal response score and other effects score (i.e., 0N, 
1N, 2N, 2A, 2B, 3N, 3A, 3B, 3C, 3F, etc.). 
       
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for all visits.  
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
159


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 108 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
 
Table 14.3.7 Summary of Plasma Asenapine and Desmethyl-asenapine Concentrations (ng/mL)) by Treatment 
PK Analysis Set 
 
Plasma Asenapine (ng/mL) 
Treatment: HP-3070 9 mg 
Visit 
Statistic 
2 hours 
14 Hours 
22 Hours 
 
 
 
 
Week 3/ Day 21 
n 
xx 
xx 
xx 
 
Mean 
xxxx.xx  
xxxx.xx  
xxxx.xx  
 
SD 
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
%CV 
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
Median  
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
Min  
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
Max 
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
Geometric Mean 
xxxx.xx  
xxxx.xx  
xxxx.xx  
 
 
 
 
Week 6/ Day 42 
n 
xx 
xx 
xx 
 
Mean 
xxxx.xx  
xxxx.xx  
xxxx.xx  
 
SD 
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
%CV 
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
Median  
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
Min  
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
Max 
xxxx.xx 
xxxx.xx 
xxxx.xx 
 
Geometric Mean 
xxxx.xx  
xxxx.xx  
xxxx.xx  
 
 
 
 
  
Note: Concentrations that are BLQ are treated as zero for descriptive statistics.   
Note: Summary statistics apply to Pharmacokinetic Population only 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Tables\xxxxx.sas ddmmmyyyy hh:mm        
Programming note: Repeat for HP-3070 18 mg. Blood samples will be collected for asenapine and desmethyl-asenapine concentration; on 
Day 21 and 42 of HP-3070 9 mg and 18 mg at 2, 14 and 22 hours after dosing. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
160


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 109 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
2. 
LISTINGS  
 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
161


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 110 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.1 Randomization 
ITT Analysis Set 
 
 
 
Subject ID 
Date of Randomization 
Randomization Number 
 Treatment Group 
Country 
 
 
 
 
xxxx-xxxx 
YYYY-MM-DD 
xxx 
18.0 mg 
xxxxx 
 
 
 
 
xxxx-xxxx 
YYYY-MM-DD 
xxx 
9.0 mg 
xxxxx 
 
 
 
 
xxxx-xxxx 
YYYY-MM-DD 
xxx 
Placebo 
xxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat. 
Note: Randomization to treatment arms is stratified by country. 
Note: The first four digits of the subject ID contains the site number. 
                                                                                                                          
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
162


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 111 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.2 Disposition 
All Subjects Screened Analysis Set 
Treatment Group: HP-3070 18.0 mg 
Subject 
ID 
Date of 
Birth 
Sex 
Race 
Region/ 
Country 
Ethnicity 
Period 
Disposition Event 
Date (Study 
Day) 
Reason 
xxxx-xxxx 
YYYY-MM-DD 
Female 
White 
Russia 
Hispanic 
or Latino 
SB 
Entered Screening/Run-In 
Period 
YYYY-MM-DD 
(XX) 
 
 
 
 
 
 
 
SB 
Entered Informed Consent 
YYYY-MM-DD 
(XX) 
 
 
 
 
 
 
 
SB 
Entered Run-In Patch 
Application 
YYYY-MM-DD 
(XX) 
 
 
 
 
 
 
 
SB 
Screening/Run-In Failure 
YYYY-MM-DD 
(XX) 
Adverse 
Event: XXXXX 
 
 
 
 
 
 
 
 
 
 
xxxx-xxxx 
YYYY-MM-DD 
Female 
OTHER: 
XXXXXXX 
North 
America/ 
United 
States 
Hispanic 
or Latino 
SB 
Entered Screening/Run-In 
Period 
YYYY-MM-DD 
(XX) 
 
 
 
 
 
 
 
SB 
Entered Informed Consent 
YYYY-MM-DD 
(XX) 
 
 
 
 
 
 
 
SB 
Entered Run-In Patch 
Application 
YYYY-MM-DD 
(XX) 
 
 
 
 
 
 
 
DB 
Randomized 
YYYY-MM-DD 
(XX) 
 
 
 
 
 
 
 
DB 
Discontinued Study Due to 
Adverse Event 
YYYY-MM-DD 
(XX) 
 
 
 
 
 
 
 
 
 
 
 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up, IVRS = Interactive Voice Activated Response System, IWRS = Interactive 
Web-based Response System. 
Note: The study includes a run-in period of 3 to 14 days, during which placebo patches are administered, screening procedures are 
completed, and antipsychotic or other prohibited medications are washed out. Demographics and Screening/Run-In dispositions 
are based on data collected in the IVRS/IWRS. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  During 
the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
163


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 112 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
Programming note: Repeat for HP-3070 9.0 mg, Placebo, and Subjects Not Randomized. Sort by subject and date. (Treatments are based on 
randomized treatment. Subjects Not Randomized are those in All Subjects Screened Analysis Set but not in ITT Analysis Set. These will 
be listed last.) 
Programming note: In Race column, if “OTHER” is selected, concatenate the Specify data following a colon (:). In the Reason column, if 
“Adverse Event” is selected, concatenate the Adverse Event specification following a colon; if “Inclusion Criteria” is selected, 
concatenate the Inclusion Reason(s), if “Exclusion Criteria” is selected, concatenate the Exclusion Reason(s). 
 
 Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
164


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 113 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.3 Demographics 
ITT Analysis Set 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
Treatment Group: HP-3070 18.0 mg 
Subject 
ID 
Date of 
Birth 
Age 
(Years) 
Sex 
Race 
Region/ 
Country 
Ethnicity 
Date of First 
Diagnosis of 
Schizophrenia 
Start Date of 
Current Acute 
Episode 
Antipsychotic 
Medication 
xxxx-xxxx 
YYYY-MM-DD 
xx 
Male 
Asian 
North 
America/ 
United 
States 
Not Hispanic or 
Latino 
YYYY-MM-DD 
YYYY-MM-DD 
Y 
xxxx-xxxx 
YYYY-MM-DD 
xx 
Female 
White 
Russia 
Hispanic or 
Latino 
YYYY-MM-DD 
YYYY-MM-DD 
N 
xxxx-xxxx 
YYYY-MM-DD 
xx 
Female 
Other: 
XXXXXXX 
Rest of 
the 
World/ 
Bulgaria 
Hispanic or 
Latino 
YYYY-MM-DD 
YYYY-MM-DD 
N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: ITT = Intent-to-treat. 
                                                                                                                        
 Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
165


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 114 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
Programming note: In Race column, if multiple races are selected, concatenate all races selected with a comma (,) in between. If 
“Other” is selected, concatenate the Specify data following a colon (:)  
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
166


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 115 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.4 Inclusion/Exclusion Criteria Not Met 
ITT Analysis Set 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Category 
Criteria not Met 
 
 
 
xxxx-xxxx 
Inclusion 
xx 
 
 
 
xxxx-xxxx 
Exclusion 
xx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat. 
                                                                                                                            
 Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
167


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 116 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.5 Medical History 
ITT Analysis Set 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
Programming note: SOC should be displayed in all caps. Preferred Term should include lower case. 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
MH Number 
SYSTEM ORGAN CLASS/ 
Preferred Term/ 
Verbatim Term 
Start date  
(Study Day) 
End date  
(Study Day) 
 
xxxx-xxxx 
xx 
xxxxxxxxxxxxx/ 
xxxxxxxxxxxxxxx/ 
xxxxxxxxxx 
YYYY-MM-DD (-xx) 
YYYY-MM-DD (-xx) 
 
 
 
 
 
 
 
 
 
 
xx 
xxxxxxxxxxxxx/ 
xxxxxxxxxxxxxxx/ 
xxxxxxxxxx 
YYYY-MM-DD (-xx) 
Ongoing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat. 
Note: Medical conditions are coded using Medical Dictionary for Regulatory Activities (MedDRA) Version xx.x. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
168


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 117 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.6 Patch Application 
ITT Analysis Set 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo.  
 
 
Treatment Group: HP-3070 18.0 mg 
Subject 
ID 
Period 
Date/Time of 
Application 
(Study Day) 
Site 
Removed 
Prior to 
Scheduled 
Time/Reaso
n 
Detach 
Completely 
(Date/Time) 
Date/Time 
of Removal 
(Study 
Day) 
Date/Time 
of 
Irritation 
Assessment 
(Study Day) 
Skin 
Irritation
: Dermal 
Response 
Scale 
 Skin 
Irritation: 
Other Effects 
xxxx-xxxx 
SB 
YYYY-MM-DD(xx) 
Abdomen
: Right 
N  
N 
YYYY-MM-DD 
(-xx) 
YYYY-MM-
DD(-xx) 
No 
evidence 
of 
irritation  
 
 
DB 
YYYY-MM-DD(xx) 
Hip: 
Left 
Y/Irritati
on 
Y(YYYY-MM-DD) 
YYYY-MM-DD 
(xx) 
YYYY-MM-
DD(xx) 
Definite 
edema 
Slightly 
glazed 
appearance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
Note: The study includes a run-in period of 3 to 14 days, during which placebo patches are administered, screening procedures are 
completed, and antipsychotic or other prohibited medications are washed out. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
169


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 118 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.7 Adhesive Residue Assessment 
ITT Analysis Set 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo.  
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Period 
Date/Time of Assessment (Study Day) 
Adhesive Residue Score 
 
 
xxxx-xxxx 
SB 
YYYY-MM-DD(xx) 
0 = None 
 
 
 
DB 
YYYY-MM-DD(xx) 
2 = Medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  During 
the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
Note: The study includes a run-in period of 3 to 14 days, during which placebo patches are administered, screening procedures are 
completed, and antipsychotic or other prohibited medications are washed out. Demographics and Screening/Run-In dispositions 
are based on data collected in the IVRS/IWRS. 
                                                                                                                           
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
170


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 119 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.8 Day Passes 
ITT Analysis Set 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo.  
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Period 
Date of Day 
Pass (Study 
Day) 
Drug Screen 
Performed/Da
te(Study 
Day) 
Drug Screen 
Result 
Alcohol 
Breathalyzer 
Performed/Date(S
tudy Day) 
Alcohol 
Breathalyze
r Result 
Pregnancy Test 
Performed/Date(S
tudy Day) 
 
Pregnancy 
Result 
xxxx-xxxx 
DB 
YYYY-MM-DD(xx) 
Y/YYYY-MM-
DD(xx) 
Negative 
Y/YYYY-MM-DD(xx) 
Negative 
Y/YYYY-MM-DD(xx) 
Negative 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
171


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 120 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.9 Prior, Concomitant, and Post-Treatment Medications 
ITT Analysis Set 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo.  
 
 
Treatment Group: HP-3070 18.0 mg 
 
Subject ID 
Med 
Numb
er 
 
Per
iod 
Preferred Name/  
Verbatim Med Name 
Start Date 
(Study Day)/ 
Stop Date 
(Study Day) 
Indication 
(Medical 
History or 
Adverse Event 
Number) 
To Treat 
Current Acute 
Exacerbation 
of Schiz 
Dose (Unit)/ 
Frequency/ 
Route 
Prior 
Med 
Concomitant 
Med 
Post-
Treatment 
Med 
xxxx-xxxx 
xx 
SB 
xxxxxxxxxxxxx/ 
xxxxxxxxxxxxxxx/ 
xxxxxxxxxx 
YYYY-MM-DD 
(xx)/ 
YYYY-MM-DD 
(xx) 
Medical 
History (MH 
Number XX) 
N 
xx/ 
xxx/ 
xxxx 
Y 
Y 
N 
 
 
 
 
 
 
 
 
 
 
 
 
xx 
DB 
xxxxxxxxxxxxx/ 
xxxxxxxxxxxxxxx/ 
xxxxxxxxxx 
YYYY-MM-DD 
(xx)/ 
YYYY-MM-DD 
(xx) 
Prophylaxis 
N 
xx/ 
xxx/ 
xxxx 
N 
Y 
N 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat, Med = Medication, Schiz = Schizophrenia, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: Prior medications are medications which started and stopped prior to the first dose of double-blind study medication. 
Medications taken from 6 months prior to screening are included. 
Note: Concomitant medications are medications which started prior to, on, or after the first dose of double-blind study medication and 
no later than 1 day following the date of last study medication patch removal, and ended on or after the date of first dose of 
study medication or were ongoing at the end of the study. 
Note: Post-treatment medications are medications which started more than 1 day following the date of last double-blind study 
medication patch removal. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  During 
the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
Note: Medications are coded using World Health Organization Drug Dictionary (WHO DD) Version 19. 
Note: Medication number is assigned separately for Lorazepam and for all other concomitant medications for each subject. 
                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm         
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
172


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 121 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.1.10 Mini International Neuropsychiatric Interview (MINI) at Screening 
ITT Analysis Set 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Date of Assessment 
(Period, Study Day) 
Module 
Item 
Result (Scoring 
Points) 
 
xxxx-xxxx 
YYYY-MM-DD (xx, xx) 
A: Major 
Depressive 
Episode 
A1a: Ever depressed for two weeks 
No 
 
 
 
 
A1b: Depressed every day for past 
two weeks 
No 
 
 
 
 
A2a: Ever less able to enjoy things 
for two weeks 
Yes 
 
 
 
 
A2b: Less able to enjoy things in 
the past 2 weeks 
No 
 
 
 
 
A3a: Appetite change over the past 
two weeks 
No 
 
 
 
 
A3a: Appetite change during most 
symptomatic episode 
Yes 
 
 
 
 
A3b: Trouble sleeping every night 
over the past two weeks 
No 
 
 
 
 
A3b: Trouble sleeping every night  
during most symptomatic episode 
Yes 
 
 
 
 
A3c: Move slowly or restlessly over 
the last two weeks 
No 
 
 
 
 
A3c: Move slowly or restlessly  
during most symptomatic episode 
Yes 
 
 
 
 
A3d: Feel tired every day over the 
last two weeks 
No 
 
 
 
 
A3d: Feel tired every day during 
most symptomatic episode 
Yes 
 
 
 
 
A3e: Worthless every day over the 
last two weeks 
No 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
173


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 122 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
 
 
A3e: Worthless every day during most 
symptomatic episode 
No 
 
 
 
 
A3f: Difficulty concentrating every 
day over past two weeks 
No 
 
 
 
 
A3f: Difficulty concentrating every 
day during most symptomatic episode 
No 
 
 
 
 
A3g: Feel suicidal over past two 
weeks 
No 
 
 
 
 
A3g: Feel suicidal during most 
symptomatic episode 
No 
 
 
 
 
A4: Symptoms cause problems over 
past two weeks 
No 
 
 
 
 
A4: Symptoms cause problems during 
most symptomatic episode 
Yes 
 
 
 
 
A5: Two month interval of no 
depression between bounts of 
depression 
No 
 
 
 
 
A6: How many episodes of depression 
in lifetime 
No 
 
 
 
 
Major Depressive Episode- Current 
No 
 
 
 
 
Major Depressive Episode- Past 
Yes 
 
 
 
 
Major Depressive Episode- Recurrent 
No 
 
 
 
 
Major Depressive Disorder- Current 
No 
 
 
 
 
Major Depressive Disorder- Past 
Yes 
 
 
 
 
Major Depressive Disorder- Recurrent 
No 
 
 
 
B: Suicidality 
B1: Have any accident in past month 
No (0) 
 
 
 
 
B1a: Plan or intend to hurt yourself 
in past month 
No (0) 
 
 
 
 
B1b: Intend to die in past month 
No (0) 
 
 
 
 
B2: Feel hopeless in past month 
Yes (1) 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
174


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 123 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Programming note: Repeat for each subject and MINI Module, for HP-3070 9.0 mg and Placebo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
B3: Better off dead in past month 
No (0) 
 
 
 
 
B4: Think about hurting or injuring 
yourself in the past month 
Yes (4) 
 
 
 
 
B5: Think about suicide in past 
month 
Yes (6) 
 
 
 
 
B5: Frequency of thoughts 
Occasionally 
 
 
 
 
B5: Intensity of suicidal thoughts 
Mild 
 
 
 
 
B6: Difficulty restraining yourself 
in past month 
No (0) 
 
 
 
 
B7: Have suicide method in mind in 
past month 
No (0) 
 
 
 
… 
… 
 
 
Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                                                                                           
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
175


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 124 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.2.1 Positive and Negative Syndrome Scale (PANSS) 
ITT Analysis Set 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) Item 
Result 
 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, -
xx) 
P1. Delusions 
xx 
 
 
 
 
P2. Conceptual Disorganization 
xx 
 
 
 
 
P3. Hallucinatory Behavior  
xx 
 
 
 
 
P4. Excitement 
xx 
 
 
 
 
P5. Grandiosity 
xx 
 
 
 
 
P6. Suspiciousness/Persecution 
xx 
 
 
 
 
P7. Hostility 
xx 
 
 
 
 
N1. Blunted Affect 
xx 
 
 
 
 
N2. Emotional Withdrawal 
xx 
 
 
 
 
N3 Poor Rapport 
xx 
 
 
 
 
… 
… 
 
 
 
 
Positive Subscale Score 
xx 
 
 
 
 
Negative Subscale Score 
xx 
 
 
 
 
General Psychopathy Subscale Score 
xx 
 
 
 
 
Total Score 
xx 
 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) P1. Delusions 
xx 
 
 
 
 
P2. Conceptual Disorganization 
xx 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
176


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 125 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
177


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 126 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.2.2 Clinical Global Impression – Severity of Illness Scale (CGI-S) 
ITT Analysis Set 
 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) 
Result 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, xx) 
4 = Moderately ill  
 
 
Week 1 
YYYY-MM-DD (xx, xx) 
xxx 
 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, xx) 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU= Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
178


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 127 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.2.3 Clinical Global Impression – Improvement Scale (CGI-I) 
ITT Analysis Set 
 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) 
Result 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) 
2 = Much Improved  
 
 
Week 2 
YYYY-MM-DD (xx, xx) 
xxx 
 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
179


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 128 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.2.4 Calgary Depression Scale for Schizophrenia (CDSS) 
ITT Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) Item 
Result 
 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, -
xx) 
1. Depression 
0 = Absent 
 
 
 
 
2. Hopelessness 
1 = Mild 
 
 
 
 
3. Self Depreciation  
2 = Moderate 
 
 
 
 
4. Guilty Ideas of Reference 
3 = Severe 
 
 
 
 
5. Pathological Guilt 
X = xxxxxx 
 
 
 
 
6. Morning Depression 
X = xxxxxx 
 
 
 
 
7. Early Wakening 
X = xxxxxx 
 
 
 
 
8. Suicide 
X = xxxxxx 
 
 
 
 
9. Observed Depression 
X = xxxxxx 
 
 
 
 
Total Score 
xx 
 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) 1. Depression 
X = xxxxxx 
 
 
 
 
2. Hopelessness 
X = xxxxxx 
 
Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication.. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
180


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 129 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.2.5 Medical Satisfaction Questionnaire 
ITT Analysis Set 
 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
 
 
 
 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) 
Overall, how satisfied are you with your current 
antipsychotic medication(s)? 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, -xx) 
1 = extremely dissatisfied  
 
 
Week 2 
YYYY-MM-DD (xx, -xx) 
4 = neither satisfied nor dissatisfied 
 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, -xx) 
2 = very dissatisfied 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: ITT = Intent-to-treat, SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication.. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
181


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 130 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.1.1 Adverse Events 
Safety Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg, and Placebo. 
Treatment Group: HP-3070 18.0 mg 
Subject ID Period 
AE 
Number 
System Organ Class/ 
Preferred Term/ 
Verbatim Term  
Start Date  
(Study Day)/ 
Stop Date  
(Study Day)   
TEAE  
SAE  
AESI  
Occur at Patch 
Application Site   Severity 
xxxx-xxxx 
SB 
xx 
xxxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxxxxxx 
YYYY-MM-DD (xx)/ 
YYYY-MM-DD (xx) 
N 
N 
N 
N 
Mild 
 
DB 
xx 
xxxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxxxxxx 
YYYY-MM-DD (xx)/ 
YYYY-MM-DD (xx) 
Y 
Y 
N 
Y 
Moderate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up, TEAE = Treatment-Emergent Adverse Event, SAE = Serious Adverse Event, 
AE = Adverse Event, AESI = Adverse Event of Special Interest. 
Note: TEAEs are defined as all AEs which start (or increase in severity) on or after the date of first dose of double-blind study 
medication through the 30 day follow-up period. 
Note: Potential Hy's Law events are to be entered as AESIs. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
Note: Adverse events are coded using Medical Dictionary for Regulatory Activities (MedDRA) Version xx.x. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
182


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 131 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 2 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.1.1 Adverse Events 
Safety Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject 
ID 
Period 
AE 
Number 
System Organ Class/ 
Preferred Term/ 
Verbatim Term  
Relationship 
to Study Drug 
Action Taken 
with Study Drug Other Action  
Outcome 
Caused 
Discontinuation 
from the Study 
xxxx-xxxx 
SB 
xx 
xxxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxxxxxx 
Unrelated 
Not Applicable 
None 
 
Recovered/ 
Resolved 
N 
 
DB 
xx 
xxxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxxxxxx 
Possible 
Dose not 
changed 
Concomitant 
Medications 
Recovering/ 
resolving 
N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up, TEAE = Treatment-Emergent Adverse Event, SAE = Serious Adverse Event, 
AE = Adverse Event, AESI = Adverse Event of Special Interest. 
Note: TEAEs are defined as all AEs which start (or increase in severity) on or after the date of first dose of double-blind study 
medication through the 30 day follow-up period. 
Note: Potential Hy's Law events are to be entered as AESIs. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
Note: Adverse events are coded using Medical Dictionary for Regulatory Activities (MedDRA) Version xx.x. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
183


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 132 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.1.2 Serious Adverse Events 
Safety Analysis Set 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID Period 
AE 
Number 
System Organ Class/ 
Preferred Term/ 
Verbatim Term  
Start Date  
(Study Day)/ 
Stop Date  
(Study Day)   
TEAE  AESI  
Occur at 
Patch 
Application 
Site   
Criteria 
Abate 
After 
Discont-
inuation 
Reappear 
After Drug 
Re-
introduction 
xxxx-xxxx 
SB 
xx 
xxxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxxxxxx 
YYYY-MM-DD (xx)/ 
YYYY-MM-DD (xx) 
N 
N 
N 
Important 
Medical 
Event 
NA 
NA 
 
DB 
xx 
xxxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxxxxxx 
YYYY-MM-DD (xx)/ 
YYYY-MM-DD (xx) 
Y 
Y 
Y 
Life-
threatening/ 
Hospital-
ization 
Y 
N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up, TEAE = Treatment-Emergent Adverse Event, SAE = Serious Adverse Event, AE 
= Adverse Event, AESI = Adverse Event of Special Interest. 
Note: TEAEs are defined as all AEs which start (or increase in severity) on or after the date of first dose of double-blind study 
medication through the 30 day follow-up period. 
Note: Potential Hy's Law events are to be entered as AESIs. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  During 
the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
Note: Adverse events are coded using Medical Dictionary for Regulatory Activities (MedDRA) Version xx.x. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
184


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 133 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Listing 16.2.3.1.3 Adverse Events Leading to Discontinuation of Study Medication 
Safety Analysis Set 
This listing will be similar to 16.3.1.1. 
Programming note: Remove column ‘Caused Discontinuation’. 
 
Listing 16.2.3.1.4 Adverse Events Leading to Death 
Safety Analysis Set 
This listing will be similar to 16.3.1.1. 
 
Listing 16.2.3.1.5 Commonly Occurring Adverse Events  
Safety Analysis Set 
This listing will be similar to 16.3.1.1. 
Programming note: Add footnote: “Note: Commonly Occurring TEAE is defined as any TEAE occurring in at least 5% of subjects in any 
treatment arm." 
 
 
Listing 16.2.3.1.6 Adverse Events at Patch Application Site 
Safety Analysis Set 
This listing will be similar to 16.3.1.1. 
Programming note: Remove column ‘Occur at Patch Application Site’. 
 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
185


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 134 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.2.1 Clinical Laboratory Results - Hematology 
Safety Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Age/Gender 
Visit 
Date 
(Period, Study Day) 
Parameter 
Result  
Unit 
Normal Range 
CTCAE Grade 
xxxx-xxxx 
xx/xxxx 
xxxxxx 
YYYY-MM-DD (xx, xx) 
xxxxxx 
xx 
xx 
xx - xx 
x 
xxxx-xxxx 
xx/xxxx 
xxxxxx 
YYYY-MM-DD (xx, xx) 
xxxxxx 
xx (H) 
xx 
xx - xx 
x 
xxxx-xxxx 
xx/xxxx 
xxxxxx 
YYYY-MM-DD (xx, xx) 
xxxxxx 
xx (L) 
xx 
xx - xx 
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: CTCAE = Common Terminology Criteria for Adverse Events, SB = Single-Blind, DB = Double-Blind, FU = Follow-up, H = High 
(above upper limit of normal), L = Low (below lower limit of normal), M = Male, F = Female. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
Note: CTCAE Grade refers to the severity.  As a general guideline:  Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or 
medically significant but not immediately life-threatening,  and Grade 4 is life-threatening consequences. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
186


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 135 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Listing 16.2.3.2.2 Clinical Laboratory Results – Blood Chemistry 
Safety Analysis Set 
This listing will be similar to 16.3.2.1. 
 
Listing 16.2.3.2.3 Clinical Laboratory Results – Urinalysis 
Safety Analysis Set 
This listing will be similar to 16.3.2.1. 
 
Programming note: This listing will include urine drug screen and pregnancy testing. 
 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
187


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 136 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04             
                                                                                          
Listing 16.2.3.2.4 Subjects with Clinically Significant or NCI CTCAE Grade >= 3 Laboratory Results 
Safety Analysis Set 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
Programming note: If a subject has any result meeting criteria, present all results the subject has for that parameter. 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Age/Gender 
Visit 
Date 
(Period, 
Study Day) 
Parameter 
(Low/High) 
Result (Unit) 
Normal Range 
CTCAE Grade 
 
xxxx-xxxx 
xx/xxxx 
xxxxxx 
YYYY-MM-DD 
(xx, xx) 
xxxxxx 
xxx (xx) (L) 
xxx - xxx 
x 
 
xxxx-xxxx 
xx/xxxx 
xxxxxx 
YYYY-MM-DD 
(xx, xx) 
xxxxxx 
xxx (xx) (H) 
xxx - xxx 
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: NCI = National Cancer Institute, CTCAE = Common Terminology Criteria for Adverse Events, SB = Single-Blind, DB = Double-
Blind, FU = Follow-up, M = Male, F = Female. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
Note: CTCAE Grade refers to the severity.  As a general guideline:  Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or 
medically significant but not immediately life-threatening,  and Grade 4 is life-threatening consequences. 
 
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
188


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 137 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.3 12-Lead ECG 
Safety Analysis Set 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) Parameter (Units) 
Result 
Markedly Abnormal 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, xx) Overall Assessment by Investigator 
Normal 
 
 
 
 
Overall Assessment by Vendor 
xxxx 
 
 
 
 
Diagnosis 1 
xxxx 
 
 
 
 
Diagnosis 2 
xxxx 
 
 
 
 
HR (bpm) 
xx 
N 
 
 
 
PR Interval (msec) 
xx 
N 
 
 
 
QRS Interval (msec) 
xx 
N 
 
 
 
QT Interval (msec) 
xx 
N 
 
 
 
RR Interval (msec) 
xx 
N 
 
 
 
QTcF Interval (msec) 
xx 
N 
 
 
 
QTcB Interval (msec) 
xx 
N 
 
 
 
 
 
 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) Comparison to Prior ECG 
xxxx 
 
 
 
 
Overall Assessment by Investigtor 
Abnormal, Clinically 
Significant 
 
 
 
 
Overall Assessment by Vendor 
xxxx 
 
 
 
 
Diagnosis 1 
xxxx 
 
 
 
 
Diagnosis 2 
xxxx 
 
 
 
 
HR (bpm) 
xx 
N 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
189


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 138 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
 
 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
 
 
 
 
PR Interval (msec) 
xx 
N 
 
 
 
QRS Interval (msec) 
xx 
N 
 
 
 
QT Interval (msec) 
xx 
N 
 
 
 
RR Interval (msec) 
xx 
N 
 
 
 
QTcF Interval (msec) 
xx 
N 
 
 
 
QTcB Interval (msec) 
xx 
N 
 
 
 
 
 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  During 
the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                                                                                           
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
190


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 139 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.4 Vital Signs 
Safety Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) Parameter/Position 
Result 
Unit 
Markedly 
Abnormal 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, xx) Oral Temperature 
xx 
xx 
N 
 
 
 
Height 
xx 
xx 
N 
 
 
 
Weight 
xx 
xx 
N 
 
 
 
BMI 
xx 
Xx 
N 
 
 
 
Systolic Blood Pressure/ Sitting 
xx 
xx 
N 
 
 
 
Diastolic Blood Pressure/ Sitting 
xx 
xx 
N 
 
 
 
Pulse/ Sitting 
xx 
xx 
N 
 
 
 
Systolic Blood Pressure/ Supine 
xx 
xx 
N 
 
 
 
Diastolic Blood Pressure/ Supine 
xx 
xx 
N 
 
 
 
Pulse/ Supine 
xx 
xx 
N 
 
 
 
Systolic Blood Pressure/ Standing 
xx 
xx 
N 
 
 
 
Diastolic Blood Pressure/  Standing 
xx 
xx 
N 
 
 
 
Pulse/  Standing 
xx 
xx 
N 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) Oral Temperature 
xx 
xx 
N 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: Sitting indicates 5 minutes sitting, supine indicates 5 minutes supine, and standing indicates 1-3 minutes after standing. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication.             
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
191


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 140 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.5 Simpson Angus Scale (SAS) 
Safety Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) 
Item 
Result 
 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, xx) 
1. Gait 
0 = Normal 
 
 
 
 
2. Arm Dropping 
xx 
 
 
 
 
3. Shoulder Shaking  
xx 
 
 
 
 
4. Elbow Rigidity 
xx 
 
 
 
 
5. Fixation of Position 
xx 
 
 
 
 
6. Leg Pendulousness 
xx 
 
 
 
 
7. Head Dropping 
xx 
 
 
 
 
8. Glabella Tap 
xx 
 
 
 
 
9. Tremor 
xx 
 
 
 
 
10. Salivation 
xx 
 
 
 
 
Total Score 
xx 
 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) 
1. Gait 
xx 
 
 
 
 
2. Arm Dropping 
xx 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication..            
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
192


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 141 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.6 Abnormal Involuntary Movement Scale (AIMS) 
Safety Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) 
Item 
Result 
 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, xx) 
1. Muscles of Facial Expression 
xx 
 
 
 
 
2. Lips and Perioral Area 
xx 
 
 
 
 
3. Jaw  
xx 
 
 
 
 
4. Tongue 
xx 
 
 
 
 
5. Upper 
xx 
 
 
 
 
6. Lower 
xx 
 
 
 
 
7. Neck, Shoulders, Hips 
xx 
 
 
 
 
8. Severity of Abnormal Movements 
xx 
 
 
 
 
9. Incapacitation due to Abnormal Movements 
xx 
 
 
 
 
10. Patient’s Awareness of Abnormal Movements 
xx 
 
 
 
 
Total Score 
xx 
 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) 
1. Muscles of Facial Expression 
xx 
 
 
 
 
2. Lips and Perioral Area 
xx 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
193


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 142 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.7 Barnes Akathisia Rating Scale (BARS) 
Safety Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
 
 
 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) Item 
Result 
 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, xx) Objective 
xx 
 
 
 
 
Awareness of Restlessness 
xx 
 
 
 
 
Distress Related to Restlessness  
xx 
 
 
 
 
Global Clinical Assessment of Akathisia 
xx 
 
 
 
 
Total Score 
xx 
 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) Objective 
xx 
 
 
 
 
Awareness of Restlessness 
xx 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication. 
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
194


 
 
Author: 
Amanda Schwab 
Version Number: 
Draft 2 
 
 
Version Date: 
09Jan2017 
Page 143 of 144 
 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
 
Noven Pharmaceuticals, Inc.                                                                                                Page 1 of x 
Protocol HP-3070-GL-04                                                                                                      
Listing 16.2.3.8 Columbia-Suicide Severity Rating Scale (C-SSRS) 
Safety Analysis Set 
Programming note: Repeat for HP-3070 9.0 mg and Placebo. 
Programming note: The non-missing descriptive variable responses should go next to the corresponding categorical result. 
Treatment Group: HP-3070 18.0 mg 
Subject ID 
Visit 
Date of Assessment 
(Period, Study Day) Item 
Result 
 
xxxx-xxxx 
Screening 
YYYY-MM-DD (xx, xx) 1. Wish to be Dead 
xx 
 
 
 
 
2. Non-Specific Active Suicidal Thoughts 
xx 
 
 
 
 
3. Active Suicidal Ideation with Any Methods 
(Not Plan) without Intent to Act  
xx 
 
 
 
 
4. Active Suicidal Ideation with Some Intent 
to Act, without Specific Plan 
xx 
 
 
 
 
5. Active Suicidal Ideation with Specific 
Plan and Intent 
xx 
 
 
 
 
Most Severe Ideation 
xx 
 
 
 
 
Frequency 
xx 
 
 
 
 
Duration 
xx 
 
 
 
 
Controllability 
xx 
 
 
 
 
Deterrents 
xx 
 
 
 
 
… 
… 
 
xxxx-xxxx 
Week 1 
YYYY-MM-DD (xx, xx) 1. Wish to be Dead 
xx 
 
 
 
 
2. Non-Specific Active Suicidal Thoughts 
xx 
 
Note: SB = Single-Blind, DB = Double-Blind, FU = Follow-up. 
Note: During the SB period, study day is calculated relative to the first dose of study medication during the run-in period.  
During the DB and FU periods, study day is calculated relative to the first dose of double-blind study medication..            
                                                                                                                            
Noven\HP-3070\XWA17541\Biostatistics\Production\Listings\xxxxx.sas ddmmmyyyy hh:mm        
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
195


Author: 
Amanda Schwab 
Version Number: 
Draft 2 
Version Date: 
09Jan2017 
Page 144 of 144 
Noven Pharmaceuticals, Inc. 
STATISTICAL ANALYSIS PLAN: PROTOCOL HP-3070-GL-04 
Noven Pharmaceuticals, Inc.
Page 1 of x 
Protocol HP-3070-GL-04
Listing 16.2.3.9 Plasma Concentrations of Asenapine and Desmethyl-asenapine (ng/mL) by Treatment 
PK Analysis Set 
Subject 
ID 
Treatment 
Visit 
Scheduled 
Time 
(hr) 
Sample 
Collection 
Date/Time 
Actual 
Time 
(hr) 
Asenapine 
Concentration 
(ng/mL) 
Desmethyl-
asenapine 
Concentration 
(ng/mL) 
Comment 
xxxx-
xxxx 
HP-3070 
9.0 mg 
Week 
3 
2 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
14 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
22 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
xxxx-
xxxx 
HP-3070 
9.0 mg 
Week 
6 
2 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
14 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
22 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
xxxx-
xxxx 
HP-3070 
18.0 mg 
Week 
3 
2 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
14 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
22 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
xxxx-
xxxx 
HP-3070 
18.0 mg 
Week 
6 
2 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
14 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
22 
DDMONYYYY/HH:MM 
x 
xx.xx 
xx.xx 
Note: The lower limit of quantification is 0.0200 ng/mL. 
Note to Programmer: Sort by Subject No. and Treatment. Blood samples will be collected for PK analysis of asenapine and desmethyl-
asenapine; on Day 21 and 42 for both treatments (9 and 18 mg) at 2, 14 and 22 hours after dosing. 
Noven Pharmaceuticals
Version No. 1.0
Protocol No. HP-3070-GL-04
14 September 2018
196